Biomarker discovery for disease progression and metastasis in prostate cancer: a multi-omic approach by Wagner, S
  
 
 
Biomarker discovery for 
disease progression and 
metastasis in prostate cancer: 
a multi-omic approach  
 
 
 
 
Sarah Wagner 
 
A thesis submitted in partial fulfilment of the requirements of Nottingham 
Trent University for the degree of Doctor of Philosophy 
 
 
February 2019 
 
 
 
 
  
Copyright statement 
 
 
 
This work is the intellectual property of the author. You may copy up to 5 % of this work 
for private study, or personal, non-commercial research. Any re-use of the information 
contained within this document should be fully referenced, quoting the author, title, 
university, degree level and pagination. Queries or requests for any other use, or if a more 
substantial copy is required, should be directed in the owner(s) of the Intellectual Property 
Rights. 
  
 
 
 
  
Publications  
• Wagner, S., Vadakekolathu, J., Tasian, S.K., Altmann, H., Bornhaeuser, M., Pockley, 
A.G., Ball, G.R., Rutella, S. (2019). A parsimonious 3-gene signature predicts clinical 
outcomes in an acute myeloid leukemia multi-cohort study (Blood Advances 2019 
3:1330-1346). 
 
• Al-Juboori, S. IK., Vadakekolathu, J., Idri, S., Wagner, S., Zafeiris, D., Pearson, J. 
RD, Almshayakhchi, R., Caraglia, M., Desiderio, V., Miles, A. K., Boocock, D. J., Ball, 
G. R., and Regad, T. (2019). PYK2 promotes HER2-positive breast cancer invasion 
(Journal of Experimental & Clinical Cancer Research 2019 38:210). 
 
• Mele, L., la Noce, M., Paino, F., Regad, T., Wagner, S., Liccardo, D., Papaccio, G., 
Lombardi, A., Caraglia, M., Tirino V., Desiderio, V. and Papaccio, F. (2019). Glucose-
6-phosphate dehydrogenase blockade potentiates tyrosine kinase inhibitor effect on 
breast cancer cells through autophagy perturbation. (Journal of Experimental & 
Clinical Cancer Research 2019 38:160). 
 
• Multhoff, G., Breuninger, S., Stangl, S., Werner, C., Sievert, W., Lobinger, D., Foulds, 
G., Wagner, S., Pickhard, A., Pointek, G., Pockley, A. G. (2018). Membrane Hsp70 
- a novel target for the isolation of circulating tumor cells after epithelial-to-
mesenchymal transition. (Front Oncol. 2018 Nov 1;8:497). 
 
• Vadakekolathu, J., Rhonda, M., Ross, P. M., Wagner, S., Reeder, S., Demirkan, G., 
Kuhar, J. R., Ball., G. R., Pockley, A. G., Rutella, S. (2017). Interferon-γ Induces 
Distinct mRNA and Protein Profiles in Acute and Chronic Myeloid Leukemia. 
(Blood, 130 (Supp 1), 3945A.). 
 
• Wagner, S., Ball, G., Pockley, G., Miles, A. K (2018). Application of ‘omic’ 
technologies in cancer research. (Translational Medicine Reports, 2). 
 
• Zafeiris, D., Vadakekolathu, J., Wagner, S., Pockley, A., Ball, G. and Rutella, S. 
(2017). Discovery and application of immune biomarkers for hematological 
malignancies. (Expert Rev Mol Diagn. 2017 Nov;17(11):983-1000.). 
 
  
 
 
  
Acknowledgements 
 
First of all, I would like to thank my supervisory team, Dr David Boocock, Prof Graham 
Ball and Dr Amanda Miles for their constant support and guidance throughout these 
wonderful years. A special thanks goes to Amanda, which is not only my supervisor, but 
also a true friend that helped me through challenging, not only PhD, times. I will never 
forget this, neither Reggie’s little “accident”! 
Furthermore, I would like to thank Prof Robert Rees and Prof Graham Pockley for giving 
me the chance to work in this great research environment and for their constant support 
and valued advice during my studies. Another big THANKS goes to Stephen Reeder and 
Anne Schneider. What would the Centre be without you two?! I do not know how often 
you helped me with your knowledge and experience as well as your well-hidden stocks of 
reagents and I am very grateful for this. 
I would also like to thank Dr Jayakumar Vadakekolathu with his immense knowledge and 
guidance. I think, I still need to find a technique you are not familiar with ☺. I also want 
to thank Dr Tarik Regad for sharing with me his valued knowledge on EMT and 
metastasis and his encouragement to believe in my skills, Dr Clare Coveney for teaching 
me my first steps into mass spectrometry and for helping me, together with my supervisor 
Dr David Boocock, in the generation of the MS, and Prof Sergio Rutella for all the 
experience I gained in the analysis of clinically-derived data. Certainly, all other staff 
members of the JvG deserve a big THANK YOU for just being great colleagues and 
friends, especially Dr Gemma Foulds, Dr Stephanie McArdle, Dr Murrium Ahmad and 
Andrew Marr.  
Of course, I don’t want to forget all my fellow PhD friends, NTU and visiting students I 
have had the chance to meet, and to work with during my 4 long years to freedom. A BIG 
thank goes to the van Geest students Abdullah, Divya, Sarra, Josh, Jenny, Melissa, Rukaia, 
Luisa, Harish and Marco. You all made my days in the office so much nicer. THANKS. 
I also want to say MERCI, GRAZIE and THANK YOU to Lucie, Simone and Michael. 
You are great scientists and friends! 
I can feel lucky that I have a great group of friends that I can count on for many years, 
even if they are far away in good old Germany, so a big DANKE goes to Fabian, Daniel, 
Michi, Albo, Kevin, Tobi and Caro. I finally made it and hopefully it won’t be too long 
until I will be back on home ground ☺. Special thanks goes to my dear friend Ramona. 
Even if you are far, far away (in Bavaria). You are always there for me, day and night, and 
I can’t tell you how grateful I am to have a friend like you!   
A special DANKE goes to my mum, my Dote, Hanni, and my Opa and Oma. Thank you 
so much for your constant support since always, during school, university and my PhD 
studies (I am finally done). VIELEN, VIELEN DANK. I also want to thank the rest of 
my family, unfortunately it would be too long to list everyone, but you all know I am 
grateful for your support.  
And last, but definitely not least, I want to thank Andrea. My better half. Thank you very 
much for being there for me during all this time. I know it was not always easy, but I am 
finally done! GRAZIE DI TUTTO! 
 
 
 
  
Table of Contents 
Figures ............................................................................................................................................. i 
Tables ............................................................................................................................................. v 
Abbreviations .............................................................................................................................. vii 
Abstract .......................................................................................................................................... 1 
1. Chapter I – Introduction......................................................................................................... 3 
1.1 Cancer ................................................................................................................................................. 3 
1.1.1 Cancer – A brief Overview...................................................................................................... 3 
1.1.3 Hallmarks of Cancer ................................................................................................................. 6 
1.1.4 Causes of cancer - carcinogenesis ........................................................................................ 13 
1.2 Prostate Cancer ...............................................................................................................................16 
1.2.1 Prostate anatomy ..................................................................................................................... 16 
1.2.2 Incidence, risk factors and clinical presentation of prostate cancer ............................... 17 
1.2.3 Prostate cancer diagnosis and limitations of currently available diagnostic tools ........ 19 
1.2.4 Staging and grading ................................................................................................................. 24 
1.3.5 Treatment options available for PCa ................................................................................... 27 
1.3 Metastasis and epithelial to mesenchymal transition (EMT) ...................................................29 
1.3.2 Types of epithelial to mesenchymal transition (EMT) ...................................................... 29 
1.3.3 Transforming growth factor β and the TGF-β superfamily ............................................ 33 
1.3.4 Transforming growth factor β as an inducer of EMT ...................................................... 33 
1.3.5 EMT associated biomarkers in cancer ................................................................................. 36 
1.4 Biomarker discovery and validation.............................................................................................37 
1.4.1 Biomarkers ............................................................................................................................... 37 
1.4.3 Sources for biomarker discovery with a focus on prostate cancer ................................. 38 
1.4.4 Discovery tools (omics) ......................................................................................................... 42 
2. Chapter II - Materials and Methods .................................................................................... 47 
2.1 Materials ...........................................................................................................................................47 
2.1.1 Reagents .................................................................................................................................... 47 
2.1.3 Buffers and Gels ..................................................................................................................... 51 
2.2 Methods............................................................................................................................................55 
2.2.1 Cell culture ............................................................................................................................... 55 
2.2.2 Molecular biology .................................................................................................................... 58 
2.2.3 Protein biology ........................................................................................................................ 63 
2.2.4 Mass spectrometry .................................................................................................................. 67 
2.2.5 Experimental layout and generation of sample material from both inducible EMT 
models ................................................................................................................................................ 73 
2.2.6 Processing and filtering of omic data generated through RNA-sequencing and mass 
spectrometry analyses....................................................................................................................... 75 
 
 
2.2.7 In silico analyses of wet-lab derived and publicly available omic datasets ....................... 77 
2.2.8 Analysis of publically available in silico data ........................................................................ 77 
2.2.9 Statistical analysis .................................................................................................................... 78 
2.2.10 Used online tools and databases ........................................................................................ 79 
3. Chapter III – Development of two inducible models of epithelial to mesenchymal 
transition for the study of disease progression in prostate cancer ...................................... 80 
3.1 Introduction .................................................................................................................................... 80 
3.2 Results .............................................................................................................................................. 85 
3.2.1 Development of an inducible model of EMT using a single cell clone derived from a 
primary prostate cancer cell line using Transforming Growth Factor β ................................. 85 
3.2.2 Development of a second inducible model of EMT using a prostate cancer cell line 
derived from a metastatic site through stimulation with Transforming Growth Factor β ....... 98 
3.3 Discussion ..................................................................................................................................... 109 
4. Chapter IV – Generation and characterisation of trancriptomic and proteomic 
profiles of two inducible models of epithelial to mesenchymal transition ..................... 113 
4.1. Introduction ................................................................................................................................. 113 
4.1.1 Summary of commonly used gene expression analysis methods for the generation of 
transcriptomic profiles ................................................................................................................... 114 
4.1.2 Summary of commonly used protein expression analysis methods for the generation 
of proteomic profiles ..................................................................................................................... 116 
4.2 Results ............................................................................................................................................ 120 
4.2.1 RNA-sequencing analysis of RNA extracted from treated and untreated P5B3 and 
DU145 cells ..................................................................................................................................... 120 
4.2.2 Mass spectrometry analysis of cell lysates generated from treated and untreated P5B3 
and DU145 cells ............................................................................................................................. 134 
4.2.3 Improved correlation of transcriptomic and proteomic changes through parallel 
treatment and harvest .................................................................................................................... 151 
4.4 Discussion ..................................................................................................................................... 154 
4.4.1 Data quality and considerations through RNA-sequencing and mass spectrometry 
analysis ............................................................................................................................................. 154 
4.4.2 Gene and protein expression changes induced in both EMT models ......................... 155 
4.4.6 Concordantly enriched pathway between P5B3 and DU145 across both omic levels
 ........................................................................................................................................................... 162 
5. Chapter V – Selection and validation of novel biomarkers of prostate cancer 
progression and epithelial to mesenchymal transition using integrative data analysis .. 164 
5.1 Introduction .................................................................................................................................. 164 
5.2 Results ............................................................................................................................................ 168 
5.2.1 Data integration and selection of a core marker list through the integration of 
generated omic profiles ................................................................................................................. 168 
5.2.2. Screening of cancerous cell lines for their expression of selected markers ................ 172 
5.2.3 Gene expression analysis of selected markers in healthy tissue RNA ......................... 174 
5.2.4 Validation of novel biomarkers using tissue microarray derived from healthy and 
diseased tissue ................................................................................................................................. 180 
5.2.6 In silico validation of selected markers in publicly available datasets ............................. 199 
5.3 Discussion ..................................................................................................................................... 210 
6. Chapter VI - Final discussion, conclusions and future work ........................................ 217 
6.1 General discussion ....................................................................................................................... 217 
6.1.1 Introduction ........................................................................................................................... 217 
6.1.2 TGF-β stimulation induces an EMT-like phenotype in the prostate cancer cell lines 
P5B3 and DU145 and alters EMT-associated signalling pathways ........................................ 218 
6.1.3 The integration of transcriptomic and proteomic profiles can identify novel 
biomarkers associated with EMT and prostate cancer progression ....................................... 220 
6.2 Conclusion .................................................................................................................................... 224 
6.3 Future work .................................................................................................................................. 225 
Web references ......................................................................................................................... 227 
Bibliography .............................................................................................................................. 229 
Appendix ................................................................................................................................... 259 
 
i 
 
Figures 
Figure 1.1: Incidence rate of the top 20 cancers in 2015 in the UK ..................................... 4 
Figure 1.2: Mortality rate for the 20 most common cancers in 2014 in the UK ................ 5 
Figure 1.3: The six hallmarks of cancer proposed by Hanahan & Weinberg ...................... 7 
Figure 1.4: Schematic representation of prostate anatomy showing three distinct zones 
within the prostate ..................................................................................................................... 16 
Figure 1.5: Age-specific cases of prostate cancer diagnoses in 2013-2015 in the UK ..... 17 
Figure 1.6: Age-specific cases of prostate cancer-associated deaths in 2012-2014 in the 
UK ................................................................................................................................................ 18 
Figure 1.7: Schematic representation of PSA and its derivatives ........................................ 21 
Figure 1.8: Schematic representation of tissue differentiation in PCa across the 5 
Gleason scores ............................................................................................................................ 25 
Figure 1.9: The invasion-metastasis cascade .......................................................................... 31 
Figure 1.10: TGF-β signalling pathways and resulting genes responses upon activation 34 
Figure 1.11: SMAD-dependent and SMAD-independent signalling cascade induced 
through the binding of TGF-β ................................................................................................. 35 
Figure 1.12: The human plasma proteome ............................................................................. 41 
Figure 2.1: Example representation of a generated standard curve for the efficiency 
testing of a novel primer set. .................................................................................................... 61 
Figure 2.2: Schematic representation of "sandwich" assembly for protein transfer onto 
nitrocellulose membrane ........................................................................................................... 66 
Figure 2.3: Schematic representation of the preparation and treatment regime of both 
cell lines for the generation of sample material ..................................................................... 74 
Figure 2.4: Schematic representation of filtering for the identification of 13 core markers
 ....................................................................................................................................................... 76 
Figure 3.1: Schematic representation of morphological changes from epithelial to 
mesenchymal cell morphology ................................................................................................. 80 
Figure 3.2: P5B3 in its natural state ......................................................................................... 82 
Figure 3.3: DU145 in its natural state...................................................................................... 83 
Figure 3.4: Morphological changes of P5B3 after treatment with TGF-β for 5 days ...... 85 
Figure 3.5: Gene expression changes of EMT markers induced in P5B3 upon 
stimulation with TGF-β. ........................................................................................................... 86 
Figure 3.6: Representative images of immunofluorescence staining of untreated and 
treated P5B3 cells ....................................................................................................................... 88 
Figure 3.7: Comparison of protein peak areas of E-cadherin (CADH1), Vimentin 
(VIME) and Fibronectin (FINC) for untreated and treated cells of P5B3........................ 89 
Figure 3.8: Analysis of significant proteins (<0.05) with an absolute fold change of 1.5 
and higher using Gene Ontology Consortium....................................................................... 90 
Figure 3.9: Morphological appearance of untreated and treated cells of P5B3 after 
growth over 10 days ................................................................................................................... 92 
Figure 3.10: Gene expression changes of known EMT markers induced in P5B3 upon 
stimulation with TGF-β ............................................................................................................ 94 
Figure 3.11: Representative images of immunofluorescence staining of untreated and 
treated P5B3 cells ....................................................................................................................... 96 
Figure 3.12: Western blot of cell lysates generated from untreated and treated P5B3 
cells. .............................................................................................................................................. 97 
ii 
 
Figure: 3.13: Morphological appearance of untreated and treated cells of DU145 after 
growth over 10 days ................................................................................................................... 99 
Figure 3.14: Gene expression changes of known EMT markers induced in DU145 upon 
stimulation with TGF-β.......................................................................................................... 101 
Figure 3.15: Representative images of immunofluorescence staining of untreated and 
treated DU145 cells ................................................................................................................. 103 
Figure 3.16: Western blot of cell lysates generated from untreated and treated DU145 
cells. ........................................................................................................................................... 104 
Figure 3.17: qRT-PCR analysis of selected EMT-associated genes and their expression 
across 4 distinct subtypes of EMT generated by Huang et al, 2013 ................................ 106 
Figure 3.18: Analysis of changes of migratory capabilities in untreated (U) and treated 
(T) P5B3 ................................................................................................................................... 107 
Figure.3.19: Analysis of changes of migratory capabilities in untreated (U) and treated 
(T) DU145 ................................................................................................................................ 108 
Figure 4.1: Schematic representation of the three major mass spectrometry analysis 
methods. ................................................................................................................................... 117 
Figure 4.2: Graph indicating the average percent alignment of all reads to exonic, 
intronic and intergenic regions for the 4 analysed sample sets, ........................................ 123 
Figure 4.3: Gene expression changes of the EMT markers .............................................. 125 
Figure 4.4: Hierarchical clustering of 4575 genes significantly (p-value <0.05) 
deregulated between untreated and treated P5B3 cells ...................................................... 126 
Figure 4.5: Top 50 most significantly enriched pathways based on significant genes in 
P5B3 .......................................................................................................................................... 127 
Figure 4.6: Hierarchical clustering of 2303 genes significantly (p-value <0.05) 
deregulated between untreated and treated DU145 cells .................................................. 129 
Figure 4.7: Top 50 most significantly enriched pathways based on significant genes in 
DU145....................................................................................................................................... 130 
Figure 4.8: Significantly deregulated genes across both cell line models ........................ 132 
Figure 4.9: Hierarchical clustering of significant genes shared between both cell line 
models ....................................................................................................................................... 133 
Figure 4.10: Proteomic changes of vimentin, E-cadherin and fibronectin in cell lysates
 .................................................................................................................................................... 136 
Figure 4.11: Hierarchical clustering of significantly altered proteins in untreated and 
treated P5B3 ............................................................................................................................. 137 
Figure 4.12: Top 50 most significantly enriched pathways based on significant proteins 
in P5B3 ...................................................................................................................................... 137 
Figure 4.13: Schematic representation of the pathway describing “TGF-beta-dependent 
induction of EMT via RhoA, PI3K and ILK” ................................................................... 140 
Figure 4.14: Hierarchical clustering of significantly altered proteins in untreated and 
treated DU145 ......................................................................................................................... 141 
Figure 4.15: Top 50 most significantly enriched pathways based on significant proteins 
in DU145 .................................................................................................................................. 142 
Figure 4.16: Schematic representation of the pathway describing “Cytoskeleton and 
adhesion module” .................................................................................................................... 145 
Figure 4.17: Significantly deregulated proteins within both cell lines models. ............... 146 
Figure 4.18: Hierarchical clustering of significantly altered proteins shared across both 
cell line models......................................................................................................................... 147 
iii 
 
Figure 4.19: Schematic representation of the pathway describing “Regulation of actin 
cytoskeleton organization by the kinase effectors of Rho GTPases” .............................. 150 
Figure 4.20: Pearson correlation of gene and protein expression between both treatment 
conditions of P5B3. ................................................................................................................. 152 
Figure 4.21: Pearson correlation of gene and protein expression between both treatment 
conditions of DU145. .............................................................................................................. 153 
Figure 5.1: qRT-PCR screening of selected markers .......................................................... 173 
Figure 5.2: Comparison of gene expression of each marker (DPYSL3, FBLIM1, SDPR 
and P4HA2) in commercially available healthy prostate tissue RNA ............................... 175 
Figure 5.3: Comparison of gene expression of DPYSL3 in a commercially available 
healthy tissue RNA panel ........................................................................................................ 176 
Figure 5.4: Comparison of gene expression of FBLIM1 in a commercially available 
healthy tissue RNA panel ........................................................................................................ 177 
Figure 5.5: Comparison of gene expression of SDPR in a commercially available healthy 
tissue RNA panel ...................................................................................................................... 178 
Figure 5.6: Comparison of gene expression of P4HA2 in a commercially available 
healthy tissue RNA panel ........................................................................................................ 179 
Figure 5.7: Images illustrating scoring method used for healthy and diseased tissue 
specimens analysed using immunohistochemistry staining ................................................ 180 
Figure 5.8: DPYL3 protein expression in healthy tissue microarray ................................ 182 
Figure 5.9: DPYL3 protein expression in healthy tissue microarray ................................ 183 
Figure 5.10: FBLI1 protein expression in healthy tissue microarray ................................ 184 
Figure 5.11: SDPR protein expression in healthy tissue microarray ................................. 185 
Figure 5.12: P4HA2 protein expression in healthy tissue microarray .............................. 186 
Figure 5.13: DPYL3 expression in healthy prostate, prostate cancer and healthy adjacent 
prostate tissue samples ............................................................................................................ 191 
Figure 5.14: FBLI1 expression in healthy prostate, prostate cancer and healthy adjacent 
prostate tissue samples ............................................................................................................ 193 
Figure 5.15: SDPR expression in healthy prostate, prostate cancer and healthy adjacent 
prostate tissue samples ............................................................................................................ 195 
Figure 5.16: P4HA2 expression in healthy prostate, prostate cancer and healthy adjacent 
prostate tissue samples ............................................................................................................ 197 
Figure 5.17: In silico gene expression analysis for DPYSL3 generated from cell-derived 
whole transcriptome analyses of EMT-induced cell lines .................................................. 200 
Figure 5.18: In silico gene expression analysis for FBLIM1 generated from cell-derived 
whole transcriptome analyses of EMT-induced cell lines .................................................. 201 
Figure 5.19: In silico gene expression analysis for SDPR generated from cell-derived 
whole transcriptome analyses of EMT-induced cell lines .................................................. 202 
Figure 5.20: In silico gene expression analysis for P4HA2 generated from cell-derived 
whole transcriptome analyses of EMT-induced cell lines .................................................. 203 
Figure 5.21: Gene expression of DPYSL3 (A), FBLIM1 (B), SDPR (C) and P4HA2 (D) 
in normal, primary tumour and CRPC tissue ....................................................................... 205 
Figure 5.22: Gene expression of DPYSL3 (A), FBLIM1 (B), SDPR (C) and P4HA2 (D) 
across four different Gleason scores ..................................................................................... 206 
Figure 5.23: Gene expression of DPYSL3 in patient-derived whole transcriptome 
datasets of recurrent and non-recurrent PCa ....................................................................... 208 
iv 
 
Figure 5.24: Gene expression of SDPR in patient-derived whole transcriptome datasets 
of recurrent and non-recurrent PCa ..................................................................................... 209 
 
  
v 
 
Tables 
Table 1.1: Summary of the TNM classification system ........................................................ 26 
Table 1.2: D'Amico risk classification system to categorise patients for risk of prostate 
cancer recurrence after radical prostatectomy ....................................................................... 27 
Table 1.3: Summary of treatment options for PCa according to the stage of PCa. ......... 28 
Table 1.4: List of genes and proteins associated with the process of EMT, their 
expression changes and impact on cellular functions. .......................................................... 32 
Table 1.5: Classes of Biomarkers and their use...................................................................... 37 
Table 1.6: Potential biomarker discovery pipeline using multi-omics discovery tools. ... 38 
Table 1.7: Comparison of the three main sample sources used for the discovery of novel 
cancer biomarkers ...................................................................................................................... 39 
Table 2.1: Table of the two prostate cancer cell lines used during the purpose of study 55 
Table 2.2: Summary of cell lines used throughout the process of this study. ................... 61 
Table 2.3: Resolving gel preparation for one 1.5 mm gel ..................................................... 64 
Table 2.4: Stacking gel preparation for one 1.5 mm gel ....................................................... 65 
Table 2.5: Summary of used public available datasets for the in silico validation of novel 
markers......................................................................................................................................... 78 
Table 2.6: List of utilised databases and online tools with their use and link.................... 79 
Table 4.1: Representative analysis of 9 randomly selected samples of both cell line 
models for the testing of the presence of genomic DNA .................................................. 121 
Table 4.2: List of generated samples of both cell line models and treatment conditions 
and their corresponding RNA concentration ...................................................................... 122 
Table 4.3: Summary of detected genes and transcripts within the analysed sample set 123 
Table 4.4: Top 15 most significant associated pathways of significantly deregulated 
genes P5B3 ................................................................................................................................ 128 
Table 4.5: Top 15 most significant associated pathways of significantly deregulated 
genes in DU145 ........................................................................................................................ 131 
Table 4.6: Shared enriched pathways within the top 15 pathways of both cell lines ..... 134 
Table 4.7: Summary of detected proteins and peptides within the analysed sample set of 
both cell line models ................................................................................................................ 135 
Table 4.8: Top 15 most enriched pathways identified through the protein list of P5B3
 ..................................................................................................................................................... 138 
Table 4.9: Shared enriched top 15 pathways between gene and protein P5B3 ............... 139 
Table 4.10: Top 15 most enriched pathways identified through the protein list of 
DU145 ....................................................................................................................................... 143 
Table 4.11: Shared enriched pathways in the top 15 between the gene and protein lists 
of DU145................................................................................................................................... 144 
Table 4.12: Shared enriched pathways within the top 15 pathways of both cell lines ... 148 
Table 4.13: Single shared pathway between all datasets and cell line models ................. 149 
Table 5.1: Identification of significantly differentially regulated markers within all 4 omic 
datasets ....................................................................................................................................... 169 
Table 5.2: List of 13 markers identified through the integration of both models and all 4 
omic profiles. ............................................................................................................................ 171 
Table 5.3: Final marker selection for further validation presenting the induced fold 
change for both cell line models and omic level.................................................................. 172 
Table 5.4: Score summary of immunohistochemistry tissue sections .............................. 187 
Table 5.5: Score summary of immunohistochemistry tissue sections .............................. 198 
vi 
 
Table 5.6: Summary of analysed cell lines for the in silico validation ................................ 199 
 
  
vii 
 
Abbreviations 
 
ABC Avidin-biotin complex 
ACN Acetonitrile 
APS Ammonium persulfate 
ATCC American Tissue Culture Collection 
ATP Adenosine triphosphate 
BCa Breast cancer 
bp base pair 
BPH Benign prostate hyperplasia 
BSA Bovine Serum Albumin 
C Celsius 
cDNA complementary DNA 
CI Confidence interval 
CID Collision induced dissociation 
CO2 Carbon dioxide 
cPSA complexed PSA 
CRPC Castration-resistant prostate cancer 
Ct Cycle time 
Da Dalton 
DAB 3,3'-diaminobenzidine 
DAPI 4′,6-diamidino-2-phenylindole 
DDA Data dependent acquisition 
ddH2O 
DIA 
double distilled water 
Data-independent acquisition 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleotide triphosphates 
DPBS Dulbecco's phosphate-buffered saline 
DPX Distyrene - plasticiser - xylene 
DRE Digital rectal examination 
dT Deoxythymine 
DTT Dithiothreitol 
DU145U DU145 untreated 
DU145T DU145 treated 
E Epithelial 
ECM Extracellular matrix 
EGF Epidermal growth factor 
ELISA enzyme-linked immunosorbent assay 
EMT Epithelial to mesenchymal transition 
ESCC oesophageal squamous cell carcinoma  
EtOH Ethanol 
FA Formic acid 
FC Fold change 
FCS Foetal calf serum 
FDR False-discovery rate 
FFPE Formalin-Fixed Paraffin-Embedded 
Fig Figure 
FITC Fluorescein isothiocyanate 
FPKM Fragments Per Kilobase of transcript per Million mapped reads 
fPSA free PSA 
g gram 
GRCh Genome Research Consortium human  
GS Gleason Score 
h hours 
viii 
 
H2O2 Hydrogen peroxide 
HCC hepatocellular carcinoma 
HCl Hydrogen chloride 
HGF hepatocyte growth factor 
HPLC High Performance Liquid Chromatography 
HPV Human papillomavirus 
HRP horseradish peroxidase 
HR 
HRM 
Hazard ratio 
Hyper reaction monitoring 
ID Identifier 
IDA Information dependent acquisition 
IF Immunofluorescence 
IHC Immunohistochemistry 
kDa kiloDalton 
LC Liquid chromatography 
LNM lymph node metastasis 
M mesenchymal 
m/z mass to charge ratio 
mA milliampere 
MET Mesenchymal to epithelial transition 
MHC Major histocompatibility complex 
min minutes 
ml millilitre 
MMPs Matrix metalloproteinase 
MRI Magnetic resonance imaging 
MRM multiple reaction monitoring 
mRNA messenger RNA 
MS Mass Spectrometry 
n number 
NCBI National Centre for Biotechnology Information 
NCI National Cancer Institute 
ns not significant 
OGP Octyl β-D-glucopyranoside 
OS Overall survival 
OSCC oral squamous cell carcinoma  
p p-value 
P Proteome 
P5B3U P5B3 untreated 
P5B3T P5B3 treated 
PBS phosphate-buffered saline 
PCa Prostate cancer 
PCR polymerase chain reaction 
PSA Prostate specific antigen 
PT Pathway topology 
Q Quartile 
qRT-PCR quantitative real-time PCR 
RFS Relapse/recurrence-free survival 
RIN RNA Integrity number 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RT Room temperature 
SDS sodium dodecyl sulphate 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis  
SRM single reaction monitoring 
SWATH sequential window acquisition of all theoretical fragment ions 
T Transcriptome 
ix 
 
Tab Table 
TBS Tris-buffered saline 
TCGA The Cancer Genome Atlas 
TEAB Triethylamonium bicarbonat 
TEMED Tetramethylethylenediamine 
TF Transcription factor 
TGF-β Transforming growth factor β 
TMA Tissue microarray 
TNF Tumour necrosis factor 
TNM Tumour - Node - Metastasis 
TOF Time of flight 
tPSA total PSA 
Tregs regulatory T cells 
Tris tris(hydroxymethyl)aminomethane 
TRUS Transrectal ultrasound 
U Untreated 
UK United Kingdom 
µl microliter 
UTR Untranslated region 
UV Ultraviolet 
V Volt 
WHO World Health Organisation 
x times 
 
1 
 
Abstract 
 
Prostate cancer (PCa) is the most common cancer in men and the third most common 
cause of cancer-related deaths in Europe, which is primarily due to the development of 
metastasis, which decreases the 5-year survival rate to 30 %. The development of 
metastasis is the major cause of death in cancer patients and the process highly implicated 
in the ability of cancer cells to spread is called epithelial to mesenchymal transition (EMT). 
The aim of this study was to use inducible in vitro EMT models for the discovery of novel 
disease associated biomarkers through the use of multi-omics datasets.  
 
For this, two PCa cell lines were stimulated with transforming growth factor β (TGF-β), 
resulting in apparent morphological changes indicating a cellular change in the direction 
of an increased mesenchymal morphology. Induction of EMT was confirmed using 
quantitative real-time PCR, immunofluorescence staining and western blot analysis. To 
improve the understanding of underlying changes and for the discovery of novel 
biomarkers, proteomic and transcriptomic profiles of both models in their induced and 
non-induced states were generated. Their subsequent integration highlighted 13 potential 
biomarkers indicative for the process of EMT in PCa and metastasis development. Out 
of the 13 core markers, four of these were taken forward and further validated using tissue 
microarrays and the in silico analysis of publicly available datasets. The generated results 
have supported the association of all 4 markers with EMT and disease progression, 
however two markers were identified to be of particular interest (DPYL3 and SDPR). 
These two markers have shown significant differences between primary PCa and 
castration-resistant prostate cancer (CRPC) and Gleason scoring. Furthermore, both of 
them were shown to be predictive for disease-recurrence. Overall, the generated results 
have highlighted the successful application of an integrated omics approach for the 
discovery of novel disease-associated biomarkers for PCa progression. 
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3 
 
1. Chapter I – Introduction 
 
1.1 Cancer 
1.1.1 Cancer – A brief Overview 
Cancer is a general term describing a large, heterogeneous group of diseases in which 
abnormal cells proliferate without control and develop, in the case of solid tumours, the 
ability to invade and disseminate to other parts of the body. These changes can be caused 
through the aberrant regulation of cell growth and resistance to regulatory cell signalling, 
which was shown to be the main cause of cancer and without intervention, this process 
can lead to death (Hanahan, Weinberg 2000). Due to its major health impact, a significant 
amount of research is undertaken in the field of cancer, which has led to an increased 
understanding of the initiation and development of the disease as well as improving the 
treatment options available to patients. Unfortunately, cancer is a multifactorial disease 
and the response to treatment can vary from patient to patient. For this reason, further 
work is urgently required to characterise cancer mechanisms and to develop tailored, 
personalised treatment options for each patient (Jackson, Chester 2015).  
1.1.2 Cancer: Incidence and mortality 
Cancer is a major cause of morbidity and mortality worldwide, and according to recent 
data, one in two people will develop cancer during their life (Cancer Research UK, 2017a). 
The most common cancer in the UK (2015) is breast cancer (15 %), followed by prostate 
(13 %), lung (13 %) and bowel cancer (12 %) (Cancer Research UK, 2018a), which 
account together for more than half (53 %) of all cancer cases occurring in the UK 
(Fig.1.1). These statistics highlight the clinical health burden in the population and justify 
the large amount of research that has been dedicated to its treatment and cure. 
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Figure 1.1: Incidence rate of the top 20 cancers in 2015 in the UK (based on a graphic created by Cancer 
Research UK., Cancer Research UK, 2018a). The blue colour represents the cancer incidence in the male 
population; the pink colour indicates the cancer incidence in the female population.  
Cancer can arise from almost any part and tissue type of the body, and the disease can be 
classified according to the cell type it resembles or originates. Carcinomas, which have 
their origin in epithelial cells, are the most common kind of cancers; sarcomas arise from 
connective tissue such as bone and muscles, whereas lymphomas and leukaemias develop 
from hematopoietic cells (Cancer Research UK, 2018b). Each cancer type presents 
different characteristics, such as in their response to treatment or aggressiveness.  
 
Lung cancer is the most common cause of cancer death in the UK (Fig.1.2), and when 
combining males and females, lung cancer accounts for more than 20 % of all cancer 
deaths, which is followed by bowel cancer (10 %). Breast and prostate cancer represent 
the third most common cause of cancer-related deaths, accounting for 7 % of all cases 
(Cancer Research UK, 2017b). According to the World Health Organisation (WHO), 8.8 
million people died from cancer in 2015, which represents nearly one in six of all global 
deaths (WHO, 2017a). As mentioned before, the mortality rate can vary from cancer type 
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to cancer type, but in addition to the inherent variability of cancers, two factors influence 
the survival chances in the majority of cancers. These are the tumour stage at the time of 
diagnosis and the presence or absence of metastases. Organ confined primary tumours 
present higher chances of cure, based on the available treatment options and the chances 
of a complete removal of the tumour, whereas metastatic cancers have a reduced survival 
rate. This is mainly due to the increased treatment resistance of advanced cancers and the 
spread of metastatic lesions (Valastyan, Weinberg 2011). 
 
The development of metastases is the main cause of death in cancer patients and it 
accounts for about 90 % of all cancer-related deaths (Chaffer, Weinberg 2011, Mehlen, 
Puisieux 2006). The 5-year survival rate of metastasised cancers varies depending on the 
type of cancer, however the presence of metastasis results overall in a shortened life 
expectancy with variable survival rates, such as 2.3 % in pancreatic cancer, lung cancer at 
4.0 % and breast cancer at 25 % (Heerboth, Housman et al. 2015).  
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Figure 1.2: Mortality rate for the 20 most common cancers in 2014 in the UK (Based on a graphic created 
by Cancer Research UK, Cancer Research UK, 2017a). The blue colour represents the cancer mortality in 
the male population; the pink colour indicates the cancer mortality in the female population.  
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1.1.3 Hallmarks of Cancer 
In 2000, Hanahan and Weinberg have proposed 6 capabilities that a cell has to acquire to 
become cancerous and to induce tumour growth and development (Fig. 1.3) (Hanahan, 
Weinberg 2000). During the process of carcinogenesis, healthy cells, which are responsive 
to regulatory signals from the surrounding microenvironment, change to cells that are 
non-responsive and are able to grow and invade tissue autonomously, independent from 
any external signalling (Bertram 2000). This independence is commonly characterised by 
an increased proliferation rate and a lack of response to apoptotic signals. The previously 
mentioned hallmarks of cancer include self-sufficiency in growth signals, insensitivity to 
growth-inhibitory signals, evasion of apoptosis, limitless self-renewal capabilities, 
sustained angiogenesis and the ability to invade tissue and form secondary tumours, so-
called metastasis. The acquisition of each of these abilities breaches an anti-cancer defence 
mechanism present in cells and tissue of the host (Hanahan, Weinberg 2000).  
 
In addition to the original 6 hallmarks, Hanahan and Weinberg proposed in 2011 two 
further factors, the so-called “emerging hallmarks” in relation to the reprogramming of 
the energy metabolism in the cell and the ability of cells to evade immune destruction 
through the host’s immune system (Hanahan, Weinberg 2011). Furthermore, Hanahan 
and Weinberg proposed the enabling characteristics crucial for the acquisition of the 
proposed hallmarks, comprised of genome instability and mutation, and tumour-
promoting inflammation. In summary, this shows that the development of cancer is a 
highly complex disease induced by multiple steps and changes within the system of 
healthy cells. In 2017, Fouad & Aanei proposed a more precise definition of the hallmarks 
of cancer as “acquired evolutionary-advantageous characteristics that complementarily promote 
transformation of phenotypically normal cells into malignant ones, and promote progression of malignant 
cells which sacrificing/exploiting host tissue” (Fouad, Aanei 2017). 
 
Normally, cells are tightly controlled and their development is based on the interaction 
with the surrounding cells. External signals determine whether a cell will differentiate, 
proliferate, migrate or undergo apoptosis. These controls ensure the healthy function of 
the tissue. Random mutations within genes involved in the control of proliferation and 
apoptosis influence the cell’s fate and the induction of cancer (Giancotti 2014). Faults in 
the regulatory systems of cells and the generation of cells that are “immune” to external 
stimuli are commonly caused through genetic aberrations (DNA damage) (Hanahan, 
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Weinberg 2011, Hanahan, Weinberg 2000). However, variations within the epigenetic 
landscape, and therefore the reduced or increased expression of genes, can also contribute 
to the development of cancer (Sharma, Kelly et al. 2010). The DNA damage can be based 
on single point mutations, in which one or a few base pairs are changed, to large 
chromosomal aberrations. A crucial aspect of the development of mutations is the further 
proliferation of the cells carrying genetic mutations. 
 
 
 
 
 
 
 
 
 
This image has been removed by the author for copyright reasons 
 
 
 
 
 
 
 
Figure 1.3: The six hallmarks of cancer proposed by Hanahan & Weinberg (Hanahan, Weinberg 2000), 
which enable a cell to become cancerous.  
 
This highlights that the ability of cells to acquire these hallmarks cannot be explained 
through a single cause based on a single genetic abnormality but represents the 
accumulation of multiple mutations within the genome. Such mutations can in some cases 
be hereditary, such as is the case for the BRCA1/2 genes (Pecorino 2012), but most 
commonly they are induced through DNA damage acquired during the lifetime. Such 
mutations can be caused by various factors, including chemical, physical and infection-
related inducers, which are discussed further in chapter 1.1.4. 
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1.1.3.1 Self-sufficiency in growth signals 
The first hallmark describes the ability of cells to become independent from growth 
signals of surrounding cells. Healthy cells normally exist in a quiescent state and are strictly 
regulated through signalling and adhesion molecules expressed by surrounding and 
adjacent cells. They require activation to change to a proliferative stage, such as growth 
factors, extracellular matrix (ECM) components and cell-cell adhesion/interaction 
molecules, which can bind to the transmembrane receptors of the cell (Hanahan, 
Weinberg 2000). Tumour cells, however, can develop an independence from external 
growth stimuli and can change into a proliferative stage via three different mechanisms. 
Firstly, by an increased production of growth signals by the cancer cell itself, which 
enables the cell to trigger its own proliferation through a positive-feedback loop (Hanahan, 
Weinberg 2000). Secondly, through an overexpression or structural alteration of growth 
signalling receptors, which can lead to a hypersensitivity of the cell to external stimuli. 
Thirdly, cells can have intracellular signalling pathways, normally only active through the 
binding of growth signals that are continuously activated without the binding of external 
stimuli (Hanahan, Weinberg 2000, Bertram 2000).  
1.1.3.2 Insensitivity to anti-growth signals 
As mentioned previously, normal cells are kept in a quiescent state aside from when they 
are required to proliferate. This means, cells not only need external stimuli to be activated 
but also signals that keep them in the quiescent state. This state is maintained through the 
operation of multiple anti-proliferative signals, generated through the activity of tumour 
suppressor genes. Functionally, tumour suppressor genes can have a suppressing effect 
on the cell cycle and are able to arrest cells at a certain stage, preventing them from further 
multiplication. Furthermore, they can promote the apoptosis of cells that have irreparable 
damage to their DNA. Mutations within tumour suppressor genes result in an alteration 
or loss of their wild type function, and therefore their ability to suppress and inhibit 
tumour growth (Muller, Vousden 2013). In cases where this DNA damage is located in 
both alleles of the tumour suppressor gene, it results in their inactivation and ultimately 
prevents the cell from being able to regulate the cell cycle and to induce apoptosis. 
A well-known tumour suppressor gene is TP53, which was shown to be one of the most 
frequently mutated genes in human cancer (Freed-Pastor, Prives 2012). The gene is 
commonly activated through cellular stress caused by conditions such as DNA damage 
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or hypoxic conditions, resulting in the induction of apoptosis or the inhibition of further 
cell cycle progression of the malfunctioning cell (Freed-Pastor, Prives 2012).  
 
If cells become unresponsive to external signalling, mutated cells can further proliferate, 
which results in an increasingly unstable condition through the accumulation of additional 
mutations. Subsequent increases in mutations in tumour suppressor and proto-oncogenes 
enable cells to eventually develop a malignant cell phenotype (Vogelstein, Kinzler 2004).  
1.1.3.3 Evasion and prevention of apoptosis 
Healthy tissue growth is maintained through a balance of proliferating and dying cells 
(Cooper, J. P., Youle 2012). The death of cells presents a natural limitation to the 
proliferation of genetically damaged cells. Such cell death can be classified into two 
categories, necrosis and apoptosis (Rock, Kono 2008). Necrosis is the death of a cell 
through traumatic cell injury, which can be caused through a lack of nutrients or via the 
direct damage of cellular components.  
 
Apoptosis is the active process used in tissue growth, tissue modelling and controlled cell 
death induced by cell stress (Pecorino 2012). This process can be triggered through events 
such as DNA damage, withdrawal of growth cytokines, viral infections and hypoxic 
conditions, resulting in the activation of intrinsic and extrinsic apoptosis pathways 
(Bertram 2000). The intrinsic signalling pathway is regulated through the function of so-
called sensors and effectors. Sensors screen the extra- and intracellular environment for 
signs of abnormality, such as DNA damage, and trigger the effectors in case of need. This 
leads to a downregulation of anti-apoptotic genes and the increased expression of pro-
apoptotic genes (Hanahan, Weinberg 2000). Extrinsic apoptosis, mediated through death 
receptors on the surface of the cell, is commonly (Green, Llambi 2015) induced through 
cells of the immune system and for the maintenance of homeostasis is induced by external 
stimuli, resulting in the cell receiving a death signal.  
 
Regardless of the apoptotic pathway triggered, it always results in the release of 
cytochrome C from the mitochondria. Cytochrome C induces the activity of various 
caspases, which rapidly degrade cellular organelles and chromatin (Bertram 2000). Most, 
if not all, tumour cells acquire the ability to prevent this process from taking place by 
making the cells insensitive to apoptotic stimuli, the upregulation of anti-apoptotic 
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proteins such as Bcl-2 and the loss of pro-apoptotic proteins such as Bax and Bak (Fouad, 
Aanei 2017, Hanahan, Weinberg 2000, Green, Llambi 2015).  
1.1.3.4 Limitless replicative potential 
The proliferation of cells is not only regulated by the interplay of growth and anti-growth 
stimuli and apoptosis, but also by an intrinsic, cell-autonomous program that limits their 
ability to multiply to a finite number (Hanahan, Weinberg 2000). Each cell can only divide 
a certain number of times (approximately 60 to 70) and once this point is reached, the cell 
stops growing. Cells that have lost their ability to multiply are referred to as senescent 
cells. This is a natural phenomenon that is correlated to the length of telomeres present 
at the end of chromosomes. Telomeres have several thousand repeats of short, 6 base 
pair (bp), sequences of which 50 – 100 bp are lost with each replication and once a critical 
telomere length is reached, the cells lose their ability to divide further (Fouad, Aanei 2017). 
This loss occurs based on the inability of DNA polymerases to fully replicate the 3’ ends 
of chromosomes (Hanahan, Weinberg 2000).  
 
For this reason, aside from the independence of growth and anti-growth stimuli, a cancer 
cell must also be able to overcome the limitation of replication and to become immortal. 
This is commonly achieved through the maintenance of their telomeres, either through 
the upregulation of the enzyme telomerase, which can reconstitute the telomere length, 
or through the activation of a mechanism which prevents the shortening of the telomeres 
during replication. It has been shown that the upregulation of the enzyme telomerase is 
present in 85-90 % of human tumours (Fouad, Aanei 2017).  
1.1.3.5 Sustained angiogenesis 
Angiogenesis is the formation of new blood vessels through branching from pre-existing 
vessels and is a natural process in healthy tissue formation, which is tightly regulated by a 
balance of pro- and anti-angiogenic factors. New blood vessels are crucial for the supply 
of oxygen and nutrients to sustain a healthy cell function. It is also crucial for the survival 
of the cell and surrounding tissues, which are dependent on their formation and 
maintenance (Hanahan, Weinberg 2000). In order to expand beyond 1-2 mm in size, a 
tumour has to ensure a sufficient supply of oxygen and nutrients (Talmadge, Fidler 2010). 
For this reason, the tumour induces angiogenesis through the secretion of growth factors 
such as the vascular endothelial growth factor (VEGF) and acidic (FGF1) and basic 
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fibroblast growth factor (FGF2) and the inhibition of anti-angiogenic factors such as 
thrombospondin-1 (Hanahan, Weinberg 2000). 
1.1.3.6 Emerging hallmark: Reprogramming of energy metabolism 
Cancer cells not only have to enable the control of cell proliferation, but they also need 
to be able to supply the cells with sufficient amounts of energy to fuel the uncontrolled 
growth and division of cells (Hanahan, Weinberg 2011). Healthy cells normally use 
aerobic respiration to produce ATP. Here, glucose is broken down through glycolysis into 
pyruvate in the cytosol, which is then transferred and oxidised in the mitochondria. Under 
anaerobic conditions, glycolysis is favoured and less pyruvate is transported to the 
mitochondria meaning that energy is produced through lactic acid fermentation. Cancer 
cells alter their energy metabolism and seem to favour glycolysis under aerobic conditions. 
This altered behaviour of cancer cells was discovered by Otto Warburg and is described 
as the “Warburg effect” or “aerobic glycolysis” (Phan, Yeung et al. 2014). Contradictory 
to the fact that aerobic energy metabolism is 18-times more efficient compared to aerobic 
glycolysis, cancer cells are able to sustain and grow through aerobic glycolysis (Hanahan, 
Weinberg 2011). This is possible through an increased uptake of glucose into the cell, 
facilitated by the increased expression of glucose transporters on the cell surface, such as 
GLUT1 (Jones, Thompson 2009). Furthermore, aerobic glycolysis seems to be associated 
with the upregulation of oncogenes, such as RAS and MYC, and the suppression of 
tumour suppressors, such as TP53 (Hanahan, Weinberg 2011). The use of this approach 
for energy production enables the use of glycolytic intermediates in various biosynthetic 
pathways for the generation of nucleosides and amino acids (Hanahan, Weinberg 2011). 
Moreover, it was shown that this kind of energy metabolism is more frequently found in 
rapidly dividing cells, such as embryonic tissue. 
1.1.3.7 Emerging hallmark: Evasion of immune destruction 
The immune system is a host defence mechanism consisting of various biological 
structures and molecules, which enable the destruction of pathogens and outcomes of 
infection. The human immune system performs constant surveillance and is responsible 
for the recognition and elimination of malignant cells. However, some cancerous cells 
have acquired the ability to avoid the recognition of the immune system thus preventing 
their eradication (Hanahan, Weinberg 2011). 
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It has been shown that tumours have a higher infiltration of regulatory T cells (Tregs) 
(Takeuchi, Nishikawa 2016), which results in immune suppression and a poorer prognosis 
in many cancers. Furthermore, it is indicated that tumour-derived Tregs have a higher 
suppressive ability compared to naturally occurring Tregs (Vinay, Ryan et al. 2015). In 
addition to this, it was also shown that tumour suppressive cytokines are expressed at a 
higher level in the tumour microenvironment. Such cytokines include TGF-β, Th2 
cytokines (IL4/5/6/10/12), chemokines and VEGF (Burkholder, Huang et al. 2014). 
Tumours are also able to down modulate the machinery of antigen processing, mainly 
affecting the major histocompatibility complex (MHC) I pathway. This leads to a reduced 
recognition of the tumour through T lymphocytes and therefore and decreased survival 
rate (Vinay, Ryan et al. 2015).  
1.1.3.8 Tissue invasion and metastasis 
The result of successful establishment of a primary tumour mass commonly leads to the 
invasion of surrounding and adjacent tissue, and the spread of tumour cells to distant sites 
(Hanahan, Weinberg 2000). This invasion and spread are more commonly referred to as 
metastasis. Metastases are responsible for 90 % of cancer-related deaths (Sporn 1996). 
Their process involves multiple steps and is commonly described as the “invasion-
metastasis cascade” (Valastyan, Weinberg 2011). It should be noted that the process of 
metastasis is rarely successful and only 1 in 10 000 cells survives the transport to distant 
sites (Pecorino 2012). During the process of metastasis, cells detach from the main 
tumour, enter the blood or lymphatic system (intravasation), circulate through the body, 
leave the circulatory system (extravasation) and initiate growth at a distant site. For this, 
the new site needs to offer sufficient nutrients and oxygen. One process highly implicated 
in the development of metastasis is the epithelial to mesenchymal transition (EMT), which 
will be discussed further in section 1.3. 
1.1.3.9 Enabling characteristics: Genome instability and mutation and tumour-
promoting inflammation 
In addition to the hallmarks of cancer, which represent steps in the process of cells 
becoming cancerous, “enabling characteristics” can facilitate the acquisition of hallmarks.  
One of these characteristics is the development of genomic instability within cells. 
Through this process, random mutations are acquired, including chromosomal 
rearrangements. This instability supports the development of mutations that are needed 
to develop some of the prior mentioned hallmarks of cancer (Hanahan, Weinberg 2011). 
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Furthermore, within the last few years it has become more apparent that tumours and 
their microenvironment vary regarding their infiltration with immune cells. An increased 
immune response within the vicinity of the tumour was initially considered a response of 
the host to eradicate the tumour; however recent research highlighted the influence and 
promotion of tumour development through immune infiltration (Hanahan, Weinberg 
2011). Such a tumour promoting effect can be caused through the secretion of growth 
factors by the immune cells and through the release of reactive oxygen species, which can 
actively function as mutagens for nearby surrounding cells (Hanahan, Weinberg 2011). 
1.1.4 Causes of cancer - carcinogenesis 
The hallmarks of cancer indicate the steps a tumour is undergoing to successfully invade 
and grow inside the host. To acquire these abilities, the genetic code of the DNA is altered. 
This occurs commonly through damage induced to the DNA, whereas single unrepaired 
mutations will increase the accumulation of further mutations. This enables mutated cells 
to behave in an autonomous manner and to develop abilities, such as stimuli-independent 
cell proliferation and tissue invasion, which was described previously. 
  
Over the years, it was shown that cancers caused by hereditary mutations only represent 
a small proportion of cases. Around 90 to 95 % of all cancers are developed through 
exogenous factors as part of the environmental exposure, such as smoking, dietary habits 
and infections, whereas only 5 – 10% of all cancers are induced through hereditary genetic 
mutations, (Anand, Kunnumakara et al. 2008) such as in the BRCA1 and BRCA2 genes 
(King, Marks et al. 2003). This was further supported by a study, which has highlighted 
that the chance of being diagnosed with cancer is more strongly influenced by the country 
you live in rather than by the country you came from (Anand, Kunnumakara et al. 2008), 
indicating that the cancer risk is highly associated with living standard, life style and dietary 
behaviour.   
 
One of the most commonly known inducers of cancer are the chemicals within tobacco 
smoke, that contains at least 40 different carcinogenic compounds, such as formaldehyde 
or benzene (Hecht 2006). Such carcinogenic compounds can lead to the development of 
mutations and altered cellular pathways, such as the NF-κB pathway. An active NF-κB 
pathway leads to the expression of cell proliferative genes and protects the cells from 
apoptosis (Xia, Shen et al. 2014). Alcohol is another environmental factor that increases 
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the risk for the development of cancer if consumed regularly. Furthermore, this damage 
is amplified if alcohol consumption and smoking are performed in parallel. Alcohol not 
only facilitates the entry of benzopyrene into the oesophagus (Anand, Kunnumakara et 
al. 2008), but alcohol consumption can also activate the NF-κB pathway (Wang, F., Yang 
et al. 2015). 
 
Eating habits can also influence the risk and the development of cancer. A heavy 
consumption of red meat is associated with cancers of the gastrointestinal tract (Bouvard, 
Loomis et al. 2015). Furthermore, the consumption of charcoaled meat leads to the 
ingestion of carbon compounds such as pyrolysates and carcinogenic amino acids. Further 
food additives, such as nitrites and nitrates, also present carcinogens. In close connection 
to food habits stands the factor of obesity. Obesity is associated with increased risks for 
the development of various cancers (Calle, Kaaks 2004) such as cancer of the colon and 
breast. This is caused through the altered regulation and expression of hormones, 
including insulin and an increased activity of inflammatory pathways, such as JAK/STAT 
and NF-κB. 
 
Viruses are a main contributor to infection-caused cancers and the most well-known virus 
is the Human Papilloma Virus (HPV). Various types of this virus were shown to be largely 
contributing to the development of cervical cancer (Burd 2003). The HPV types 16 and 
18 alone cause 70 % of cervical cancers (WHO, 2019b). Based on its large contributions, 
a vaccine designed against these HPV types has been created to protect women from 
developing ovarian cancer that occurs due to HPV infection (Shukla, Shirish, Bharti et al. 
2009, Wu, Guo et al. 2003).  
 
Further factors that can increase cancer risk and introduced DNA damage are 
environmental pollutants, such as radiation or air pollutions. There are two main types of 
radiation that can cause cancer, namely ionising radiation and electromagnetic radiation. 
Ionising radiation can directly cause damage to the DNA and results in the development 
of reactive oxygen species (ROS). Such radiation can be the results of atomic fallout, as 
that caused during the atomic bombing of Japan (Douple, Mabuchi et al. 2011). 
Ultraviolet (UV) radiation belongs to the group of electromagnetic radiation and is highly 
associated with the development of skin cancer based on DNA damage and genetic 
mutations (Narayanan, Saladi et al. 2010). A well-known indoor-air pollutant with strong 
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implication in the development of lung cancer and mesothelioma is asbestos. Asbestos is 
a fibrous material, which was commonly used for insulation purposes. Based on its 
carcinogenic nature, it is now banned from use in many countries. Exposure to asbestos 
can result in chromosomal aberrations, ani- and polyploidy as well as epigenetic 
modifications (Pecorino 2012). 
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1.2 Prostate Cancer 
1.2.1 Prostate anatomy  
The prostate is a gland of the male reproductive system approximately the size of a large 
walnut and is surrounded by the prostatic capsule. It is located in the pelvis, surrounds 
the urethra, sits below the bladder and is anterior to the rectum. Due to its anatomical 
position, its texture can be examined through rectal examination. The prostate can be 
divided into three distinct zones called the central, transitional and peripheral zone, which 
differ both histologically and anatomically (Fig. 1.4) (Aaron, Franco et al. 2016, Lee, Akin-
Olugbade et al. 2011). Some publications indicate a fourth zone, which is referred to as 
the fibromuscular zone (Dunn, Kazer 2011). Each zone differs in their embryological 
origin and can be distinguished by their histological appearance, biological function and 
development of pathologic disorders (Lee, Akin-Olugbade et al. 2011). This variant 
susceptibility to pathological diseases is illustrated by the fact that the majority of PCa (70 
to 75 %) develop in the peripheral zone and are defined as adenocarcinomas (Lee, Akin-
Olugbade et al. 2011, Kulasingam, V., Diamandis 2008a, Dunn, Kazer 2011). The 
transitional zone on the other hand is rarely a source of PCa, however it is the exclusive 
site for the development of benign prostatic hyperplasia (BPH) (Ward, Catto et al. 2001). 
 
 
 
 
  
This image has been removed by the author for copyright reasons 
 
 
 
 
 
 
Figure 1.4: Schematic representation of prostate anatomy showing three distinct zones within the prostate  
(Valkenburg, Williams 2011). The prostate is divided into the peripheral, transition and central zone. 
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1.2.2 Incidence, risk factors and clinical presentation of prostate cancer 
Prostate cancer is defined as the development of malignant cell growth in the prostate. It 
is the most common cancer in men in Europe and the third most common cancer overall. 
In 2014 around 47 000 men in the UK were diagnosed with PCa (Cancer Research UK, 
2017a), whereas the highest incidence rate was shown in men between the ages of 65 and 
69 (Fig. 1.5). 
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Figure 1.5: Age-specific cases of prostate cancer diagnoses in 2013-2015 in the UK. (Based on a graphic 
created by Cancer Research UK, Cancer Research UK, 2018c)  
 
In Europe, PCa represents the third most common cause of cancer-related deaths, with a 
death rate of about 11 300 men in the UK in 2014 (Cancer Research UK, 2017b). The 
death rates due to prostate cancer highly correlated with age and increase sharply from 
around age 55 with the highest rate in the 90+ age group (Fig. 1.6) (Cancer Research UK, 
2017b). Reduced chances of survival are correlated with the stage of prostate cancer at 
the time of diagnosis and increased mortality is mainly due to the development of 
metastasis. About 4 % of PCa patients will develop metastases, which reduces their 5-year 
survival rate to only 30 % (Thobe, Clark et al. 2011). 
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Figure 1.6: Age-specific cases of prostate cancer-associated deaths in 2012-2014 in the UK (Based on a 
graphic created by Cancer Research UK, Cancer Research UK, 2018d). 
 
Recent statistics indicate that 1 in 8 men will develop PCa within their lifetime (Prostate 
Cancer UK, 2017a), however, not each case will be diagnosed and many will remain 
without symptoms. Through post-mortem analysis it was shown that many more men die 
with PCa than from it (Dunn, Kazer 2011).  
 
There are three major risk factors for the development of PCa; age, ethnic origin and 
genetic predisposition. Furthermore, having a first-degree relative with PCa increases the 
risk of developing the disease by 2-fold (Dunn, Kazer 2011). Studies in the US have shown 
a lifetime risk for the development of PCa is 18.25 % in African-American and 15.25 % 
in Caucasians. However, the probability of dying through PCa during the lifetime is 2-
fold higher in African-American men compared to men from Caucasian descent (Dunn, 
Kazer 2011). 
 
In PCa, the late onset of symptoms, which are often nonspecific to cancer, increases the 
difficulty in diagnosis and therefore reduces the chance for the successful prevention of 
metastasis. Currently employed diagnostic tools are unable to predict whether a tumour 
will spread or has already spread. For this reason, the identification of biomarkers that 
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will help to elucidate the aggressiveness of a tumour and its future development will 
drastically increase the chances of survival for the patient.  
1.2.3 Prostate cancer diagnosis and limitations of currently available 
diagnostic tools  
One of the crucial aspects of PCa development is that it remains, in most cases, 
asymptomatic and often symptoms arise once the tumour is present at an advanced stage 
or has metastasised (Dunn, Kazer 2011). Despite this, there is currently no routine 
screening of all men performed. The lack of a robust screening program is based on the 
limited performance of currently available detection tools, which can lead to false-positive 
and false-negative results (Slatkoff, Gamboa et al. 2011, Lin, K., Croswell et al. 2011). 
 
For this reason, patients that are initially categorised into a group of increased risk are 
subjected to further tests. Factors that result in the classification to a high risk group are 
aspects such as age, ethnicity, family history or obesity. The next step for these patients 
in commonly the measurement of prostate-specific antigen (PSA) in the serum (Section 
1.2.3.1). Elevated levels might indicate the presence of PCa and warrant therefore the 
further examination using digital rectal examination (DRE) and transrectal ultrasound 
(TRUS) guided biopsy (Heidenreich, Bastian et al. 2014a) (Section 1.2.3.2).  
1.2.3.1 Prostate specific antigen (PSA) 
As previously mentioned, the only marker which is currently in routine use in the 
diagnostic and surveillance of PCa, is called prostate specific antigen (PSA). PSA is 
encoded by the KLK3 genes and is also known as kallikrein-3 and gamma-seminoprotein. 
Other members of the kallikrein family, as well as PSA, are expressed in multiple tissues 
including many that are steroid hormone regulated (Balk, Ko et al. 2003), such as the 
prostate. The protein is secreted by the prostate gland and is a major component of 
seminal fluid. PSA levels are measured in the serum for the diagnosis and surveillance of 
PCa, however, its utility and contribution to the patient’s health and survival are regularly 
under debate and constant efforts are made for the discovery of better biomarkers 
(Prensner, Rubin et al. 2012).  
 
As the name already indicates, PSA is not a marker for PCa but is generally associated 
with the prostate. Increased PSA levels can be associated with PCa but can also be 
elevated in other prostatic diseases such as benign prostatic hyperplasia (BPH) and 
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prostatitis (Chiam, Ricciardelli et al. 2014). In addition to this, no defined PSA value is 
descriptive for a secure positive or negative cancer diagnosis and the measured 
concentration should be considered a continuous value. Despite this, serum PSA levels 
of 0 to 4.0 ng/ml are considered to be within the normal range, whereas a concentration 
above 4.0 ng/ml may warrant follow-up screening, but this would be dependent on 
further factors such as age, ethnicity and family history (Dunn, Kazer 2011). Normally, 
DRE and potentially a TRUS biopsy will be performed to secure the diagnosis and to 
adjust the treatment options available for each patient based on the tumour stage and 
grade. 
 
A higher PSA concentration suggests an increased likelihood for the presence of PCa, 
however patients with low PSA levels have also subsequently demonstrated the presence 
of cancer after follow-up. Due to its variable nature, PSA testing can lead to false-positive 
diagnoses and over-treatment of healthy patients, as well as overlooked and missed cases 
of diseased patients. Furthermore, in recent years it was discovered that single nucleotide 
polymorphisms within KLK3 influences the serum levels of PSA (Filella, Foj 2016) and it 
was suggested that a genetic analysis of KLK3 was performed in addition to routinely 
performed PSA testing (Filella, Foj 2016).  
 
The increased PSA levels are based on the increased disruption of epithelial cell 
attachments within the prostate basal membrane and luminal secretions of the tumour 
cells. Later stage PCa invades stromal layers and the blood circulation through the total 
loss of glandular organisation (Kulasingam, V., Diamandis 2008a, Romero Otero, Garcia 
Gomez et al. 2014). This enables cancerous cells to spread throughout the body and can 
lead to increased chances for the development of metastasis.  
 
PSA exists in various forms throughout its cellular processing from its mRNA to the final 
protein (Fig. 1.7). Some forms have shown, either alone or in combination, increased 
specificity and sensitivity for PCa compared to the common measurement of total PSA. 
ProPSA represents an inactive pro-enzyme which has a 7 amino acid long leader peptide. 
This leader peptide is cleaved by HK2 or HK4 to produce active PSA. ProPSA is also 
present in three truncated isoforms, of which [-2]proPSA presents the most stable form. 
This isoform was shown to be highly associated with PCa compared to BPH and could 
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be used for early detection as well as the definition of aggressiveness of a tumour (Saini 
2016a).  
 
Another use of PSA and its various forms was suggested by using the prostate health 
index (PHI). This consists of three PSA biomarkers, which are used in the following 
formula: [-2]proPSA/free PSA)*√PSA (Catalona, W. J., Partin et al. 2011). The PHI is 
considered to be of use for patients with a PSA range of 4-10 ng/ml and a normal DRE 
result. It contributes to the reduction of unnecessary biopsies (Saini 2016a).  
 
 
Figure 1.7: Schematic representation of PSA and its derivatives from its mRNA to the final protein, 
functioning as potential biomarker for PCa detection and monitoring (Saini 2016b). Chr. = Chromosome, 
KLK3 = Kallikrein-3, PSA = prostate specific antigen, cPSA = complexed PSA, bPSA = benign PSA, iPSA 
= intact PSA, ACT = alpha(1)-antichymotrypsin, hk-2 = human kallikrein-2, hk-4 = human kallikrein-4, 
PSA isoforms = [-5]proPSA, [-4]proPSA, [-2]proPSA. Graph adapted from (Hatakeyama, Yoneyama et al. 
2017). 
1.2.3.2 Other currently studied potential biomarkers for the detection of PCa 
PSA and its various forms are not the only potential biomarkers associated with PCa. 
Continuous research is focussed on the discovery of novel, more improved biomarkers 
for the screening and prognosis of PCA.  
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A well-studied marker for the diagnosis of PCa and differentiation from benign cases is 
the α-methylacyl coenzyme A racemase (AMACR). This enzyme is highly overexpressed 
in PCa compared to benign cases. In a study comparing PCa with benign prostate tissue, 
AMACR was detected in more than 90 % of the PCa cases and in less than 20 % of the 
benign prostate cases (Jiang, Zhu et al. 2013).  
 
PCA3 is a novel potential biomarker for PCa. It was initially described as DD3 
(Bussemakers, van Bokhoven et al. 1999), where it was shown to have an increased 
expression in prostate cancer tissue compared to non-neoplastic prostate tissue. 
Furthermore, it could not be quantified in healthy tissue, including the prostate. This 
marker can be detected in urine, which presents a minimal invasive screening method.  
 
PCA3/DD3 originates from a non-coding region and its function is still mainly unknown 
(Wang, Y., Liu et al. 2014). However, work on PCA3 in prostate cancer has shown that 
the inhibition of PCA3 through transfection leads to a significant decrease in cell viability 
and growth in LNCaP cells (Ferreira, Palumbo et al. 2012). It also shows a high specificity, 
ranging between 80 and 90 %, in the diagnosis of PCA, which could potentially lead to a 
reduction in unnecessary biopsies and over-treatment. (Roobol, Haese et al. 2011). 
However, dependent on the applied PCA3 score cut-off, lower sensitivities (58 %) and 
specificities (72 %) were detected (Marks, Fradet et al. 2007). This indicates that the 
clinical utility of PC3 varies based on the study and the applied cut-off of detection.  
 
Another potential biomarker that is detectable in the urine is the fusion gene 
TMPRSS2:ERG. It is generally caused by an interstitial deletion at the locus 21q22 and a 
reciprocal translocation (Gleason 1966, Romero Otero, Garcia Gomez et al. 2014) and is 
present in about 50  % of PCa cases (Hagglof, Hammarsten et al. 2014). The 
Transmembrane Protease, Serine 2 (TMPSS2) gene transcriptional promotor is strongly 
regulated through the stimulation with androgens (Lin, B., Ferguson et al. 1999, Roobol, 
Haese et al. 2011) and the ETS transcription factor (ERG), which is an oncogene. 
Through its function as a transcription factor for genes in the ETS family, it is directly 
involved in cell proliferation, angiogenesis and differentiation. TMPRSS2:ERG can be 
detected in the urine after prostate massage and shows a high specificity and sensitivity; 
however, it shows a low frequency in some populations (Romero Otero, Garcia Gomez 
et al. 2014).  
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Reliable screening methods for PCa are urgently needed, but currently available tools lack 
specificity and sensitivity. A very important aspect in the management of prostate cancer 
is the ability to distinguish indolent PCa from aggressive disease. Unfortunately, PSA is 
unable to perform this task. The other presented markers, AMACR, PC3 and 
TMPRSS2:ERG present potentially useful biomarkers for the detection and disease 
surveillance of PCa, however, none of these markers have been routinely implemented in 
clinical settings and further clinical validation is needed.  
1.2.3.2 Clinical approaches for the detection and diagnosis of PCa 
As mentioned previously, patients that were categorised into a high risk group are 
subjected to PSA testing. If the test results show abnormal values or if symptoms could 
be based on the development of PCa, further examinations are performed to confirm the 
presence or absence of PCa. These further examinations include digital rectal examination 
(DRE) and biopsy approaches.  
1.2.3.2.1 DRE – Digital Rectal Examination 
Digital rectal examination (DRE) is a routine test for the screening of PCa, commonly 
performed after an abnormal PSA test showing elevated blood levels. Here, a rectal 
examination of the prostate is performed for the feeling of irregularities in size, shape and 
texture and for the presence of lumps. DRE is only of limited use for small tumours and 
lacks sensitivity for their detection (Woolf, MD, MPH, Steven H, Rothemich 1999). 
Furthermore, irregularities, such as an enlarged prostate, are only an indication for the 
presence of prostate cancer and the results of a DRE should be followed up with further 
diagnostic testing.  
1.2.3.2.2 Biopsy approaches 
Biopsies are not routinely applied screening methods, but normally follow elevated PSA 
concentrations and/or abnormal DRE results. For further clarification as to the potential 
presence of PCa a biopsy is performed. The guidance of the sample taking can be 
performed either through ultrasound, such as in the transrectal ultrasound (TRUS) guided 
imaging technique, and more recently through magnetic resonance imaging (MRI).  
TRUS guided biopsies present a sampling error >20 %, which is based on the inability of 
an ultrasound to image a clear difference between prostate and cancerous tissue (Peltier, 
Aoun et al. 2015). MRI-guided biopsies enable the identification of lesions within the 
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prostate, which enables a more targeted sampling. For this reason, MRI-guided biopsies 
outperform TRUS-guided.  
1.2.4 Staging and grading 
PCa is the most commonly diagnosed cancer in men and a crucial factor for patient 
survival is the accurate grading of the tumour. It is vital that this occurs in a uniform 
manner to ensure an accurate prediction of the tumour behaviour and an optimal selection 
of treatment (Cheng, Liang, Montironi et al. 2012). Currently, there are two major staging 
systems applied in clinical practice, the pathological based Gleason scoring and the 
Tumour-Node-Metastasis (TNM) staging based on clinical parameters. Gleason scoring 
is based on the histological appearance of tumour material within the prostate, whereas 
the TNM staging is considered to be clinical staging based on multiple clinically assessed 
parameters (Dunn, Kazer 2011).  
1.3.4.1 Gleason scoring 
Gleason scoring was developed by Dr Donald F Gleason (Gleason 1966). A reason for 
its success and wide application was its successful validation in about 5000 patients. The 
system is based on the pathological inspection of prostatic tissue sections and the 
categorisation of carcinoma cells into histological patterns (Humphrey 2004). The system 
uses five grades, which are used to calculate a score based on the sum of the first and 
second most prominent patterns. The differentiation of cells decreases from stage one to 
stage five (Fig. 1.8). Grade one presents well differentiated growth of closely packed, 
round and uniform acini (Humphrey 2004), whereas grade 5 tissue does not present any 
glandular differentiation and has lost resemblance to healthy prostate tissue. Gleason 
scoring is an important tool for the prediction of outcome of PCa patients.  
 
Currently there are some debates about the differences of Gleason 7, which can be 
generated through 4+3 and 3+4 presented morphologies within the tumour specimen. 
Studies have shown that disease outcome varies depending on the prominence of stage 4 
tissue (Stark, Perner et al. 2009). A study comparing disease outcome in patients with both 
categories of Gleason 7 has shown a three-fold higher likelihood of lethal PCa in patients 
with 4+3 compared to 3+4 (Stark, Perner et al. 2009). A further study has also shown a 
higher risk of cancer related mortality in cases of 4+3 compared to 3+4 (Wright, Salinas 
et al. 2009).  
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Another debate is regarding the Gleason score 6 and whether or not it should be 
categorised as cancer. A change in its category could have serious implications on the 
patient’s treatment and disease outcome. Autopsies on men over 50 have frequently 
identified the presence of Gleason 6 PCa. On a histological basis, Gleason 6 PCa is 
fulfilling the histopathological requirements to be defined as PCa; however, some 
scientists argue that Gleason 6 cancer does not fulfil all 6 hallmarks of cancer (section 
1.1.3), and should therefore be treated differently (Carter, Partin et al. 2012, Eggener, 
Badani et al. 2015). A study on more than 14 000 patients with a Gleason score of six and 
below, which underwent radical prostatectomy, has shown in only 22 cases an 
involvement of the lymph nodes (Ross, Kryvenko et al. 2012). This supports the idea that 
active surveillance offers a favourable option for patients with Gleason 6. 
 
 
 
 
 
This image has been removed by the author for copyright reasons 
 
 
 
 
 
 
Figure 1.8: Schematic representation of tissue differentiation in PCa across the 5 Gleason scores (PCEC, 
2019). Increased Gleason scoring correlated with decreased tissue differentiation.  
 
1.3.4.2 Tumour – Nodes – Metastasis (TNM) Staging 
TNM staging (Tab. 1.1) is a pathological staging method for the characterisation of solid 
tumours and is used to describe the tumour and its current state in more detail. T stands 
for the primary tumour and its potential invasion into surrounding tissue. N describes 
lymph node involvement and M stands for metastasis and gives information regarding 
tumour spread to distant sites (Sobin, Gospodarowicz 2009). The involvement of lymph 
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nodes is one of the most important prognostic factors and the aggressiveness of PCa is 
closely linked to the tumour volume (Cheng, Liang et al. 2012).  
 
 
Table 1.1: Summary of the TNM classification system  adapted from (Sobin, Gospodarowicz 2009) 
T – primary tumour 
TX Primary tumour cannot be assessed 
T0  No evidence of primary tumour  
T1  
(T1a, T1b, T1c) 
Tumour does not cause any sign of symptoms. Tumour cannot be 
detected though palpation or digital imaging. However, 
histopathological analysis can detect the presence of malignant 
cells.  
T2  
(T2a, T2b, T2c) 
Tumour can be detected with DRE but is still confined within the 
prostate. Subcategories describe size and penetration of the tumour 
within the prostate capsule.  
T3  
(T3a and T3b) 
Tumour extends outside the prostate capsule. Subcategories 
describe the extension into further detail.  
T4 Tumour has invaded tissues outside the prostate and seminal 
vesicles and has spread to nearby organs, such as the bladder or 
lymph nodes.  
N – Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed.  
N0 No metastasis found in regional lymph nodes. 
N1 Metastasis found in regional lymph nodes.  
M – Distant metastasis 
M0 No distant metastasis present 
M1  
(M1a, M1b, M1c) 
Distant metastasis. Subtypes describe the location of the 
metastases.  
 
Through the combination of the defined TNM stages, Gleason score and PSA levels, the 
tumour can be attributed to a certain stage and the stages range from I to IV (Cheng, 
Liang et al. 2012).   
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1.3.4.3 D’Amico risk classification system 
A further risk classification system is the D’Amico scoring. This system is designed to 
categorise patients into 3 distinct groups of risk for recurrence of PCa after radical 
prostatectomy through the combination of TNM stage, biopsy Gleason score, and the 
PSA level prior to surgery (Tab. 1.2) (D'amico, Whittington et al. 1998) (Tab. 1.2). 
 
Table 1.2: D'Amico risk classification system to categorise patients for risk of prostate cancer recurrence 
after radical prostatectomy . Risk classification is based on Gleason score, TNM stage and PSA levels prior 
surgery. Adapted from: (D'amico, Whittington et al. 1998) 
D’Amico Risk 
Group 
Gleason Score TNM Stage 
Pre-operative serum 
PSA (ng/ml) 
Low Risk ≤6 T1 or T2a <10 
Intermediate Risk ≤6-7 T1 or T2a/b 10-20 
High Risk 
≤7 T1 or T2a/b/c >20 
8-10 T1 or T2a/b/c Any PSA 
1.3.5 Treatment options available for PCa 
The treatment options vary based on the type of PCa present (Tab. 1.3). Low-risk PCa 
are patients with clinically confined PCa (T1-T2) and a Gleason score below six, 
additionally the PSA should be below 10 ng/ml (Heidenreich, Bastian et al. 2014a). These 
patients are normally subjected to active surveillance, which means that the patients are 
initially not treated and the development of the disease is checked in regular intervals to 
ensure the tumour does not progress. In case of disease progression, the treatment is 
performed with curable intent, through active treatment. Active treatment options include 
radical prostatectomy, which is the only surgical treatment for localised PCa. Furthermore, 
localised PCa can be treated using radiation therapy and low-dose-rate brachytherapy. 
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Table 1.3: Summary of treatment options for PCa according to the stage of PCa. Adapted from 
(Heidenreich, Bastian et al. 2014a, Heidenreich, Bastian et al. 2014b) 
Stage of PCa Treatment options 
Localised PCa Active surveillance 
Localised/locally 
advanced PCa 
Radical prostatectomy 
External Beam Radiation Therapy 
Permanent seed brachytherapy 
Cryotherapy 
High-intensity focused ultrasound 
Advanced PCa Hormone Therapy 
 Chemotherapy 
 
Advanced PCa patients presenting metastatic disease or castrate resistant PCa (CRPC) are 
commonly subjected to a different treatment regime compared to localised, low risk PCa 
patients (Heidenreich, Bastian et al. 2014a, Heidenreich, Bastian et al. 2014b). The 
intention of treatment is commonly focussed on the management of the disease and the 
improvement of life quality rather than curing the disease. Such treatment includes 
hormone and chemotherapy. Hormone therapy aims to block the access of PCa cells to 
dihydrotestosterone. Testosterone is commonly required by PCa cells for their growth 
and proliferation, however, commonly after a mean time of 2 to 3 years, PCa cells develop 
an independence from testosterone (Karantanos, Corn et al. 2013). The cancer is then 
described as CRPC. The treatment choice for these patients is limited and they commonly 
receive chemotherapy, however a substantial proportion of men do not benefit from this 
treatment and only small improvements in the overall median survival of CRPC patients 
can be achieved (Teply, Hauke 2016).  
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1.3 Metastasis and epithelial to mesenchymal 
transition (EMT) 
The discovery of a molecular pathway involved in the development of metastasis, called 
epithelial to mesenchymal transition, presented an important step for the understanding 
of metastasis and for the future discovery of novel prognostic biomarkers (Das, R., 
Gregory et al. 2014). 
1.3.2 Types of epithelial to mesenchymal transition (EMT) 
EMT is an evolutionary highly conserved developmental process (Lim, J., Thiery 2012). 
The first pioneering work on EMT was performed by Elizabeth Hay, who observed the 
process in chick embryos and described it originally as epithelial-mesenchymal 
transformation (Greenburg, Hay 1982). Here, polarised epithelial cells, which are attached 
to a basement membrane and the neighbouring cells, undergo biochemical changes to 
acquire mesenchymal cell properties. These changes result in an altered gene expression, 
which leads to increased motility through the degradation of intracellular contacts, 
increased invasiveness, migratory potential and resistance to apoptotic signals (Kalluri, 
Weinberg 2009). Morphologically this is visible through the change from a “cobblestone” 
morphology with highly organised cells to solitary, spindle-shaped cells with a fibroblastic 
morphology (Thiery, Sleeman 2006). On a molecular level these changes are shown 
through a reduction of epithelial gene expression and an increase in mesenchymal 
associated genes. These changes are based on multiple molecular alterations such as the 
activation of EMT specific transcription factors, an altered expression of cell-surface 
proteins, additional changes in the expression of cytoskeletal proteins, microRNAs and 
the production of ECM-degrading proteins. Major genes associated with epithelial cells 
include E-cadherin (CDH1) (Pećina-Šlaus 2003), and genes associated with mesenchymal 
cells include N-cadherin (CDH2) (Zeisberg, Neilson 2009), Vimentin (VIM), Fibronectin 
(FN1) (Sudo, Iwaya et al. 2013) and metalloproteases (MMPs) (Lozito, Tuan 2011). The 
key players involved with the process of EMT are highly conserved and can be found 
across multiple species (Heerboth, Housman et al. 2015). Furthermore, this process is not 
unidirectional and it should be highlighted that the cells can reverse the process back into 
an epithelial morphology. This is called mesenchymal to epithelial transition (MET) (Lim, 
J., Thiery 2012). 
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During two consecutive meetings, which took place in 2007 in Poland and in 2008 at Cold 
Spring Harbor Laboratories, three distinct EMT subtypes were defined (Kalluri, 
Weinberg 2009). In general, EMT is considered to be a normal and healthy biological 
process, which plays an important role during embryogenesis (Micalizzi, Farabaugh et al. 
2010) and wound healing (Zeisberg, Neilson 2009), but is re-activated during cancer 
progression (Nieto 2013).  
 
Type I EMT is involved during multiple stages of embryonal development, including the 
implantation of the embryo and the formation of the placenta. After fertilisation, the 
embryo undergoes gastrulation, in which the three germ layers are formed. During this 
process, EMT is occurring when cells migrate into predefined regions of the embryo (Lim, 
J., Thiery 2012). These migratory cells are then involved in heart morphogenesis, where 
they undergo multiple cycles of EMT and MET. This process is also initiated during 
gastrulation to develop multiple compartments of the heart.  
 
Type II EMT is involved in wound healing and organ fibrosis and is mediated and directed 
by inflammatory cells and fibroblasts (Kalluri, Weinberg 2009). Type II EMT 
differentiates from Type I EMT through the generation of fibroblasts instead of 
mesenchymal cells. Here, the process is commonly induced through inflammatory signals 
or tissue damage and is normally limited with the end occurring at cessation of the healing 
process (Foroni, Broggini et al. 2012). The third type of EMT is involved in the spread of 
cancerous cells and the subsequent development of metastasis at distant sites and will be 
discussed in further detail in the following section (1.3.2.1). 
1.3.2.1 Type III EMT: Cancer progression and metastasis – the Invasion-
Metastasis Cascade 
As mentioned previously the process of EMT is part of a healthy functioning biological 
system. However, during the development of cancer this process, also described as the 
“invasion-metastasis cascade”, is utilised in the development of metastasis and hence 
cancer progression (Fig. 1.9) (Kalluri, Weinberg 2009). Here the cells lose their apical-
basal cell polarity (Acloque, Adams et al. 2009), invade the surrounding extracellular 
matrix (ECM) and stromal cell layers, intravasate into blood or lymphatic vessels, through 
which they are dispersed throughout the body. To sustain this process, the cells must 
show an increased survival capability, for example through the development of resistance 
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to anoikis. Anoikis is a form of programmed cell death, which takes place when an 
anchorage-dependent cell detaches from the associated ECM (Frisch, Screaton 2001).  
Following resistance to anoikis-induced cell death and circulation throughout the body, 
the cells extravasate from the circulatory system and into the tissue, where they are able 
to adapt to the new host microenvironment, colonise and develop secondary tumours 
(Valastyan, Weinberg 2011). Despite the access of these cells to the lymphatic and blood 
circulatory systems and their potential to initiate tumour growth in various organs, certain 
cancer types show preferred sites of secondary tumours, for example PCa metastases are 
commonly found in the bones, lungs and liver (Bubendorf, L., Schopfer et al. 2000).  
 
 
 
 
 
 
This image has been removed by the author for copyright reasons 
 
 
 
 
 
 
Figure 1.9: The invasion-metastasis cascade describing the process of tumour spread from the primary 
tumour to a distant site (Valastyan, Weinberg 2011) 
 
EMT is a highly conserved process, which presents highly similar molecular processes 
across all three types of EMT (Foroni, Broggini et al. 2012, Heerboth, Housman et al. 
2015). The process can be triggered through intra- and extracellular stimuli, including 
growth factors such as TGF-β, HGF, EGF and IL-6, and as a response to hypoxia, 
tumour-stromal cell interactions and chemotherapy (Foroni, Broggini et al. 2012, Kalluri, 
Weinberg 2009).  
The main indicator for the induction of EMT is the loss or reduction of E-cadherin 
expression, which also represents a hallmark of EMT (Serrano-Gomez, Maziveyi et al. 
2016). E-cadherin is a calcium-dependent cell surface protein, which is involved in the 
cell adhesion of epithelial cells (Liu, F., Gu et al. 2016) and it limits the expression of 
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mesenchymal genes (Garcia de Herreros 2014). Its reduced expression is caused through 
the induction of a set of highly conserved transcription factors, so called EMT-TFs, 
including SNAI1, SNAI2, TWIST, ZEB1 and ZEB2. They suppress, upon activation, the 
expression of epithelial markers and induce genes associated with mesenchymal cells. 
SNAI1, ZEB1 and TWIST are all individually able to induce EMT in most cell lines. 
ZEB1 can directly repress the expression of E-cadherin, whereas TWIST is involved 
downstream in the induction of mesenchymal genes (Lamouille, Xu et al. 2014). In 
contrast to these, SNAI1 is involved in both tasks (Garcia de Herreros 2014). Aside from 
this, the transcription factors show a timely difference in their response. SNAI1 is the 
first factor to be induced. In cell culture systems its expression was detectable as early as 
30 min after TGF-β treatment, followed by ZEB1 and other mesenchymal markers after 
more than 4 h (Garcia de Herreros 2014). The interplay of the EMT-TFs leads to a 
widespread alteration in gene expression (Tab. 1.4), which is a major field of research. 
However, the commonly studied genes for the validation of EMT induction are coding 
for the intermediate filament protein vimentin (VIM), the trans-membrane protein N-
cadherin (CDH2), the glycoprotein fibronectin (FN1) and the cell-adhesion protein E-
cadherin (CDH1).  
 
Table 1.4: List of genes and proteins associated with the process of EMT, their expression changes and 
impact on cellular functions.  (adapted from (Foroni, Broggini et al. 2012)) 
Upregulated genes Downregulated 
genes 
Activation of Changes in cellular 
functions 
Vimentin (VIM) E-cadherin (CDH1) β-catenin Increased invasion 
N-cadherin 
(CDH2) 
Desmoplakin SMAD2/3 Increased migration 
Fibronectin (FN1) Cytokeratin NF-κβ Chemotherapy 
resistance 
SNAIL (SNAI1) Occludin SNAIL Increased resistance to 
apoptosis SLUG (SNAI2) Claudin SLUG 
TWIST miRNA200 family TWIST  
ZEB1/2  ZEB1/2  
Goosecoid (GSC)    
FOXC2    
MMP2/3/9    
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1.3.3 Transforming growth factor β and the TGF-β superfamily 
Transforming growth factor β is a ligand that performs two opposite tasks within cancer 
development and progression. In early stage tumours, TGF-β functions as a tumour 
suppressor ligand through the promotion of cell cycle arrest and the induction of 
apoptosis, however in late stage cancer, TGF-β increases cell motility, invasion and 
metastasis as well as cell “stemness” (Neuzillet, Tijeras-Raballand et al. 2015). This change 
is described as the “TGF-β paradox”.  
 
The TGF-β superfamily consists of multiple secreted homodimeric signalling proteins 
(Hinck 2012), including the three isoforms; transforming growth factor β1 (TGFB1), β2 
(TGFB2) and β3 (TGFB3). TGF-β1 is the most studied isoform. These three isoforms 
share about 70  % homology within their sequence (Lebrun 2012), are synthesised in the 
cell and are secreted in a latent dimeric form into the extracellular matrix. Here, the latent 
TGF-β is activated through the cleavage by furins and other convertases (Padua, 
Massagué 2009). The active TGF-β isoform can then induce the TGF-β signalling cascade 
by binding to surface receptors. The receptors can be grouped in 3 categories, consisting 
of 7 type I, 5 type II and 1 type III receptor. These receptors are paired in different 
combinations to form receptor complexes for the members of the TGF-β superfamily 
(Padua, Massagué 2009). Other members include bone morphogenic proteins (BMPs), 
which are involved in the embryonic development, and growth and differentiation factors 
(GDFs) (Hinck 2012).  
1.3.4 Transforming growth factor β as an inducer of EMT 
As mentioned previously, EMT can be induced through various growth factors. The first 
described and most commonly used cytokine in the study of EMT is TGF-β (Fig. 1.10) 
(Serrano, McDonald et al. 2013, Iordanskaia, Nawshad 2011, Raghavan, Smuda et al. 
2016).  
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Figure 1.10: TGF-β signalling pathways and resulting genes responses upon activation (Padua, Massagué 
2009) 
 
TGF-β present in the microenvironment of a cell can bind to the TGF-β receptor II 
(TGFBR2), which leads to the formation of a heterotetrameric active receptor complex 
and results in the unidirectional phosphorylation of a 30-amino-acid regulatory segment 
called the GS region of the TGF-β receptor I (TGFBR1) (Padua, Massagué 2009). This 
phosphorylation activates the complex and through this, signalling through SMAD-
dependent and SMAD-independent cascades (Pickup, Novitskiy et al. 2013) (Fig.1.11) 
can occur. TGF-β receptor III (TGFBR3) is not directly involved in the signalling cascade 
induced through TGF-β, however it functions as a co-receptor by binding TGF-β and 
presenting it to TGFBR2.  
1.3.4.1 Canonical (SMAD-dependent) signalling cascade 
One of the induced pathways is the canonical (SMAD-dependent) pathway. The 
activation of the TGF-β receptor complex leads to the release of the FK506 Binding 
Protein 1A (FKBP12) (signalling inhibitor) from the active site of TGFβR1. Through the 
release of FKBP12, the SMAD complex consisting of SMAD2 and SMAD3, also called 
R-SMAD, can bind to the active site through the support of the SMAD anchoring protein 
(SARA). This binding leads to the phosphorylation and release of SMAD2/3 from SARA 
(Attisano, Wrana 2002). The activated SMAD2/3 binds to SMAD4 to form a 
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heterodimeric complex before translocating into the cell nucleus. Here the complex binds 
to one of the many DNA binding partners or transcriptional co-activator/repressors, 
which initiates transcriptional activation or repression of several hundred genes, inducing 
the previously mentioned EMT-TFs SNAI1, SNAI2 and ZEB1 (Pickup, Novitskiy et al. 
2013, Ikushima, Miyazono 2010).  
1.3.4.2 Non-canonical (SMAD-independent) signalling cascade 
TGF-β is also known to induce SMAD-independent pathways such as JNK/p38 Pi3K-
Akt and Rho-like GTPases (Fig. 1.10) (Ikushima, Miyazono 2010). The JNK/p38 
pathway plays an important role in TGF-β induced EMT. Studies have shown that the 
inhibition of p38 leads to an impairment of changes in the cell shape and the 
reorganisation of cytoskeletal structures. The binding of TGF-β to TGFBR2 leads to the 
phosphorylation of PAR6 thereby promoting the degradation of cell junction complexes 
(Padua, Massagué 2009).  
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Figure 1.11: SMAD-dependent and SMAD-independent signalling cascade induced through the binding of 
TGF-β (Adapted from (Pickup, Novitskiy et al. 2013)). 
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1.3.5 EMT associated biomarkers in cancer 
It has been shown that an increased expression of TGF-β1 in PCa cells correlates with 
disease progression and metastasis (Wikström, Stattin et al. 1998). The investigation of 
this process and associated pathways might indicate the usefulness of associated genes as 
markers for metastasis and their clinical utility, however difficulties exists in 
demonstrating EMT in vivo. This is due to two main factors; firstly, it is challenging to 
distinguish mesenchymal cells of different origin. Currently, it is not possible to define 
whether a cell is mesenchymal through EMT and exhibits an increased metastatic 
potential, or whether they are normal stromal cells that exhibit mesenchymal cell 
properties.  
 
Mesenchymal cells can be identified within the tumour composition; however, it is not 
possible to define whether these are a natural component of the tumour or cells that 
underwent the process of EMT (Gao, D., Vahdat et al. 2012). Furthermore, the process 
of EMT is transient, the cells can change from epithelial to mesenchymal, and then back 
to an epithelial cell state once it has invaded a secondary site. This leads to the loss of 
mesenchymal cell properties and the increased expression of epithelial cell markers (Gao, 
D., Vahdat et al. 2012). A recent study in which 205 tissue specimens of localised PCa 
were analysed using the common markers for EMT showed no significant association of 
the expression of any of these markers with clinical outcome. Furthermore, it highlighted 
the common expression of multiple mesenchymal markers in low-grade tumours 
(Armstrong, Healy et al. 2016). However, a different study has shown an increase in EMT-
TFs correlated with the intensity of tumour progression (Imani, Hosseinifard et al. 2016). 
In addition, a drastic increase of ZEB1 was detected in CRPC and was more frequently 
present in PCa metastasis compared to non-metastatic PCa. It was previously shown that 
androgen-deprivation could induce EMT in LNCaP cells (cells derived from an androgen-
sensitive human prostate adenocarcinoma), which was presented through a reduced 
adherence as well as increased expression of the mesenchymal markers CDH2 on protein 
level, as well as ZEB1 of mRNA level. This process could be reversed through a 
testosterone rescue, resulting in an increased cell attachment and a reduced expression of 
CDH2 and ZEB1 compared to the deprived cell lines (Sun, Y., Wang et al. 2012).  
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1.4 Biomarker discovery and validation 
1.4.1 Biomarkers 
A biomarker is a molecule, which can be assessed for the definition of a biological status. 
This molecule can be descriptive for a healthy or pathogenic process, the response to a 
treatment or prognostic for the future development of disease (progression) (Ilyin, 
Belkowski et al. 2004). The National Cancer Institute (NCI) defines a tumour marker as 
“A substance found in tissue, blood, or other body fluids that may be a sign of cancer or certain benign 
(noncancerous) conditions” (National Cancer Institute, 2018a). Many studies focus on the 
discovery of novel tumour markers to improve the early detection of cancer, thereby 
preventing further cancer growth and mortality. Biomarkers can be categorised into six 
main groups based on their field of application (Tab. 1.5).  
 
Table 1.5: Classes of Biomarkers and their use. Adapted from (Shariat, Scherr et al. 2011) and (Bensalah, 
Montorsi et al. 2007). 
Type of 
Biomarker 
Application of Biomarker 
Early Detection 
Systematic screening of a population for the identification of 
subjects with an increased risk for the presence of a disease. 
Diagnostic 
Used for the assessment and definition of absence or presence 
of cancer. 
Prognostic 
Prediction of disease outcome and categorisation of patients 
into risk groups. Provision on information regarding the clinical 
development of the disease.   
Predictive 
Information on the response and effectiveness of a certain 
treatment. 
Therapeutic Target 
Identification of patients, which will benefit from a treatment 
targeting a particular variation of the disease.  
Surrogate endpoint 
Can be used instead of a clinical endpoint for the measurement 
of relapse or recurrence and mortality.  
 
A biomarker can be an endogenous marker, which presents an altered expression in 
malignant tissue, or can be a novel expressed gene induced through the presence of the 
tumour (Malati 2007, Kulasingam, V., Diamandis 2008a). An ideal biomarker should be 
detectable through non-invasive sampling, for example in a blood or tissue sample, and 
show a high specificity and sensitivity for the studied disease. To be successful, the 
biomarker needs to prove its clinical utility and have a positive impact on patient 
outcomes (Kulasingam, V., Diamandis 2008a). Overall, it should fulfil the following 
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criteria “better”, “easier” and “cheaper”, when compared to currently implemented 
markers (Bensalah, Montorsi et al. 2007, Kulasingam, V., Diamandis 2008a). Currently 
proposed biomarkers are commonly lacking the necessary specificity and sensitivity and 
are therefore rarely validated in clinical studies. Figure 1.12 highlights the available 
possible sources and available wet-lab methods for the discovery and validation of novel 
biomarkers (Tab. 1.6).  
 
Table 1.6: Potential biomarker discovery pipeline using multi-omics discovery tools. Adapted from Broad 
Institute, 2018a 
 Phase 
Discovery Verification Validation 
Analysed 
material 
• Cell line 
model 
• Mouse 
model 
• Clinical 
specimens 
Clinical specimens 
• Tissue microarrays 
• Body fluids (e.g. 
Blood, Urine, Saliva) 
• Tumour material 
Clinical specimens 
• Body fluids 
• Tumour material 
Analysis 
method 
• Genomic 
sequencing 
• RNA 
sequencing 
• Targeted gene 
sequencing 
• Quantitative real-time 
PCR 
• Targeted gene 
sequencing 
• Quantitative real-time 
PCR 
• Mass 
spectrometry 
analysis 
• Immuno-
histochemistry 
• ELISA 
• Immuno-
histochemistry 
• ELISA 
Number of 
candidates 
>10 000 <100 <10 
Number of 
samples 
<100 >100 >1000 
1.4.3 Sources for biomarker discovery with a focus on prostate cancer  
A crucial aspect for successful biomarker discovery studies are numbers. It is important 
to have a sufficient sample number, increasing with the complexity and variability of the 
analysed material (Tab. 1.7). For this reason, a larger sample size is important when using 
clinical material, compared to more “uniform” cell line material. The choice of sample 
material depends on the planned experimental approach and the desired outcome of the 
study. Each material can offer advantages and disadvantages. Cell lines offer a highly 
controlled and more reproducible environment; additionally, large quantities of material 
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to analyse and high numbers of replicates are easily generated. On the other hand cell 
lines represent a highly artificial phenotype and it is very difficult to translate this system 
to represent what goes on in a biological system.  
 
Clinical material, such as blood (plasma) or tissue specimens, offer a closer relationship 
to real life than cell lines, however these are difficult to analyse due to their heterogeneous 
nature and the difficulty in obtaining sufficient replicates to overcome inherent sample 
complexity and variation. It should be highlighted that the novel biomarker does not 
necessarily have to be screened in the same clinical material as it was discovered.   
 
Table 1.7: Comparison of the three main sample sources used for the discovery of novel cancer biomarkers 
(adapted from (Drabovich, Martinez-Morillo et al. 2015)) 
 
Tissue Blood Cell lines 
Availability Limited Good Very Good 
Non-invasive 
sampling 
No Yes Yes 
Detection of 
low 
abundance 
molecules 
Possible Difficult Good 
Use in 
diagnostics 
Not suitable for 
routine screening. 
Suitable Not applicable 
Clinical 
Application 
Immunohistochemistry ELISA Not applicable 
 
1.4.3.1 Tissue specimens 
Tissue specimens can be obtained through surgery or biopsy and can be used for the 
discovery of tumour markers. Tumour tissue should, in theory, contain a high 
concentration of tumour specific markers and could therefore represent a valuable source 
for the discovery of novel biomarkers. However, biopsies, in which the sample material 
is collected, extract not only cancerous tissue, but also healthy and neoplastic surrounding 
material, which results in a heterogeneous mixture. Furthermore, only small quantities of 
sample material can be extracted through the biopsy, which limits the number of analyses 
and the applicable tools. Laser-capture microdissection can be used to separate cancerous 
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cells from the surrounding tissue, which enables the focussed profiling of only the 
cancerous cells. However, this leads to a further reduction of sample material (Kulasingam, 
V., Diamandis 2008b). Additional problems can arise through the storage of tissue 
material. Samples are commonly stored as formalin fixed paraffin embedded (FFPE), 
which can affect the ability to detect some proteins and strongly reduces the quality of 
RNA and DNA.  
 
Tissue invasion and angiogenesis might allow the tumour to shed molecules into the 
lymphatic system and the blood stream. Epithelial cancers invade surrounding tissues 
during their growth. This would enable the use of biomarkers discovered in tissue to be 
applied through a blood test, especially in the case of tumour markers that are related to 
disease progression.  
1.4.3.2 Blood 
Human blood or plasma is the most commonly used sample material in clinical practice. 
It represents a large, and minimal invasive source for the detection of biomarkers, in 
which molecules associated with various pathological states can be present. Based on its 
circulation throughout the body, it has contact to a wide range of organs and tissues and 
can therefore carry information provided by them. It is estimated that blood contains 
more than 100 000 different protein variants (Ponomarenko, Poverennaya et al. 2016, 
Archakov, Lisitsa et al. 2015), however the 20 most abundant proteins account for 99 % 
of the present protein mass (Anderson, Anderson 2002a). These variations in protein 
concentrations, which span 10 to 12 orders of magnitude, increase the challenges when 
analysing blood (Fig. 1.12). 
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Figure 1.12: The human plasma proteome according to (Anderson, Anderson 2002b) 
 
Current mass spectrometry technology can reach a range of 4-5 orders of magnitude. 
Potential biomarkers are most likely to be present in the low ng-pg/ml concentration 
range (Kulasingam, V., Diamandis 2008b). It is therefore likely that highly diluted tumour 
markers will be missed or defined as background noise. In addition, the detection of 
circulatory tumour cells can be difficult due to their presence at low concentrations. The 
presence of identified biomarkers in the serum of patients also depends on the protein 
stability, its clearance and potential post-translational modifications (Kulasingam, V., 
Diamandis 2008a). For the routine use of blood for biomarker discovery, improvements 
in the technology are necessary.  
1.4.3.3 Immortalised cell lines 
Clinical material presents a high complexity, which can be challenging for the discovery 
of novel biomarkers. Therefore, a less complex sample material, such as cell lines, offers 
a good alternative solution for the initial discovery phase.  
 
Immortalised cell lines are taken from a population of cells and are able, through the 
immortalisation, to be cultured for an increased duration. Cell lines enable the study of 
cellular processing within the cell and also any interaction or influence on the external 
system through the study of their secretome (Kulasingam, V., Diamandis 2008b). Despite 
the reduced cell variation present within a sample, cell lines still present a certain degree 
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of complexity, however the material is readily available and is easier to process and handle 
than complex clinical samples. On the other side, this sample source also presents some 
limitations. Cell lines are highly artificial and lack stimuli through the microenvironment. 
Many cancer cells lines, including the PCa cell lines DU145 and LNCaP, are generated 
from metastatic tumour cells, which potentially exhibit an altered cell phenotype 
compared to the primary tumour. Furthermore, a single cell line represents only one 
genetic variation of a cancer and is therefore unable to represent the true complexity and 
variability in a clinical setting (Kulasingam, V., Diamandis 2008b). 
1.4.4 Discovery tools (omics) 
As described in the previous section, biomarkers can originate from various omic levels, 
such as genomics, transcriptomics and proteomics. The described complexity of sample 
material highlighted the need for more thorough analysis; however, some limitations in 
the analysis are still present, especially in the field of proteomics. To overcome such 
challenges and to achieve a more complete picture of interactions, not only across one 
type of omic, but also across biological levels, novel approaches, such as the integration 
of multi-omics platforms, offer an alternative for the discovery of new biomarkers.  
1.4.4.1 Strategies for the discovery of novel cancer biomarkers 
1.4.4.1.1 Genomic profiling 
The human genome is made of a genetic sequence, which represents the instructions to a 
functional biological system. The genetic code is comprised of building blocks, the so-
called nucleotides, which code for single, coding or non-coding, genes. The completed 
sequencing of the human genome in 2001 (Venter, Adams et al. 2001) by the Human 
Genome Project, has reformed the world of science. The human genome enabled a 
comprehensive search for abnormal sequences, mutations, within the genome, generating 
a greater understanding of the genetic landscape in diseases, such as cancer. A widely-
known example of disease-associated genetic mutations lay within the BRCA1 (Miki, 
Swensen et al. 1994) and BRCA2 (Wooster, Bignell et al. 1995) genes. Mutations within 
these genes can increase the risk for the development of ovarian and breast cancer. 
Patients with a known family history of BCa are categorised into high-risk groups and are 
nowadays regularly screened for potential changes in the sequence of these two genes 
(Wagner, Ball et al. 2018).  
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1.4.4.1.2 Transcriptomic profiling 
The Transcriptome describes the complete collection of actively transcribed genes within 
a cell at a set point of time. The transcriptome is comprised of coding and non-coding 
RNA molecules, of which the first can be translated into proteins. After many years, in 
which the main attention was focussed on coding genes, in recent years, more and more 
attention was given to transcripts that do not result in a protein (non-coding RNA) 
(Khurana, Fu et al. 2016, Shabalina, Spiridonov 2004, Wagner, Ball et al. 2018). These 
non-coding RNA include microRNAs, and small nucleolar RNAs (Mattick, Makunin 
2006). Commonly used techniques for transcriptome profiling of samples include gene 
expression microarrays and RNA-sequencing.  
 
Microarrays are based on cDNA molecules, spotted on a chip, to which complimentary 
sequences within a sample of interest can bind (Baldi, Hatfield 2011, Schulze, Downward 
2001). Microarrays are commonly used due to their affordability and robustness; however, 
the approach is limited to a priori knowledge of genes. For this reason, RNA-sequencing 
shows a great advantage over microarrays, based on this independence from sequence 
knowledge (Wang, Z., Gerstein et al. 2009). Furthermore, RNA-sequencing offers a large 
range of magnitude in the detection and quantification of RNA molecules. RNA-
sequencing platforms can not only analyse coding-RNA, but can also be used to focus on 
non-coding RNA or a closer look can be taken at active translated genes through the 
screening of ribosome-bound transcripts (Ingolia, Brar et al. 2012). The understanding of 
the complete complexity of tumour cells and associated interactions can be achieved 
through recent advantages that enable the analysis of single cell transcriptomes (Ramskold, 
Luo et al. 2012). The generated transcriptomic profiles of sample material can provide, to 
a certain degree, information in the potentially present proteome, however the correlation 
can be influenced by factors such as half-life time of transcripts and protein, as well as 
post-translational modifications, which can lead to variations between the transcriptome 
and proteome (Maier, Guell et al. 2009, Kulasingam, V., Diamandis 2008a). 
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1.4.4.1.3 Proteomic profiling  
The proteome is defined by the entirety of proteins present within a cell at the point of 
sampling. Currently the human proteome compendium consists of approximately 30 000 
proteins, which are represented by around 17 000 genes (Human Proteome Map, 2018). 
This increased number of proteins compared to the number of genes can be explained 
through alternative splicing event resulting within one gene that can result in the 
translation of different protein isoforms (Black 2000). Compared to the generation of 
transcriptomic profiles, the study of the proteome presents difficulties and limitations 
resulting in lower numbers of routinely quantified proteins.  
 
A continuous challenge is the complexity and large dynamic range of proteins in lysates, 
especially material derived from clinical specimens (See section 1.4.3.1). As previously 
mentioned in section 1.4.4.1.2, also in proteomic studies, it is possible to focus the analysis 
on a subsection of particular interest, such as proteins associated with distinct 
compartments (e.g. membrane, cytoplasmic, nuclear). A big improvement in the analysis 
of proteomes was achieved through the development of data-independent acquisition 
approach in tandem mass spectrometry (Gillet, Navarro et al. 2012), which enabled the 
routine quantification of more than 3000 proteins present in one sample. Applied to a 
high-throughput approach, such numbers of protein quantifications could be achieved 
within 60 to 120 min per sample.  Furthermore, current developments in technology have 
resulted in a higher mass accuracy, higher detection capability and shorter cycling times 
(Sciex, 2018a), which further helped to increase the quality of results and the throughput 
of sample material (Gillet, Navarro et al. 2012, Domon, Aebersold 2006). 
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1.5 Aims and Objectives of the Study  
The underlying questions of this study was whether the use of parallel generated multi-
omic profiles of two cell-line derived metastasis models will enable and facilitate the 
discovery of novel disease-associated biomarkers. In addition to this, the study should 
also investigate the potentially improved correlation of gene and protein expression data 
through parallel sample collection and omics profiling and furthermore, if the use of 
proteomic profiling will contribute to a better understanding of underlying changes. Based 
on these questions, the study was separated into three separate miles stones represented 
by the chapter 3, 4 and 5.  
 
Milestone 1 (Chapter 3): Development of two in vitro models of EMT and their 
characterisation using the analysis of EMT markers on a gene and protein expression level. 
The successful development of both models will present the basis for the generation of 
matching multi-omic profiles in the following chapter 4. 
 
Milestone 2 (Chapter 4): The previously development models of EMT are used for the 
generation of matching transcriptomic and proteomic profiles of both cell line models 
and the validation of their desired phenotype using pathway analyses. Furthermore, the 
generated profiles will be used for the integration of matching genes and proteins and the 
analysis of their expression correlation. The successful validation and additional 
characterisation of underlying changes within the transcriptomic and proteomic profiles 
of both models will support the further use of these profiles as part of an integrative 
biomarker discovery approach, which is described in chapter 5.  
 
Milestone 3 (Chapter 5): The omic profiles generated in chapter 4 will we integrated for 
the identification of a core marker set, followed by the characterisation and validation of 
a selection of markers in a broader context through the screening of cell lines and clinical 
specimens. Furthermore, in silico analyses are to be used for the identification of an 
association of clinical parameters with the expression of the selected markers. 
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2. Chapter II - Materials and Methods 
 
2.1 Materials 
2.1.1 Reagents 
All reagents were stored according to manufacturer’s instruction and used within the 
defined expiry date.  
 
Cell Culture Media 
 
Supplier 
Keratinocyte-SFM, with L-glutamine Gibco Life Technologies 
MEM Eagle with Earle's BSS, without L-glutamine SLS (Lonza) 
  
Cell Culture Media Supplements Supplier 
Foetel Calf Serum (FCS) GE Healthcare Hyclone 
L-Glutamine SLS (Lonza) 
Transforming Growth Factor β1 (TGF-β) Peprotech 
  
Further Cell Culture Reagents Supplier 
Dimethyl sulfoxide (DMSO) Santa Cruz Biotechnology 
Dulbecco’s phosphate buffered saline (DPBS) SLS (Lonza) 
Trypan Blue solution 0.4 % Sigma-Aldrich 
Trypsin/Versene (T&V) SLS (Lonza) 
  
Chemical Reagents Supplier 
alamarBlue™ 
2-mercaptoethanol 
Invitrogen 
Sigma-Aldrich 
2-Propanol Sigma-Aldrich 
4x Protogel Resolving Buffer Geneflow 
10x TRIS/Glycine/SDS Geneflow 
10x TRIS/Glycine Geneflow 
Acetonitrile + 0.1 % Formic Acid  Fluka Analytical 
Acetonitrile Fluka Analytical 
Ammonium Persulphate (APS) Geneflow 
Bovine Serum Albumin (BSA) Calbiochem 
Chloroform Sigma-Aldrich 
Citric acid Sigma-Aldrich 
Deoxyribonucleotide triphosphate (dNTP) Promega 
Dithiothreitol (DTT) Melford 
Double distilled water (ddH2O) Barnstead 
DPX mountant for histology Sigma-Aldrich 
Ethanol Fisher Scientific 
Ethanol absolute Electran® molecular biology VWR Chemicals 
Formaldehyde solution (37 %) Sigma-Aldrich 
Haematoxylin Sigma-Aldrich 
Hydrochloric acid (HCl) Fisher Scientific 
Hydrogen peroxidase (H2O2) Sigma-Aldrich 
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Iodoacetamide Sigma-Aldrich 
Isopropanol Fisher Chemical 
Liquid nitrogen BOC 
Instant Dried Skimmed Milk Co-operative 
Methanol Fisher Chemical 
N-Octyl-Beta-Glycopyranoside (OGP) Apollo Scientific Limited 
Nuclease-free water Ambion 
Oligo(dT)15 Primer Promega 
Phosphate buffer saline (PBS) tablets Oxoid 
Presept tablets Johnson and Johnson 
Ponceau S solution Sigma-Aldrich 
Protease Inhibitor Sigma-Aldrich 
Protein Assay Dye Reagent Concentrate Bio Rad 
ProteaseMAX™ Sufactant, Trypsin Enhancer Promega 
Protogel Stacking Buffer Geneflow 
Protogel (30 % Acylamide mix) Geneflow 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich 
Reverse Transcriptase Promega 
RNaseZAP Ambion 
RNasin Promega 
RNA-STAT-60  Amsbio 
RT 5x Buffer Promega 
SYBR® Green BioRad 
Teepol Johnson and Johnson 
TEMED Geneflow 
Triethylammonium bicarbonate buffer (TEAB) Sigma-Aldrich 
Trizma (Tris) base Sigma-Aldrich 
Trypsin/Lys-C Mix, Mass Spec Grade Promega 
Tween 20 Sigma-Aldrich 
Urea Melford 
Vectashield® Mounting Medium with DAPI Vector Laboratories 
Water with 0.1 % Formic Acid Fluka Analytical 
Xylene Fisher Scientific 
  
Immunochemical Reagents Supplier 
Rabbit anti-human CDH1 (24E10) Cell Signaling 
Rabbit anti-human FN1 (F3648) Sigma-Aldrich 
Rabbit anti-human CDH2 (D4R1H) Cell Signaling 
Rabbit anti-human VIM (D21H3) Cell Signaling 
Rabbit anti-human CRMP4 (DPYL3) (ab101009) Abcam 
Rabbit anti-human FBLI1 (ab154417) Abcam 
Rabbit anti-human P4HA2 (PA5-53530) ThermoFisher Scientific 
Rabbit anti-human SDPR (ab103230) Abcam 
Rabbit anti-human CYCA (ab41684) Abcam 
Goat anti-rabbit IgG Biotin (B8895) Sigma-Aldrich 
Goat anti-rabbit IgG HRP-linked Antibody (7074S) Cell Signaling 
Swine anti-rabbit FITC (F0205) Dako 
Precision Plus WesternC Standards Bio Rad 
Precision Protein StrepTacin-HRP Conjugate Bio Rad 
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Kits Supplier 
Avidin/Biotin Blocking Kit Vector Laboratories 
HRM Calibration Kit Biognosys 
RNeasy Mini Kit (250) Qiagen 
R.T.U. Vectastain Universal Elite ABC Kit Vector Laboratories 
Clarity Western ECL Substrate 
CyQUANT® Direct Cell Proliferation Assay Kit 
Bio Rad 
Invitrogen 
  
  
2.1.2 Consumables and Equipment 
All glassware was washed using Teepol, rinsed twice with distilled water before 
sterilisation using autoclaving.  
 
Laboratory Plastics, Glassware and Sharps Supplier 
Bijou tubes (7 mL) Starlab 
Bioanalyser chips  
Cell culture flasks (T25, T75, T175) Sarstedt 
Cell scraper  
Clear flat bottom 6-well plate, sterile (cell culture) Sarstedt 
Clear flat bottom 96-well plate (protein assay) Starlab 
Cryogenic vials (1.0 mL)  Starlab 
Falcon tubes (15 mL, 50 mL) Sarstedt 
Filter tips (10ul, 20ul, 100ul, 200ul, 1000ul) Starlab 
Glass bottles Duran 
Glass coverslips  
Glass slides  
Hypersep™ Spin Tip C18  Thermo Scientific 
LC vials & Caps Chromatography Direct 
Micro tubes (0.5 mL, 1.5 mL, 2.0 mL) Sarstedt 
Nitrocellulose membrane GE Water & Process Techn.  
Rotor-Gene Strip Tubes & Caps Starlab 
Pasteur pipettes Sarstedt 
Petri dishes Sarstedt 
Scalpels SLS 
Serological pipettes (5 mL, 10 mL, 25 mL) Sarstedt 
Syringe filter 0.2µm Sartorius 
Syringes (20 mL) Medicina 
Western Blot filter paper GE Healthcare 
  
Equipment Supplier 
4 °C Fridge LEC Medical 
-20 °C Freezer LEC Medical 
-80 °C Freezer Panasonic 
2100 Bionanalyzer Agilent Technologies 
37 °C/5 % CO2 Incubator Scientific Laboratory Supplies 
4 °C Centrifuge Eppendorf 
Autoclave Rodwell 
Benchtop vortex mixer Scientific Industries 
Class II Safety Cabinet Walker 
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Ekspert™ nanoLC 425  eksigent 
Axio Observer.Z1 microscope ZEISS 
Haemocytometer (counting chamber) Weber 
Heating block Lab-Line 
Micropipettes (2 µl, 10 µl, 100 µl, 200 µl, 1000 µl) Gilson/Starlab 
Minispin benchtop centrifuge Eppendorf 
Mixing block Bioer 
Multichannel pipette (300 µl) Eppendorf 
Nanodrop ND-8000 spectrophotometer Thermo Scientific 
Nanopure Diamond water reservoir Barnstead 
Nikon Eclipse Ts100 Light Microscope Olypmus 
PCR workstation cabinet  Grant-Bio 
Real-time qPCR thermal cycler Qiagen 
Rocker Stuart 
SCIEX TripleTOF 6600 
Syngene G:Box 
SCIEX 
Syngene 
Sonicator Fisherbrand 
Tecan Ultra Microtiter Plate Reader Tecan 
Thermoblock Biometra 
Vacuum concentrator Eppendorf 
Waterbath Clifton 
Weighing Scale Fisher Scientific 
  
Software Company 
AxioVision SE64 Rel.4.8.  ZEISS 
BaseSpace (Online) Illumina 
GraphPad Prism v7 GraphPad Software Inc. 
Morpheus (Online) Broadinstitute 
NPD.view 2 v2.7.25 Hamamatsu 
OneOmicsTM (Online) Illumina/Sciex 
Protein Pilot v5.0 Sciex 
Peak view v2.1 Sciex 
Rotor-GeneQ Series Software v2.3.1 Qiagen 
Statistica v13.3 
MetaCore v6.37 
TIBCO 
Clarivate Analytics 
Genesys v1.5.4.0 Syngene 
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2.1.3 Buffers and Gels 
2.1.3.1 Cell culture growth media 
Growth medium for P5B3 For 500 ml 
Keratinocyte-SFM, with L-glutamine 487.5 ml 
Fetal Calf Serum 12.5 ml (2.5 %) 
 
Growth medium for DU145 For 500 ml 
MEM Eagle with Earle’s BSS 487.0 ml 
Fetal Calf Serum 12.5 ml (2.5 %) 
L-Glutamine 5 ml (2 mM) 
  
2.1.3.2 Immunofluorescence staining 
Blocking buffer For 50 ml 
Phosphate Buffer Saline 45 ml 
Fetal Calf Serum 5 ml 
Tween 20 50 µl 
 
Washing buffer For 100 ml 
Phosphate Buffer Saline 100 ml 
Tween 20 100 µl 
 
4 % Formaldehyde For 40 ml 
Phosphate Buffer Saline 35.7 ml 
37 % Formaldehyde 4.3 ml 
 
2.1.3.3 Mass spectrometry analysis 
Cell lysis buffer For 50 ml 
Urea 28.5 g 
Dithiothreitol (DTT) 1 g 
N-Octyl-Beta-Glycopyranoside (OGP) 0.5 g 
ddH20 50 ml 
Prior use, Protease Inhibitor was added in a dilution of 1:100 to the cell lysis buffer 
 
2.1.3.4 Immunohistochemistry staining 
Antigen retrieval buffer  For 1 L 
Sodium Citrate tribasic dihydrate 2.94 g 
ddH20 1000 ml 
pH was adjusted to a pH of 6.0 
 
Blocking buffer for IHC staining using fluorescent 2nd AB For 50 ml 
DBPS 50 ml 
BSA 
Tween20 
5 g 
50 µl 
 
Phosphate buffer saline  For 1 L 
Phosphate buffer saline (PBS) tablets 10 x 
ddH20 1000 ml 
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2.1.3.5 Western blot analysis 
4x Laemmli buffer For 50 ml 
1M Tris-HCl pH 6.8 10 ml 
Glycerol 20 ml 
SDS  4.0 g 
β-mercaptoethanol 10 ml 
Bromophenolblue 0.1 g 
ddH2O Up to 50 ml 
 
Running buffer For 1 L 
10x TRIS/Glycine/SDS 100 ml 
ddH20 900 ml 
 
Transfer buffer For 1 L 
10x TRIS/Glycine 100 ml 
Methanol 200 ml 
ddH20 700 ml 
 
10x Tris-buffered saline (TBS) For 1 L 
Trizma Base 24.2 g 
Sodium chloride 80 g 
ddH20 1000 ml 
pH was adjusted to 7.6 
 
Blocking buffer (5 %) For 50 ml 
Instant Dried Skimmed Milk 2.5 g 
ddH20 50 ml 
  
2.1.3.6 Antibodies used throughout this study 
2.1.3.6.1 Western blot analysis 
Antibody (Host species) Expected size Dilution 
VIME (Rabbit) 57 kDa 1/1000 
CADH1 (Rabbit) 135 kDa 1/1000 
CADH2 (Rabbit) 140 kDa 1/1000 
FINC (Rabbit) 220 kDa  1/1000 
CYPA (Rabbit) 18 kDa 1/1000 
Goat anti-rabbit IgG HRP-linked  NA 1/1000 
Precision Protein StrepTacin-HRP Conjugate   NA 1/5000 
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2.1.3.6.2 Antibodies used for immunofluorescence and immunohistochemistry 
analysis on cells and TMAs  
Antibody (Host species) IF IHC IF on TMA 
VIME (Rabbit) 1/100 NA NA 
CADH1 (Rabbit) 1/200 NA NA 
FINC (Rabbit) 1/400 NA NA 
CRMP4 (DPYL3) (Rabbit) NA 1/250 1/250 
FBLI1 (Rabbit) NA 1/100 1/100 
P4HA2 (Rabbit) NA 1/350 1/350 
SDPR (Rabbit) NA 1/50 1/50 
CADH1 (Mouse) 
CADH2 (Mouse) 
NA 
NA 
NA 
NA 
1/250 
1/500 
Goat anti-rabbit IgG Biotin  NA 1/1000 NA 
Goat anti-rabbit FITC 1/40 NA NA 
Goat anti-mouse Alexa Fluor 568 NA NA 1/500 
Donkey anti-rabbit Alexa Fluor 488 NA NA 1/500 
 
2.1.3.7 Quantitative real-time PCR primer used throughout this study 
Primer Gene Primer 5‘-3‘ 
Annealing 
Temp. 
η* 
DPYSL3 F 
DPYSL3 R 
Dihydropyrimidinase 
like 3  
GGACAACTTCACAGCCATTCCTG 
GTGCTTGTCACAGCCACGAACT 60˚C 95 % 
FBLIM1 F 
FBLIM1 R 
Filamin binding LIM 
protein 1 
CGGCAGAACCTGTTGAGAAAGG 
ACGTGAAGCACTGGGCATGGTA 60˚C 98 % 
SDPR F 
SDPR R 
Serum deprivation 
response protein 
TCTTCCAGGAGGAAAATGAG 
CAAATCATCATCTGAGGAGAG 54˚C 90 % 
P4HA2 F 
P4HA2 R 
Prolyl 4-hydroxylase 
subunit alpha 2 
CGAATTCTTCACCTCTATTGG 
GATGTACTCTTTCAGAGACTG 52˚C 91 % 
VIM F 
VIM R 
Vimentin 
GAGAACTTTGCCGTTGAAGC 
GCTTCCTGTAGGTGGCAATC 58˚C N/A 
FN1 F 
FN1 R 
Fibronectin 
CAGTGGGAGACCTCGAGAAG 
TCCCTCGGAACATCAGAAAC 58˚C N/A 
CDH1 F 
CDH1 R 
E-cadherin  
TGCCCAGAAAATGAAAAAGG 
GTGTATGTGGCAATGCGTTC 58˚C N/A 
CDH2 F 
CDH2 R 
N-cadherin 
ACAGTGGCCACCTACAAAGG 
CCGAGATGGGGTTGATAATG 58˚C N/A 
TBP F 
TBP R 
TATA-box binding 
protein 
TATAATCCCAAGCGGTTTGC 
GCTGGAAAACCCAACTTCTG 58˚C N/A 
ZEB1 F 
ZEB1 R 
Zinc finger E-box-
binding homeobox 1 
GGCATACACCTACTCAACTACGG 
TGGGCGGTGTAGAATCAGAGTC 58˚C N/A 
TWIST1 F 
TWIST1 R 
Twist-related protein 
1 
GGAGTCCGCAGTCTTACGAG  
TCTGGAGGACCTGGTAGAGG 58˚C N/A 
SNAI1 F 
SNAI1 R 
Zinc finger protein 
SNAI1 
CCTCCCTGTCAGATGAGGAC  
CCAGGCTGAGGTATTCCTTG 58˚C N/A 
SNAI2 F 
SNAI2 R 
Zinc finger protein 
SNAI2 
GGGGAGAAGCCTTTTTCTTG 
TCCTCATGTTTGTGCAGGAG 58˚C N/A 
*Primer efficiency 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Routine Cell Culture of prostate cancer cell lines 
Two independent prostate cancer cell lines/clones were used during the study (Tab. 2.1). 
Both cell lines were of androgen-independent prostate cancer, originating from either the 
primary or the metastatic/secondary tumour site. The growing cells were routinely 
checked for growth, necessity of media replacement and potential contamination and 
grown at 37 °C in a humidified atmosphere with 5 % (v/v) CO2. Cells were further 
processed at a confluency of 70 – 80 %. For this, the cell medium was removed and the 
cells washed twice with Dulbecco’s phosphate buffered saline (DPBS) for a complete 
removal of the remaining medium. 5 ml of 0.05 % trypsin mixed with 0.02 % versene was 
added and incubated at 37 °C and 5 % CO2 until cells presented a rounded up cell shape, 
indicating detachment from the surface. Following trypsinisation an equal amount of 
medium was added to the cells, which were transferred into a collection tube and 
centrifuged at 240 x g for 5 min. The supernatant was removed and the resulting cell pellet 
resuspended in 10 ml of fresh medium. Each cell line was used within 10 passages from 
master stock.  
 
Table 2.1: Table of the two prostate cancer cell lines used during the purpose of study , describing their 
source, growth conditions and characteristics 
Cell line Description Source Growth Condition 
P5B3 
Single cell clone derived from 
OPCT-1, a androgen 
independent primary prostate 
cancer cell line (T1cN0M0, 
Gleason 3+3) 
ONYVAX 
KSFM + 2.5 % (v/v) 
FCS 
DU145 
Androgen independent 
metastatic prostate cancer 
cell line 
American 
Tissue Culture 
Collection 
(ATCC® HTB-
81™) 
EMEM + 2.5 % 
(v/v) FCS + 2mM  
L-Glutamine 
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The counting of the cells was performed using trypan blue and a haemocytometer. Trypan 
blue highlights dead cells through blue staining, which were excluded from the cell count. 
A desired amount of cells was transferred into a fresh cell culture flask. This step was 
considered as a passage. For the generation of stocks, the cell pellet was resuspended in 
FCS and DMSO (10:1) (freezing media) and stored until further use at -80 °C. Each vial 
was gently thawed and immediately transferred into a new tissue culture flask containing 
fresh media. 
2.2.1.2 Treatment with Transforming Growth Factor β – preliminary work 
(Chapter III) 
For the development of inducible EMT models using P5B3, cells were treated with 10 
ng/ml TGF-β for 5 days. The cells were initially passaged into a new flask, after 24h the 
media was exchanged with new supplemented or non-supplemented media. During the 
stimulation for 5 days, the medium was exchanged every second day with fresh 
supplemented or non-supplemented medium.  
2.2.1.3 Treatment with Transforming Growth Factor β – dataset generation and 
further work (Chapter III, IV, V) 
To keep the response to the TGF-β treatment constant, the cells were seeded at a density 
of 50 000 cells for P5B3 or 75 000 cells for DU145 into a T175 cell culture flask to prevent 
the necessity to passage the cells during the treatment. Prior testing on the adequate 
seeding density identified the required seeding density (data not shown).  
 
The cells were prepared as described above. The treatment length varied from 3 to 10 
days, counting from the first addition of supplemented media. P5B3 and DU145 were 
cells were treated with 10 ng/ml TGF-β. Medium was replaced in regular intervals 
(Monday, Wednesday, Friday) to maintain a steady level of TGF-β and a healthy nutrient 
supply.  
2.2.1.4 Scratch Assay 
Scratch assays are commonly used for the definition of migratory capabilities of cell lines 
of interest. Here, cells of each model were grown for 10 days at their respective conditions, 
harvested and counted. 1 x 105 cells were transferred into each well of a 24-well plate and 
incubated for 24 hours. Then media was removed, each well was washed twice with PBS 
and then fresh FCS-free media was added. Treated cells were further supplemented with 
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TGF-β. After 24 hours, a scratch was applied to the surface of each well using a sterile 
100 µl tip. Media was removed and the wells washed twice with PBS. New FCS-free media 
(with or without supplementation) was added and the created scratch was imaged and 
measured on an Axio Observer.Z1 microscope. Prior to the start of the experiment, a line 
was drawn on the bottom of each well and the images were taken above the line. This 
enabled accurate, matching measurements over 24h. After 24h, the scratches were imaged 
and measured again at the identical position. Wound closure was calculated in %. The 
initial scratch measured at t0 was defined as 100 %. The measurement at 24h defined the 
% of wound closure.  
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2.2.2 Molecular biology 
2.2.2.1 RNA-extraction  
The performed method for the extraction of RNA depended on planned downstream use. 
RNA was extracted for the targeted analysis of single genes using quantitative real-time 
PCR and whole transcriptome analysis by RNA-sequencing. Both approaches are 
described below.  
2.2.2.1.1 RNA-extraction for downstream use in quantitative real-time PCR 
The cells were grown as previously described (section 2.2.1.2/2.2.1.3). Then they were 
trypsinised and collected in a collection tube, centrifuged and the resulting cell pellet was, 
after the complete removal of the remaining medium, immediately frozen in liquid 
nitrogen. The samples were stored -80 °C until further use.  
 
The extraction was performed using the RNeasy Mini Kit (Qiagen). For the improved 
quality of extracted RNA and the inactivation of potentially present RNases the RLT 
buffer was prepared by adding 10 µl of β-mercaptoethanol to 1 ml Buffer RLT.  
 
The generated cell pellet was mixed with 350 to 700 µl of Buffer RLT. In case the result 
of this step was showing a viscous liquid, the volume of RLT Buffer was increased from 
350 to 700 µl. One volume of 70 % EtOH was added to the tube and mixed by pipetting. 
The sample was transferred onto a provided spin column centrifuged for 15 s at 8000 x 
g, the flow-through was discarded and 700 µl of Buffer RW1 added. The spin column was 
centrifuged at 8000 x g for 30 secs and the flow through discarded. 500 µl Buffer RPE 
was added and the column centrifuged as described before. This step was repeated twice. 
After the second repeat, the filter column was placed in a new collection tube and the 
column was centrifuged at full speed. This step secured the complete removal of buffer 
RPE. For the final elution the filters were placed in 1.5 ml micro tubes, 30 µl of RNase-
free water was added onto the surface of the filter, incubated at RT for 10 min and the 
column was centrifuged for 1 min at 8000 x g. Until further use, the samples were stored 
at -80 °C.  
2.2.2.1.2 RNA-extraction for downstream use in RNA-sequencing 
For the analysis of the extracted RNA with RNA sequencing, the extraction of the cells 
was performed using RNA-STAT-60.  
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Here, the media was fully removed from the cell culture flask and 1 ml of RNA-STAT-
60 was added to a T175 flask. The liquid was spread on the surface by inclining the flasks 
and after a short incubation, the liquid containing the cells was collected at one corner of 
the flask using a cell scraper. For homogenising of the samples, the liquid was mixed by 
pipetting, transferred into a 2 ml micro tube and stored at -80 °C until further use. 
 
Prior to RNA extraction, the samples were fully thawed and equilibrated to room 
temperature. 200 µl of chloroform was added per 1 ml RNA-STAT-60 used and the 
samples were mixed by shaking for 60 seconds and rested for 2-3 min at RT. Then, 
samples were centrifuged at 12 000 x g for 15 min at 4 °C resulting in a red phenol 
chloroform phase and the clear aqueous phase. The aqueous phase (containing the RNA) 
was transferred into a new 1.5 ml micro tube and 0.5 ml isopropanol added to each 1 ml 
of RNA-STAT-60 initially used. The liquid was mixed by pipetting and rested for 8 min 
at RT. After this, the samples were centrifuged at 12 000 x g for 10 min at 4 °C, resulting 
in the formation of a white pellet on the bottom of the tube, containing the RNA. The 
supernatant was removed and the pellet washed with 1 ml of 75 % EtOH by vortexing. 
Then, the tube was centrifuged at 7500 x g for 5 min at 4 °C, the EtOH was completely 
removed and the pellet dried under the fume hood. This step was checked regularly to 
ensure the complete evaporation of the EtOH without a too intensive drying of the 
samples. As a final step, the samples were resuspended in 100 µl of RNase-free water. 
 
Following the initial RNA-extraction, the samples were further purified using the RNeasy 
Mini Kit from Qiagen. The RNA was extracted as described above (section 2.2.2.1.1). An 
additional on-column DNase digestion was performed after the washing step using 700 
µl of Buffer RW1. 80 µl of the DNase digestion buffer, prepared according to 
manufacturer’s protocol, was added directly onto the spin column filter and incubated for 
15 min at RT. Then the protocol was followed as described above (section 2.2.2.1.1). 
2.2.2.2 Quantification of extracted RNA 
Independent from the further use of the RNA was each sample initially quantified using 
the NanoDrop 8000. Samples with a 260/280 value of 1.6 and above were deemed to be 
sufficient for the downstream use in qRT-PCR. The sample analysis was performed 
according to manufacturer’s protocol.  
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Samples for use in RNA-sequencing experiments were initially quantified using the 
NanoDrop 8000 and according to the resulting quantification diluted to a concentration 
of 500 ng/ml. Following this, the samples were analysed with the Agilent Bioanalyzer 
using the RNA Agilent Nano Kit with RNA Nano Chips as recommended by 
manufacturer’s protocol (see appendix A2). 
2.2.2.3 Reverse transcription 
For the use of the extracted RNA in qRT-PCR analysis, it was necessary to convert the 
RNA into cDNA. This process is called reverse transcription. For this, 1.5 µg of RNA 
were mixed with 1 µl Oligo dT and adjusted to 10 µl with molecular grade water. The mix 
was incubated at 70 °C for 5 min and immediately transferred onto ice for a further 5 min. 
Following this, 5 µl 5x buffer, 1 µl Reverse Transcriptase, 1 µl dNTPs, 0.7 µl RNasin® 
and 7.3 µl molecular grade water were added to each tube and incubated in a water bath 
at 40 °C for one hour. For the inactivation of the reaction, the samples were incubated 
for 5 min at 95 °C and then stored at -20 °C until further use.  
2.2.2.4 Quantitative real-time PCR 
Quantitative real-time PCR was used for the analysis and measurement of mRNA 
expression levels of markers of interest. For each reaction, 1 µl of cDNA was mixed with 
5.75 µl SYBR® Green, 0.5 µl of the forward and reverse primer at a concentration of 10 
µM and 3.75 µl of molecular grade water. The analysis of each sample was performed 
twice in duplicates on a Rotor-Gene Q real-time PCR cycler manufactured by Qiagen. 
Samples were repeated according to necessity. The analysis was performed with 40 cycles.   
The initial denaturation was 5 min at 95˚C, followed by 40 cycles. These 40 cycles were 
based on 10 secs denaturation (95˚C), 20 secs annealing (temperature optimised for each 
gene of interest) and 20 elongation (72˚C). After the  40 cycles, a melt curve analysis was 
performed in every analysis to ensure targeted amplification of the gene of interest and 
not primer-dimers.  
2.2.2.5 Primer efficiency testing 
Each primer was tested for its efficiency after purchase and prior to experimental 
application. For this, a serial dilution of a test sample was generated consisting of a 5-fold 
dilution each time to create five separate samples/dilutions. The new primer was then 
analysed as described in section 2.2.2.4, with an estimated annealing temperature. Each 
measured data point was then assigned to a given concentration resulting in a standard 
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curve. The x-axis indicates the given concentrations of the used samples compared to the 
y-axis, which describes the cycling time (Ct) value of each sample (Fig. 2.1). The steepness 
describes as M is the efficiency of a primer. An m=-3.32 represents 100 % efficiency. If 
the slope of the standard is too steep, the primer is over-efficient, if the slope is more 
negative, it gives indications of an inefficient primer. Ideally, the measured efficiency 
should be 100 % however; a range from 90-110 % was defined as sufficient.  
 
 
Figure 2.1: Example representation of a generated standard curve for the efficiency testing of a novel primer 
set. 
 
Table 2.2: Summary of cell lines used throughout the process of this study.  
Cell line Tissue Type 
SKBR3 Breast cancer Pleural effusion metastasis 
MCF7 Breast cancer Pleural effusion metastasis 
MDA231 Breast cancer Pleural effusion metastasis 
MDA453 Breast cancer Pericardial effusion metastasis 
MDA468 Breast cancer Pleural effusion metastasis 
MCF10A Breast Fibrocystic disease 
OPCT1 Prostate cancer Primary tumour 
P4B6 Prostate cancer Single cell clone derived from OPCT-1 
P4B6B Prostate cancer Single cell clone derived from OPCT-1 
PC-3 Prostate cancer  Bone metastasis 
LNCaP Prostate cancer Left supraclavicular lymph node metastasis 
SAOS Osteosarcoma Primary tumour 
P5B3 Prostate cancer Single cell cline derived from OPCT-1 
DU145 Prostate cancer Central nervous system metastasis 
 
2.2.2.6 RNA-sequencing analysis 
The RNA-sequencing analysis was performed by the DeepSeq facility of the University 
of Nottingham (DeepSeq, 2019). The facility requested 2 µg of RNA with a concentration 
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of 200 ng/µl and a RNA integrity number (RIN) of 8. Samples were prepared accordingly 
and submitted to DeepSeq, where they were further processed and analysed. 
 
Solely members of DeepSeq performed the sample processing, however their protocol 
was described as the following: To ensure the quality and quantity of measured RNA, a 
repeated measurement of total RNA using the Qubit RNA BR assay kit was performed. 
This assay is highly selective for RNA and can well tolerate any contaminants within the 
sample. The fluorescent dye of the assay emits a signal only when it is bound to RNA. 
Then an additional quality control step using the Agilent 2100 Bioanalyser was performed. 
Libraries were created using 1 µg of total RNA for each sample and the standard protocol 
for the IlluminaTruSeq Stranded Total RNA with Ribo-Zero (Human/Mouse/Rat) kit 
was followed. Library quality control was performed using the 2100 Bioanalyser and High 
Sensitivity Kit. Libraries were quantified using qRT-PCR, pooled at desired 
concentrations, denatured and loaded for sequencing according to manufacturer’s 
instructions. Sequencing was performed on Illumina NextSeq500 sequencing platform, 
and the samples were run over four NextSeq500 High Output v2 150cycle kits to generate 
75bp paired-end reads. 
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2.2.3 Protein biology 
2.2.3.1 Protein extraction for use in Western blot and mass spectrometry analysis  
For the analysis of the proteomic profile, the cells were grown under the described 
conditions until 70-80 % confluent and for the defined treatment period. On the day, the 
remaining media was removed, the cells were washed twice with DPBS and the remaining 
DPBS was removed as completely as possible. Then 300 - 750 µl of cell lysis buffer was 
added and the cells were incubated for 2 min. The amount of cell lysis buffer used was 
dependent on the flask size. A cell scraper was used to detach the cells from the surface 
and to collect them in one corner of the flask. After homogenisation, the liquid was 
transferred into a collection tube. The lysed cells were sonicated for 5 min and stored on 
ice for 5 min; this was performed twice followed by a centrifugation for 10 min at 10 000 
x g and at 4 °C. The resulting supernatant was transferred into a new collection tube. 
Potential remaining cell pellets were stored, together with the supernatant, at -80 °C until 
further use.  
2.2.3.2 Measurement of protein concentration using BioRad DC protein assay 
Protein concentration was measured using a protein assay based on the Bradford method 
and bovine serum albumin (BSA) was used as a standard at the concentrations of 500, 
450, 400, 300, 200, 100, 50, 0 µg/ml BSA. The standards were generated by resuspending 
a BSA stock of 1 mg/ml in undiluted cell lysis buffer, which was then diluted to the 
described concentration using 1:10 diluted cell lysis buffer.  
The utilised cell lysis buffer contained 9.5M urea, for this reason, the samples were diluted 
at least 1:3. This was necessary to reduce the concentration of urea in the samples to a 
level that is compatible with the assay. For the dilution, cell lysis buffer diluted 1:10 in 
H20 was used. As preparation, the dye reagent was diluted 1:5 with H20 (working dye). 
Then 10 µl of each sample was added into one well. The standards were analysed in 
quadruplicates and the samples in triplicates using a 96-well plate. Then 200 µl of the 
working dye were added and the absorbance was measured at 570 nm after an incubation 
of 10 min at RT. The measurement was performed, using a Tecan Ultra Microtiter Plate 
Reader. 
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2.2.3.3 SDS-PAGE and Western blot 
For the detection of a target protein expression, cell lysates were separated by SDS-PAGE 
and transferred onto a nitrocellulose membrane. For each sample, 50 µg of protein was 
used in the experimental procedure.  
2.2.3.3.1 SDS-PAGE in reducing conditions 
For a successful separation according to molecular weight, the intra- and inter-molecular 
disulphide bonds within the sample material had to be reduced. This process denaturated 
the proteins and additionally provides each with a negative charge. This enables the 
separation of the proteins according to size. For this, 3 volumes of sample were mixed 
with 1 volume of 4 x Laemmli buffer and incubated at 95˚C for 10 min on a heating block. 
Then the samples were cooled to RT and were ready to use or stored at -80˚C until further 
use.  
 
The identification of single proteins within a sample using Western blot analysis required 
the initial separation of proteins according to their size. For this SDS polyacrylamide gel 
electrophoreses (SDS-PAGE) was performed. Here, 1.5 mm thick mini SDS gels with 10-
well capacity were prepared (Tab. 2.3). Each gel consisted of two parts, a resolving and a 
stacking gel. First, the resolving gel was prepared and immediately poured between two 
glass slides, filling it until 2 cm to the top then directly covered with Isopropanol for a 
levelled border of the gel.  
 
Table 2.3: Resolving gel preparation for one 1.5 mm gel 
Resolving gel (8 ml) 10 % 
Protogel (30 %) 2.7 ml 
Resolving Buffer 4x 2.0 ml 
ddH20 3.3 ml 
10 % ammonium persulphate (APS) 80 µl 
N,N,N‘,N‘-Tetramethylethylenediamine (TEMED) 8 µl 
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The gel was left to set for about 15 – 20 min. After complete setting of the gel, the 
Isopropanol was removed, the space between the glass slides washed twice with H2O and 
the remaining H2O was removed with filter paper. In the meantime, the stacking gel was 
prepared (Tab. 2.4) and immediately added on top of the resolving gel and after pouring 
the 10-well combs were inserted. Again, the gel was left to set for about 15-20 min.  
 
Table 2.4: Stacking gel preparation for one 1.5 mm gel 
Stacking Gel (3 ml) 5 % 
Protogel (30 %)  500 µl 
Stacking Buffer 4x 800 µl 
ddH20 1.8 ml 
10 % ammonium persulphate (APS) 30 µl 
N,N,N‘,N‘-Tetramethylethylenediamine (TEMED) 3 µl 
 
The prepared gels were inserted into the appropriate running modules and placed inside 
the buffer tank. The tank was filled with running buffer. 5 µl of protein ladder was loaded 
into the first well, followed by the generated sample material. In all experiments, 50 µg of 
each sample was loaded. Following this, the samples were separated by electrophoresis 
using a constant voltage of 100 V over 45 min. 
2.2.3.4 Western blot 
2.2.3.4.1 Protein transfer to nitrocellulose membrane  
After the separation by SDS-PAGE, the proteins were transferred from the gel onto a 
nitrocellulose membrane. For this, the gel was assembled into a so-called “sandwich”. The 
“sandwich” was composed of the negative electrode, 2 sponges soaked in transfer buffer, 
a filter paper, the gel, the membrane, another filter paper, 2 sponges and the positive 
electrode (Fig. 2.2). Prior to use, the membrane was soaked in dH2O and shortly prior to 
assembly, transferred into transfer buffer. The filter paper, as well as the sponges, were 
pre-conditioned in transfer buffer. 
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Black plate 
2 – 3 sponges 
Filter paper 
Gel 
Membrane 
Filter paper 
2 – 3 sponges 
Red plate 
Figure 2.2: Schematic representation of "sandwich" assembly for protein transfer onto nitrocellulose 
membrane 
 
Then, the sandwich was placed into the transfer tank according to the direction of the 
respective electrode orientation, fully covered with transfer buffer and a constant current 
of 180 mA was applied for 75 min. The transfer was performed at 4˚C. After the transfer, 
an optional Ponceau Red staining was performed. This staining enabled a quick reversible 
staining for protein bands and can be performed as a quality control of the transfer. The 
staining can be easily removed through washes with 1X TSBT.  
2.2.3.5.2 Immunoprobing of target proteins on nitrocellulose membrane 
After the transfer, the membrane was cut according to the molecular weight of proteins 
of interests. The selected sections of the membrane were incubated with blocking buffer 
(1x TBST + 5 % milk) for 1h at RT under constant shaking. This step was performed to 
prevent non-specific binding of later-used antibodies. After 1 h, the blocking buffer was 
replaced by fresh buffer containing the desired antibody at the recommended 
concentration, and the membranes were incubated overnight at 4˚C under constant 
shaking.  
 
On the following day, the primary antibody was removed and the membranes washed 
three times with 1X TBST for 10 min at RT and under constant shaking. Then, the 
secondary antibody (host specific) and the conjugate specific for the used molecular 
weight ladder were diluted in blocking buffer according to the recommended 
concentration and then added to the membrane, which was then incubated for 2 h at RT 
under constant shaking. After this, the membrane was washed again three times with 1X 
TSBT. In the meantime, the Clarity Western ECL Substrate was prepared at a 1:1 dilution. 
After washing, the membrane was placed onto a dark background, covered with the 
previously prepared EZ-ECL substrate and the chemiluminescent image acquisition was 
performed. Exposure times were adapted to target protein quantities, ranging from 1 sec 
to 5 min.  
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2.2.4 Mass spectrometry 
2.2.4.1 Sample preparation for pilot work (Chapter III) 
For the analysis, 25 µg of protein was transferred into single 1.5 ml collection tubes and 
placed into a vacuum spin concentrator with a temperature of 45 °C until complete 
evaporation. Each sample was resuspended with 93.5 µl of TEAB (50 mM) and 
transferred into a new 0.5 ml collection tubes. Here, 1 µl of 0.5 mM DTT was added and 
the samples incubated for 20 min at 56˚C. After this, 2.7 µl of 0.55mM Iodoacetamide 
was added and incubated at RT for 15 min in the darkness. Finally, 1 µl of 1 % 
ProteaseMax™ and 2 µl of Trypsin were added and the samples were incubated at 37 °C 
overnight. After this, the samples were evaporated to dryness (as before) and resuspended 
in 25 µl of 5 % ACN + 0.1 % FA. A volume of 12 µl of this was transferred into LC vials.   
2.2.4.2 Sample preparation for data set generation (Chapter IV + V) 
All samples were normalised, by adjusting volume of cell lysis buffer in the sample, to the 
lowest protein concentration. 50 µg of protein was transferred into single 0.5 ml micro 
tubes. The cell lysates of the samples were stored in cell lysis buffer, which contained 
9.5M Urea. A reduction of the urea concentration to less than 6 M was necessary in order 
to perform the reduction and alkylation of the proteins, by addition of varying volumes 
of 50 mM TEAB. The reduction was performed using DTT at a final concentration of 5 
mM and an incubation at 37 °C for 30 min. This step was followed by iodoacetamide 
alkylation at a final concentration of 15 mM and an incubation of 30 min at RT in the 
dark. Urea concentration was reduced to < 1.2 M to improve Trypsin/Lys-C efficiency. 
The dilution was performed using 50 mM TEAB. Trypsin/Lys-C was prepared according 
to manufacturer’s instruction and used for the trypsinisation at a ratio of 20:1 
protein:trypsin. The samples were then incubated at 37 °C for 16 h on a heated shaking 
plate. Then Trypsin/Lys-C was added a second time at a ratio of 20:1 (as per 
manufacturer’s optional digestion protocol) to the samples, followed by incubation at 
37 °C for 3 h.  
2.2.4.3 Sample clean-up using Hypersep™ C18 spin column 
The cell lysate samples were desalted and concentrated using a C18 spin column. Each 
column was placed together with the supplied holder into a 2.0 ml micro tube and 
processed according to manufacturer’s protocol following conditioning. The following 
bullet points describe the procedure. Each time, the described volume was added on top 
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of the column and then centrifuged at 1073 x g (4000 rpm) in an Eppendorf™ 
MiniSpin™ for 30 s (time and rpm optimised for the lab, data not shown). The flow 
through was discarded after each step. 
 
- 3 x 50 µl of 60 % ACN + 0.1 % Formic acid  
- 3 x 50 µl of 0.1 % Formic acid 
- 50 µl of sample. (Multiple repeats might be necessary, dependent on the 
amount of sample)  
- 3 x 50 µl 0.1 % Formic acid (washing step) 
- 3 x 50 µl of 60 % ACN +0.1 % Formic acid (Elution)   
 
Then all samples were placed in a vacuum spin concentrator until the full liquid was 
evaporated. Finally, the samples were reconstituted in 5 % ACN + 0.1 % Formic acid to 
a concentration of 2 µg/µl.  
2.2.4.4 Mass Spectrometry Analysis 
The mass spectrometry analyses were performed by Dr David Boocock and Dr Clare 
Coveney.  
2.2.4.1.1 Pilot work (Chapter III) 
All analyses were performed on a SCIEX TripleTOF6600 instrument (Sciex, Warrington, 
UK). For the creation of a peptide library, 10 µl of each sample was collected in a separate 
LC vial, 1 µl of HRM peptide mix (selection of non-naturally occurring synthetic peptides 
in a pooled mix used to calibrate retention time) was added to each LC vial and analysed 
IDA mode (information or data-dependent acquisition): Top 30; dynamic exclusion 20 s 
after 2 occurrences, 50 ms accumulation time per target and a cycle time of 1.8 s. The 
gradient elution was 2-40 % ACN/0.1 % FA over 110 min and 40-80 % ACN/0.1 % FA 
over 5min. After this, the column was washed at 80 % for 2 min prior to re-equilibration. 
The total run time was 120 min. 
 
The same samples were then analysed by quantitative SWATH™ (data-independent 
acquisition developed by SCIEX – Sequential Window Acquisition of all THeoretical ions) 
mass spectrometry (SCIEX, Warrington, UK) using 40 variable m/z windows, a 40 ms 
accumulation time and a cycle time of 1.8 secs. The samples were fractionated by online 
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reversed phase HPLC (YMC 12 nm C18 3μm, 15cm x 300 μm column, 5 µl/min) with a 
gradient elution of 2-35 % ACN/0.1 % FA over 35 min and 35-80 % ACN/0.1 % FA 
over 5min. After this, the column washed at 80 % for 5 min prior to re-equilibration. The 
total run time was 60 min.  
2.2.4.1.2 Dataset generation (Chapter IV + V) 
The samples for the dataset generation were prepared as described in section 2.2.4.1.1 
with the following changes:  
 
For the IDA analysis, the gradient elution was 3-30 % ACN/0.1 % FA over 68 min and 
40-80 % ACN/0.1 % FA over 5min. After this, the column was washed at 80 % for 3 
min prior to re-equilibration. The total run time was 87 min. For the DIA/SWATH™ 
analysis, gradient elution was 3-30 % ACN/0.1 % FA over 38 min and 30-40 % ACN/0.1 % 
FA over 5min. After this, the column was washed at 80 % for 3 min prior to re-
equilibration. The total run time was 57 min. Here, the analysis was performed using 100 
variable m/z windows, optimised on cell lysate, 25 ms accumulation time and a cycle time 
of 2.8 secs.  
2.2.4.5 Immunohistochemistry of paraffin-embedded tissue sections 
Immunohistochemistry was performed for the analysis of the protein expression of 
selected markers in healthy and diseased tissue sections.  
The slides were initially incubated/baked for up to 2 h at 60 °C to ensure and facilitate 
the complete removal of the paraffin wax and to unmask the antigen epitopes. The slides 
were then processed according to the following steps. 
 
- Incubation in Xylene (1) for 5 min 
- Incubation in Xylene (2) for 5 min 
- Incubation in 100 % EtOH (1) for 3 min 
- Incubation in 100 % EtOH (2) for 3 min 
- Incubation in 70 % EtOH for 3 min 
 
Afterwards, the slides were placed into a bath with running water for 15 min. Citrate 
buffer was preheated by microwaving it for 10 min, then the slides were slowly dipped 
into the near-boiling buffer to prevent damage to the slides through the rapid temperature 
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change. Following this, the slides were microwaved in the citrate buffer for 10 min at 
maximum intensity. Then the slides were transferred into distilled water, slowly to prevent 
damage to the slides. The slides were washed in the distilled water for 3 x 5 min, of which 
after 5 min the water was exchanged. The slides were dried carefully around the tissue 
sections and placed into a black plastic container. 0.3 % H2O2 was added onto of the 
tissue sections and incubated for 5 min. Following this, the slides were washed for 3 x 5 
min in DPBS. In every washing step, the DPBS was exchanged after each 5 min wash 
cycle.  
The slides were dried and 10 % goat serum diluted in DPBS were added onto the tissue 
sections and incubated for 30 min in the dark. The liquid was tipped off after the 
incubation and avidin solution was added for 15 min. Following this, the slides were 
washed for 3 x 5 minutes in DPBS. Then the biotin solution was added to the slides and 
also incubated for 15 min, then the slides were washed for 3 x 5 minutes in DPBS. In the 
meantime, the primary antibody was prepared. The concentration optimum of each 
antibody was defined through dilution series prior the use in relevant tissue sections. The 
antibody was diluted in 10 % goat serum diluted in DPBS according to the optimised 
concentration. The primary antibody was added to the sections, after the last wash, then 
incubated in the dark for 40 min at RT and then transferred to 4 °C overnight. 
 
On the next day, the slides were washed for 3 x 5 min in DPBS, then the secondary 
antibody was added. The ideal concentration optimised prior final use. The secondary 
antibody was diluted in a 1.5 % goat serum solution, diluted in DPBS. The secondary 
antibody was added and the slides incubated for 30 min at RT in the dark. Then the slides 
were washed for 3 x 5 minutes in DPBS. Following this, ABC buffer was added to the 
slides and incubated for 30 min at RT in the dark. The slides were washed for 3 x 5 min 
in DPBS. In the meantime, the DAB reagent was prepared. Here, 2.5 ml dH20 were mixed 
with 1 drop of buffer, 2 drops of DAB reagent, and 1 drop of H2O2. The DAB reagent 
was added onto the slides and the slides were observed under the microscope for the 
development of a staining. The slides were transferred into dH20 once a sufficient staining 
was reached. After this, the slides were transferred into running water for 2.5 min and 
then into dH20 for 2.5 min. The counterstain and dehydration was performed to the 
following steps: 
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- Incubation in Mayer’s haematoxylin for 90 secs 
- Washing with running water for 1 min 
- Incubation in 70 % EtOH for 1 min 
- Incubation in 100 % EtOH (2) for 1 min 
- Incubation in 100 % EtOH (1) for 2 min 
- Incubation in Xylene (2) for 1 min 
- Incubation in Xylene (1) for 1 min 
Then the slides were left to dry to ensure the complete evaporation of Xylene, before 
coverslips were fixed in place using DPX.  
2.2.4.6 Immunohistochemistry staining of paraffin-embedded prostate cancer 
tissue sections using fluorescent secondary antibodies 
Immunohistochemistry staining on paraffin-embedded tissue microarray slides using 
fluorescent secondary antibodies was performed in diseased tissue sections.  
The slides were initially incubated/baked for up to 2 h at 60 °C. The slides were then 
processed according to the following steps 
. 
- Incubation in Xylene (1) for 20 min 
- Incubation in Xylene (2) for 20 min 
- Incubation in Xylene (3) for 20 min 
- Incubation in 100 % EtOH (1) for 3 min 
- Incubation in 100 % EtOH (2) for 3 min 
- Incubation in 100 % EtOH (3) for 3 min 
- Incubation in 70 % EtOH for 3 min 
 
Afterwards, the slides were placed into a bath with running water for 5 min and 3 min in 
dH2O. Citrate buffer was preheated by microwaving it for 10 min and the slides were 
slowly dipped into the near-boiling buffer to prevent damage to the slides through the 
rapid temperature change. Following this, the slides were microwaved in the citrate buffer 
for 20 min at maximum intensity. Then the slides were transferred into distilled water, 
slowly to prevent damage to the slides. The slides were washed in the distilled water for 3 
x 2 min, of which after 2 min the water was exchanged. After this, the slides were rinsed 
with DPBS and placed in a DPBS bath for 3 x 10 min. The slides were dried carefully 
around the tissue sections and placed into a black plastic container. There, the slides were 
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blocked against unspecific binding for 1h through the addition of 10 % BSA and 0.1 % 
Tween20 in DPBS. The liquid was tipped off and the primary antibodies were added, 
diluted in blocking buffer. The optimal antibody concentration was defined prior use. The 
samples were incubated in the dark for 60 min at RT and then transferred to 4 °C 
overnight. 
 
On the next day, the slides were washed for 3 x 10 min in DPBS, then the secondary 
antibody was added and slides incubated for 1 h at RT in the dark. Then the slides were 
washed for 3 x 10 minutes in DPBS. The slides were dried, mounting fluid with DAPI 
was added and covered with a cover slip. The edges were sealed using nail varnish and 
the slides stored at 4˚C until imaging.  
2.2.4.7 Immunofluorescence staining of adherent P5B3 and DU145 cells grown on 
cover slips 
Immunofluorescence staining of the cells was performed for the visualisation of the 
epithelial and mesenchymal marker expression. This was necessary to define the 
presence/absence of epithelial and mesenchymal cells and for a better characterisation of 
the cell population. Furthermore, it was also used to confirm the purity of the cell clones 
according to their phenotypic characteristics and to maintain a high quality standard in 
the experiments.  
 
The cells were grown for the defined period of time of treatment in flasks and 72 h prior 
to the staining they were transferred into 24-well plates. The 24-well plate was prior 
prepared as follows. Cover slips were dipped into 100 % methanol and placed into each 
well. The cells were added after the complete evaporation of the methanol. This was 
performed in a hood to ensure sterility was maintained.  
  
After the growth, the media was removed and three wash cycles with DPBS were 
performed followed by the fixation of the cells with 200 µl of 4 % formaldehyde for 15 
min at RT. Next, the formaldehyde was removed and the cells were washed 3x with 250 
µl wash solution (100 µl Tween 20 + 100 ml DPBS), which was replaced by 200 µl of 
blocking solution (10 % ml FCS + 45 ml DPBS + 0.001 % TWEEN 20) and incubated 
for 60 min at RT. During this time, the primary antibodies were prepared according to 
manufacturer’s recommendation.  
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After 60 min of incubation, the blocking solution was removed and the primary antibody 
was added to each well. The plate was then covered in aluminium foil and incubated 
overnight at 4 °C on a rocker. On the next day, the primary antibodies were removed and 
each well was washed 3x with 300 µl wash solution for 10 min and placed on a rocker. 
During this time, the secondary antibody was prepared and after the third washing cycle, 
100 µl of it was applied to each well. This step was followed by a 2 h incubation at RT. 
The plate was covered in aluminium foil and placed on a rocker. Again, the antibody was 
removed after the 2 h and each well was washed 3x  with 300 µl of DPBS for 10 min on 
a rocker. After the last washing step, the a small drop of mounting fluid with DAPI was 
placed inside each well and the plate was then stored until imaging at 4 °C.  
2.2.5 Experimental layout and generation of sample material from both 
inducible EMT models  
Here, two cell line models of EMT were developed and characterised (Chapter III), and 
used for the generation of gene and protein expression profiles. To minimise the variation 
between the sample materials, the cells were grown in parallel and the collection of cell 
lysates and RNA was performed within 1 hour to minimise protein degradation. 
Furthermore, each model used media of the same lot number (respectively to cell line) 
and the TGF-β used was of the same batch. To counteract potential batch effects, samples 
of both models were generated in two separate treatment rounds, of which half of the 
sample material of each model was collected in round one, and the other half at round 
two. Seeded cells remained within the flask during the whole treatment to prevent 
variation of treatment response based on trypsinisation and potentially induced changes 
in the expression of the TGF-β receptor. Under normal conditions, cells are seeded at a 
higher density and are passaged from one flask into a new one in regular intervals, e.g. 
weekly. However, these passages can influence the cell behaviour. The media changes 
were performed according to the frequency described in Figure 2.3. 
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Figure 2.3: Schematic representation of the preparation and treatment regime of both cell lines for the 
generation of sample material for multi-omics approach and additional experiments conducted for the 
characterisation of both cell line models.  
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2.2.6 Processing and filtering of omic data generated through RNA-
sequencing and mass spectrometry analyses  
2.2.6.1 Processing of RNA-sequencing generated data output  
The output generated by DeepSeq were FASTQ-files for each sample was uploaded to 
Illumina’s BaseSpace Sequence platform, where the further processing was performed. 
The data was aligned using the Homo sapiens (PAR-masked)/hg38 reference genome and 
the Tuxedo suite with Tophat (Trapnell, Cole, Pachter et al. 2009) and Bowtie 2 
(Langmead, Salzberg 2012). In addition, novel transcript assembly was performed. The 
generated output was presented as FPKM values (Fragments per Kilobase Million) of 
each gene, which was used for further analysis.  
 
The reference genome was provided by the Genome Research Consortium called 
“Genome Research Consortium human build 38” (GRCh38). This reference genome, 
first released in 2013, updated the so far used GRCh19. GRCh19 functioned as a single 
representation of multiple genomes. GRCh38, however, offers alternate sequences for 
selected regions, using so-called alternate haplotypes. For this reason, the use of 
GRChg38 offers a more realistic presentation of the human genome and was therefore 
selected for the alignment of the generated RNA-sequencing data.  
2.2.6.2 Processing of mass spectrometry generated data output 
Files generated through IDA analyses of cell lysates (e.g. cytoplasmic, nuclear and 
membranous fractions of P5B3 and P4B6, as well as a pooled sample of all samples of 
the dataset generation study) were searched together in Protein Pilot 5.0 with the 
following parameters; Digestion: Trypsin, Cys Alkylation: Iodoacetamide, ID focus: 
Biological modifications, Search effort: Thorough ID search effort. The database used 
was Human Swissprot (Jan 2015).  The combined results file (.group) was opened in 
PeakView 2.1 SWATH microapp (Sciex) and converted to a .txt file.  The IDA based 
library (120 min or 87 min LC run) was aligned to the SWATH data (60 min or 57 min 
LC run) using the spiked in  iRT peptides (HRM kit, Biognosys). The aligned library was 
extracted from the SWATH data using the OneOmics cloud software suite on the 
Illumina BaseSpace app platform with the following parameters:  6 peptides per proteins, 
6 transitions per peptide, 75 ppm XIC width and a 6 min retention time window.  Data 
was then assembled using the OneOmics Assembler to generate fold change and 
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confidence data for each protein.  Processed data was then downloaded from Illumina 
BaseSpace as .csv. 
2.2.6.3 Filtering of pilot mass spectrometry analysis of P5B3 (Chapter III) 
The generated protein expression lists were subjected to a t-test analysis and a p-value of 
each sample was generated based on a 2-tailed, 2 pairs equal variance analysis. Significant 
altered proteins <0.05 were selected for further analysis. 
2.2.6.4 Initial gene selection and pathway and enrichment analysis (Chapter IV) 
The generated p-value of each sample was based on a 2-tailed, 2 pairs equal variance 
analysis. In addition, the generated p-value was corrected for false discovery using the 
Bonferroni correction. This correction was used to reduce the likeliness of a type I error 
(false-positives). In this initial analysis, no filter regarding the fold change was applied.  
2.2.6.5 Identification of key marker selection (Chapter V) 
The generated p-value of each sample was based on a 2-tailed, 2 pairs equal variance 
analysis. In addition, the generated p-value was corrected for false discovery using the 
Bonferroni correction. Furthermore, genes were filtered on a FPKM value of 2 or above 
in at least one group and an absolute fold change of 2 and above. Protein expression data 
were filtered for a confidence value of 70 % and above and an absolute fold change of 2 
and above (Fig. 2.5).  
 
Figure 2.4: Schematic representation of filtering for the identification of 13 core markers 
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2.2.7 In silico analyses of wet-lab derived and publicly available omic 
datasets 
2.2.7.1 Gene Ontology (Chapter III) 
The resulting significant proteins (section 3.6.3.1) were subjected to a Gene Ontology 
analysis. For this, the derived gene list was analysed for the identification of enriched 
biological processes (http://www.geneontology.org/). Biological processes associated 
with EMT were selected, affiliated genes selected and presented in a heat map. Venny 2.1 
(https://bioinfogp.cnb.csic.es/tools/venny/) was used to generate the Venn diagrams of 
proteins assigned to the different Gene Ontology terms.   
2.2.7.2 Heat map Clustering (Chapter III and Chapter IV) 
Identified significant markers based on either of the filtering methods described in section 
2.2.6.3 and section 2.2.6.4 were applied to MORPHEUS for the generation of a heat map 
(https://software.broadinstitute.org/morpheus/). Furthermore, the samples of interest 
were subjected to a clustering approach using Euclidean distance and complete linkage. 
This clustering approached helped the potential identification of outliers.  
2.2.7.3 MetaCoreTM analysis (Chapter IV) 
A pathway enrichment analysis of significant altered genes and proteins was performed 
using MetaCore™. The data was uploaded to the cloud-based platform using the gene list 
and corresponding fold change. A so-called “one click” analysis was performed and 
enriched pathway maps identified.  
2.2.8 Analysis of publically available in silico data  
Publically available transcriptomic data of cell line and patient-material derived specimens 
were analysed for further validation. The data was either downloaded from the NCBI 
Omnibus platform (https://www.ncbi.nlm.nih.gov/geo/), a public accessible repository 
of generated omic profiles, from CANCERTOOL (Cortazar, A. R., Torrano et al. 2018) 
(http://web.bioinformatics.cicbiogune.es/CANCERTOOL/), or The Cancer Genome 
Atlas data portal (https://portal.gdc.cancer.gov/). The origin of the expression data is 
highlighted in table 2.5. The gene expression of each gene was selected and analysed, 
either using a t-test, Kaplan-Meier analysis or cox regression analysis. The used method 
is highlighted in each figure.  
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Table 2.5: Summary of used public available datasets for the in silico validation of novel markers for prostate 
cancer progression and EMT.  
Origin Sample origin n1 Treatment Accession  
Cell line A549 3 2 ng/ml TGF-β for 2 weeks 
GSE496442 Cell line HCC287 3 2 ng/ml TGF-β for 2 weeks 
Cell line NCI-H358 3 2 ng/ml TGF-β for 2 weeks 
Cell line PANC-1 3 5 ng/ml TGF-β for 5 weeks GSE239522 
Cell line ARPE-19 3 
5 ng/ml TGF-β and  
10 ng/ml TNF-α for 60 hours 
GSE125482 
Patient benign prostate tissue 28 None 
GSE359882 Patient localised PCa 59 None 
Patient CPRC/metastasis  35 None 
Patient Gleason score 6 44 None 
TCGA 
Data 
Portal3 
Patient Gleason score 7 247 None 
Patient Gleason score 8 64 None 
Patient Gleason score 9 137 None 
Patient PCa no recurrence 37 None 
Cancertool4 
Patient PCa recurrence 42 None 
1 n = numbers of replicates or patients assigned to the respective group 
2 https://www.ncbi.nlm.nih.gov/geo/ 
3 http://web.bioinformatics.cicbiogune.es/CANCERTOOL/ 
4 https://portal.gdc.cancer.gov/ 
 
2.2.9 Statistical analysis 
Error bars describe standard deviation and statistical differences between analysed 
experimental groups. For this the unpaired t-test was used (p≤0.05 = *, p≤0.01 = **, 
p≤0.001 = *** and p≤0.0001 = ****). Figures were generated using GraphPad Prism 7. 
Univariate cox regression analysis was performed for the identification of predictive 
capabilities of genes using TIBCO Statistica 13.3. Kaplan-Meier analysis was performed 
using GraphPad Prism 7. Gene expression values were sorted according to intensity (low 
to high) and separated into quartiles. Q2 and Q3 were merged based on better separation.  
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2.2.10 Used online tools and databases 
Table 2.6: List of utilised databases and online tools with their use and link 
Database/ 
Online tool 
Use Link 
BaseSpace Processing of RNA-sequencing 
data 
https://basespace.illumina.com/ 
OneOmics Processing of Mass spectrometry 
data 
https://sciex.com/applications/ 
life-science-research/oneomics 
MetaCore Pathway enrichment analysis https://portal.genego.com/ 
GeneOntology Identification of enriched 
biological processes 
www.geneontology.org/ 
NCBI Omnibus Database for omics-derived 
datasets 
https://www.ncbi.nlm.nih.gov/geo/ 
TCGA Database of cancer datasets https://portal.gdc.cancer.gov/ 
CANCERTOOL Online platform for cancer data 
analysis and source of omics data 
http://web.bioinformatics. 
cicbiogune.es/CANCERTOOL/ 
MORPHEUS Generation of heat maps and 
clustering 
https://software.broadinstitute.org/ 
morpheus/ 
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3. Chapter III – Development of two inducible 
models of epithelial to mesenchymal transition 
for the study of disease progression in prostate 
cancer  
3.1 Introduction 
 
Prostate cancer (PCa) is the most common cancer in men in Europe and the second most 
common cause of cancer-related deaths in the United Kingdom (Cancer Research UK, 
2017a), primarily due to the development of metastasis. The development of metastasis 
decreases the 5-year survival rate to only 30 % (Thobe, Clark et al. 2011). At some point 
during development and growth, cells of the primary tumour gain the ability to spread to 
distant organs. These characteristics can be acquired through the process of epithelial to 
mesenchymal transition (Heerboth, Housman et al. 2015). During this, cells change from 
an epithelial to a mesenchymal-like cell state, invade the blood or lymphatic system, and 
are distributed throughout the body. At a distant site they undergo mesenchymal to 
epithelial transition (MET) and initiate the growth of secondary tumours (Kalluri, 
Weinberg 2009). Epithelial cells are firmly attached cells that are growing in clusters. They 
are tightly connected by different types of cell junctions, such as tight, gap and adherens 
junctions, as well as desmosomes. Furthermore, they have an apico-basal polarity. 
Mesenchymal cells cannot form connective cell layers and they only focally connect to 
surrounding mesenchymal cells. In culture, mesenchymal cells show a fibroblastic, spindle 
shape morphology (Thiery, Sleeman 2006), whereas epithelial cells commonly present 
polygonal shapes, building patches of attached cells. 
 
 
 
This image has been removed by the author for copyright reasons 
 
 
 
Figure 3.1: Schematic representation of morphological changes from epithelial to mesenchymal cell 
morphology and cell-state associated genes and proteins. 
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Certain genes, such as E-cadherin (CHD1), N-cadherin (CDH2) and Vimentin (VIM) are 
genes indicative for this process; however, their suitability in clinical use is limited. This is 
based, on the one hand, on the fact that EMT is a natural process occurring during healthy 
biological processes, such as wound healing, and on the other hand that the process of 
EMT can be reversed on cells therefore they do not continuously express mesenchymal 
(EMT) markers. In addition to this, studies have presented variable results regarding the 
associated significance of EMT marker expression with survival and disease progression 
in prostate cancer (Nauseef, Henry 2011). For this reason, the discovery of novel markers 
indicative for the process of EMT and disease progression is crucial. Such markers could 
present a potential strategy for routine screening, cancer surveillance and treatment 
response, as well as potential treatment targets for the suppression and inhibition of 
cancer spread. 
 
For the discovery and study of novel markers, cell line models present a useful tool for 
the simulation of EMT in vitro. Cell line material can be easily genetically modified and 
treated with various reagents; furthermore, they present nearly limitless availability. 
However, many of these cell line models are based on cell lines of metastatic origin, such 
as MDA-MB-468 (breast cancer) (Bonnomet, Syne et al. 2012), NCI-H358 (lung cancer) 
(Argast, Krueger et al. 2011) and ARCaP (prostate cancer) (Zhau, Odero-Marah et al. 
2008). In this chapter, the development of two inducible cell line models is described, one 
of which was generated from a primary tumour cell line. 
 
The first model was generated from a single cell clone (P5B3) derived from the parental 
cell line OPCT-1 (Harner-Foreman, Vadakekolathu et al. 2017). The parental cell line was 
generated from a primary prostate tumour epithelium and was staged as T1cN0M0 and 
as Gleason 3+3. Harner-Foreman et al, generated multiple single cell clones from the 
parental cell line and characterised them with regards to their invasive and metastatic 
potential and their EMT profile.  
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P5B3 presents a highly epithelial morphology (Fig. 3.2A+B) and a low EMT profile with 
a high expression of the epithelial cell marker CDH1 and less than 0.5 % of VIM-positive 
cells. Furthermore, cells of this single cell clone did not exhibit invasive capabilities and 
were unable to initiate tumour growth once implanted into mice (Harner-Foreman, 
Vadakekolathu et al. 2017).  
 
Figure 3.2: P5B3 in its natural state showing a highly epithelial cell morphology with a small proportion of 
single cells presented at a 4x (A) and 10x (B) magnification The scale bar shows a length of 10 µm 
 
The second model of EMT was generated using the metastatic prostate cancer cell line 
DU145. DU145 is a commonly-used and well-studied prostate cancer cell line derived 
from the metastatic tumour site located in the brain (Stone, K. R., Mickey et al. 1978). 
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The patient from whom DU145 was derived presented a poorly differentiated prostate 
adenocarcinoma exhibiting metastatic lesions in the central nervous system, liver, lungs 
and brain (Stone, K. R., Mickey et al. 1978). DU145 is an adherent epithelial cell line (Fig. 
3.3A+B), which is hormone-insensitive and hormone-independent (not required for 
growth) and does not express the prostate specific antigen. Cells injected into nude mice 
were able to induce tumour growth (ATCC 2018a). The morphology of DU145 can be 
described as predominantly epithelial. Despite this, it presents a less distinct cobblestone 
morphology when compared to P5B3.  
 
 
Figure 3.3: DU145 in its natural state showing a highly epithelial cell morphology with a small proportion 
of single cells presented at a 4x (A) and 10x (B) magnification. The scale bar shows a length of 10 µm.  
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The aims of this chapter are the development of two inducible in vitro models of EMT. 
The process of the model development will be characterised by multiple checkpoints to 
be successfully completed prior further proceeding of the experiments. 
• Treatment of the cell lines with TGF-β and the observation of morphological changes 
associated with the induction of a more mesenchymal cell state, highlighted through 
the development of elongated, potentially solitary, cells.  
• Validation of transcriptomic changes associated with a mesenchymal cell state 
through the use of quantitative real-time PCR analysing most commonly used genes 
associated with EMT. An increased expression of CDH2, FN1, VIM, TWIST1, 
SNAI1, SNAI2 and ZEB1 and a reduced expression of CDH1 will indicate the 
successful induction of an EMT-like phenotype.  
• Validation of proteomic changes to a mesenchymal cell state through the use of 
Western blot and immunofluorescence analysis for the proteins CADH1, CADH2, 
FN1 and VIME. Also here, an increased expression of CADH2, VIME and FINC, 
and a decreased expression of CADH1, supports an induction of an EMT-like 
phenotype.  
• Analysis of potential changes in the invasive behaviour of both cell line models 
through the performance of scratch assays. The experiment will elucidate potential 
changes in the cell line behaviour induced through the stimulation with EMT. The 
induction of EMT can contribute to a more invasive behaviour.  
Overall, the successful confirmation of gene and protein expression associated with an 
induction of EMT will enable the use of both models for the generation of matching 
transcriptomic and proteomic profiles for the use of data-integration and potential 
discovery of novel disease-associated biomarkers.  
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3.2 Results 
3.2.1 Development of an inducible model of EMT using a single cell 
clone derived from a primary prostate cancer cell line using 
Transforming Growth Factor β 
3.2.1.1 Morphological changes induced in P5B3 through the treatment with 10 
ng/ml TGF-β for 5 days 
Transforming growth factor β, which is a known inducer of EMT in vitro, was selected for 
this study. The untreated cells of P5B3 present a “cobblestone” morphology of epithelial 
cells tightly attached to each other and the flask surface. Initially, the cells were treated 
with 10 ng/ml TGF-β for 5 days, which induced morphological changes compared to the 
untreated control (Fig. 3.4), showing a change from connected island of cells to dispersed 
elongated cells. The cells developed an elongated cell shape and isolation from 
surrounding cells. Furthermore, their adherence to the flask surface was reduced. The 
untreated P5B3 cells did not show any changes in their morphology nor their adherence 
to the cell culture flask after 5 consecutive days of growth. 
 
 
Figure 3.4: Morphological changes of P5B3 after treatment with TGF-β for 5 days with 10 ng/ml TGF-β. 
The scale bars indicate 10 µm. 
 
3.2.1.2 Gene expression changes induced in P5B3 through the treatment with 10 
ng/ml TGF-β for 5 days 
After morphological changes were observed through the treatment with TGF-β, the cells 
were screened for potential changes in the molecular EMT profile. For this, extracted 
RNA of both conditions was analysed for the following genes: VIM, CDH1, CDH2, FN1, 
and the EMT-Transcription factors (EMT-TFs) SNAI1, SNAI2, TWIST1 and ZEB1 
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using quantitative real-time PCR. Figure 3.5 demonstrates the expression changes of these 
genes at the mRNA level in treated cells compared to the natural P5B3 profile. It could 
be shown that the treatment induced an expression of the analysed markers associated 
with a mesenchymal cell state, whereas the epithelial associated gene, CDH1, showed a 
decreased expression. Of all the analysed genes, VIM showed the strongest increase with 
about 1000 times the expression compared to the untreated cells. The other mesenchymal 
associated genes, CDH2 and FN1, showed the second and third strongest upregulation, 
respectively. Additionally, the EMT-TFs all showed an increase in their expression, of 
which ZEB1 was showing the strongest fold change increase, induced through the 
treatment. Based on the detected molecular changes indicating morphological changes to 
an increased mesenchymal phenotype and subsequent induction of EMT, this cell line 
model was selected for further characterisation and analysis. 
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Figure 3.5: Gene expression changes of EMT markers induced in P5B3 upon stimulation with TGF-β. The 
expression of VIM, CDH1, CDH2, FN1, SNAI1, SNAI2, TWIST1 and ZEB1 was compared between 
untreated and treated P5B3 cells after incubation with 10 ng/ml TGF-β for 5 days. Results were analysed 
using the comparative ΔΔCT method (Schmittgen, Livak 2008) (n=4). The gene expression was normalised 
against the TATA-box protein (TBP) gene, which was utilised as reference gene. 
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3.2.1.3 Protein expression changes induced in P5B3 through the treatment with 10 
ng/ml TGF-β for 5 days 
The molecular changes induced through the treatment of P5B3 indicate the induction of 
EMT, however, based on the potential variations between gene and protein expression, 
additional analysis of EMT-associated proteins was performed using immunofluorecense 
staining. The staining (Fig. 3.6) has shown that P5B3 untreated has a strong expression 
of CADH1, located at the cell membranes of the cells, whereas no expression of VIME 
and only low, dispersed FINC expression was detectable at an untreated condition. Upon 
treatment the expression of CADH1 was strongly reduced and the expression of VIME 
and FINC strongly increased. The expression of VIME was detected in the cytoplasm, 
where it comprises, together with the microtubules and microfilaments, the cytoskeleton. 
Also the expression of FINC was localised in the cytoplasm of the cell. This shows a 
confirmation of the previously measured molecular changes. The analysis of the EMT-
associated proteins confirmed previous findings of the altered gene expression of CDH1, 
VIM and FN1 upon stimulation with TGF-β (Fig. 3.5). 
3.2.1.4 Quantitative mass spectrometry analysis of untreated and treated P5B3 cell 
extracts using 10 ng/ml TGF-β for 5 days  
 
In order to investigate proteomic changes through the stimulation with TGF-β, 25 ug of 
total protein of each growth condition (n=3) was used and label-free quantitative 
proteomics was performed on the complete cell lysate. The generated library based on all 
samples contained 1308 different proteins using a 1 % FDR cut-off. Within this library, 
only 3 EMT markers, CADH1, VIM and FINC, were identified. The comparison of the 
protein peak areas of treated and untreated samples have shown significant changes in the 
expression of VIME and FINC, whereas the decrease in the expression of CADH1 was 
detected, however this decrease did not present a significant difference (Fig. 3.7).  
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Figure 3.6: Representative images of immunofluorescence staining of untreated and treated P5B3 cells after 
incubation with 10 ng/ml TGF-β for 5 days. The cells were stained for the mesenchymal marker 
Fibronectin and Vimentin, as well as the epithelial marker E-cadherin. Staining with DAPI is presented as 
blue and FITC staining represents staining with the marker of interest. The scale bar shows a length of 50 
µm 
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Figure 3.7: Comparison of protein peak areas of E-cadherin (CADH1), Vimentin (VIME) and Fibronectin 
(FINC) for untreated and treated cells of P5B3 using quantitative mass spectrometry analysis (n=3). 
 
For the further analysis, the list of 1308 proteins was reduced through the application of 
a significance cut-off of 0.05. 365 proteins showed significant differences between the 
untreated and treated sample groups. Of these 365 proteins, 195 were additionally 
showing an absolute change of expression of at least 1.5 fold. These 195 proteins were 
applied to an enrichment analysis using the enrichment tools supplied by the Gene 
Ontology Consortium (http://www.geneontology.org/ (Accessed 15.03.18). All together, 
71 unique proteins were assigned to Gene Ontology terms widely associated with 
metastasis (Fig. 3.8A). 33 of these were assigned to “cell adhesion”, 24 to “cell migration” 
and 55 to “tissue development”. Figure 3.8B presents the numbers of unique and shared 
genes of each of the three selected Gene Ontology terms. Furthermore, their expression 
directionality and their assigned categories are represented in a heat map (Fig. 3.8C). 
The terms “cell adhesion”, “cell migration” and “tissue development” were selected due 
to their involvement in the process of EMT. The analysis using Gene Ontology indicated 
a succesful alteration of epithelial cells into an increased mesenchymal cell state. An 
example for protein changes in accordance with the induction EMT are the upregulation 
of migratory proteins, such as ANXA3 (Annexin 3), and ITAV (Integrin Subunit Alpha 
V) and the reduced expression of cytoskeletal proteins, such as KRT19 (Keratin 19). 
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Figure 3.8: Analysis of significant proteins (<0.05) with an absolute fold change of 1.5 and higher using 
Gene Ontology Consortium (http://www.geneontology.org). 71 proteins were assigned to the biological 
terms of “cell adhesion”, “cell migration” and “tissue development” (A). 12 proteins were detected in all 3 
terms (B). The heat map (C) indicates the expression of each protein and the assignment of the proteins to 
each term. Blue = reduced expression, red = increased expression. The colour coding at the side of the heat 
map highlights the assigned group (tissue development = purple, cell migration = blue, cell adhesion = 
green, shared tissue development/cell migration = orange, shared cell migration and cell adhesion = red, 
shared tissue development/cell adhesion = yellow and detected in all 3 terms = grey). 
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3.2.1.5 Time-point optimisation of treatment length with TGF-β of P5B3 through 
the analysis of morphological and gene expression changes 
The initial results strongly support the use of this cell line model for the discovery of 
novel biomarkers associated with the process of disease progression in prostate cancer. 
Based on this, a time point optimisation experiment was performed in which the length 
of the treatment was optimised and selected. The treatment length was limited to 10 days, 
based on the minimal required seeding density of the P5B3 cells for healthy cell growth. 
For the definition of an optimal time point regarding the successful induction of EMT, 
morphological observations and molecular changes were analysed using bright field 
microscopy and qRT-PCR on EMT genes and EMT-TFs.  
 
3.2.1.5.1 Morphological changes in P5B3 over time when treated with 10 ng/ml 
TGF-β 
Cells of P5B3 were treated consecutively for 3, 5, 7 and 10 days with 10 ng/ml TGF-β. 
During this time, the cells were not passaged and kept in one flask throughout the 
duration of the experiment. This was done to ensure the uninterrupted treatment with 
TGF-β. Prior to this, a minimum seeding density was defined as 50 000 cells per T175 
flask to ensure the healthy growth of the cells (data not shown).  
 
During the time point experiment, the media was changed every second day in both 
conditions, untreated and treated. The treated media was supplemented with 10 ng/ml 
TGF-β in each media exchange. The morphological changes in P5B3 across the time 
points are shown in Figure 3.9. It can be seen that untreated P5B3 do not alter their 
morphology throughout the growth on tissue culture plastic for 10 consecutive days. 
Furthermore, the stimulation of P5B3 with TGF-β led, after 3 days, to morphologically 
visible changes, which increased throughout the stimulation, showing the clearest 
difference between treated and untreated cells at day 10 (Fig. 3.9). The treated cells have 
developed an increased elongated cell shape and have shown a separation from the 
neighbouring cells, whereas the untreated cells retained the “cobblestone” morphology 
(Fig. 3.9).  
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Figure 3.9: Morphological appearance of untreated and treated cells of P5B3 after growth over 10 days. 
Brightfield images were taken at the timepoints of 3, 5, 7 and 10 days at a 4x magnification. The scale bar 
indicates 10 µm. 
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3.2.1.5.2 Gene expression changes in P5B3 over time when treated with 10 ng/ml 
TGF-β 
In addition to the morphological changes observed across the 4 time points, analysis of 
the gene expression changes of the previously analysed EMT markers; VIM, CDH1, 
CDH2, FN1, SNAI1, SNAI2, TWIST1 and ZEB1, was performed across the time points 
of 3, 5, 7 and 10 days (Fig. 3.10). The gene expression changes based on the induced fold 
change of the days 5, 7 and 10 were compared to the fold change induced after the 
stimulation for 3 days. Vimentin showed an upregulation after 3 days, however a 
significant stronger increase could be observed after 5 days of stimulation. The vimentin 
expression at time point 7 still presents a significant increase compared to the time point 
of 3 days, however less intense when compared to 5 days (Fig. 3.10A). CDH1, the only 
marker that shows a reduction in its expression is slightly downregulated at the time points 
3, 5 and 10, presenting a similar reduction in their expression without any significant 
differences. The decrease at the time point 7 days presented the strongest and only 
significant decrease (Fig. 3.10B). CDH2 (Fig. 3.10C), FN1 (Fig. 3.10D), SNAI2 (Fig. 
3.10E) and ZEB1 (Fig. 3.10H) have shown a steady increase in the induced gene 
expression fold change from day 3 to day 10. CDH2 and SNAI2 have presented the 
strongest fold change increase at day 10, with a more than 150-fold and 6-fold increase in 
its expression for CDH2 and SNAI2, respectively. The overall analysis highlighted a 
consistent increase of CDH2 from time point to time point (Fig. 3.10C). Despite the 
consistent increase of the FN1 expression, no significant differences were detected 
compared to day 3. It highlights a consistent upregulation of FN1 throughout the length 
of the stimulation. The expression of the EMT-TF SNAI1 showed strong variation for 
the days 5 and 7, and therefore only day 10 presented significant increased expression 
compared to the first induction at day 3 (Fig. 3.10D). ZEB1 presented a consistent 20-
fold change across the time point 3, 5 and 7 days and sharply rose to a significant fold 
change of 60 at day 10. The EMT-TF TWIST1 showed an upregulation of its expression 
throughout the treatment, with a plateau over 5, 7 and 10 days, however, their overall 
expression was very low and, for this reason, the fold change analysis showed large 
variations across repeats and limited significance in their changes was observed (Fig. 
3.10G). Significant differences were detected when comparing expressions of 5 and 7 days 
to 3 days.  
Based on the results of this analysis, in which 50 % of the markers showed their strongest 
upregulation at the time point of 10 days, and the clear morphological changes observed 
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at this time point, 10 days of treatment were selected for the further experimental 
procedures.  
 
Figure 3.10: Gene expression changes of known EMT markers induced in P5B3 upon stimulation with 
TGF-β . The gene expression of Vimentin (A), E-cadherin (B), N-cadherin (C), Fibronectin (D), and the 
EMT-TFs Snail (E), Slug (F), Twist (G) and ZEB1 (H) was measured across four different time points 
using quantitative real-time PCR and 2-ΔΔCT method (Schmittgen, Livak 2008) (n=4). The significance 
analysis was performed comparing the fold change of days 5, 7 and 10 with the fold change difference of 
each gene induced after treatment for 3 days. The gene expression was normalised against the TATA-box 
protein (TBP) gene, which was utilised as reference gene. 
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3.2.1.6 Protein expression changes in P5B3 after treatment with 10 ng/ml TGF-β 
for 10 days using Immunofluorescence staining 
 
To further confirm the changes of expression at time point 10 days, immunofluorescence 
staining of cells was performed. Cells of both treatment conditions were grown on 
coverslips placed inside 24-well plates and the immunofluorescence staining was 
performed inside each well. The staining was performed in triplicate across three separate 
experiments and representative results are shown in Figure 3.11. 
 
Visible changes in their protein expression were detected for all markers based on the 
comparison of untreated and treated P5B3 cells. Untreated P5B3 cells did not show 
VIME expression, and the treatment with TGF-β resulted in an increased expression of 
VIME visible in the cytoplasm. On the other hand, untreated P5B3 cells have shown a 
strong expression of the epithelial cell marker CADH1 in the membranes of the cells, 
which was strongly reduced upon treatment. However, a low protein expression remained 
detectable in the treated cells, indicating a reduction in the protein expression, but not a 
complete loss. The third studied marker, FINC, could be detected in single, untreated 
cells, but a strong increase in its expression was observed through the treatment, resulting 
in its expression in the majority of the cells (Fig. 3.11). In both conditions, the expression 
of FINC was associated with the cytoplasm.   
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Figure 3.11: Representative images of immunofluorescence staining of untreated and treated P5B3 cells 
after treatment for 10 days with 10 ng/ml TGF-β showing the EMT marker E-cadherin, vimentin and 
fibronectin. Staining with DAPI is presented as blue and FITC staining represents staining with marker of 
interest. The scale bar shows a length of 50µm. 
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3.2.1.7 Protein expression changes in P5B3 after treatment with 10 ng/ml TGF-β 
for 10 days using Western blot analysis  
As an additional validation of the protein changes induced through the treatment with 
TGF-β, cell lysates of P5B3 cells in the uninduced and induced cell states were collected 
and analysed using Western blot analysis (Fig. 3.12). The markers analysed were FINC, 
VIME, CADH1 and CADH2. Commonly used loading controls are actins or tubulins, 
which are highly associated with the cytoskeleton. However, during the process of EMT, 
the cytoskeleton is strongly influenced. To counteract potential bias through this, 
Cyclophilin A was selected as loading control. In the analysis of the generated sample 
material, the expression of FINC was consistently upregulated in both biological repeats 
of the treated compared to the untreated samples. The same was shown for VIME. A 
reduction in the expression of CADH1 could also be observed, however the intensity of 
reduction varied between the samples. CADH2 was shown to be upregulated in the 
treated sample 1 and to a smaller extent also in the treated sample 2, and was not 
detectable in both untreated samples. Across all samples, the loading control showed a 
consistent intensity.  
 
 
Figure 3.12: Western blot of cell lysates generated from untreated and treated P5B3 cells. Protein analysis 
of the EMT markers Fibronectin, Vimentin, E-cadherin and N-cadherin. Cyclophilin A was used as loading 
control. 50 µg of protein was loaded for each sample.   
 
 
98 
 
3.2.2 Development of a second inducible model of 
EMT using a prostate cancer cell line derived from a 
metastatic site through stimulation with Transforming 
Growth Factor β 
 
As previoulsy described in section 3.2.1, EMT was sucessfully induced in the single cell 
clone P5B3. This cell clone was derived from the cell line OPCT-1, which is not as well 
studied as other prostate cancer cell lines. For this reason, and for the increase in 
robustness of novel defined biomarkers, it was decided to generate a further cell line 
model of inducible EMT using the well-studied metastatic prostate cancer cell line DU145.  
3.2.2.1 Time point optimisation of treatment length of DU145 through the analysis 
of morphological and gene expression changes. 
3.2.2.1.1 Morphological changes in DU145 over time when treated with 10 ng/ml 
TGF-β  
The treatment of DU145 with TGF-β resulted in a seeminlgy slower reponse over the 10 
days treatment compared to the response observed in P5B3, based on the morphological 
observations over the time course experiment. The first clear changes could be observed 
after 5 days (Fig. 3.13), whereas P5B3 showed visible changes after 3 days of stimulation. 
Furthermore, the morphological changes indicated a response of a subpopulation of cells 
to the stimulation with TGF-β (green cirle. Fig. 3.13), whereas the remaining cells seemed 
to remain unaffected (red circle, Fig. 3.13)  
 
Also in this cell line, the strongest mesenchymal-like cell morphology could be observed 
after 10 days, however the morphology varies from P5B3 (Fig. 3.9). DU145 does not 
develop single cells, but presents grouped islands of elongated cells next to groups of 
epithelial-like cells. These morphological changes were not observed in the untreated 
DU145 throughout the growth for 10 consecutive days in the same tissue culture flask.  
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Figure: 3.13: Morphological appearance of untreated and treated cells of DU145 after growth over 10 days. 
Images were taken at the timepoints of  3, 5, 7 and 10 days at a 4x magnification. The scale bar indicates 10 
µm. 
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3.2.2.1.2 Gene expression changes in DU145 over time when treated with 10 ng/ml 
TGF-β 
The gene expression profiles of EMT markers were studied to further support the 
observed morphological changes. It has to be noted that no dectection of CDH2 (Fig. 
3.14C) was possible, either in the untreated or treated cell state because the detected Ct 
values were equal to the performed negative controls or did not cross the defined 
threshold. 
 
Vimentin showed a 2-fold increase in expression after treatment for 3 days, which further 
increased across 5 and 7 days. These increases were significantly higher compared to 3 
days. After this, the expression of VIM reduced by about 1-fold, presenting a slightly 
lower fold change compared to 3 days. Despite the small differences between these 2 days, 
the difference is significant (Fig. 3.14A).  
 
The strongest change of CDH1 expression was observed after 3 days, with a fold change 
reduction of about 15-fold. This strength of reduction was highly significantly increased, 
compared to the redution at the time points of 5, 7 and 10 days, which plateau at a fold 
change level of about 2 across all 3 time points (Fig. 3.14B). Fibronectin showed no 
change in expression after treatment for 3 days, however a strong and significant 
induction after 5, 7 and 10 days, compared to the change after 3 days, was observed (Fig. 
3.14D). The EMT-TFs SNAI1 and SNAI2 showed a clear increase in their expression, 
presenting across all time points a fold change increase of about 4, both presenting a peak 
at day 7 (Fig. 3.14E+F). The TF TWIST1 however showed a strong increase in expression 
after 3 days, followed by a visibly reduced upregulation at the time points 5, 7 and 10 days. 
The increase after 3 days presented variation across the repeats through which no 
significant differences could be observed compared to the remaining time points (Fig. 
3.14G). The TF ZEB1 showed a consistent upregulation across all 4 time points with the 
highest, and significant increase compared to day 3 at the time point 10 days (Fig. 3.14H). 
 
Based on the most characteristic EMT morphology after 10 days and the clear 
detectability of molecular EMT markers at the same time point, 10 days were selected for 
further studies. The selection of 10 days as a treatment length also enabled an increased 
comparability to the model of P5B3, because the treatment length of both is identical.  
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Figure 3.14: Gene expression changes of known EMT markers induced in DU145 upon stimulation with 
TGF-β . The gene expression of Vimentin (A), E-cadherin (B), N-cadherin (C), Fibronectin (D), and the 
EMT-TFs Snail (E), Slug (F), Twist (G) and ZEB1 (H) was measured across four different time points 
using quantitative real-time PCR and 2-ΔΔCT method (Schmittgen, Livak 2008) (n=4). The expression of 
CDH2 (C) could not be detected. The significance analysis was performed comparing the fold change of 
days 5, 7 and 10 with the fold change difference of each gene induced after treatment for 3 days. The gene 
expression was normalised against the TATA-box protein (TBP) gene, which was utilised as reference gene. 
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3.2.2.2 Protein expression changes in DU145 after treatment with 10 ng/ml TGF-
β for 10 days using immunofluorescence staining  
To further confirm the changes of expression at time point 10 days, immunofluorescence 
staining of cells was performed for observation of potential changes in the protein 
expression of the VIME, CADH1 and FINC (Fig. 3.15). No apparent changes, neither in 
the protein expression nor the protein localisation could be observed for VIME 
comparing both conditions. In both conditions, the expression of VIME was localised in 
the cytoplasm presenting no visual differences in their expression between stimulated and 
unstimulated cells. The expression of VIME in DU145 was previously shown in 
independent studies (Bizzarro, Belvedere et al. 2017, Qin, Pan et al. 2014). Untreated 
DU145 cells showed weak expression of CADH1, which was not detectable after the 
treatment with TGF-β. The strongest change could be observed in the expression of 
FINC, which was initially not detected in untreated DU145 cells and strongly increased 
in its expression after 10 days of treatment.  
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Figure 3.15: Representative images of immunofluorescence staining of untreated and treated DU145 cells 
after treatment for 10 days with 10 ng/ml TGF-β showing the EMT marker E-cadherin, vimentin and 
fibronectin. Staining with DAPI is presented as blue and FITC staining represents staining with marker of 
interest. The scale bar shows a length of 50µm. 
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3.2.2.3 Protein expression changes in DU145 after treatment with 10 ng/ml TGF-
β for 10 days using Western blot analysis  
The strong upregulation in the expression of FINC in both treated compared to the 
untreated samples was also confirmed using Western blot. No clear difference in the 
expression intensity of VIME was shown. However, the band of VIME was presented as 
a double band, of which the higher molecular weight band seems to be reduced, whereas 
the intensity of the lower molecular weight band remains consistent in the treated samples 
(Fig. 3.16). CADH2 could not be detected through Western blot analysis. A lack of CDH2 
expression was also previously shown in the screening of EMT markers via qRT-PCR 
(Fig. 3.14).   
 
 
Figure 3.16: Western blot of cell lysates generated from untreated and treated DU145 cells. Protein analysis 
of the EMT markers fibronectin, vimentin, E-cadherin and N-cadherin. Cyclophilin A was used as loading 
control. 50 µg of protein was loaded for each sample.   
3.2.2.4 Comparison of generated models with the study that defined EMT 
spectrum 
Many studies are focussing on the extreme phenotype of epithelial and mesenchymal cells. 
However, stimulation and induction of a mesenchymal cell state does not always translate 
into a complete change to a mesenchymal cell (Lundgren, Nordenskjöld et al. 2009, Hiew, 
Cheng et al. 2018). Based on these experiences, Huang et al. tried to identify molecular 
characteristics of cells undergoing EMT that will enable the categorisation of cells based 
on their degree of EMT. For this, they studied the expression profiles of 43 ovarian cancer 
cell lines and identified four separate phenotypic subgroups: epithelial, intermediate 
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epithelial (E), intermediate mesenchymal (M) and mesenchymal (Huang, R. Y., Wong et 
al. 2013), based on their expression of EMT markers, including VIM, CDH1, CDH2, 
ZEB1, TWIST1 and SNAI1 (Fig. 3.17). Other genes were studied in addition (e.g. KRT19, 
ITAG5, MMP2 and ZEB2) (Huang, R. Y., Wong et al. 2013). These genes were not 
analysed in the process of this study, instead, other markers, including FN1 and SNAI2 
were used.  
 
A full epithelial cell subtype was characterised in the study of Huang et al. through high 
expression of CDH1 and low expression of all other markers. A full mesenchymal cell 
subtype, however, presented the lowest expression of CDH1, whereas the expression of 
VIM and TWIST1 was the highest. An intermediate E stage shows a reduction of CDH1 
expression and a slight increase in the expression of VIM, CDH2 and ZEB1. The 
transcription factor SNAI1 shows a peak in its expression at an intermediate E stage, 
whereas no differences in the expression of TWIST1 can be shown between epithelial and 
intermediate E. An intermediate M phenotype is characterised by an increased expression 
of VIM and TWIST1. Furthermore, the highest expression of CDH2 and ZEB1 is 
detected at an intermediate M stage and CDH1 is more strongly decreased compared to 
intermediate E. 
 
The comparison of the gene expression changes over time indicates that both models are 
in the intermediate M stage. This was shown through the highest expression of ZEB1 
(Fig. 3.10H and Fig. 3.14H) at 10 days, whereas a reduction of ZEB1 is correlated with a 
full mesenchymal state. Furthermore, for P5B3, CDH2 also shows the strongest 
expression across all time points at day 10 (Fig. 3.10C). In addition, a reduction of CDH2 
correlates with full mesenchymal cell state. Unfortunately, CDH2 was not detectable in 
DU145 and could therefore not be utilised for a more in-depth characterisation Other 
markers, such as TWIST1 (Fig. 3.10G and Fig. 3.14G) and VIM (Fig. 3.10A and Fig. 
3.14A) do not present conclusive correlations with the published proposal, therefore 
further factors most likely influenced the expression of these EMT genes.   
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This image has been removed by the author for copyright reasons 
 
 
 
 
 
 
 
 
 
Figure 3.17: qRT-PCR analysis of selected EMT-associated genes and their expression across 4 distinct 
subtypes of EMT generated by Huang et al, 2013: epithelial, intermediate epithelial (E), intermediate 
mesenchymal (M) and mesenchymal. The images were taken from (Huang, R. Y., Wong et al. 2013). The 
raw data was not available.  
3.2.2.5 Analysis of changes in the migratory behaviour of both cell line models 
upon treatment with 10 ng/ml TGF-β for 10 days using scratch assays 
The study of changes in the migratory capabilities of treated cells, which is an important 
characteristic of cancers developing metastatic potential, was studied through the use of 
scratch assays. These assays are an easy and commonly used method to analyse the 
migratory potential of cells. Here, cells were grown in a monolayer to full confluency, and 
a scratch applied through the layer. The distance between the cellular borders were 
measured at the same location at time point 0 and 24 h. The percentages of the wound 
closure of both conditions were calculated and compared. 
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In P5B3, a complete wound closure could be observed in the induced state of EMT after 
24 hours, whereas the wound closure of P5B3 untreated accounted for only about 6 %. 
These differences present a significant increase in the migratory potential of P5B3 
through the treatment with TGF-β (Fig. 3.18).  
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Figure 3.18: Analysis of changes of migratory capabilities in untreated (U) and treated (T) P5B3. 
Morphological observations and measurements were performed at time point 0 and 24 hours. 
Measurements were taken at same locations for each well (n=6). A T-test was performed to test for 
significance on the percentage of wound closure.  
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The analysis of DU145 untreated and treated showed a wound closure of 28 and 29 %, 
respectively (Fig. 3.19) over a 24 h period, which did not present a significant difference. 
Difficulties in the imaging of treated DU145 cells were observed. Through the treatment, 
the cells changed their morphology resulting in difficulties in imaging using a conventional 
bright field microscope. In the represented images, black dots are visible within the 
scratch. These are not cells and are most likely caused by cellular debris or scratches on 
the tissue culture plastic.  
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Figure.3.19: Analysis of changes of migratory capabilities in untreated (U) and treated (T) DU145 . 
Morphological observations and measurements were performed at time point 0 and 24 hours. 
Measurements were taken at same locations for each well (n=6). A T-test was performed to test for 
significance on the percentage of wound closure.  
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3.3 Discussion 
The aim of this chapter was the development and the characterisation of two EMT 
models based on independent prostate cancer cell lines through the stimulation with 
transforming growth factor β. 
 
The first part of the work focused on the single, highly epithelial cell clone P5B3, which 
was derived from the parental cell line OPCT-1. The initial results, based on the 
stimulation of P5B3 with 10 ng/ml TGF-β, showed morphological changes of the cells, 
exhibiting elongated cell shape and detachment from surrounding cells (Fig. 3.4). 
Furthermore, the analysis of gene expression changes confirmed an upregulation of 
known EMT-induced genes, inducing VIM, FN1, CDH2, SNAI1, SNAI2, TWIST1 and 
ZEB1 (Fig. 3.5). Furthermore, CDH1 was downregulated. Based on this cell lysates of 
both cell line conditions were analysed using quantitative mass spectrometry resulting in 
a significant enrichment of Gene Ontology terms associated with EMT, including “tissue 
development”, “cell adhesion” and “cell migration” (Fig. 3.8). The process of tissue 
development is associated with EMT type I and type II. Type I EMT is involved in the 
formation of new tissue and embryonal structures (Kalluri 2009), whereas in type II EMT 
the process of wound healing leads to the regeneration of tissues (Stone, R. C., Pastar et 
al. 2016) and the development of fibrosis (Section 1.3.2). Alterations in cell adhesion and 
the interaction with the ECM enable the cells to increase their motility and their migratory 
capabilities (Lamouille, Xu et al. 2014).  
 
Focussing on a selection of significantly altered proteins, including ANXA3, ITAV and 
KRT19, showed an additional support to the induction of an EMT-phenotype in P5B3 
(Fig. 3.8). ANXA3 is a calcium-dependent phospholipid-binding protein, which plays a 
role in cell differentiation and migration (Du, Liu et al. 2018), furthermore its deregulation 
was shown in various cancers, such as prostate and hepatocellular carcinoma (Tong, Fung 
et al. 2015). ITAV functions as the alpha chain V of heterodimeric integrins. Together 
with CD61 (integrin beta 3) it functions as a receptor for proteins involved in the EMT 
process, such as fibronectin, vitronectin and metalloproteinases. An increased expression 
of ITAV was also shown to be involved in disease progression in prostate (Cooper, C. R., 
Chay et al. 2002) and colorectal cancer (Waisberg, De Souza Viana et al. 2014). Keratin 
19 is a member of the keratin family. This protein was downregulated through the 
treatment with TGF-β. Previous studies have shown that a knockdown of KRT19 in the 
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breast cancer cell lines MDA-MB-231 and MCF-7 resulted in an induction of cell 
profileration, migration and invasion (Saha, Choi et al. 2017) and furthermore, patients 
with a low expression of KRT19 have shown a significantly worse survival rate compared 
to patients with a higher KRT19 expression shown in neuroblastoma patients (Nozato, 
Kaneko et al. 2013). Based on the morphological changes to an increased mesenchymal 
cell type, as well as molecular and proteomic changes related to the process of EMT, the 
stimulation of P5B3 with TGF-β was characterised as an induction of an increased 
mesenchymal phenotype. This hypothesis was further supported by the in-depth analysis 
of cell lysates. This enabled the characterisation of the P5B3 cell line model in a wider 
context, disregarding commonly studied EMT markers.  
 
Studies on cell migration and development of metastasis have shown that migration can 
take place either as single cells or in collective sheets (van Zijl, Krupitza et al. 2011). 
Furthermore, the degree of EMT seems to affect the cell morphology where it was shown 
that cells in an intermediate epithelial/mesenchymal cell state can present cell cluster 
formation (Huang, B., Jolly et al. 2015) with cells showing EMT induced genes or double 
positive cells presenting epithelial and mesenchymal markers (Fustaino, Presutti et al. 
2017). Upon stimulation of both cell lines, morphological changes have presented 
themselves through the development of single, elongated cells (P5B3) (Fig. 3.9) and 
grouped elongated cells (DU145) (Fig. 3.13). The morphological differences between 
both models could highlight potential differences in their stage of EMT, in which P5B3 
is further along the EMT pathway compared to DU145. This hypothesis, however, is 
solely based on morphological observations. Furthermore, it needs to be highlighted that 
DU145 is a heterogeneous cell line with different cell populations, which can potentially 
give some indication of the limited morphological response of DU145 to the stimulation 
with TGF-β. Chunthapong et al. have shown that DU145 cells can be separated into 2 
subpopulations, which they named as DU145-E (epithelial) and DU145-F (fibroblastic-
like), of which the latter presented a higher invasive phenotype compared to the other 
(Chunthapong, Seftor et al. 2004). These differences in the phenotype of subpopulations 
of cells within DU145 might explain and correspond to the differential response of cells 
within the cell line model of EMT (Fig. 3.13). It might be the case that single, responding 
cells present a similar EMT-state compared to P5B3, whereas the remaining non-
responding cells inhibit strong morphological changes.  
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The time point optimisation experiment, based on EMT-associated gene expression 
analysis, has shown strong changes in the majority of the analysed EMT markers and 
therefore 10 days stimulation was selected for the future work (Fig. 3.10 and Fig. 3.14). 
The analysis of protein expression in P5B3 untreated and treated for the proteins CADH1, 
CADH2, VIME and FINC using Western blot (Fig. 3.12) and immunofluorescence 
analysis (Fig. 3.11) correlated with the measured gene expression. For DU145, the changes 
in the protein profile with regard to EMT was most clearly visible for FINC, which was 
strongly expressed in treated cells compared to no visible protein expression based on 
immunofluorescence staining (Fig. 3.15) and Western blot analysis (Fig. 3.16). The 
increased expression was also supported by a more than 15-fold upregulation of FN1 
after 10 days of stimulation (Fig. 3.14). Vimentin expression was already present in 
untreated DU145 and no apparent upregulation of this protein could be seen using either 
method, whereas a 2 to 3-fold upregulation of VIM was observed on a molecular level 
(Fig. 3.14). Confirming previous qRT-PCR (Fig. 3.14) results, no expression of CADH2 
was detectable using Western blot analysis (Fig. 3.16).  
 
Furthermore, the comparison of the gene expression profiles of P5B3 (Fig. 3.10) and 
DU145 (Fig. 3.14) according to the definitions of EMT subtypes (Fig. 3.17) (Huang, R. 
Y., Wong et al. 2013) has indicated that both generated models are present at an 
intermediate mesenchymal cell stage and have not fully converted to a mesenchymal cell 
stage (Huang, R. Y., Wong et al. 2013). A complete transition to a full mesenchymal 
phenotype was not achieved, potentially due to the restricted length of treatment or the 
use of a single cytokine for the induction of EMT. The EMT program can be initiated 
through various stimuli, including surrounding cells and soluble factors. One of these 
factors is TGF-β, however this cytokine is only one part of the microenvironment. The 
combination of multiple cytokines might have supported a full transition to a 
mesenchymal cell type (Sistigu, Di Modugno et al. 2017). 
 
Overall, the analysis of molecular and protein-based EMT-markers have highlighted a 
change of expression correlating to a more mesenchymal cell state. Furthermore, 
morphological changes indicated a response to the stimulation with TGF-β, which 
presented itself with single, elongated cells of P5B3 (Fig. 3.9) and grouped, elongated cells 
of DU145 (Fig. 3.13). Based on these analyses, a successful induction of an increased 
mesenchymal-like phenotype could be confirmed in both cell line models induced 
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through the stimulation with 10 ng/ml TGF-β. For this reason, both models were selected 
for the generation of multi-omic profiles based on their molecular and proteomic changes 
of core-EMT markers.   
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4. Chapter IV – Generation and characterisation 
of trancriptomic and proteomic profiles of two 
inducible models of epithelial to mesenchymal 
transition 
4.1. Introduction 
Cancer is a heterogeneous disease and various changes in omic levels, such as the 
transcriptome and proteome, can lead to changes in pathways that alter downstream 
processes such as disease development and progression. To date, many one-dimensional 
studies (Huang, S., Chaudhary et al. 2017), focussing on a single omic level, have been 
performed characterising cancerous material from cell lines (Bainbridge, Warren et al. 
2006, Beck, Schmidt et al. 2011), in vivo models (Takaishi, Wang 2007) and real-life tumour 
tissue made available through clinical studies (Shukla, Sudhanshu, Zhang et al. 2016, Long, 
Xu et al. 2014). However, despite regular discoveries of novel disease-associated markers 
and deregulated pathways of significance, novel findings rarely proceed further into 
clinical trials (Poste 2011). Reasons for this are difficulties in the translation of wet-lab 
findings into a clinical setting (Drucker, Krapfenbauer 2013) and the fact that many 
studies are performed studying solely the transcriptome; and such findings do not 
necessarily translate into changes in the protein expression (Vogel, Marcotte 2012). For 
this reason, improvements could be made through the use of multi-platform based 
profiling (Murphy, Murphy et al. 2018, Kulasingam, Vathany, Pavlou et al. 2010). Such an 
integration of multi-omics data could result in an accelerated discovery of novel 
biomarkers, potentially presenting more robust and reliable findings that are easier 
translated into a clinical validation process (Seyhan 2010).  
 
In the case of cancer, the survival-limiting factor is, in the majority of cases, the 
development of distant metastases (Chaffer, Weinberg 2011). During metastasis changes 
at various omic levels result in alterations in gene and protein expressions, which enable 
primary tumours to invade the surrounding tissue, disperse throughout the body and to 
initiate the growth of secondary tumours at distant sites (Valastyan, Weinberg 2011). 
Based on the potential alterations of involved features across the different transcriptional 
and translational steps from a genetic sequence to the proteins, the use of multi-omics 
profiling presents a promising possibility to derive an increased understanding of changes 
in the signalling pathway. Such an understanding would potentially not be possible 
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through the analysis of a single-omic approach (Seyhan 2010). Therefore, the multi-omics 
study of EMT in prostate cancer could contribute to a better understanding of the 
underlying changes enabling tumours to invade (Balbin, Prensner et al. 2013).  
4.1.1 Summary of commonly used gene expression analysis methods 
for the generation of transcriptomic profiles 
The activation of a gene results in its expression in the form of a so-called messenger 
RNA (mRNA) and the abundance of mRNAs can give indications in their activity. The 
comparison of gene expression changes between multiple groups, such as diseased or 
healthy, can highlight underlying patterns and subtypes relevant for the study of interest, 
such as cancer. Gene expression profiles can be generated from in vitro and in vivo, or even 
patient material, and can be utilised for the discovery and validation of novel markers 
associated with biological processes or disease states.  
 
Two routinely-used methods for the study of the whole transcriptome are available and 
these are microarray profiling (Baldi, Hatfield 2011) and RNA-sequencing (Wang, Z., 
Gerstein et al. 2009). Both methods enable the analysis of coding and non-coding RNA 
and are routinely and successfully applied in the field of cancer research. An example of 
the successful application of microarray analysis was shown in the study of Lapointe et al, 
which profiled 225 prostate tumours for the identification of clinically relevant subtypes 
of PCa patients (Lapointe, Li et al. 2004). On the other hand, RNA-sequencing analysis 
was successfully used for the generation of 585 patient-derived gene expression profiles, 
which resulted in the identification of PCAT14 as a significant predictor for the 
development of metastasis, as well as biochemical-progression free survival (Shukla, 
Sudhanshu, Zhang et al. 2016). Both examples have shown that the study of 
transcriptomic profiles, independent from the generated platform, can generate 
meaningful outputs, potentially resulting in future clinically utilised information.  
 
For both methods, RNA is extracted from a specific sample of interest, such as cell line 
material or tissue sections and cDNA is generated and tagged with either a fluorescence 
label or a sequencing adaptor. In the case of a microarray analysis, the cDNA material is 
then hybridised onto an array, which is covered with thousands of pre-defined DNA spots 
and incubated. During this step, the fluorescent-tagged cDNA can bind to covalent 
strands of DNA on the chip. After this, non-bound and non-specific bound cDNA 
molecules are removed during a washing step, and only specific bound cDNA is further 
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analysed. In the end, the array is scanned and excited with a laser, resulting in the ability 
to detect fluorescence intensity records for each DNA spot, presenting a single probe ID 
(Schulze, Downward 2001). In silico processing enables the normalisation and 
quantification of mRNA for each gene of interest. After this, expression intensities can 
be analysed, for example through the comparison of genes or sample groups.  
 
RNA-sequencing started with the development of a chain-termination sequencing by Dr 
Frederick Sanger, which is therefore also called Sanger-sequencing (Sanger, Coulson 
1975). This method is the gold standard for the sequencing of single genes and is still 
commonly used for the identification of the genetic sequence of single genes. The second 
generation of sequencing methods, mainly known as next-generation sequencing (NGS) 
enables the massive-parallel analysis and quantitation of thousands of genes. In this case, 
the most commonly used approach is a process called “Sequencing by synthesis” (SBS). 
Various companies, such as Illumina (Bentley, Balasubramanian et al. 2008) and Applied 
Biosystems (Voelkerding, Dames et al. 2009) are offering this type of sequencing. In this 
study, the RNA-sequencing was performed on an Illumina NextSeq500, therefore the 
sequencing method is described based on the companies’ approach.  
 
SBS can be divided into 2 major steps, cluster generation and the actual sequencing. 
Initially, libraries of cDNA are generated. Adapter regions are added on both sides, then 
the cDNA is transferred onto a flow cell. This flow cell is a glass slide containing two 
types of oligos corresponding to one or the other adapter regions previously added to the 
cDNA. Initial copies of the bound cDNA fragments are generated, and the original 
template removed. The generated copy is then used to create clusters of identical 
complementary template molecules based on bridge amplification (Buermans, Den 
Dunnen 2014). After this, sequencing of the generated strands begins. During the cluster 
analysis, repeats of both strands are generated and for the first sequencing, one type of 
molecule is removed and the sequential extension of cDNA copies by fluorescent-tagged 
nucleotides is performed. The fluorescence tag differs for each single nucleotide, 
furthermore each nucleotide is attached to a terminator sequence. Every cycle, one 
nucleotide binds to the cDNA attached to the flow cell, the fluorescence is detected, and 
the terminator removed. This enables the binding of a new nucleotide to the analysed 
strand (Buermans, Den Dunnen 2014, Bentley, Balasubramanian et al. 2008). After a 
predefined number of cycles, the generated strand is removed, and a complete 
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complementary sequence is generated. This sequence is then used as a template for a 
second round of sequencing (Buermans, Den Dunnen 2014). The previously described 
sequencing process is repeated, resulting in so-called paired-end sequencing products. In 
silico processing of the generated reads enables the identification and quantification of 
RNA molecules in the analysed sample material.  
 
Despite the successful application of both methods, RNA-sequencing offers strong 
advantages over microarray profiling. These include the unbiased screening of RNA 
present within the sample, which is limited in microarray analysis by the use of predefined 
probe sequences (Kukurba, Montgomery 2015). Furthermore, novel transcripts and gene 
variants at lower abundances can be routinely detected using RNA-sequencing. RNA-
sequencing presents a broader dynamic range that can provide a more accurate detection 
of strong differentially expressed genes (Zhao, S., Fung-Leung et al. 2014, Nookaew, 
Papini et al. 2012). Microarray analysis shows limitations in the accurate quantification of 
very low and very highly expressed genes and transcripts (Kukurba, Montgomery 2015). 
Furthermore, microarray analyses generate gene expression values for multiple probe IDs 
per gene. These probe IDs cover different sequence segments of each gene and the 
binding affinity can vary. This commonly results in variations related to their significance 
and association across genes and can therefore limit the discovery of markers.  
4.1.2 Summary of commonly used protein expression analysis methods 
for the generation of proteomic profiles  
Proteomic profiles can be generated using mass spectrometry analysis. The major options 
available can be categorised into three main approaches. Data-dependent, also called 
information-dependent acquisition (IDA/DDA) (Fig. 4.1A), targeted proteomics through 
selected reaction monitoring (SRM), also known as multiple reaction monitoring (MRM) 
(Fig. 4.1B), and data-independent acquisition (DIA) (Fig. 4.1C) (Sajic, Liu et al. 2015, Hu, 
Noble et al. 2016, Sidoli, Lin et al. 2015).  
 
All three analysis methods can be performed on tandem mass spectrometers, also known 
as MS/MS or MS2. During an MS/MS analysis precursor ions (ions of a defined m/z ratio) 
are identified in a survey scan (MS1). The ions are then, unfiltered or filtered, selected for 
further fragmentation (Edmond de Hoffmann, Vincent Stroobant 2007). These 
fragments are then detected in fragment ion spectra (MS2), matched to a library and the 
peptides are identified based on their amino acid sequences.  
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Figure 4.1: Schematic representation of the three major mass spectrometry analysis methods. A = shotgun 
or data-dependent acquisition, B = selected reaction monitoring (SRM) or multiple reaction monitoring 
(MRM) and C = data-independent acquisition (DIA), such as SWATH MS (Liu, Yansheng, Huettenhain et 
al. 2013) 
 
Using data-dependent analysis (DDA), the most abundant ions are selected after the MS1 
scan and subjected to further fragmentation and detection in MS2. An advantage of this 
approach is that it does not require any prior knowledge about the analytes and enables a 
hypothesis-free analysis (Sidoli, Lin et al. 2015, Aebersold, Mann 2016). Despite this, a 
DDA approach also presents limitations, mainly based on the sampling of most abundant 
ions, which can vary in each sample. For this reason, the reproducibility is very limited. 
Furthermore, the detection of low abundance peptides is difficult, and an accurate 
quantification of co-eluting peptides is challenging (Sidoli, Lin et al. 2015, Hu, Noble et 
al. 2016). 
 
The second analysis method is the use of selected reaction monitoring (SRM). Here, a 
predefined group of previously identified peptides is selected in MS1 and analysed in MS2. 
This enables a reproducible quantification of targets but requires prior knowledge of the 
peptides of interest (Hu, Noble et al. 2016). Based on the prior knowledge and its defined 
selection, an SRM analysis presents a high degree of sensitivity, which enables therefore 
the detection of low abundance proteins. However, the analysis is restricted to a selection 
of pre-defined proteins of interest (Aebersold, Mann 2016).  
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The last analysis method widely used for the analysis of the proteome is called DIA (Sidoli, 
Lin et al. 2015). Specific DIA acquisition methods are available, such as SWATH-MS 
(Gillet, Navarro et al. 2012), Shotgun-CID (Purvine, Eppel* et al. 2003) and MSE (Waters, 
2018, (Plumb, Johnson et al. 2006). In this study, the generated protein lysates were 
analysed using SWATH-MS (Gillet, Navarro et al. 2012). SWATH-MS stands for 
sequential window acquisition of all theoretical fragment ion mass spectra (Ludwig, Gillet 
et al. 2018, Gillet, Navarro et al. 2012). Here fragment ion spectra of each precursor ion 
within a defined m/z window are measured, enabling the generation of multiplexed 
recordings of all peptides present. The analysis of m/z windows is performed through 
their cycling across the complete m/z precursor range. In the initially developed DIA 
approach, the width of the m/z window was defined as an equal width across the complete 
m/z range, however novel developments enable nowadays the use of variable m/z 
windows (Zhang, Y., Bilbao et al. 2015, Ludwig, Gillet et al. 2018). These variable m/z 
are useful for mass regions of higher precursor density or intensity, resulting in increased 
protein identifications (Zhang, Y., Bilbao et al. 2015). The importance in this approach is 
the ability to assign the three-dimensional information (retention time, fragment ion m/z 
and intensity) correctly. This information can be matched to a library, whereas the correct 
identification and quantification depends on the quality of the previously generated library 
(Schubert, Gillet et al. 2015). Overall, a DIA approach enables a more in-depth analysis 
(Borràs, Sabidó 2017) and high-throughput analysis of sample material. Furthermore, an 
improved quantification of low abundance proteins is possible; however, SRM still 
presents a better ability for undertaking this task, based on its high sensitivity in the 
quantitation of targeted proteins and peptides (Hu, Noble et al. 2016).  
 
In the previous chapter, two inducible models of EMT were successfully generated and 
characterised through the analysis of morphological, gene and protein expression changes. 
The generated data confirmed the induction of an EMT phenotype, enabling the use of 
these models for the further scope of the study.  
 
This chapter will describe the generation of matching transcriptomic and proteomic 
profiles of both cell line models in their “natural” and induced cell state and the use of 
these profiles for the in-depth characterisation of changes in underlying pathway through 
the use of Metacore™, a pathway analysis tool. Each cell line and omic profile will be 
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analysed separately and in combination with their proteomic counterpart. Based on this, 
the chapter is separated into multiple parts.  
 
• Initially, the generated omics profiles will be used to validate the successful EMT 
induction through the repeated analysis of the well-studied EMT markers (CDH1, 
CDH2, VIM, FN1, ZEB1, SNAI1, SNAI2, TWIST1). The repeated comparison of 
gene and protein expression changes in both cell line models and omic levels will 
ensure the induction of EMT throughout the dataset generation experiment. 
 
• A selection of significant altered markers (genes or proteins) will be identified and 
applied using Metacore™ pathway analysis. The selection of these markers and the 
application of these, will enable the validation of EMT induction and potential 
identification of additionally affected pathways through the stimulation with TGF-β. 
This step will be used as additional quality control for the induction of EMT. The 
pathway analysis will highlight potential off target effects on pathways that might alter 
the desired phenotypic changes. 
 
• To identify the impact of matching sample collection on the correlation of gene and 
protein expression, matching markers will be selected and a correlation analysis 
performed. This analysis will help to highlight potential improvements possible 
through the parallel extraction of RNA and protein.  
 
The successful performance of these steps will enable the use of these profiles for their 
integration and the identification of a core marker set, which will be performed in chapter 
5.  
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4.2 Results 
The hypothesis behind the study was that matching transcriptomic and proteomic profiles 
from the same cells in the same condition could facilitate the discovery of novel disease-
associated biomarkers (Seyhan 2010) and that markers with a concordant expression on 
a transcriptomic and proteomic profile could indicate a more robust and reliable 
biomarker, based on a consistent stability enabling long term detectability. Furthermore, 
the majority of large patient-derived omic profiles, which are publicly available, have been 
generated through transcriptomic and genomic analyses, and only limited information was 
provided on the proteome of these samples. An example for this is “The Cancer Genome 
Atlas” (Tomczak, Czerwinska et al. 2015), which generated multi-omics profiles of more 
than 30 cancer types. These profiles cover coding and non-coding transcriptomics, as well 
as single nucleotide variants and copy number variations. Based on this, the inclusion of 
quantitative proteomic profiling could increase the implications of detected markers and 
their potential utility as therapeutic targets, especially since the majority of approved 
therapeutic drugs target cellular proteins (Landry, Gies 2008). 
 
4.2.1 RNA-sequencing analysis of RNA extracted from treated and 
untreated P5B3 and DU145 cells 
4.2.1.1 Preparation of sample material, analysis and data output 
RNA was extracted from four different experimental cell groups; P5B3 untreated, P5B3 
treated, DU145 untreated and DU145 treated. A reduced number of biological replicates 
for both treatment conditions of DU145 (n=9) were used due to space limitations on the 
analysis platform. As part of the RNA extraction, a DNase treatment was performed for 
each sample to ensure the complete removal of genomic DNA from the RNA samples. 
This step was necessary due to the nature of the sequencing approach. The sequencing is 
performed on cDNA generated from the isolated RNA. Presence of genomic DNA could 
affect the quality of the generated data and bias the results, since it is not possible to 
differentiate between reads generated from cDNA and reads generated from genomic 
DNA.  
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To confirm the successful removal of genomic DNA, 9 out of 38 samples were randomly 
selected and used as template for a quantitative real-time PCR analysis. Previously 
generated cDNA of the same cell line models was used as positive control. The presence 
of genomic DNA in the analysed samples would result in the detection of the control 
gene. An absence of genomic DNA is shown through the absence of an amplification 
product in the randomly selected samples. All tested samples were showing no measurable 
CT value in the RNA-sequencing samples and therefore a negative result for the presence 
of genomic DNA (Table. 4.1).  
 
Table 4.1: Representative analysis of 9 randomly selected samples of both cell line models for the testing of 
the presence of genomic DNA using quantitative real-time PCR (n=2). PCR primers for the reference gene 
TBP were used for the analysis.  
Sample Cycle Time 
P5B3U T8 Not detected 
P5B3U T9 Not detected 
P5B3U T12 Not detected 
DU145U T1 Not detected 
DU145T T1 Not detected 
DU145T T4 Not detected 
P5B3T T13 Not detected 
P5B3U T14 Not detected 
P5B3T T17 Not detected 
Positive control 28.36 
Positive control 28.1 
 
The negative results for the detection of genomic DNA in the sample material allowed 
further quality control of the samples prior to the RNA-sequencing analysis. RNA for use 
in sequencing approaches has to be of high quality. For the assessment of the quality, the 
so-called “RNA Integrity Number” (RIN) can be defined. The RIN output is a value 
between 1 and 10, of which 10 indicates the best quality, representing RNA in the least 
degraded form (Kukurba, Montgomery 2015). For this study, the cut-off was defined as 
a RIN of 8 or higher and a concentration of 200 ng/µl per sample, as this was requested 
by the DeepSeq facility, which further processed the extracted RNA and generated the 
transcriptomic profile of each supplied sample. Each sample was analysed using the 
Agilent RNA 6000 Nano Kit with RNA Nano Chips (See Appendix). In Table 4.2 the 
generated RNA concentrations and RIN values are shown for each analysed sample. All 
analysed samples have shown a RIN of 10 and a concentration above 200 ng/µl and 
therefore passed the quality criteria for downstream analysis using RNA-sequencing.  
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Table 4.2: List of generated samples of both cell line models and treatment conditions and their 
corresponding RNA concentration (ng/µl) and RNA Integrity Number (RIN), which were downstream 
subjected to RNA-sequencing analysis. 
Sample ng/µl RIN  Sample ng/µl RIN 
P5B3U T7 513.15 10  DU145U T2 411.57 10 
P5B3U T8 401.10 10  DU145U T3 402.65 10 
P5B3U T9 401.72 10  DU145U T5 573.51 10 
P5B3U T10 416.28 10  DU145U T6 517.58 10 
P5B3U T11 443.69 10  DU145U T13 419.72 10 
P5B3U T12 349.46 10  DU145U T15 424.10 10 
P5B3U T13 498.83 10  DU145U T16 353.45 10 
P5B3U T16 448.16 10  DU145U T17 414.06 10 
P5B3U T17 683.22 10  DU145U T18 335.80 10 
P5B3U T18 479.62 10  DU145T T1 317.13 10 
P5B3T T7 449.29 10  DU145T T2 445.77 10 
P5B3T T8 525.28 10  DU145T T3 393.17 10 
P5B3T T9 375.12 10  DU145T T4 427.92 10 
P5B3T T10 492.79 10  DU145T T6 479.32 10 
P5B3T T11 435.13 10  DU145T T13 585.57 10 
P5B3T T12 385.11 10  DU145T T15 359.81 10 
P5B3T T13 416.96 10  DU145T T17 395.60 10 
P5B3T T16 504.81 10  DU145U T2 411.57 10 
P5B3T T17 439.02 10 
P5B3T T18 439.10 10 
 
The RNA-sequencing analysis and data generation was performed by the DeepSeq facility 
located at the University of Nottingham, UK (DeepSeq, 2019). The delivered results of 
their analysis were FASTQ files of each sample and both read directions. FASTQ files are 
a file format that enables the storage of sequence data in a text format (Cock, Fields et al. 
2009). The files were subjected to in silico processing using the BaseSpace Sequence Hub 
of Illumina (BaseSpace, 2019) with the Tuxedo suite (Trapnell, Cole, Roberts et al. 2012). 
Here, the reads generated in this RNA-sequencing experiment were associated to one of 
three different sequence types within the genome; so-called exonic, intronic and intergenic 
regions (Fig. 4.2). The exonic region is comprised of the exons and the untranslated 
regions (UTR). Untranslated regions can be separated into 5’UTR and 3’UTR, which are 
located upstream and downstream of the coding regions, respectively, whereas exons 
present the sequences that code for genes. The other two sequence types are the intragenic 
and intergenic regions, which are non-coding regions either located within a gene, 
between the exons, or between genes, outside the coding regions, respectively.  
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In the analysed samples, the majority of the reads were assigned to the exonic (Fig. 4.2), 
followed by intronic regions. The least number of reads were assigned to intergenic areas. 
In P5B3, the percentages of aligned sequences were identical, whereas in DU145, a small 
reduction in the exonic and a small increase in the number of reads assigned to the intronic 
region could be observed upon treatment.  
 
 
Figure 4.2: Graph indicating the average percent alignment of all reads to exonic, intronic and intergenic 
regions for the 4 analysed sample sets, namely P5B3 untreated (n=10), P5B3 treated (n=10), DU145 
untreated (n=9) and DU145 treated (n=9). 
 
The second output type through the data alignment and processing resulted in a 
normalised read count per gene and sample. This value is represented by the metric 
fragments per kilobase of transcript per million (FPKM) mapped reads (Trapnell, C., 
Williams et al. 2010). This method takes into account the variation of read counts based 
on the length of a gene. Longer genes will produce a higher number of read counts 
compared to shorter genes, despite the same expression intensity. For this reason, the 
count of fragments per gene is divided by its total length. The output value is the 
previously mentioned FPKM. In total, 26354 genes based on 56891 transcripts were 
detected within the analysed sample set (Tab. 4.3). 
 
Table 4.3: Summary of detected genes and transcripts within the analysed sample set of untreated (n=10) 
and treated (n=10) P5B3 and untreated (n=9) and treated (n=9) DU145 cell line samples 
 Unique genes Transcripts 
RNA-sequencing analysis 26354 56891 
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4.2.1.2 Validation of EMT gene panel in generated RNA-sequencing profiles  
The initial analysis of the generated RNA-sequencing data was focused on the validation 
of a successful EMT induction. For this, the previously analysed EMT-associated genes 
(section 3.2.1.2), VIM, CDH1, CDH2, FN1, TWIST1, ZEB1, SNAI1 and SNAI2 were 
selected and their expression compared between the untreated and treated cell line 
conditions for P5B3 and DU145 (Fig. 4.3). In the sample set of P5B3, 7 out of 8 genes 
were detected with a significant difference between the untreated and treated cell state, 
showing an upregulation of VIM (Fig. 4.3A), CDH2 (Fig. 4.3C), FN1 (Fig. 4.3D), ZEB1 
(Fig. 4.3H), SNAI1 (Fig. 4.3E) and SNAI2 (Fig. 4.3F), and a downregulation of CDH1 
(Fig. 4.3B). The expression of TWIST1 (Fig. 4.3G) has shown no significant difference 
between untreated and treated cell line samples. A high variability in the expression of 
this gene was already shown in the initial qRT-PCR analysis, limiting the significance 
between both cell line conditions.  
 
In DU145, TWIST1 (Fig. 4.3G) and CDH2 (Fig. 4.3C) were not detected (nd), however, 
the remaining 6 markers were significantly deregulated in their expression between 
untreated and treated conditions. CDH1 (Fig. 4.3B) was significantly reduced, whereas 
VIM (Fig. 4.3A), FN1 (Fig. 4.3D), ZEB1 (Fig. 4.3H), SNAI1 (Fig. 4.3E) and SNAI2 (Fig. 
4.3F) showed a significant increase. All together in P5B3 and DU145, the expression of 
significantly deregulated genes was detected according to the expectation of an induced 
EMT phenotype, meaning that all significant genes, aside from CDH1, were upregulated 
through the stimulation with TGF-β. CDH1 was downregulated in both cell lines upon 
treatment.  
 
This analysis confirmed the successful induction of EMT on a transcriptomic level in 
both models and the desired molecular changes within the samples. This allowed their 
use in further analyses and biomarker discovery experiments.  
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Figure 4.3: Gene expression changes of the EMT markers  Vimentin (VIM), E-cadherin (CDH1), N-
cadherin (CDH2), Fibronectin (FN1), Snail (SNAI1), Slug (SNAI2), Twist (TWIST1) and ZEB1 across the 
sample population of untreated and treated P5B3 (n=10 per condition) and DU145 (n=9 per condition) 
represented in FPKM values.  
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4.2.1.3 Analysis of RNA-sequencing derived gene expression profiles of both cell 
line models for the characterisation of underlying pathway changes  
For the further downstream analysis, genes that presented a significant difference between 
the treated and untreated condition after correction for false discovery were selected. The 
statistical analysis performed is described in Methods (section 2.2.6.4). 
4.2.1.3.1 Identification of significant altered genes within the inducible EMT 
model of P5B3 
The analysis of the significantly altered genes detected in P5B3 using the previously 
described filters resulted in a list of 4575 genes, of which 2787 were up- and 1697 were 
downregulated (Fig. 4.8A). The 4575 genes were applied to a hierarchical clustering and 
are presented in a heat map (Fig. 4.4), which has shown a clustering of the samples 
according to their treatment group, without apparent outliers. This indicated a stable 
induction state across all samples.  
 
 
Figure 4.4: Hierarchical clustering of 4575 genes significantly (p-value <0.05) deregulated between untreated 
and treated P5B3 cells (n=10 per condition) using Euclidean distance and complete linkage. 
 
The analysis of induced changes has highlighted a wide range of expression changes, 
ranging from fold change increases +1494.53 to fold change decreases of up to -120.44 
fold. Within the strongest up- and downregulated genes, markers of EMT and metastasis 
association were identified. This included upregulated genes such as CDH11 (+303.40), 
VCAN (+214.21) and TWIST2 (+178.19) and the downregulated markers GKN2 (FC = 
-118.65) and PSCA (FC = -103.70). 
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4.2.1.3.2 Analysis of pathways altered upon stimulation of P5B3 with TGF-β based 
on significant deregulated genes 
For a more detailed analysis of the phenotypic changes induced by the treatment of P5B3, 
the selected genes and their associated fold changes were applied to the MetaCoreTM 
pathway analysis tool from Clarivate Analytics (https://portal.genego.com/) (Park, A., 
Lee et al. 2017, Loughran, Leonard et al. 2018). This software enables the association of 
genes within a given list to defined pathways based on pathway topology. Pathway 
topology enables the analysis of pathways using not only the detection of markers, but 
also their expression information, to compute gene level statistics (Khatri, Sirota et al. 
2012). The involvement of the genes of a dataset in the described pathways is indicated 
through a p-value, the corrected p-value and a ratio of detected genes compared to the 
total number of genes within the pathway. Furthermore, each of the enriched pathways 
is assigned to a broader category, such as “cell adhesion” or “development”.  
 
In the case of the significant altered genes of P5B3, a total of 779 pathways were shown 
to be significantly enriched, using a cut-off of <0.05 after correction for false discovery 
(FDR). Within the top 50 most significantly enriched pathways, the majority of pathways 
were associated with the categories of “Development”, followed by “immune response” 
and “cell adhesion” (Fig. 4.5). 
 
 
Figure 4.5: Top 50 most significantly enriched pathways based on significant genes in P5B3 grouped by 
their respective categories (n=4575). List derived from Metacore™ (accessed 02/07/18). 
 
The top 15 most significantly enriched pathways are shown in table 4.4. Of these, 10 
pathways are directly associated with TGF-β treatment, the process of EMT or the 
development of metastasis. The remaining 5 pathways are mainly connected to 
cytoskeletal rearrangements, which are commonly occurring during the change of 
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epithelial cells to cells with mesenchymal cell properties (Sun, BO, Fang et al. 2015, Nalluri, 
O'Connor et al. 2015). 
  
Table 4.4: Top 15 most significant associated pathways of significantly deregulated genes P5B3 sorted by 
significance after FDR. List derived from Metacore™ (accessed 02/07/18). 
Category Pathway Total 1 In data2  
Development 
TGF-β-dependent induction of EMT via 
RhoA, PI3K and ILK 
46 33 (72 %) 
Development 
Regulation of epithelial-to-mesenchymal 
transition (EMT) 
64 40 (63 %) 
Cytoskeleton 
remodelling 
Regulation of actin cytoskeleton organization 
by the kinase effectors of Rho GTPases 
58 37 (64 %) 
Cell adhesion ECM remodelling 55 35 (64 %) 
Immune 
response 
IL-1 signalling pathway 82 44 (54 %) 
Not assigned ErbB2-induced breast cancer cell invasion 67 38 (57 %) 
Not assigned 
TGF-β 1-mediated induction of EMT in 
normal and asthmatic airway epithelium 
44 29 (66 %) 
Not assigned 
TGF-β 1-induced transactivation of membrane 
receptors signalling in HCC 
50 31 (62 %) 
Development 
TGF-β-dependent induction of EMT via 
SMADs  
35 25 (71 %) 
Not assigned 
Role of stellate cells in progression of 
pancreatic cancer 
60 34 (57 %) 
Not assigned Stimulation of TGF-β signalling in lung cancer 48 29 (60 %) 
Not assigned Glomerular injury in Lupus Nephritis 92 43 (47 %) 
Not assigned Stellate cells activation and liver fibrosis 70 35 (50 %) 
Not assigned 
TGF-β-induced fibroblast/ myofibroblast 
migration and extracellular matrix production 
in asthmatic airways 
64 33 (52 %) 
Not assigned 
IGF family, invasion and metastasis in 
colorectal cancer 
33 22 (67 %) 
1Total: Total number of markers present in the pathway 
2In data: Number of identified markers of given pathway through the analysis of generated omic profiles 
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4.2.1.3.3 Identification of significant altered genes within the inducible EMT 
model of DU145 
The dataset of DU145 was applied to the same stringent filters as previously described 
(Methods). Here, this approach resulted in a list of 2303 significantly altered genes, of 
which 1324 were up- and 979 were downregulated (Fig. 4.8B). The hierarchical clustering 
showed a clustering according to treatment group and did not indicate any outliers within 
the samples set (Fig. 4.6).  
 
 
Figure 4.6: Hierarchical clustering of 2303 genes significantly (p-value <0.05) deregulated between untreated 
and treated DU145 cells (n=10 per condition) using Euclidean distance and complete linkage. 
 
The analysis of induced changes highlighted a wide range of expression changes, ranging 
from +84.71 to -50.24 fold. Within the strongest up- and downregulated genes, markers 
of EMT and metastasis association were identified, including BMP2 (84.71) and SPOCK1 
(70.63) as well as the downregulated markers KRT32 (-27.18) and KRT4 (-24.70).  
  
130 
 
4.2.1.3.4 Analysis of pathways altered upon stimulation of DU145 with TGF-β 
based on significant deregulated genes 
For further characterisation, the significant genes were applied to the MetaCoreTM 
pathway analysis tool. Here, 292 pathways were indicated to be significantly enriched 
within the supplied gene list. Within the top 50 most significant pathways, the majority 
were associated with “Cell adhesion”, followed by “Development” and “Cytoskeleton 
remodelling” (Fig. 4.7).  
 
 
 
Figure 4.7: Top 50 most significantly enriched pathways based on significant genes in DU145 grouped by 
their respective categories (n=2303). List derived from Metacore™ (accessed 02/07/18). 
. 
The top 15 most significant pathways are shown in Table 4.5. A large number of pathways 
are associated with cytoskeletal changes and interaction of cells with the ECM. However, 
also pathways involved in the SMAD-dependent and independent signalling activated via 
the TGF-β receptors were enriched. These results show the successful alteration of the 
physiological cell state involving cytoskeletal remodelling as well as the induction of EMT. 
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Table 4.5: Top 15 most significant associated pathways of significantly deregulated genes in DU145 treated 
compared to DU145 untreated. List derived from Metacore™ (accessed 02/07/18). 
Category Pathway Total1 In data2  
Cytoskeleton 
remodeling 
Regulation of actin cytoskeleton organization 
by the kinase effectors of Rho GTPases 
58 
23 
(40 %) 
Not assigned TGF-β signalling via SMADs in breast cancer 47 
20 
(43 %) 
Neurogenesis NGF/ TrkA MAPK-mediated signalling 105 
31 
(30 %) 
Not assigned 
Β-catenin-dependent transcription regulation 
in colorectal cancer 
36 
17 
(47 %) 
Not assigned 
IGF family, invasion and metastasis in 
colorectal cancer 
33 
16 
(48 %) 
Not assigned 
TGF-β 1-induced transactivation of 
membrane receptors signalling in HCC 
50 
19 
(38 %) 
Cell adhesion ECM remodelling 55 
20 
(36 %) 
Not assigned 
Insulin-like growth factor family signalling in 
melanoma 
38 
16 
(42 %) 
Cell adhesion 
Endothelial cell contacts by non-junctional 
mechanisms 
24 
12 
(50 %) 
Not assigned Cytoskeleton and adhesion module 64 
20 
(31 %) 
Cytoskeleton 
remodeling 
Integrin outside-in signalling 49 
17 
(35 %) 
Immune 
response 
Function of MEF2 in T lymphocytes 51 
17 
(33 %) 
Not assigned Causal network (positive) 36 
14 
(39 %) 
Cytoskeleton 
remodeling 
Regulation of actin cytoskeleton nucleation 
and polymerization by Rho GTPases 
46 
16 
(35 %) 
Development 
TGF-β-dependent induction of EMT via 
RhoA,  PI3K and ILK 
46 
16 
(35 %) 
1 Total: Total number of markers present in the pathway 
2 In data: Number of identified markers of given pathway through the analysis of generated omic profiles 
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4.2.1.3.5 Comparison of significant gene expression changes induced in both cell 
lines models upon stimulation with TGF-β 
Both cell line models were treated according to the same treatment regime, including 
synchronised media changes, TGF-β concentrations and sample collection time. Both cell 
lines have shown molecular changes associated with epithelial to mesenchymal transition 
as well as morphological changes associated with a more elongated cell morphology 
(Chapter III).  
 
To see the similarity of molecular changes within both cell line models, the number of 
overlapping genes between both cell lines and their expression directionality were 
investigated. In total 1173 genes were significantly detected in both cell line models, of 
which 699 genes were upregulated and 365 genes were downregulated in both cell lines 
(Fig. 4.8C). 109 of the significant genes showed an inverse regulation, which means that 
an upregulation occurred in one cell line which presented itself as a downregulation in the 
other cell line, and vice versa.  
 
 
Figure 4.8: Significantly deregulated genes across both cell line models . P5B3 treated with P5B3 untreated 
(n = 4575) (A) and DU145 treated with DU145 untreated (n=2303) (B) cell lines model (p-value below 0.05 
after Bonferroni correction). C represents shared significant genes (n = 1173) between both models. Red 
indicates an upregulation, blue a downregulation and green an inverse change of expression comparing both 
models with each other.  
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Hierarchical clustering was applied for the investigation of a correlation between the cell 
line models and to infer whether the relationship of the gene expression is stronger 
between the cell lines or the treatment. The generated heat map (Fig. 4.9) shows a 
clustering of the treated samples together, with a sub-clustering according to their 
respective cell line and treatment.  
 
 
 
Figure 4.9: Hierarchical clustering of significant genes shared between both cell line models (n = 1173). The 
clustering was performed using complete linkage and Euclidean distance. 
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4.2.1.3.6 Identification of shared pathways altered upon stimulation of P5B3 and 
DU145 with TGF-β based on significant deregulated genes 
To analyse further commonalities across the molecular composition of both cell lines, the 
enriched pathways defined through MetaCoreTM were analysed for any overlap. The 
comparison of the top 15 most enriched pathways [Tab. 4.4 (P5B3) and Tab. 4.5 (DU145)] 
showed 5 pathways, which were present in both cell line models. Of these 5 pathways, 2 
are related to the activation of signalling pathways through TGF-β, furthermore another 
pathway is involved in the remodelling of the extracellular matrix (ECM) and the IGF 
family involved in invasion and metastasis in colorectal cancer.  
 
Table 4.6: Shared enriched pathways within the top 15 pathways of both cell lines . Gene numbers per 
pathway and number of detected genes are shown and the coverage of genes within the pathway through 
the defined gene list is indicated as a %. List derived from Metacore™ (accessed 02/07/18). 
Category Pathway 
Total1 
(Genes) 
In data2 
(P5B3) 
In data2 
(DU145) 
Development 
TGF-β-dependent induction of 
EMT via RhoA, PI3K and ILK 
46 33 (72 %) 16 (35 %) 
Cell adhesion ECM remodelling 55 35 (64 %) 20 (36 %) 
Cytoskeleton 
remodelling 
Regulation of actin cytoskeleton 
organization by the kinase 
effectors of Rho GTPases 
58 37 (64 %) 23 (40 %) 
Not assigned 
TGF-β 1-induced transactivation 
of membrane receptors signalling 
in HCC 
50 31 (62 %) 19 (38 %) 
Not assigned 
IGF family, invasion and 
metastasis in colorectal cancer 
33 22 (67 %) 16 (48 %) 
1 Total: Total number of markers present in the pathway 
2 In data: Number of identified markers of given pathway through the analysis of generated omic profiles 
 
4.2.2 Mass spectrometry analysis of cell lysates generated from treated 
and untreated P5B3 and DU145 cells 
For the identification of differentially regulated proteins in P5B3 and DU145 through the 
treatment with TGF-β, a label-free quantitative mass spectrometry analysis was performed 
on whole cell lysates. Here, the prepared sample material was further processed by Dr 
David Boocock and Dr Clare Coveney on a Sciex TripleTOF6600 mass spectrometer 
using two analysis methods enabling the quantitative analysis of the proteome. For this, 
initially a spectral library, based on data-dependent acquisition, was generated using 
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pooled sample material of each sample. This library was used downstream for the 
identification of peaks generated during the data-independent approach (SWATH-MS).  
 
For the library generation, previously generated cytoplasmic and nuclear fractions, 
extracted according to the Abcam subcellular fractionation protocol (Abcam, 2019) were 
included for an increased coverage of potentially present peptides. These fractions were 
previously generated as part of a separate study by Dr Jayakumar Vadakekolathu, follow 
on work to (Harner-Foreman, Vadakekolathu et al. 2017) (data not shown). The 
generation of the spectral library resulted in the detection of 2448 proteins, comprising of 
27981 peptides. This, however, includes shared peptides, which could be originating from 
multiple different proteins. These shared peptides, and also proteins whose identification 
was based solely on shared peptides, were excluded. For this reason, the further analysis 
was performed with a list of 2197 proteins. Each protein identification was based on up 
to 6 single unique peptides. 
  
Table 4.7: Summary of detected proteins and peptides within the analysed sample set of both cell line 
models. Untreated and treated P5B3 (n=10) and untreated (n=9) and treated (n=8) DU145. 
Sample 
Proteins (unique 
peptides) 
Proteins Peptides Spectra 
Library of pooled samples 2197 2448 27981 63469 
 
4.2.2.1 Validation of EMT protein panel in generated mass spectrometry-derived 
protein expression profiles 
As previously performed in the analysis of the generated RNA-sequencing data, the 
generated proteomic data was analysed for their EMT profile. For this, the normalised 
protein peak areas of EMT-associated proteins were selected for both conditions and cell 
lines and analysed for their differences in intensities. Here, VIME, CADH1 and FINC 
were detected in both cell line models. Figure 12 shows the expression changes of these 
proteins in both cell lines. A significant deregulation of VIME, CADH1 and FINC was 
detected in P5B3, however in DU145 only VIME showed a significant change induced 
through the treatment (Fig. 4.10).  
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Overall, the changes indicate an induction of an EMT profile on a proteomic level, 
however in the case of the cell line model of DU145, these changes were not as clear as 
in the model of P5B3.  
 
Figure 4.10: Proteomic changes of vimentin, E-cadherin and fibronectin in cell lysates of untreated and 
treated P5B3 (n=10) and DU145[ n= 9 (DU145U), n=8 (DU145T)] analysed with the Sciex TripleTOF 
6600 using a data-independent acquisition mode (SWATH MS). The data is presented using the normalised 
protein peak area of each protein across the sample population.  
4.2.2.2 Analysis of mass spectrometry derived protein expression profiles of both 
cell line models for the characterisation of underlying pathway changes  
For the further downstream analysis, proteins that presented a significant difference 
between the treated and untreated condition after correction for false discovery were 
selected. The statistical analysis performed is described in Methods (section 2.2.6.4) 
4.2.2.2.1 Identification of significant altered proteins within the inducible EMT 
model of P5B3 
The proteins detected in both P5B3 cell states were analysed as described previously. This 
resulted in the detection of 297 significantly altered proteins, of which 167 were up- and 
130 downregulated (Fig. 4.17A). The protein peak areas of these proteins were applied to 
hierarchical clustering, which confirmed the clustering of the samples according to 
treatment type (Fig. 4.11) (section 2.2.7.2). Furthermore, it highlighted no distinct outliers 
within the population. Despite this, the generated heat map highlights variation across the 
samples of one treatment group.   
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Figure 4.11: Hierarchical clustering of significantly altered proteins in untreated and treated P5B3 (n=10) 
using complete linkage and Euclidean distance (n=297).  
 
The comparison of protein expression across both conditions showed a wide range of 
expression changes with fold changes ranging from +184.84 to -39.42.  The top 3 most 
upregulated proteins were VIME (+181.84), FINC (+19.38) and BGH3 (+15.05), 
whereas the top 3 downregulated proteins were K1C13 (-39.42), LY6D (-6.02) and AGR2 
(-5.91).  
4.2.2.2.2 Analysis of pathways altered upon stimulation of P5B3 with TGF-β based 
on significant deregulated proteins 
After the application of the significant protein list to the MetaCoreTM pathway analysis 
tool from Clarivate Analytics, 96 pathways were significantly enriched. Within the top 50, 
“cytoskeletal remodelling” was the most frequent pathway category. The second most 
common category was “cell adhesion” (Fig. 4.12). This indicates a strong involvement of 
the protein expression with the morphological changes of the cells and the adjustment of 
their cellular changes to a more mesenchymal cell state.  
 
 
Figure 4.12: Top 50 most significantly enriched pathways based on significant proteins in P5B3 grouped by 
their respective categories (n=297). List derived from Metacore™ (accessed 02/07/18). 
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The top 15 most significant pathways enriched through the supplied protein list are shown 
in Table 4.8. The majority of the defined pathways are associated with “Cytoskeletal 
remodelling” and “Cellular adhesion”, highlighting changes in the cellular morphology 
through the stimulation with TGF-β. However, also the “EMT induction via the RhoA, 
PI3K and ILK” pathway is present within the list, showing changes within the system 
that reach further than morphological alterations, such as reduced adhesion and elongated 
cell shapes.  
 
Table 4.8: Top 15 most enriched pathways identified through the protein list of P5B3. List derived from 
Metacore™ (accessed 02/07/18). 
Category Pathway Total1 In data2  
Cytoskeleton 
remodelling 
Regulation of actin cytoskeleton organization 
by the kinase effectors of Rho GTPases 
58 
19 
(33 %) 
Cytoskeleton 
remodelling 
Keratin filaments 36 
13 
(36 %) 
Not assigned 
Inhibition of re-myelination in multiple 
sclerosis: regulation of cytoskeleton proteins 
44 
12 
(27 %) 
Development 
Regulation of cytoskeleton proteins in 
oligodendrocyte differentiation and 
myelination 
58 
13 
(22 %) 
Cell adhesion 
Histamine H1 receptor signalling in the 
interruption of cell barrier integrity 
45 
11 
(24 %) 
Development 
TGF-β-dependent induction of EMT via 
RhoA, PI3K and ILK 
46 
11 
(24 %) 
Cell adhesion Integrin-mediated cell adhesion and migration 48 
11 
(23 %) 
Not assigned LRRK2 in neurons in Parkinson's disease 33 
9 
(27 %) 
Not assigned Cytoskeleton and adhesion module 64 
11 
(17 %) 
Not assigned 
Effect of H. pylori infection on gastric 
epithelial cells motility 
43 
9 
(21 %) 
Apoptosis 
and survival 
NGF/ TrkA PI3K-mediated signalling 77 
11 
(21 %) 
Cytoskeleton 
remodelling 
Neurofilaments 25 
7 
(28 %) 
Transport 
The role of AVP in regulation of Aquaporin 2 
and renal water reabsorption 
50 
9 
(18 %) 
Chemotaxis 
Inhibitory action of lipoxins on IL-8- and 
Leukotriene B4-induced neutrophil migration 
53 
9 
(17 %) 
Cell adhesion Gap junctions 30 
7 
(23 %) 
1 Total: Total number of markers present in the pathway 
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2 In data: Number of identified markers of given pathway through the analysis of generated omics profiles 
4.2.2.2.3 Comparison of pathways altered upon stimulation of P5B3 with TGF-β 
based on significant deregulated genes and proteins  
In further analyses, the top 15 enriched pathways of both P5B3 lists, genes and proteins, 
were compared and this highlighted two shared pathways (Tab. 4.9). One was involved in 
the “Regulation of actin cytoskeleton organisation by the kinase effectors of Rho 
GTPases” and the other one in “TGF-beta-dependent induction of EMT via RhoA, PI3K 
and ILK”. The pathway “Regulation of actin cytoskeleton organization by the kinase 
effectors of Rho GTPases” will be discussed further in subsection 4.4.6.  
 
Table 4.9: Shared enriched top 15 pathways between gene and protein P5B3. List derived from Metacore™ 
(accessed 02/07/18). 
Category Pathway Total1 
In 
data2 
Genes3 Proteins4 
Cytoskeleton 
remodelling 
Regulation of actin 
cytoskeleton organisation by 
the kinase effectors of Rho 
GTPases 
58 
40 
(69 %) 
37 
(64 %) 
19 (33 %) 
Development 
TGF-β-dependent induction 
of EMT via RhoA, PI3K and 
ILK 
46 
33 
(72 %) 
33 
(72 %) 
11 (24 %) 
1 Total: Total number of markers present in the pathway 
2 In data: Total number of identified markers of given pathway through the analysis of generated omic 
profiles 
3 Genes: Total number of genes identified in given pathway through the analysis of generated omic profiles 
4 Proteins: Total number of proteins identified in given pathway through the analysis of generated omic 
profiles 
 
140 
 
 
Figure 4.13: Schematic representation of the pathway describing “TGF-beta-dependent induction of EMT 
via RhoA, PI3K and ILK”. Pathway image was generated with MetaCore™ one-click analysis (Metacore™ 
accessed 02/07/18). Markers covered within either of the lists, genes or proteins, are highlighted with 
intensity bars representing the induced fold change. Red bars indicate an upregulation and blue bars a 
downregulation of the gene/protein and the numbers 1 (genes) and 2 (proteins).   
Overall, a high number of binding proteins (blue symbols) was observed to be covered 
by both the genes and proteins identified in the analysis.  
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4.2.2.2.4 Identification of significant altered proteins within the inducible EMT 
model of DU145 
The proteins detected in both DU145 cell states were analysed as described previously. 
This resulted in the detection of 187 significantly altered proteins, of which 93 were up- 
and 94 downregulated (Fig. 4.17B). The protein peak areas of these proteins were applied 
to hierarchical clustering (complete linkage, Euclidean distance), which confirmed the 
clustering of the samples according to treatment type (Fig. 4.14), indicating no distinct 
outliers within the population. Furthermore, the heat map shows a stronger variation 
between the significant altered proteins across the samples, compared to the previously 
described transcriptomic changes.  
 
 
 
Figure 4.14: Hierarchical clustering of significantly altered proteins in untreated and treated DU145 (n=9 
(DU145U), n=8 (DU145T)) using complete linkage and Euclidean distance (n=178). 
 
Also in this analysis, the intensity of protein expression varied greatly between the treated 
and untreated cells. The two strongest increased proteins were TAGL (8.51) and ITAV 
whereas one of the most downregulated proteins was TADC2 (-3.66).   
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4.2.2.2.5 Analysis of pathways altered upon stimulation of DU145 with TGF-β 
based on significant deregulated proteins 
The analysis of significant altered proteins in DU145 with MetaCore™ highlighted 82 
significantly enriched pathways. Figure 4.15 shows the associated groups of the top 50 
pathways. The top two most frequent categories were associated with “cytoskeleton 
remodelling” and “cell adhesion”, however pathways indicating developmental changes 
were also enriched.  
 
 
Figure 4.15: Top 50 most significantly enriched pathways based on significant proteins in DU145 grouped 
by their respective categories (n=187). List derived from Metacore™ (accessed 02/07/18). 
 
Also here the top 15 enriched pathways were identified and are shown in Table 4.10. A 
strong enrichment of pathways associated with cytoskeleton remodelling and cell 
adhesion is apparent, which might indicate stronger changes in proteins associated with 
these processes.  
  
Total = 50
Cytoskeleton remodeling (8)
Cell adhesion (5)
Development (4)
Immune response (3)
Apoptosis and survival (2)
Blood coagulation (2)
Chemotaxis (2)
Muscle contraction (1)
Oxidative stress (1)
Regulation of lipid metabolism (1)
Stem cells (1)
Transport (1)
Others (19)
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Table 4.10: Top 15 most enriched pathways identified through the protein list of DU145. List derived from 
Metacore™ (accessed 02/07/18). 
Category Pathway Total1 In data2  
Cytoskeleton 
remodelling 
Regulation of actin cytoskeleton organization 
by the kinase effectors of Rho GTPases 
58 
16 
(28 %) 
Development 
Regulation of cytoskeleton proteins in 
oligodendrocyte differentiation and 
myelination 
58 
11 
(19 %) 
Not assigned 
Inhibition of re-myelination in multiple 
sclerosis: regulation of cytoskeleton proteins 
44 
10 
(23 %) 
Cell adhesion Integrin-mediated cell adhesion and migration 48 
10 
(21 %) 
Cytoskeleton 
remodelling 
Role of PKA in cytoskeleton reorganisation 41 
8 
(20 %) 
Cell adhesion 
Histamine H1 receptor signalling in the 
interruption of cell barrier integrity 
45 
8 
(18 %) 
Transport 
The role of AVP in regulation of Aquaporin 2 
and renal water reabsorption 
50 
8 
(16 %) 
Not assigned 
Regulation of degradation of deltaF508-CFTR 
in CF 
39 
7 
(18 %) 
Apoptosis 
and survival 
NGF/ TrkA PI3K-mediated signalling 77 
9 
(12 %) 
Cytoskeleton 
remodelling 
Substance P mediated membrane blebbing 16 
5 
(31 %) 
Not assigned Cytoskeleton and adhesion module 64 
8 
(13 %) 
Not assigned LRRK2 in neurons in Parkinson's disease 33 
6 
(18 %) 
Chemotaxis 
Inhibitory action of lipoxins on IL-8- and 
Leukotriene B4-induced neutrophil migration 
53 
7 
(13 %) 
Not assigned 
Possible regulation of HSF-1/ chaperone 
pathway in Huntington's disease 
21 
5 
(24 %) 
Development 
MAG-dependent inhibition of neurite 
outgrowth 
37 
6 
(16 %) 
1 Total: Total number of markers present in the pathway 
2 In data: Number of identified markers of given pathway through the analysis of generated omic profiles 
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4.2.2.2.6 Comparison of pathways altered upon stimulation of DU145 with TGF-β 
based on significant deregulated genes and proteins  
The top 15 enriched pathways between the significant gene and proteins lists of DU145 
were compared and two pathways were shown to be present in both (Tab. 4.11). One is 
the “regulation of actin cytoskeleton organisation by the kinase effectors of Rho GTPases” 
and the other one is the “cytoskeleton and adhesion module”. The first one will be 
discussed further in subsection 4.4.6.  
 
Table 4.11: Shared enriched pathways in the top 15 between the gene and protein lists of DU145. List 
derived from Metacore™ (accessed 02/07/18). 
Category Pathway Total1 
In 
data2 
Genes3 Proteins4 
Cytoskeleton 
remodelling 
Regulation of actin 
cytoskeleton organization 
by the kinase effectors of 
Rho GTPases 
58 
28 
(48 %) 
23 
(40 %) 
16 
(28 %) 
Not assigned 
Cytoskeleton and adhesion 
module 
64 
24 
(38 %) 
20 
(31 %) 
8 
(13 %) 
1 Total: Total number of markers present in the pathway 
2 In data: Total number of identified markers of given pathway through the analysis of generated omic 
profiles 
3 Genes: Total number of genes identified in given pathway through the analysis of generated omic profiles 
4 Proteins: Total number of proteins identified in given pathway through the analysis of generated omic 
profiles 
 
The pathway of “cytoskeleton and adhesion module” (Fig. 4.16) identified genes and 
proteins within the signalling resulting in cytoskeleton remodelling (orange square) and 
survival. A strong overlay of identified proteins and genes can be observed, highlighting 
the correlation between the generated transcriptomic and proteomic profiles. 
145 
 
 
 
Figure 4.16: Schematic representation of the pathway describing “Cytoskeleton and adhesion module” 
enriched in both gene and protein lists, of DU145. Pathway image was generated with MetaCore™ one-
click analysis (Metacore™ accessed 02/07/18). Markers covered within either of the lists, genes or proteins, 
are highlighted with intensity bars representing the induced fold change. Red bars indicate an upregulation 
and blue bars a downregulation of the gene/protein and the numbers 1 (genes) and 2 (proteins). 
HD=Huntington’s disease. 
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4.2.2.2.7 Comparison of significant protein expression changes induced in both 
cell line models upon stimulation with TGF-β 
To see the similarity of proteomic changes within both cell line models, it was investigated 
how many significant proteins overlap between both cell lines and whether these 
overlapping proteins show the same expressional changes through the treatment. In total 
89 genes were significantly detected in both cell line models (Fig. 4.17C), of which 55 
genes were upregulated and 24 genes were downregulated. 10 of these significant proteins 
showed an inverse regulation, which means that an upregulation occurred in one cell line, 
which presented itself in a downregulation in the other cell line, and vice versa.  
 
 
Figure 4.17: Significantly deregulated proteins within both cell lines models.  P5B3 (A) and DU145 (B) (p-
value below 0.05 after Bonferroni correction). C represents shared significant proteins between both 
models. Red indicates an upregulation, blue a downregulation and green an inverse regulation between the 
two models. 
 
For further confirmation of the induction of EMT and the correlation of both cell line 
models, a hierarchical clustering approach was applied to the significant protein 
expression data shared between both models. For this, complete linkage and Euclidean 
distance was used. The generated heat map (Fig. 4.18) shows a clustering of the samples 
according to the cell type. This means, the samples of P5B3 separate into treated and 
untreated samples, as well as the samples of DU145, in which treated and untreated 
samples cluster together. However, within both cell lines, the treatment conditions 
present further clustering. This might be indicative that the significant protein changes 
within the cell lines are impacted stronger by the individual response of the cell line to the 
treatment than the induction of the particular pathways.  
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Figure 4.18: Hierarchical clustering of significantly altered proteins shared across both cell line models 
(n=89) in untreated and treated P5B3T (n=10), P5B3U (n=10) and DU145 (n=9 (DU145U), n=8 
(DU145T)) using complete linkage and Euclidean distance. 
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4.2.2.2.8 Identification of shared pathways altered upon stimulation of P5B3 and 
DU145 with TGF-β based on significant deregulated proteins  
The identification of shared pathways between P5B3 and DU145, identified through the 
analysis of proteomic profiles, highlighted also here a strong enrichment of pathways 
associated with the cytoskeleton, and the process of cell adhesion (Tab. 4.12).  
 
Table 4.12: Shared enriched pathways within the top 15 pathways of both cell lines. Protein numbers per 
pathway and number of detected genes are shown and also indicated as a %. List derived from Metacore™ 
(accessed 02/07/18). 
Category Pathway 
Total1 
(Proteins) 
In data2 
(P5B3) 
In data2 
(DU145) 
Cytoskeleton 
remodelling 
Regulation of actin cytoskeleton 
organization by the kinase 
effectors of Rho GTPases 
58 
19 
(33 %) 
16 
(28 %) 
Not assigned 
Inhibition of re-myelination in 
multiple sclerosis: regulation of 
cytoskeleton proteins 
44 
12 
(27 %) 
10 
(23 %) 
Not assigned 
LRRK2 in neurons in Parkinson's 
disease 
33 9 (27 %) 6 (18 %) 
Cell adhesion 
Histamine H1 receptor signalling 
in the interruption of cell barrier 
integrity 
45 
11 
(24 %) 
8 (18 %) 
Cell adhesion 
Integrin-mediated cell adhesion 
and migration 
48 
11 
(23 %) 
10 
(21 %) 
Development 
Regulation of cytoskeleton 
proteins in oligodendrocyte 
differentiation and myelination 
58 
13 
(22 %) 
11 
(19 %) 
Transport 
The role of AVP in regulation of 
Aquaporin 2 and renal water 
reabsorption 
50 9 (18 %) 8 (16 %) 
Not assigned 
Cytoskeleton and adhesion 
module 
64 
11 
(17 %) 
8 (13 %) 
Chemotaxis 
Inhibitory action of lipoxins on 
IL-8- and Leukotriene B4-induced 
neutrophil migration 
53 9 (17 %) 7 (13 %) 
Apoptosis 
and survival 
NGF/ TrkA PI3K-mediated 
signalling 
77 
11 
(14 %) 
9 (12 %) 
1 Total: Total number of markers present in the pathway 
2 In data: Number of identified markers of given pathway through the analysis of generated omic profiles 
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4.2.2.2.9 Identification of unique shared pathways identified across both omic 
levels of P5B3 and DU145 following treatment with TGF-β  
Overall, one pathway was found to be enriched between both omic levels and cell line 
models (Tab. 4.13). This pathway is associated with the “Regulation of actin cytoskeleton 
organization by the kinase effectors of Rho GTPases”. The pathway is shown in Fig. 4.19, 
whereas the numbers 1 and 2 indicate genes and proteins of DU145, and 3 and 4 indicate 
genes and proteins of P5B3.  
 
Table 4.13: Single shared pathway between all datasets and cell line models. List derived from Metacore™ 
(accessed 02/07/18). 
Category Pathway Total1 
In data2 
(P5B3) 
In data2 
(DU145) 
Cytoskeleton 
remodelling 
Regulation of actin cytoskeleton 
organization by the kinase 
effectors of Rho GTPases 
58 
40 
(69 %) 
28 
(48 %) 
1 Total: Total number of markers present in the pathway 
2 In data: Number of identified markers of given pathway through the analysis of generated omic profiles 
 
Overall it can be seen that a strong concordance of expression across P5B3 and DU145 
exists. 10 features within the pathway, namely caldesmon, MRLC, ERM proteins, moesin, 
vinculin, alpha actin, talin, actin cytoskeletal, F-actin cytoskeletal and filamin A, showed a 
concordant expression across all 4 omic profiles (P5B3 genes and proteins, DU145 genes 
and proteins), showing the same expression directionality. However, as illustrated in Fig. 
4.19, 3 markers (RAC2, PRK1 and ARPC1) were detected in at least one profile of both 
cell lines, and all 3 show a reduced expression in DU145, whereas their expression was 
increased in P5B3.  
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Figure 4.19: Schematic representation of the pathway describing “Regulation of actin cytoskeleton 
organization by the kinase effectors of Rho GTPases” enriched in both omic levels of both EMT models. 
Pathway image was generated with MetaCore™ one-click analysis (Metacore™ accessed 02/07/18). 
Markers covered within either of the lists, genes or proteins, are highlighted with intensity bars representing 
the induced fold change. Red bars indicate an upregulation and blue bars a downregulation of the 
gene/protein. The different omic levels are indicated with numbers 1-4; DU145 genes (1), DU145 proteins 
(2), P5B3 genes (3), P5B3 proteins (4). 
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4.2.3 Improved correlation of transcriptomic and proteomic changes 
through parallel treatment and harvest 
A common question is the potential correlation between the gene and resulting protein 
expression. The R2 of an analysis can indicate a presence or absence of any correlation 
between 2 given factors, such as the gene and protein expression. Initial studies comparing 
the gene and protein expression in yeast have not shown any correlation between both 
expression levels (Gygi, Rochon et al. 1999), more recent studies in human circulating 
monocytes and NIH3T3 cells (primary mouse embryonic fibroblasts) have shown 
significant correlations presenting an R2 of 0.41 and 0.235 respectively (Schwanhäusser, 
Busse et al. 2011, Guo, Xiao et al. 2008). Therefore, one major question of the study was 
whether a matching growth and harvest of proteins and RNA of both models will 
improve the correlation between these omic levels.  
 
For the analysis of potential correlations between the gene and protein expression levels, 
only significantly deregulated genes and proteins were selected, which were detected at 
both omic levels. This was done to reduce the generated noise across the samples. The 
correlation analysis was performed using Pearson correlation. The applied gene and 
proteins expression values were min-max normalised across the complete selection of 
significant genes.  
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In P5B3, it can be shown that the expression of both untreated (Fig. 4.20A) and treated 
(Fig. 4.20B) samples show a significant correlation with a p-value below 0.0001 and R2 
above 0.55 for both conditions. A correlation of the fold changes (Fig. 4.20C) shows an 
even higher correlation of 0.80. However, the outliers VIME and ANXA6 were excluded 
to calculate the correlation in the fold change without their impact. This resulted in a 
slight decrease in the correlation to 0.76 (Fig. 4.20D). Both calculations were significant.  
 
 
Figure 4.20: Pearson correlation of gene and protein expression between both treatment conditions of 
P5B3. Untreated P5B3 (n= 10) (A), treated P5B3 (n=10) (B). C shows the correlation of the fold change 
between gene and protein expression. Two markers were highlighted in C and removed in D. These two 
markers were excluded due to their outlier nature in order to generate a more realistic correlation analysis. 
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The same approach was applied to the generated profiles of DU145. Here, limited 
correlations between the untreated (Fig. 4.21A) and treated (Fig. 4.21B) gene and protein 
profiles with R2 of 0.088 and 0.094 respectively were observed. An increase in correlation 
can be observed through the comparison of fold changes (Fig. 4.21C), which increases 
the R2 to 0.80. As previously shown for P5B3, all correlation analyses were statistically 
significant.  
  
 
Figure 4.21: Pearson correlation of gene and protein expression between both treatment conditions of 
DU145. Untreated DU145 (n=9) (A) and treated DU145 (protein: n=8, gene: n=8) (B). C shows the 
correlation of the fold change between gene and protein expression.  
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4.4 Discussion 
4.4.1 Data quality and considerations through RNA-sequencing and 
mass spectrometry analysis 
The aim of this chapter was the generation and characterisation of matching 
transcriptomic and proteomic profiles of two models for EMT using the prostate cancer 
cell lines P5B3 (Harner-Foreman, Vadakekolathu et al. 2017) and DU145.  
The analysis of the transcriptome resulted in the detection and quantification of 
approximately 26 000 genes, of which a larger proportion were significantly altered in 
P5B3 (n=4575) compared to DU145 (n=2303) (Fig. 4.8A+B). A similar picture was 
shown at the proteomic level, where approximately 2200 proteins were quantified, and a 
larger proportion were significantly altered in P5B3 (n=297) compared to DU145 (n=187) 
(Fig. 4.17A+B). These differences could be based on the response of both cell lines to 
the stimulation with TGF-β. In P5B3, morphologically all cells responded to the treatment, 
whereas only a subpopulation of DU145 changed through TGF-β stimulation. Based on 
the limited response, the intensity of transcriptomic and proteomic changes might have 
been diluted by the unaltered expression of the non-responsive cells.  
 
Aside from the differences between the two cell lines, a large discrepancy was also shown 
in the number of detected genes compared to proteins. In an ideal world, matching 
profiles of translated genes and proteins would present a full coverage of matching gene 
and protein expression data. This would enable a highly informative characterisation of 
phenotypic changes and post-translational influences on the steps from gene to protein. 
However, large differences between the number of detected genes (~26 000) and proteins 
(~2200) are apparent. Furthermore, with an RNA-sequencing approach, not only coding, 
but also non-coding genes which don’t result in a protein product are detected. Another 
large contribution to this is based on the limitations of current mass spectrometry 
methods. Proteins show a large order of magnitude across their expression, and this range 
can be over more than 10 orders of magnitude, whereas the gene expression ranges are 
only over 3 to 4 orders of magnitude (Zubarev 2013). Compared to mass spectrometry, 
RNA-sequencing technology is able to quantify low abundance gene products. The wide 
spread of protein abundances increases the difficulty in confidently detecting and 
quantifying all present proteins.  However, recent developments in the technology of mass 
spectrometry analysis based on instrumentation improvements, and advances in 
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methodologies have enabled nowadays an increased routine quantification of proteins to 
approximately 4000 to 5000 proteins (Hülsmann, Kravic et al. 2018, He, M., Gou et al. 
2018, Bruderer, Bernhardt et al. 2015, Shishkova, Hebert et al. 2016). 
 
Based on the limited number of detected proteins, a correlation analysis was only possible 
for a small number of significantly detected and matching genes and proteins. Of the 
identified genes and proteins, the overlap presented a significant correlation in both 
models and conditions, however in DU145 (Fig. 4.21), the expression showed a large 
amount of variation and noise across the genes and proteins, for which reason the R2 
remained very low. Therefore, an improved R2 compared to previously published 
information (Schwanhäusser, Busse et al. 2011, Guo, Xiao et al. 2008) could only be 
shown for P5B3 (Fig. 4.20). This increased correlation could be supported by the fact that 
P5B3 is a highly homogeneous cell line, based on a single cell clone. Therefore, variations 
due to the heterogeneity of the cell populations are minimal. Based on these findings, the 
analysis shows that to a certain degree the parallel extraction of genes and proteins can 
improve the correlation between their expression (Yamasaki, Anderson 2008).  
4.4.2 Gene and protein expression changes induced in both EMT 
models 
The analysis of gene expression profiles of both models showed changes to the majority 
of previously studied EMT genes and EMT-TFs. In P5B3, all genes aside from TWIST1 
(Fig. 4.3G) were significantly deregulated corresponding to an EMT-phenotype (Fig. 4.3). 
This was also shown in the majority of the genes screened in DU145, however here no 
gene expression was detected for CDH2 (Fig. 4.3C) and TWIST1 (Fig. 4.3G). A lack of 
detection of CDH2 was previously shown in the analysis through qRT-PCR and Western 
blot. These results were confirmed through the RNA-sequencing analysis (Wang, W., 
Wang et al. 2017, Shankar, Nabi 2015).  
 
As mentioned previously, the use of mass spectrometry resulted in a smaller number of 
proteins quantified and for this reason, only 3 of the 8 EMT markers were detected at the 
proteomic level, CADH1, VIME and FINC (Fig. 4.10). Of these, only VIME was 
significantly upregulated in DU145 upon stimulation, whereas all 3 proteins were 
significantly changed in P5B3. This analysis confirmed the successful induction of an 
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EMT-phenotype, based on the previously studied EMT gene profile on a transcriptomic 
and to a certain degree on a proteomic level.  
4.4.2.1 Gene expression changes induced in P5B3  
The identification of significantly deregulated genes revealed a large number of highly 
confident markers (n=4575), which showed a consistent clustering according to their 
respective group (Fig. 4.4). This clustering, represented in a heat map, also confirmed the 
absence of outliers, further supporting the consistent stimulation of all 10 replicates (Fig. 
4.4). The identification of deregulated genes has highlighted a wide range of expression 
changes across the significantly altered genes. This included upregulated genes such as 
CDH11 (+303.40) and TWIST2 (+178.19) and downregulated markers such as GKN2 
(FC = -118.65) and PSCA (FC = -103.70). 
 
CDH11 (Cadherin-11) belongs to the cadherin superfamily, the same family as the well-
known EMT markers CDH1 and CDH2. Studies have shown that it not only belongs to 
the same family, but also interacts with CDH2, a gene upregulated during EMT-induction 
(Straub, Boda et al. 2003). Its association with poor prognosis in malignancies and 
rheumatoid arthritis further supports its role in the process of disease progression 
(Assefnia, Dakshanamurthy et al. 2014). Another EMT-associated marker identified was 
the transcription factor TWIST2 (Twist-related protein 2), which belongs together with 
TWIST1 to the Twist superfamily. It promotes EMT and was documented to be involved 
in breast (Fang, Cai et al. 2011), cervical (Wang, T., Li et al. 2014) and ovarian cancer 
(Mao, Xu et al. 2013). The downregulated marker GKN2 (gastrokine 2) is a secretory 
protein expressed on the gastric surface of mucous cells and has been shown to inhibit 
the growth and induce apoptosis in gastric cancer cells (Shi, Wang et al. 2014). A further 
study has also indicated an inhibiting function of GKN2 on proliferation, migration and 
invasion of gastric cancer cells (Dai, Zhang et al. 2014). Whereas the other marker PSCA 
(prostate stem cell antigen) was the third most strongly downregulated gene and studies 
have shown an involvement of this gene with an increase of proliferation and cell cycle 
progression of PCa cells (Li, E., Liu et al. 2017). 
 
Overall, the identification of these markers within the list of the most deregulated genes 
in P5B3 has supported their selection for further pathway enrichment analysis, based on 
the high association with disease progression, poor prognosis and EMT.  
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4.4.2.2 Gene expression changes induced in DU145  
The identification of significantly deregulated genes in DU145 has revealed a large 
number of highly confident markers (n=2303), which have shown a consistent clustering 
of the analysed samples according to their respective group (Fig. 4.6). This clustering, 
represented in a heat map, also confirmed the absence of outliers, further supporting the 
consistent stimulation of all 9 replicates per treatment group (Fig. 4.6). However, despite 
their significance, after correction for false discovery, the heat map presented a stronger 
degree of variability in the expression of these genes across the replicates, compared to 
P5B3 (Fig. 4.4). Such variation could be caused by the heterogeneity of the cell line and 
potential variation in the percentage of stimulated and unstimulated cells of each analysed 
sample. Despite this heterogeneity, the analysis has enabled the identification of 
deregulated genes with a wide range of expression changes. One of these was the BMP2 
(Bone morphogenic protein 2), which is a secreted ligand of the TGF-β superfamily and 
is involved in the recruitment and activation of SMAD family members. It was shown to 
induce EMT in pancreatic cancers (Chen, Liao et al. 2011) and to enhance migration, 
invasion and metastasis in gastric cancers (Park, Y., Kim et al. 2008). Another gene, which 
was also the third most upregulated gene, was SPOCK1 (SPARC/Osteonectin, Cwcv And 
Kazal Like Domains Proteoglycan 1). It was shown to be induced through TGF-β in 
breast cancer and correlates with invasion and poor prognosis (Fan, Jeng et al. 2016). 
Furthermore, it is upregulated in colorectal cancers, promoting the activation of the 
PI3K/Akt pathway (Zhao, P., Guan et al. 2016). Interestingly, two of the most 
deregulated markers were both keratins, including KRT32 and KRT4. Despite their limited 
documentation on EMT association, studies on keratins and disease progression and 
EMT have shown a strong association. Keratins form major intermediate filaments of 
epithelial cells, which are downregulated upon EMT induction. Their main function is the 
promotion of strong adhesion across epithelial cells (Nalluri, O'Connor et al. 2015). One 
study has suggested that the negative correlation of vimentin and keratin, and their ratio 
to each other, could be prognostic for postmenopausal breast cancer patients (Thomas, 
Kirschmann et al. 1999). KRT4 was shown to be reduced in paired cancerous/non-
cancerous tissue of oesophageal squamous cell carcinoma (Uchikado, Inoue et al. 2006), 
whereas no information on the association of KRT32 and disease progression was known. 
However, based on their functionality in epithelial cells, a loss of KRT32 could be 
correlated with the induction of EMT and the related loss of epithelial cell characteristics. 
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Overall, the identification of the above discussed markers, such as BMP2, which is highly 
associated with the TGF-β and EMT induction, supports the selection of EMT-associated 
genes and is therefore suitable to be used further in pathway enrichment analysis. 
4.4.2.3 Topology-based pathway enrichment of significantly altered genes of both 
cell line models 
The significantly altered genes were applied to the Metacore™ pathway analysis tool, 
which is based on a pathway topology (PT) method. The analysis of significant genes has 
highlighted the enrichment of pathways involved in “development”, “cell adhesion” and 
“cytoskeletal remodelling” in both, P5B3 (Fig. 4.5) and DU145 (Fig. 4.7). The category of 
“development” is of interest, since EMT can be categorised into 3 types, of which type I 
EMT is involved in processes during embryonal development (Kalluri, Weinberg 2009). 
EMT is a highly conserved process, of which the major genetic components are the same 
throughout the different types and enrichment of developmental pathways confirms the 
activation of EMT-associated pathways in the context of cancer. The enrichment of 
“cytoskeletal remodelling” and “cell adhesion” pathways can be explained by the 
morphological changes that are induced through the induction of EMT. An epithelial cell 
with an apico-basal orientation changes into a motile, elongated mesenchymal cell. This 
process requires major changes in the structure of the cell, resulting in the remodelling of 
the cytoskeleton. Furthermore, mesenchymal cells present a reduced adhesion to the cell 
surface, enabling them to present an increased motility, resulting in the alteration of cell 
adhesion-associated pathways. 
 
The enriched pathways of both cell line models showed the activation of TGF-β-
associated pathways, such as the SMAD-dependent and SMAD-independent signalling 
pathway (Tab. 4.4 and 4.5). Both present routes for the induction of EMT after the 
binding of TGF-β to the receptor (Derynck, Zhang 2003). In addition, pathways involved 
with disease progression and the development of metastasis were present as well. 
Interestingly, in P5B3 a pathway called “Glomerular injury of Lupus nephritis” was shown 
to be enriched. During the progression of Lupus nephritis, renal tissue is destroyed based 
on consistent inflammatory processes, resulting in the development of fibrotic tissue. As 
previously mentioned, EMT is a conserved process which is categorised into three types. 
This pathway describes EMT type II, which is activated during wound healing and tissue 
fibrosis (Tennakoon, Izawa et al. 2015, Morishita, Kusano 2011). Overall, P5B3 and 
DU145 showed an enrichment of common pathways, including the SMAD-independent 
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signalling pathway (Tab. 4.6). However, the treatment of DU145 visibly presents a 
stronger effect on morphological changes and cytoskeletal remodelling induced through 
the process of EMT (Tab. 4.5), whereas P5B3 presents a stronger change based on 
phenotypic components of EMT (Tab. 4.4). Overall, these results show the successful 
targeting of the TGF-β pathways, on either a SMAD-dependent or independent route, as 
well as the alteration of EMT and metastasis-associated pathways. 
4.4.3.1 Protein expression changes induced in P5B3  
The identification of significantly deregulated proteins in P5B3 has shown a selection of 
highly confident proteins (n=297), which have shown a consistent clustering according 
to their respective group (Fig. 4.11). The clustering analysis, presented in a heat map, did 
not present any obvious outliers (Fig. 4.11). Despite this, compared to the analysis of the 
altered gene expression, this heat map highlighted a wider range of variations in the 
expression of the significantly altered proteins across the replicates of each respective 
group (Fig. 4.11).  
 
Despite the smaller number of significantly identified proteins, the top 3 most induced 
proteins (VIME, FINC and BGH3) could be confidently associated with the process of 
EMT. The most upregulated protein was vimentin, presenting a fold change increase of 
181.84. This protein, and its corresponding gene, were studied throughout this work as a 
marker indicative of the induction of EMT. Vimentin is a type III intermediate filament 
protein, which is a marker of cells with mesenchymal origin and is involved in cell motility 
(Challa, Stefanovic 2011). The second strongest induced protein is fibronectin with a fold 
change of 19.38. As with VIME, this protein is also commonly detected and analysed in 
EMT studies, and also in this study, VIME was used as a marker for the successful 
induction of EMT upon TGF-β stimulation. FINC is a glycoprotein, which mediates 
multiple interactions with the extracellular matrix, including cell migration and adhesion 
(Pankov, Yamada 2002). The third most upregulated marker was BGH3. This protein is 
also known as the transforming growth factor-beta induced protein ig-h3. It has shown a 
fold change increase of 15-fold. This protein is commonly induced by TGF-β and is 
secreted by the ECM (Ween, Oehler and Ricciardelli 2012), furthermore, it is functionally 
associated with adhesion, migration, proliferation and differentiation (H. J. Kim, et al. 
2009). One of the most downregulated proteins was another keratin, keratin 13 (K1C13). 
Keratins, as previously discussed, are highly associated with epithelial cells and support 
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their anchorage to neighbouring cells. Through the stimulation, K1C13 was 
downregulated by nearly 40-fold in P5B3. Previous studies in a human keratinocyte cell 
line have also shown a downregulation of this protein during EMT induction via TGF-β. 
Based on this, the study has categorised it as an epithelial marker (Hatta, Miyake et al. 
2018). Another marker of interest that presented a downregulation was AGR2 (anterior 
gradient protein 2). Studies have shown an increased expression of this protein in PCa 
tissue compared to healthy prostate, however at the same time a loss of this protein was 
highly associated with disease recurrence of patients with radical prostatectomy (Maresh, 
Mah et al. 2010).  
4.4.3.2 Protein expression changes induced in DU145  
The identification of significantly deregulated proteins in DU145 has shown a selection 
of highly confident proteins (n=187), which have shown a consistent clustering according 
to their respective group (Fig. 4.14). The clustering analysis, presented in a heat map, did 
not present any obvious outliers (Fig. 4.14). Despite this, compared to the analysis of the 
altered gene expression, this heat map highlighted a wider range of variations in the 
expression of the significantly altered proteins across the replicates of each respective 
group (Fig. 4.14).  
The protein list of DU145 was shown to be the smallest list of significant markers (n=187), 
however this list contained markers associated with the process of EMT, such as the 
proteins transgelin, integrin subunit alpha V and Tumor-associated calcium signal 
transducer 2 precursor, which are discussed below. The strongest induced protein was 
shown to be transgelin (TAGL). It is an early marker for smooth muscle differentiation 
and is known to mediate TGF-β induced proliferation (Mitarai, Wada et al. 2017). 
Furthermore, a correlation of TAGL expression in colorectal cancer cells seems to 
increase their metastatic potential (Zhou, Fang et al. 2016). This protein was followed by 
the integrin subunit alpha V (ITAV, also known as CD51) that functions as a receptor for 
EMT-associated proteins such as FN1 and thrombospondin 1 (THBS1). CD51+ 
colorectal cancer cells were shown to exhibit traits associated with cancer stem cells, such 
as enhanced migratory potential, as well as tumour initiation capabilities (Wang, J., Zhang 
et al. 2017). One of the most downregulated markers was identified as TACD2. TACD2 
is a tumour associated calcium signal transducer 2 and studies have shown that the 
stepwise progression of squamous cell carcinoma is significantly associated with the 
gradual loss of TAGL expression (Wang, Y., Liu et al. 2014). The presence of known 
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markers associated with EMT and disease progression has confirmed that the analysis of 
a small list of significant markers can be attributed successfully to the desired phenotype.  
4.4.3.3 Topology based pathway enrichment of significantly altered proteins in 
both cell line models 
The analysis of both lists of significantly altered proteins was applied to the Metacore™ 
pathway analysis tool. The analysis of significant proteins in P5B3 (n=297) and DU145 
(n=187) highlighted a strong enrichment of pathways associated with “cytoskeletal 
remodelling” and “cell adhesion”. 
 
Compared to the analysis of enriched genes, two pathways were shared in P5B3 (Tab. 
4.9). One of these was the “TGF-β-dependent induction of EMT via RhoA, PI3K and 
ILK” (Fig. 4.13), also known as the SMAD-independent signalling. On the supplied 
graphic representation of this pathway (Fig. 4.13), an overall higher coverage through 
significant genes compared to significant proteins can be observed. Furthermore, each 
significant protein is also covered by the corresponding gene, showing identical 
directionality. In addition to the SMAD-independent pathway, it is also shown that a high 
coverage of the SMAD-dependent pathway is provided. Both pathways are highly 
involved in the induction of EMT and present the two major routes for its initiation. The 
analysis of both genes and proteins has also shown that despite the fact that some markers 
were solely identified through one omic level, such as SRF (serum response activator), the 
proteomic analysis, as well as the RNA-sequencing analysis, confidently identified 
downstream activated markers, such as tropomyosin 1, caldesmon and ACTB (Fig. 4.13). 
SRF was shown to be upregulated in metastatic gastric cancer cells (X. Zhao, et al. 2014) 
and in addition, is linked to the development of the mesoderm during embryonal 
development (Barron, et al. 2005).  
 
The comparison of the enriched pathways of DU145 through gene and protein lists have 
also shown two shared pathways, of which one was related to the “Cytoskeleton and 
adhesion module” (Tab. 4.11). The schematic representation of this has shown a frequent 
identification of proteins involved with the ECM and cytoskeletal remodelling (Fig. 4.16). 
Furthermore, in the case of DU145, the additional analysis of the proteome has increased 
the coverage of this pathway by 7 % (Tab. 4.11).  
Overall the comparison of the top 15 enriched pathways of both models through their 
proteomic profiles have shown a high overlap, with the identification of 10 shared 
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pathways (Tab. 4.12). A reduced level of correlation was identified following the 
comparison of enriched pathways through the analysis of the gene expression (Tab. 4.6). 
4.4.6 Concordantly enriched pathway between P5B3 and DU145 across 
both omic levels 
Interestingly, one pathway was detected across both cell models and both profiles types, 
despite the differences in the phenotypic response through the stimulation with TGF-β. 
This pathway was described as “Regulation of actin cytoskeleton organization by the 
kinase effectors of Rho GTPases”. The coverage of P5B3 was higher, compared to 
DU145 with 69 % versus 48 % respectively (Tab. 4.13), however the analysis showed 
throughout a larger list of significant markers on both omic analyses in P5B3 compared 
to DU145, which is most likely reflected here. The schematic representation highlighted 
a high overlay at the downstream targets of this pathway (Fig. 4.19), with a detection of 
these targets in at least 3 significant marker lists, such as Cofilin, which was identified in 
the lists of DU145 proteins, P5B3 genes and proteins. 
 
Rho GTPases are a small family of G proteins with a size ranging from 20 to 40 kDa. 
Most GTPases are activated through the binding of GTP and inactivated through the 
binding of GDP (Ridley 2015). The GTPases are involved in the regulation of cell motility 
cycles and play a role in the changes in the actin cytoskeleton structure (Hanna, El-Sibai 
2013). Studies of various cancer models have shown an alteration in the signalling of small 
Rho GTPases, which present important factors in the initiation and progression of cancer 
(Ellenbroek, Collard 2007). Furthermore, studies have shown their function in the 
regulation of the ECM remodelling (Hanna, El-Sibai 2013), and their involvement in the 
formation of adherence junctions (Jansen, Gosens et al. 2017). It has also been shown 
that there is crosstalk between Rho GTPases and the TGF-β signalling via several 
mechanisms using factors such as Rho and Rac1 (Ungefroren, Witte et al. 2018). The 
consistent alteration of this pathway highlights the underlying changes induced in both 
cell line models and supports the previous findings describing an EMT-phenotype and 
their function as models of metastasis. 
 
Overall, the generation of omic profiles have shown that both analysis methods and cell 
line models enable a characterisation of the desired and induced phenotype, whereas the 
proteomic analysis has shown an enrichment of cytoskeletal-associated proteins within 
the list of significant markers. The process of EMT can be characterised by multiple 
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factors, inducing changes in the gene and protein expression of EMT associated markers 
(VIME, FINC, CADH1, CADH2 and additional transcription factors). These changes of 
expression were confirmed in both models. Furthermore, through the induction of EMT, 
cytoskeletal changes result in the alterations of cytoskeletal associated proteins and 
adhesion. These changes could also be confirmed through the performed pathway 
enrichment analyses. Based on this, all analyses have successfully supported and 
confirmed the induction of EMT and supported the desired phenotype, enabling the use 
of these datasets for the potential identification of novel disease-associated biomarkers.  
 
In the following chapter, these datasets are further subjected to stringent filtering methods 
enabling the identification of a core set of EMT markers in both cell line models and omic 
levels. This set was used for the selection of single markers, which were validated using 
wet-lab and in silico methods. 
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5. Chapter V – Selection and validation of novel 
biomarkers of prostate cancer progression and 
epithelial to mesenchymal transition using 
integrative data analysis 
 
5.1 Introduction 
Over the last 20 years, a single biomarker has been used in the routine clinical testing for 
prostate cancer of men above 50. This marker, PSA, is secreted by the prostate gland and 
can be detected through the non-invasive analysis of serum samples (Prensner, Rubin et 
al. 2012). The introduction of routine analysis of PSA resulted in the increased detection 
of prostate cancers, including a large proportion of indolent and low stage cancers 
(Catalona, William J., Smith et al. 1993) and decreased the frequency of high-grade 
tumours. However, PSA lacks specificity, and it is not possible to define a cut-off PSA-
level that enables a secure exclusion of cancer presence (Tanguay, Begin et al. 2002). 
Various studies have been performed to improve the specificity. For example, Tanguay 
et al. compared the specificity and sensitivity of total PSA (tPSA), free/total PSA (f/tPSA), 
and complexed PSA (cPSA) in a cohort of 535 patients, of which nearly 40 % were 
diagnosed with cancer (Tanguay, Begin et al. 2002). When the regularly used cut-off of 
tPSA of 4.0 ng/ml was used, a sensitivity and specificity of 87 % and 27 % respectively 
were measured in the cohort. As a comparison, at a cut-off of 21 %, f/tPSA enabled a 
maximum sensitivity to specificity combination of 84 % to 50 % respectively. Complexed 
PSA presented only low specificities with a maximum specificity of 33 % at a sensitivity 
of 83 % (Tanguay, Begin et al. 2002). Despite improvements in the of use of f/tPSA over 
the clinically used tPSA, none of the 3 combinations fulfilled the criteria of a suitable new 
biomarker, which should ideally have a specificity and sensitivity close to 90 %.    
 
Based on the lack of specificity in the tPSA test, an increased number of indolent cases is 
detected, which means more patients are subjected to “active surveillance”, a process that 
includes routine PSA-level checks every 3 to 6 months and repeated biopsies every 1 to 2 
years (Choyke, Loeb 2017). However, active surveillance is still mainly based on regular 
PSA tests and is often correlated with a strong impact on the mental health of patients 
(Xu, Neale et al. 2012). Aside from its use for diagnostics after positive DRE-results and 
the routine screening during active surveillance, PSA is also used as a measurement for 
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disease recurrence. A biochemical recurrence of increased PSA occurs frequently, 
however this is often without the actual presence of the disease or any disease-related 
symptoms (Adhyam, Gupta 2012). Overall, PSA is a routine tool for various prostate 
cancer related conditions, and is used for detection, prognosis and surveillance, despite 
showing visible limitations for each of the tasks. Based on its high sensitivity and low 
specificity, additional markers for follow-up approaches are needed, ideally in the form of 
biomarker screening that enables the targeted intervention at the required time point (See 
chapter 1.2.3.1 and 1.2.3.2). 
 
For this reason, large efforts are being made in the discovery of novel disease-associated 
biomarkers. Over the years, many new biomarkers have been proposed to replace PSA 
including the α-methylacyl coenzyme A racemase (AMACR) (Jiang, Zhu et al. 2013), 
PCA3  (Marks, Fradet et al. 2007, Wang, Y., Liu et al. 2014), and the fusion gene 
TMPRSS2:ERG translocation (Gleason 1966, Romero Otero, Garcia Gomez et al. 2014). 
Some of these biomarkers and others are commercially available (McGrath, Christidis et 
al. 2016), however none are applied routinely in a clinical setting, mainly because they do 
not present a major improvement compared to the established PSA method. This is 
mainly due to the variation of their specificity and sensitivity based on their cut-off 
thresholds as well as a limited number of clinical studies validating the suitability of the 
findings.  
 
There is still an urgent unmet need for the discovery of novel, disease-associated 
biomarkers of prostate cancer, showing improved specificity and sensitivity compared to 
current markers. This search is supported by the development and improvement of high-
throughput technologies, which has resulted in an exponential increase of new proposed 
biomarkers of various conditions and disease states; however, despite this, only a small 
percentage (estimated at 0.1 %) are successfully translated into clinical use (Poste 2011). 
The limited translation of novel biomarkers can be attributed to multiple factors, 
including problems in the study design, the utilised platforms for the discovery of 
proposed markers, and the type of clinical specimens used throughout the study 
(Goossens, Nakagawa et al. 2015). These factors commonly limit the transferability into 
a routine clinical setting. All this highlights the fact that despite the increased efforts in 
the discovery of novel biomarkers, the clinical need for it was not met.  
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The major clinical concern in prostate cancer is the development of metastasis, which 
reduces the survival to less than 30 % (Thobe, Clark et al. 2011). For this reason, 
biomarkers indicative for the development of metastasis or disease progression could 
improve current active surveillance approaches. Since the life-limiting factor of PCa 
patients is the development of metastasis, the study of pathways associated with this 
process could harbour the knowledge necessary to elucidate novel biomarkers.  
 
The aim of this chapter is the increased understanding of the selected biomarkers based 
on the integration of transcriptomic and proteomic EMT profiles and their further 
evaluation as potential disease-associated markers in prostate cancer progression. This 
evaluation will be based on multiple aims, categorised into the further understanding of 
four markers and their association with EMT and cancer and their evaluation as disease-
associated biomarker.  
 
• First, the gene expression of 4 selected markers will be analysed in cell line 
material. These experiments will be performed to test for correlation of the 
marker expression with phenotypic characteristics of different cell lines and the 
potential detectability and applicability of these markers in other cancers (section 
5.2.2).  
 
• This will be followed by the screening of healthy tissue RNA. Novel biomarkers 
always present a new potential drug target, however for this the expression under 
healthy conditions needs to be identified.  
 
• The initial analyses were focussed on the expression of the respective genes, to 
further understand their capabilities as biomarkers, a routine method for 
biomarker screening, immunohistochemistry, will be applied. This method is 
routinely used as a diagnostic procedure and the successful validation of any of 
the markers through IHC will support their use as biomarker. 
 
• To overcome the limitations of available models for EMT models, 5 publicly 
available model data sets were selected and will be analysed gene expression 
changes induced through the stimulation with EMT-inducing cytokines. The 
results of these analyses will enable to evaluate and translate the findings of the 
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EMT-models of this study to a wider context. The use of 2 cell line models could 
potentially results in the detection of biomarkers with limited use and the 
successful validation in other cell line models will support the association with the 
process of EMT.  
 
• Finally, to overcome the limited availability of clinical specimens, publicly 
available gene expression datasets derived from clinical specimens will be used to 
further evaluate the capabilities of all four markers with the prediction of clinical 
conditions, such as Gleason score, disease-recurrence and for the differentiation 
between localised and advanced prostate cancer.  
 
The experiments performed in this chapter will generate an overview of the characteristics 
of all four selected markers with different cancerous conditions and their suitability as 
potential new biomarkers. These results will enable the guidance of future experiments.  
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5.2 Results 
5.2.1 Data integration and selection of a core marker list through the 
integration of generated omic profiles 
The generation of omics profiles commonly results in long lists of potential novel 
candidates. In this study the analysis of both cell lines models has resulted in the 
quantification of approximately 26 000 genes and approximately 2000 proteins. To reduce 
such a number to a potentially more meaningful, and more manageable list, all markers 
that could potentially be considered were subjected to the following criteria; a p-value 
below 0.05 after correction for false-discovery using Bonferroni correction and an 
absolute fold change of 2 and above. Furthermore, the transcriptomic data had to present 
FPKM values of 2 or more in at least one sample group. This cut-off was selected to 
ensure the detectability of the marker in routine applications such as quantitative real-time 
PCR whilst taking into account the variability of human specimens. In addition, the 
detected proteins had to present a confidence value of at least 70 %. This cut off was 
selected based on the advice of Dr Stephen Tate, SCIEX Senior Research Scientist and 
Manager of Software Applications Research, who contributed to the development of the 
proprietary confidence value (Lambert, Ivosev et al. 2013). Table 5.1 shows the resulting 
number of significant unique and shared markers based on different comparisons across 
each model and omic levels. The application of these criteria resulted in the identification 
of 1461 significant genes and 84 significant proteins for P5B3 and 838 significant genes 
and 38 significant proteins for DU145 (Tab. 5.1).  
 
Overall, more significantly altered markers were detected in P5B3 compared to DU145 
(Tab. 5.1), at both the gene and protein level. Also, when the absolute number of shared 
markers in both omic analyses was considered, a higher concordant number was detected 
in P5B3 compared to DU145.  Out of the 64 shared significant genes and proteins in 
P5B3, all shared markers, aside from one (KRT5), presented the same expression 
directionality. KRT5 demonstrated an upregulation on the gene level and a 
downregulation on the protein level. In DU145, 29 markers were shared and all of them 
presented the same directionality (Tab. 5.1).  
 
To answer the question as to whether, after the application of stringent filters, the analysis 
of proteomic data resulted in the identification of additional markers not identified 
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through the analysis of transcriptomic data, the lists were compared. In P5B3, the analysis 
of proteomic data resulted in the discovery of an additional 20 markers, which were 
uniquely identified to present significant differences at the protein level (Tab. 5.1). In 
DU145, the protein analysis resulted in 9 additional proteins (Tab. 5.1). 
 
Table 5.1: Identification of significantly differentially regulated markers within all 4 omic datasets and their 
overlap between cell lines and omic-levels. The two gene expression datasets were subjected to the following 
criteria: p-value below 0.05 after correction for false-discovery using Bonferroni correction, an absolute 
fold change of 2 and above and FPKM values of 2 or more in at least one sample group. The protein 
datasets were filtered based on: a p-value below 0.05 after correction for false-discovery using Bonferroni 
correction, an absolute fold change of 2 and above and a confidence value of 70 %.   
Integration of datasets 
Number of 
markers 
Significant deregulated genes P5B3  1461 
Significant deregulated genes DU145  838 
Significant degregulated proteins P5B3  84 
Significant degregulated proteins DU145  38 
Shared significant deregulated genes and proteins P5B3 64 
Shared significant deregulated genes and proteins DU145 29 
Shared significant deregulated genes P5B3 and DU145 322 
Shared significant deregulated proteins P5B3 and DU145 18 
Unique significant deregulated markers (genes and proteins) P5B3 1481 
Unique significant deregulated markers (genes and proteins) DU145 847 
Shared markers (genes and proteins) both models and omic levels 13 
 
 
Despite the efforts to reduce the number of genes and proteins, the significant marker 
selection exceeded the logistics available for routine wet-lab validation approaches. For 
this reason a core marker set was identified. This core marker set was generated through 
the integration of markers present on all omics levels and both cell line models. This 
resulted in a final selection of 13 markers, which are shown in table 5.2, including their 
respective fold change for each omic level and cell line. The p-value is shown as a 
representation for all 4 omic level, since all p-values were below 0.0001 (****). Out of the 
13 markers, only one marker, SDPR, showed a reduced expression through treatment, 
whereas the remaining 12 markers presented an increase in their expression. Additionally, 
the gene and protein expression within and across each model presented the same 
directionality.  
 
  
170 
 
One of the identified markers was BGH3 or TGFBI (transforming growth factor β-
induced) (Tab. 5.2). This protein is induced by the cytokine TGF-β and its induction can 
be associated with the successful stimulation of both cell lines with TGF-β. The presence 
of this marker supports the association of the remaining 12 markers with the process of 
TGF-β induced EMT (Tab. 5.2). ACTN1 and TUBA4A are directly associated with the 
cytoskeleton and TPM1, as well as MYL9, and are strongly associated with muscular 
contractions. Therefore, based on their widespread expression and their associated 
limitations as potential therapeutic targets, these markers were excluded from further 
validation. The same decision was made for BGH3, which is also known as TGFBI, and 
the marker TSP1. Both are well known and well-studied markers in cancer and EMT-
associated studies, for example in relation to cancer metastasis and renal diseases (Suzuki, 
Yokobori et al. 2018, Kurpinski, Chu et al. 2009, Brennan, Morine et al. 2012, Hugo 2003, 
Sweetwyne, Murphy-Ullrich 2012). 
 
Overall it can be seen that the response of both cell lines resulted in the induction of a 
core set of genes, however the strength of response varied from cell line to cell line.  This 
is clearly visible for example in the change of DPYL3, which shows a very strong 
upregulation in P5B3 on both the protein and gene levels, whereas SDPR has shown a 
stronger downregulation in DU145 compared to P5B3 (Tab. 5.2). 
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Table 5.2: List of 13 markers identified through the integration of both models and all 4 omic profiles. 
These 13 markers were shared in both cell lines at both the gene and protein levels. FC = fold change. The 
p-value [p-value (all)] is presented together showing a concordant, highly significant p-value **** across 
both models and omic profiles.  
 
Protein 
ID 
FC 
P5B3 
Gene 
FC 
P5B3 
Protein 
FC 
DU145 
Gene 
FC 
DU145 
Protein 
p-
value 
(all) 
Gene/Protein 
ACTN1 2.62 2.20 2.08 2.07 **** Actinin alpha 1 
DPYL3 21.51 11.79 3.52 2.52 **** 
Dihydropyrimidinase 
like 3 
FBLI1 2.33 2.24 3.37 2.89 **** 
Filamin binding LIM 
protein 1 
LMCD1 3.77 3.66 7.36 5.22 **** 
LIM and cysteine rich 
domains 1 
MYL9 4.48 3.80 2.98 3.17 **** Myosin light chain 9 
P4HA2 2.39 2.78 2.36 2.81 **** 
Prolyl-4-hydroxylase 
subunit alpha 2 
PALLD 5.12 5.38 3.03 2.06 **** 
Palladin, cytoskeletal 
associated protein 
PDLI7 3.35 4.09 2.15 2.45 **** PDZ and LIM domain 7 
SDPR -5.99 -3.80 -13.61 -7.51 **** 
Serum deprivation-
response protein 
BGH3 15.60 15.05 10.50 4.90 **** 
Transforming growth 
factor beta induced 
TSP1 8.84 5.98 9.61 3.56 **** Thrombospondin 1 
TPM1 5.98 3.24 11.63 6.65 **** Tropomyosin 1 
TUBA4A 2.81 2.37 4.11 3.52 **** Tubulin alpha 4a 
 
Of the remaining list of 7 markers, the following 4 markers were selected for further 
verification: DPYL3, FBLI1, SDPR and P4HA2 (Tab. 5.3). The selection of these was 
based on a literature search and the consolidation of multiple online available resources.  
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Table 5.3: Final marker selection for further validation presenting the induced fold change for both cell line 
models and omic level . The p-value [p-value (all)] is presented together showing a concordant, highly 
significant p-value across both models and omics profiles.  
 
Protein 
ID 
FC 
P5B3 
Gene 
FC 
P5B3 
Protein 
FC 
DU145 
gene 
FC 
DU145 
Protein 
p-
value 
(all) 
Gene 
DPYL3 21.51 11.79 3.52 2.52 **** 
Dihydropyrimidinase like 
3 
FBLI1 2.33 2.24 3.37 2.89 **** 
Filamin binding LIM 
protein 1 
SDPR -5.99 -3.80 -13.61 -7.51 **** 
Serum deprivation-
response protein 
P4HA2 2.39 2.78 2.36 2.81 **** 
Prolyl-4-hydroxylase 
subunit alpha 2 
 
5.2.2. Screening of cancerous cell lines for their expression of selected 
markers 
To further analyse the association of these markers with cancer, various cell lines, 
including breast and prostate cancer, as well as one osteosarcoma cell line were screened. 
Additionally, a previously developed cell line model of TGF-β treated MCF10A cells was 
analysed for the involvement of these markers with the TGF-β pathway (data not shown).  
DPYSL3 showed overall a low expression across all cell lines compared to the induced 
state of both models. The expression of DPYSL3 in PC-3 and SAOS cells was comparable 
to untreated DU145 cells. Overall, the expression in all BCa cell lines showed levels 
comparable to the reference gene, whereas the PCa cell line PC-3 showed a similar 
expression to DU145 untreated and a stronger expression than P4B3 untreated (Fig. 5.1).  
The expression of FBLIM1 was shown to be variable across all cell lines, showing the 
highest relative expression in both cell line models. The expression of FBLIM1 was 
induced in MCF10A upon treatment with TGF-β (Fig. 5.1), however the expression in 
both conditions was comparable to P5B3 untreated. An increased expression was also 
shown in OPCT-1 and the single cell clones of this cell line: P4B6 and P4B6B (Harner-
Foreman, Vadakekolathu et al. 2017) as well as SAOS (Fig. 5.1). 
 
The highest expression of SDPR was detected in the breast cancer cell line MDA-MB-
231, presenting an increased expression compared to P5B3 and DU145 untreated (Fig. 
5.1). A reduction of its expression was shown in the EMT models of P4B3 and DU145, 
as well as in the stimulated MCF10A cells. All other cell lines presented a very low 
expression of SDPR (Fig. 5.10).  
173 
 
P4HA2 presented a variable expression across the studied cell line samples, showing the 
highest expression in the TGF-β stimulated MCF10A cells. It was also highly expressed 
in the single cell clone P4B6B (Harner-Foreman, Vadakekolathu et al. 2017) and the 
osteosarcoma cell line, SAOS, showing a comparable expression to the stimulated DU145 
cells, and an increased expression when compared to the cell line model of P5B3 (Fig. 
5.1).  
 
 
 
Figure 5.1: qRT-PCR screening of selected markers (DPYSL3, FBLIM1, SDPR and P4HA2) in in-house 
derived cell line material from various primary and metastatic breast and prostate cancer cell lines as well as 
one osteosarcoma cell line. Pink represents cell lines associated with breast cancer, blue cell lines associated 
with prostate cancer and green, the osteosarcoma cell line SAOS. P5B3 is coloured in grey and DU145 in 
black. Results were analysed using the comparative 2-ΔΔCT method (Schmittgen and Livak 2008) (n=4). The 
gene expression was normalised against the TATA-box protein (TBP) gene, which was utilised as the 
reference gene. Details on the used cell lines can be found in Table 2.2. 
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5.2.3 Gene expression analysis of selected markers in healthy tissue 
RNA 
5.2.3.1 Comparison of marker expression in healthy prostate tissue with both cell 
line models 
An ideal biomarker should present an inverse expression in the target tissue compared to 
the expression in a healthy or non-cancerous state. This means that a marker, whose 
increased expression is associated with poor survival, should ideally present a low or no 
expression in healthy, or non-cancerous target tissue. On the other hand, a marker whose 
loss or reduced expression is associated with negative disease development should ideally 
present a high expression in healthy tissue. This would enable an easier detection of 
changes through the development or progression of a disease. For this reason, the gene 
expression of the 4 selected markers in their treated and untreated condition was 
compared to their gene expression in healthy prostate tissue (Fig. 5.2).  
 
The expression of DPYSL3 showed a lower expression level in both untreated cell lines, 
compared to the healthy tissue control, with a significant difference in P5B3. The 
expression of DPYSL3 through the stimulation with TGF-β was significantly increased 
compared to the healthy tissue in both cell line models (Fig. 5.2A+E).  
 
The expression of FBLIM1 in the untreated cell lines showed a significant increase in 
P5B3 and a significant decrease in DU145, whereas the expression was significantly 
induced in both cell line models upon stimulation (Fig. 5.2B+F). 
 
SDPR showed a consistent expression between the healthy tissue and the unstimulated 
P5B3 cells (Fig. 5.2C), presenting a significant decrease after the stimulation with TGF-β. 
The gene expression of SDPR in DU145 showed a significantly decreased expression 
compared to the healthy control (Fig. 5.2G), which was further decreased upon 
stimulation.  
 
The expression of P4HA2 showed the lowest expression in the healthy tissue, increasing 
with the untreated cell lines and showing the highest expression through the stimulation 
with TGF-β for 10 days in both cell line models (Fig. 5.2D+E). The difference in the 
expression was significant between the healthy control and P5B3 treated, whereas the 
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expression in DU145 untreated and treated showed both a significantly increased 
expression compared to the healthy control (Fig. 5.2E). 
 
 
 
Figure 5.2: Comparison of gene expression of each marker (DPYSL3, FBLIM1, SDPR and P4HA2) in 
commercially available healthy prostate tissue RNA (Clontech) with the expression in both cell line models 
in an untreated and treated state. Results were analysed using the comparative 2-ΔΔCT method (Schmittgen 
and Livak 2008) (n=4). The gene expression was normalised against the TATA-box protein (TBP) gene, 
which was utilised as reference gene. 
5.2.3.2 Gene expression analysis of all four markers in healthy tissue in comparison 
to healthy prostate  
Some, however not all, novel biomarkers present the option to be utilised as a therapeutic 
target (Shen 2013). Crucial for this is the information as to whether these markers function 
as a “messenger” and are only a consequence of underlying changes, or whether they are 
“driver” markers, such as genes or proteins, that directly influence factors such as tumour 
growth or disease progression (Shen 2013). For this reason, the measurement of gene and 
protein expression of novel markers in healthy tissue is crucial to validate the suitability 
of the studied marker as a therapeutic target.  
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To evaluate the potential use of the selected markers, RNA extracted from healthy tissue 
material was screened for their expression and was compared to the expression levels in 
healthy prostate tissue. 
 
The expression of DPYSL3 in a healthy tissue panel (Fig. 5.3) showed a significantly 
higher and overall stronger expression in tissue extracted from the ovary and spinal cord. 
These were followed by uterus, trachea and retina, however no significant differences 
compared to the prostate could be detected in the latter two. RNA extracted from breast, 
colon and skeletal muscle showed a non-significant decreased expression compared to 
prostate. A significantly lower expression was detected in various tissues (thyroid, spleen, 
adrenal gland, salivary gland, placenta, thymus, testis), including the essential organs lung, 
heart, brain, liver and kidney (Fig. 5.3).  
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Figure 5.3: Comparison of gene expression of DPYSL3 in a commercially available healthy tissue RNA 
panel (Clontech). The expression was compared to the expression in RNA from healthy prostate tissue 
(Clontech) (red). Results were analysed using the comparative 2-ΔΔCT method (Schmittgen and Livak 2008) 
(n=4). The gene expression was normalised against the TATA-box protein (TBP) gene, which was utilised 
as reference gene. 
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FBLIM1 showed the highest, significantly increased expression in colon and heart (Fig. 
5.4). The expression of FBLIM1 in healthy prostate tissue was comparable to its 
expression in uterus, spleen and breast tissue. A significantly lower level of expression 
was detected in multiple essential organs, including lung, liver, kidney and brain, as well 
as ovary, placenta, trachea, salivary gland, retina, spinal cord, thymus, skeletal muscle and 
testis (Fig. 5.4).  
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Figure 5.4: Comparison of gene expression of FBLIM1 in a commercially available healthy tissue RNA 
panel (Clontech). The expression was compared to the expression in RNA from healthy prostate tissue 
(Clontech) (red). Results were analysed using the comparative 2-ΔΔCT method (Schmittgen and Livak 2008) 
(n=4). The gene expression was normalised against the TATA-box protein (TBP) gene, which was utilised 
as reference gene. 
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The serum-deprivation response protein (SDPR) was the only marker in this selection 
that presented a reduced expression upon stimulation with TGF-β. By far the highest, and 
most significant elevated expression compared to healthy prostate tissue was detected in 
the spleen, presenting a nearly 8-fold difference. High expression of SDPR was also 
shown in both lung and thyroid, followed by uterus and breast. A comparable expression 
of SDPR in prostate was shown for material extracted from heart, ovary, skeletal muscle, 
colon, retina and adrenal gland. The lowest expression, showing a significant difference 
to healthy prostate tissue, was measured in the following organs; spinal cord, placenta, 
kidney, liver, thymus, trachea, salivary gland, brain and testis (Fig. 5.5). 
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Figure 5.5: Comparison of gene expression of SDPR in a commercially available healthy tissue RNA panel 
(Clontech). The expression was compared to the expression in RNA from healthy prostate tissue (Clontech) 
(red). Results were analysed using the comparative 2-ΔΔCT method (Schmittgen and Livak 2008) (n=4). The 
gene expression was normalised against the TATA-box protein (TBP) gene, which was utilised as reference 
gene. 
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P4HA2 showed a strong variation in its expression across the measured sample material, 
however the overall expression was very low, compared to the used reference gene (TBP) 
(Fig. 5.6). A significantly higher expression of P4HA2 was detected in material of the 
salivary gland, followed by heart, kidney, lung, trachea and uterus and a comparable 
expression to prostate tissue was detected the adrenal gland, thymus, spinal cord and brain. 
The lowest, and most significantly different expression level, was measured in testis (Fig. 
5.6).  
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Figure 5.6: Comparison of gene expression of P4HA2 in a commercially available healthy tissue RNA panel 
(Clontech). The expression was compared to the expression in RNA from healthy prostate tissue (Clontech) 
(red). Results were analysed using the comparative 2-ΔΔCT method (Schmittgen and Livak 2008) (n=4). The 
gene expression was normalised against the TATA-box protein (TBP) gene, which was utilised as reference 
gene. 
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5.2.4 Validation of novel biomarkers using tissue microarray derived 
from healthy and diseased tissue 
The analysis of gene expression in healthy tissue RNA enables an initial overview, 
however only limited conclusions regarding the protein expression can be made on the 
basis of this (Vogel, Marcotte 2012). For this reason, the protein expression of all four 
markers in healthy tissue was analysed using immunohistochemistry staining on 
commercially available healthy tissues microarrays (US Biomax). Staining intensity was 
categorised into 4 categories (Fig. 5.7), including 0 = no staining, 1 = weak staining, 2 = 
moderate staining and 3 = strong staining. Localised staining, as for example shown in 
Figure 5.7 – Staining intensity: 3, resulted in the assignment of the tissue to the higher 
category and the sample was marked with an * to highlight the focally increased expression. 
 
 
 
Figure 5.7: Images illustrating scoring method used for healthy and diseased tissue specimens analysed using 
immunohistochemistry staining . The staining intensity was categorised into 4 intenstities (0  = no staining, 
1 = weak staining, 2 = moderate staining and 3 = strong staining). Representative images at 20x 
magnification. Scale bar represents 100 µm. 
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5.2.4.1 Screening of protein expression in healthy tissue specimens using 
immunohistochemistry staining on tissue microarrays  
The analysis of the selected 4 markers was performed on 3 different TMAs, which was 
based on their availability. Altogether, all 4 markers could be analysed in the following 
tissue types: prostate, skin, colon, heart, kidney, liver, lung, brain, pancreas, uterus, ovary 
and breast. DPYL3 and FBLI1 were furthermore analysed in additional healthy tissue 
types.  
 
The protein expression of DPYL3 showed a moderate to high expression across all tissues. 
Locally intensified staining was detected in the samples of skin (Fig. 5.8B), kidney (Fig. 
5.8E), breast (Fig. 5.8L), placenta (Fig. 5.9N), stratified muscle (Fig. 5.9O), urethra (Fig. 
5.9P), testes (Fig. 5.8Q) and bladder (Fig. 5.9R). This localised expression was mainly 
found in the glandular structures, such as prostate gland (Fig. 5.8A), acini and ducts in 
breast tissue (Fig. 5.8L) and uterine glands (Fig. 5.8J). The lowest expression was detected 
in the lung (Fig. 5.8G), pancreas (Fig. 5.8I), thymus (Fig. 5.9T), spinal cord (Fig. 5.9V) 
and umbilical cord (Fig. 5.9AA). The localisation of DPYL3 was mainly detected in the 
cytoplasm with localised presence in the nucleus (Fig. 5.8/5.9).  
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Figure 5.8: DPYL3 protein expression in healthy tissue microarray  (US Biomax MNO341). Prostate (A), 
skin (B), colon (C), heart (D), kidney (E), liver (F), lung (G), brain (H), pancreas (I), uterus (J), ovary (K) 
and breast (L). Representative images at 20x magnification. Scale bar represents 100 µm. 
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Figure 5.9: DPYL3 protein expression in healthy tissue microarray  (US Biomax MNO341). Adrenal gland 
(M), placenta (N), stratified muscle (O), urethra (P), testes (Q), bladder (R), fallopian tube (S), thymus (T), 
thyroid (U), spinal cord (V), small intestine (W), pituitary gland (X), spleen (Y), stomach (Z) and umbilical 
cord (AA). Representative images at 20x magnification. Scale bar represents 100 µm. 
 
The expression of FBLI1 showed an overall low expression in the analysed tissue sections. 
No staining was detected in pancreatic (Fig. 5.10I) and tonsil (Fig. 5.10O) tissue. Localised 
staining was shown in the epidermis of the skin (Fig. 5.10B), uterine glands (Fig. 5.10J) 
and seminiferous tubules located in the testes (Fig. 5.10M). The remaining tissue sections 
presented a ubiquitous low staining (Fig. 5.10). The expression of FBLI1 was mainly 
focussed on the cytoplasm of the cell, however nuclear staining was observed in primary 
spermatocytes located in the seminiferous tubules (Fig. 5.10M).  
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Figure 5.10: FBLI1 protein expression in healthy tissue microarray  (US Biomax MNO381). Prostate (A), 
skin (B), colon (C), heart (D), kidney (E), liver (F), lung (G), brain (H), pancreas (I), uterus (J), ovary (K), 
breast (L), testes (M), thyroid (N), tonsil (O), stomach (P), small Intestine (Q) and oesophagus (R). 
Representative images at 20x magnification. Scale bar represents 100 µm. 
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The protein expression of SDPR showed a variable expression across the analysed 
samples, presenting a low to moderate expression in specimens of prostate (Fig. 5.11A), 
lung (Fig. 5.11B) and breast (Fig. 5.11L), and no staining in ovarian tissue (Fig. 5.11K). 
Locally increased staining was detected in the epidermis of the skin (Fig. 5.11B) and the 
endometrium localised in the uterus (Fig. 5.11J). The protein expression in the kidney 
showed an overall ubiquitous expression with reduced expression in the glomeruli (Fig. 
5.11E). A similar presentation was observed in the liver sections (Fig. 5.11F), where a 
reduced expression is shown in the tissue surrounding the portal tracts. Furthermore, the 
expression in the lamina propria of the analysed colon section showed a reduced 
expression compared to the intestinal glands (Fig. 5.11C). The expression of SDPR was 
mainly found in the cytoplasm of the cells, with limited expression in the nucleus of cells 
from colon (Fig. 5.11C), skin (Fig. 5.11B) and uterus (Fig. 5.11J).  
 
 
 
Figure 5.11: SDPR protein expression in healthy tissue microarray (US Biomax BN243c). Prostate (A), skin 
(B), colon (C), heart (D), kidney (E), liver (F), lung (G), brain (H), pancreas (I), uterus (J), ovary (K) and 
breast (L). Representative images at 20x magnification. Scale bar represents 100 µm. 
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In P4HA2, the protein expression was overall ranging from very low to not detectable in 
all samples (Fig. 5.12). An increased expression was detected in the skin (Fig. 5.12B) 
presented locally in the epidermal layer. Overall, the expression in kidney (Fig. 5.12E) and 
liver (Fig. 5.12F) was elevated compared to the other tissue sections, also showing a 
homogeneously distributed expression. In the section of the kidney, a lower expression 
in the renal corpuscles could be observed (Fig. 5.12E). In specimens with a visible 
detection of P4HA2, the protein was localised in the cytoplasm (Fig. 5.12). 
 
 
 
Figure 5.12: P4HA2 protein expression in healthy tissue microarray (US Biomax BN243d). Prostate (A), 
skin (B), colon (C), heart (D), kidney (E), liver (F), lung (G), brain (H), pancreas (I), uterus (J), ovary (K) 
and breast (L). Representative images at 20x magnification. Scale bar represents 100 µm. 
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Table 5.4 presents a summary of the staining intensity detected in the analysed healthy 
tissue sections. In DPYL3 (Fig. 5.8/5.9), the majority of analysed tissue sections showed 
a moderate staining intensity, whereas in FBLI1 (Fig. 5.10) the expression was mainly 
categorised as low staining. The intensity of SDPR presented variability, with tissues 
mainly assigned to 3 intensity groups (Fig. 5.11). The most frequent staining intensity in 
P4HA2 (Fig. 5.12) was low staining, followed by no staining and only one tissue section 
was shown to have a moderate, localised expression (Fig. 5.12B).  
 
Table 5.4: Score summary of immunohistochemistry tissue sections for DPYL3 (Fig. 3.12), FBLI1 (Fig. 
3.13), SDPR (Fig. 3.14) and P4HA2 (Fig. 3.15). Table representing staining intensities observed in normal 
tissue (MNO341 (DPYL3), MNO381 (FBLI1), BN243c (SDPR) and BN243d (P4HA2)). Staining 
intensities were assigned as previously described (Fig. 5.7) into 4 categories; 0 = no staining, 1 = weak 
staining, 2 = moderate staining and 3 = strong staining used. * indicates localised increased expression. 
Numbers in cells (column #) represent the total number of individual cores analysed and shaded areas 
represent the number of cores assigned to this staining intensity. 
 
 
* localised
Tissue type # 0 1 2 3 # 0 1 2 3 # 0 1 2 3 # 0 1 2 3
Prostate 1 1* 1 1 2 2 2
Skin 1 1* 1 1* 2 2* 2 2*
Colon 1 1* 1 1 2 2* 2 2
Heart 1 1 1 1 2 2 2 2
Kindey 1 1* 1 1 2 2 2 2
Liver 1 1 1 1 2 2 2 2
Lung 1 1 1 1 2 2 2 2
Brain 1 1 1 1 2 2 2 2
Pancreas 1 1 1 1 2 2 2 2
Uterus 1 1* 1 1 2 2* 2 2
Ovary 1 1 1 1 2 2 2 2
Breast 1 1* 1 1 2 2 2 2
Adrenal gland 1 1 - - -
Placenta 1 1 - - -
Stratified muscle 1 1 - - -
Urethra 1 1* - - -
Testes 1 1* 1 1* - -
Bladder 1 1* - - -
Fallopian tube 1 1 - - -
Thymus 1 1 - - -
Thyroid 1 1 1 1 - -
Spinal cord 1 1 - - -
Small intestine 1 1 1 1 - -
Pituitary gland 1 1* - - -
Spleen 1 1 - - -
Stomach 1 1 1 1 - -
Umbilical cord 1 1 - - -
Tonsil - 1 1 - -
Oesophagus - 1 1 - -
DPYL3 FBLI1 SDPR P4HA2
staining intensity staining intensity staining intensity staining intensity
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5.2.4.2 Screening of protein expression in prostate cancer specimens using 
immunohistochemistry and immunofluorescence on tissue microarrays  
The validation of novel biomarkers is commonly performed using tissue microarrays 
(Hassan, Ferrario et al. 2008) derived from diseased specimens, annotated with clinical 
parameters, such as Gleason score or tumour stage. Here, a prostate cancer TMA was 
selected for the screening of all 4 biomarkers in different tumour stages, as well as adjacent 
healthy prostate tissue (US Biomax PR242b). In this TMA, specimens of 5 patients with 
Stage II and 5 patients with Stage IV PCa were included in duplicates. Furthermore, there 
were 4 cores, derived from 2 individuals, of adjacent healthy tissue. In addition to the 
analysis by IHC, the protein expression was further analysed using immunofluorescence 
(IF) in the same TMAs. As previously described, the staining intensity through IHC was 
categorised into 4 categories (Fig. 5.7), including 0 = no staining, 1 = weak staining, 2 = 
moderate staining and 3 = strong staining. Strong localised staining resulted in the 
assignment of the tissue to the related category, even if the remaining tissue did present a 
lower staining intensity. An example for this can be seen in Figure 5.7 in the staining 
intensity 3. Such samples were marked with an * to highlight the focal increased 
expression, which defined the assigned category.  
The analysis of DPYL3 showed a strong expression in healthy prostate tissue, which was 
shown in the stroma and glands through IHC and mainly in the stroma through IF (Fig. 
5.13). Compared to this, adjacent tissue seemed to express a lower intensity of DPYL3 
compared to healthy, which was apparent through both analyses. The expression was 
localised in the cytoplasm of the analysed specimens. Comparing the expression in healthy 
tissue with stage II PCa, no obvious differences in the expression of DPYL3 could be 
observed using IHC. However, through IF, a strong expression, mainly localised in the 
glands, could be observed in 3 out of 5 patients. Stage IV PCa showed none or weak 
staining through IHC and also the analysis with IF showed a lower expression of DPYL3 
in stage IV compared to stage II as well as healthy tissue (Fig. 5.13). 
The IHC analysis of FBLI1 in prostate (cancer) sections showed none to faint staining, 
however below the category of “weak staining”. The IF analysis of healthy tissue showed 
a weak, homogeneous expression of FBLI1 in the stroma (Fig. 5.14). The IF analysis of 
the tissue sections showed some cores with a strong localised expression of FBLI1, 
however based on their cell shape and lack of a nucleus, these cells can most likely be 
assigned to erythrocytes trapped and fixed within the tissue.  
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The IHC analysis of SDPR in healthy and diseased prostate tissue showed limited 
differences across the cores (Fig. 5.15). Two patients with stage II PCa showed a moderate 
staining compared to the low staining detected in the remaining cores. The additional 
analysis using IF showed a greater range of variability in the expression of SDPR. The 
strongest expression was observed in the stroma of healthy prostate tissue, with additional 
staining in the prostate glands, whereas only faint staining was detected in the stroma of 
adjacent tissue. The expression of SDPR in stage II PCa showed a more homogeneous 
expression and stronger across the stroma of all 5 patients, compared to stage IV PCa 
patients. In stage IV PCa the expression overall seems to be reduced and the remaining 
expression tends to be accumulated in glandular structures and less in the stroma. 
However, one patient showed a similar stromal expression of SDPR to stage II PCa (Fig. 
5.15). The expression of SDPR was localised in the cytoplasm of the cell.  
The IHC analysis of P4HA2 in healthy and diseased prostate sections showed no or only 
faint staining. The faint staining detected was not intense enough to be categorised as 
“weak staining” (Fig. 5.16). The use of IF staining on the section enabled the detection of 
P4HA2 expression in these sections. Ubiquitous expression was detected in the stroma 
of healthy and adjacent healthy tissue, as well as on all 5 stage II tissue sections. The 
detected expression was comparable to healthy tissue (Fig. 5.16). The expression of 
P4HA2 in stage IV PCa was not detectable for 2 patients and detectable with a low 
expression in 2 patients. One patient showed a stronger expression of P4HA2 with focal 
hotspots of increased expression, which was located in the stroma and the cytoplasm of 
the cell.  
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Figure 5.13: DPYL3 expression in healthy prostate, prostate cancer and healthy adjacent prostate tissue samples (PR242B US Biomax). Staining was performed using 
immunohistochemistry staining (IHC) and immunofluorescence (IF) staining on matching tissue samples. Representative images were taken at 20x magnification. Scale bar represents 
100 µm (IHC) and 50 µm (IF). In the IF pictures blue = DAPI staining (cell nucleus) and green = protein of interest, here DPYL3. 
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Figure 5.14: FBLI1 expression in healthy prostate, prostate cancer and healthy adjacent prostate tissue samples (PR242B US Biomax). Staining was performed using 
immunohistochemistry staining (IHC) and immunofluorescence (IF) staining on matching tissue samples. Representative images were taken at 20x magnification. Scale bar represents 
100 µm (IHC) and 50 µm (IF). In the IF pictures blue = DAPI staining (cell nucleus) and green = protein of interest, here FBLI1. 
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Figure 5.15: SDPR expression in healthy prostate, prostate cancer and healthy adjacent prostate tissue samples (PR242B US Biomax). Staining was performed using 
immunohistochemistry staining (IHC) and immunofluorescence (IF) staining on matching tissue samples. Representative images were taken at 20x magnification. Scale bar represents 
100 µm (IHC) and 50 µm (IF). In the IF pictures blue = DAPI staining (cell nucleus) and green = protein of interest, here SDPR. 
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Figure 5.16: P4HA2 expression in healthy prostate, prostate cancer and healthy adjacent prostate tissue samples (PR242B US Biomax). Staining was performed using 
immunohistochemistry staining (IHC) and immunofluorescence (IF) staining on matching tissue samples. Representative images were taken at 20x magnification. Scale bar represents 
100 µm (IHC) and 50 µm (IF). In the IF pictures blue = DAPI staining (cell nucleus) and green = protein of interest, here P4HA2. 
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Table 5.5: Score summary of immunohistochemistry tissue sections for DPYL3 (Fig.3.12), FBLI1 (Fig. 
3.13), SDPR (Fig. 3.14) and P4HA2 (Fig. 3.15). Table representing staining intensities observed in normal 
prostate tissue taken from the previously analysed healthy tissue TMAs (MNO341 (DPYL3), MNO381 
(FBLI1), BN243c (SDPR) and BN243d (P4HA2)) and a TMA comprised of adjacent normal, Stage II and 
Stage IV prostate cancer tissue (PR242b). Staining intensities were assigned as previously describes (Fig. 
5.7) into 4 categories; 0 = no staining, 1 = weak staining, 2 = moderate staining and 3 = strong staining 
used. * indicates localised increased expression. Numbers in cells (column #) represents the total number 
of individual cores analysed and shaded areas represent number of cores assigned to this staining intensity. 
 
  
* localised
Tissue type # 0 1 2 3 # 0 1 2 3 # 0 1 2 3 # 0 1 2 3
Healthy tissue 1 1* 1 1 2 2 2 2
Adjacent normal 4 4 4 4 4 4 4 4
Stage II 10 8 2 10 10 10 6 4 10 10
Stage IV 10 6 4 10 4 10 10 10 10
DPYL3 FBLI1 SDPR P4HA2
staining intensity staining intensity staining intensity staining intensity
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5.2.6 In silico validation of selected markers in publicly available 
datasets 
Publicly available datasets have the potential to be mined for quick and easy biomarker 
validation; furthermore, they overcome the limitations based on the availability of sample 
material. In silico validation has previously been successfully performed in various cancers, 
including gastric cancer (Szász, Lánczky et al. 2016) and non-small cell lung cancer (Yu, 
Xu et al. 2015). 
5.2.6.1 In silico validation of selected markers in publicly available datasets of 
TGF-β induced cell lines models 
The use of publicly available data sets also enables the study of markers of interest in 
additional cell line models. For this, 5 independent models of EMT, generated in 3 studies, 
were selected and the expression of DPYSL3, FBLIM1, SDPR and P4HA2 was analysed. 
In the first study, three lung cancer cell lines (A549, HCC827 and NCI-H358) were treated 
with 2 ng/ml TGF-β for 3 weeks (Sun, Yuting, Daemen et al. 2014). The second study 
stimulated a pancreatic cancer cell line (PANC-1) with 5 ng/ml TGF-β for 5 days (Maupin, 
Sinha et al. 2010) and the third study treated a cell line derived from healthy retinal 
pigmented epithelium (ARPE-19) with 5 ng/ml TGF-β together with 10 ng/ml TNF-α 
for 60 hours (Takahashi, Nagano et al. 2010). Three of the analysed cell lines were derived 
from the primary tumour, one from the metastatic site and one was generated from 
healthy tissue (Tab. 5.6). All 5 cell lines are characterised as epithelial, adherent cells.  
 
Table 5.6: Summary of analysed cell lines for the in silico validation of DPYSL3, FBLIM1, SDPR and 
P4HA2.  
Cell line Disease Type Morphology 
A5491 Lung cancer Primary tumour – lung Epithelial  
HCC8271 Lung cancer Primary tumour – lung Epithelial 
NCI-H3581 Lung cancer Metastasis – alveolus Epithelial 
PANC-12 Pancreatic cancer Primary tumour – pancreas/duct Epithelial 
ARPE-193 Healthy tissue Healthy – retina - eye Epithelial 
1(Sun, Yuting, Daemen et al. 2014) 
2(Maupin, Sinha et al. 2010) 
3(Takahashi, Nagano et al. 2010) 
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All three lung cancer cell lines showed a significant increase in the expression of DPYSL3 
upon stimulation with TGF-β (Fig. 5.17A-C), whereas the intensity of induction varied. 
The treatment of PANC-1 showed a slight increase in the expression; however, this 
increase did not show a significant change (Fig. 5.17D). Compared to this, treatment of 
ARPE-19 showed both a significant and the most intense increase in the expression of 
DPYSL3 when the stimulation of all 5 cell lines was compared (Fig. 5.17E).  
  
 
 
Figure 5.17: In silico gene expression analysis for DPYSL3 generated from cell-derived whole transcriptome 
analyses of EMT-induced cell lines. A549, HCC827 and NCI-H358 (GSE49644) (Sun, Yuting, Daemen et 
al. 2014), PANC-1 (GSE23952) (Maupin, Sinha et al. 2010) and APRE-19 (GSE12548) (Takahashi, Nagano 
et al. 2010). The profiles were generated in triplicates per condition using Affymetrix Human Genome U133 
Plus 2.0 Array 
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The expression of FBLIM1 showed a significant change in all 3 lung cancer cell lines; 
however, the expression was upregulated upon stimulation in A549 and NCI-H358 (Fig. 
5.18A+C), whereas the expression was decreased in HCC827 (Fig. 5.18B). A faint increase 
in the expression was detected in PANC-1 upon stimulation, but the difference was not 
significant (Fig. 5.18D). FBLIM1 was shown to be reduced in APRE-19, but with a high 
degree of variation. Based on this, the decreased expression did not present a significant 
difference (Fig. 518E).  
 
 
 
Figure 5.18: In silico gene expression analysis for FBLIM1 generated from cell-derived whole transcriptome 
analyses of EMT-induced cell lines. A549, HCC827 and NCI-H358 (GSE49644) (Sun, Yuting, Daemen et 
al. 2014), PANC-1 (GSE23952) (Maupin, Sinha et al. 2010) and APRE-19 (GSE12548) (Takahashi, Nagano 
et al. 2010). The profiles were generated in triplicates per condition using Affymetrix Human Genome U133 
Plus 2.0 Array. 
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The analysis of SDPR showed a consistent, significant decrease in its expression upon 
stimulation (Fig. 5.19A-E) in all 5 cell lines. The strongest reduction was observed in 
ARPE-19 with approximately 9-fold decrease, followed by A549 and HCC827, with a 
fold change reduction ranging from -3 to -2, respectively (Fig. 5.19A+B). The least intense 
decrease was observed in the pancreatic cell line PANC-1 (Fig. 5.19D).  
 
 
 
Figure 5.19: In silico gene expression analysis for SDPR generated from cell-derived whole transcriptome 
analyses of EMT-induced cell lines. A549, HCC827 and NCI-H358 (GSE49644) (Sun, Yuting, Daemen et 
al. 2014), PANC-1 (GSE23952) (Maupin, Sinha et al. 2010) and APRE-19 (GSE12548) (Takahashi, Nagano 
et al. 2010). The profiles were generated in triplicates per condition using Affymetrix Human Genome U133 
Plus 2.0 Array.   
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In all 5 analysed cell line models, a significant alteration in the expression of P4HA2 was 
shown. A significant increase was detected in all cancerous cell lines, namely A549 (Fig. 
5.20A), HCC827 (Fig. 5.20B), NCI-H358 (Fig. 5.20C) and PANC-1 (Fig. 5.20D), whereas 
a significant reduction was observed in the healthy tissue derived cell line ARPE-19 (Fig. 
5.20E).  
 
 
 
 
Figure 5.20: In silico gene expression analysis for P4HA2 generated from cell-derived whole transcriptome 
analyses of EMT-induced cell lines. A549, HCC827 and NCI-H358 (GSE49644) (Sun, Yuting, Daemen et 
al. 2014), PANC-1 (GSE23952) (Maupin, Sinha et al. 2010) and APRE-19 (GSE12548) (Takahashi, Nagano 
et al. 2010). The profiles were generated in triplicates per condition using Affymetrix Human Genome U133 
Plus 2.0 Array.   
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5.2.6.2 In silico validation of selected markers in publicly available datasets of 
patient derived transcriptomic profiles 
The analysis of tissue microarrays enables the study of protein expression in patient 
material and can give indications on the expression intensity and protein localisation in 
healthy and diseased tissue specimens. However, the available cores on a single slide 
present only a snapshot of a few cases and tissue areas, and potential clinical associations 
of novel markers can be missed. To overcome the limitations of tissue microarrays, an in 
silico analysis of patient-derived gene expression profiles was performed in addition to the 
previously performed wet lab validation (Chapter 5.2.4.2). 
5.2.6.2.1 Comparison of benign tissue with primary PCa and CRPC 
The utilised datasets were generated previously in a study on the lethal landscape of 
castration-resistant prostate cancer (Grasso, Wu et al. 2012). The sample material was 
categorised into normal (benign prostate tissue) (n = 28), localised PCa (n = 59) and 
castration-resistant prostate cancer/metastasis (n = 35) (Grasso, Wu et al. 2012).  
  
In the analysed data, the expression of DPYSL3 decreased significantly with disease 
progression, showing the highest expression in non-cancerous prostate tissue, a 
significant lower expression in primary PCa and a further, significant decrease in CRPC 
(Fig. 5.21A).  
 
When investigating FBLIM1, a significantly lower expression was observed in primary 
PCa compared to healthy tissue and CRPC. The expression of FBLIM1 in healthy and 
CRPC specimens presented a comparable intensity and did not show any significant 
difference (Fig. 5.21B).  
 
A similar expression pattern to DPYSL3 was also observed in SDPR, (Fig. 5.21C), which 
showed a significant reduction from healthy tissue, via primary PCa and CRPC. The 
reduction of its expression was shown to be significantly different across all 3 conditions 
(healthy, localised PCa and CRPC) (Fig. 5.21C).  
 
The comparison of P4HA2 expression in normal tissue with primary PCa and CPRC 
tissue showed significant differences. Initially, the expression of P4HA2 was slightly 
decreased in primary PCa compared to healthy, whereas the expression in CRPC was 
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increased by about 1.5 and 2-fold when compared to healthy tissue and primary PCa, 
respectively (Fig. 5.21D).  
 
 
Figure 5.21: Gene expression of DPYSL3 (A), FBLIM1 (B), SDPR (C) and P4HA2 (D) in normal, primary 
tumour and CRPC tissue generated from patient-derived whole transcriptome analyses (Grasso, Wu et al. 
2012). The data is publicly available under the following accession number: GSE35988. The profiles were 
generated using Agilent-014850 Whole Human Genome Microarray 4x44K G4112F. Gene expression was 
normalised using min-max normalisation. The sample material was categorised into normal (benign prostate 
tissue) (n = 28), localised PCa (n = 59) and castration-resistant prostate cancer/metastasis (n = 35). 
 
5.2.6.2.2 Comparison of the gene expression of all 4 markers across different 
Gleason scores 
A second dataset was generated as part of “The Cancer Genome Atlas” TCGA- project. 
In this project, large sample numbers of various cancers were selected and analysed on 
multiple omic levels, including the genome and transcriptome. Here, the gene expression 
profiles of the 4 markers of interest were selected and their expression compared across 
four different Gleason scores (Abeshouse, Ahn et al. 2015), GS6 (n = 44), GS7 (n = 247), 
GS8 (n = 64) and GS9 (n = 137).  
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A significant difference could be observed in DPYSL3 expression across GS7, GS8 and 
GS9 compared to GS6, whereas the expression of DPYSL3 was reduced with the increase 
in Gleason score (Fig. 5.22A). The same pattern was also observed for SDPR (decrease 
with increased Gleason Grade), in which the differences across the Gleason scores were 
also shown to be significant (Fig. 5.22C). FBLIM1 and P4HA2 showed only limited 
association with defined Gleason scoring, presenting for all or the majority of the 
comparisons no significant differences (Fig. 5.22B+D).  
 
 
 
Figure 5.22: Gene expression of DPYSL3 (A), FBLIM1 (B), SDPR (C) and P4HA2 (D) across four different 
Gleason scores generated from patient-derived whole transcriptome analyses (Abeshouse, Ahn et al. 2015). 
The data is publicly available from the TCGA data portal (https://portal.gdc.cancer.gov/) under the project 
number TCGA-PRAD. The profiles were generated using RNA-sequencing on a HiSeq2000 platform. The 
sample material was categorised into the Gleason scores GS6 (n =44), GS7 (n = 247), GS8 (n = 64) and 
GS9 (n = 137). 
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5.2.6.2.3 Impact of DPYSL3 and SDPR expression on disease-free survival of 
prostate cancer patients 
Previous analyses (Chapter 5.2.6.2.2) showed a significant association of DPYSL3 and 
SDPR expression with the tissue-derived Gleason score (Fig. 5.23A+C) and were 
therefore subjected to further validation. For this, another publicly available dataset was 
selected, in which gene expression profiles as well as clinical information regarding the 
relapse-status were supplied (Glinsky, Glinskii et al. 2004). Overall, the dataset contained 
79 patients, 37 without and 42 with disease-recurrence.  
 
The expression of DPYSL3 was shown to be significantly lower in patients with disease-
recurrence compared to patients without (Fig. 5.23A). Additionally, the Kaplan-Meier 
analysis of quartiles, sorted by gene expression from low to high, showed visible 
differences (Fig. 5.23B). In DPYSL3, patients assigned to Q4 (presenting the highest 
expression) showed a significant longer disease-free survival length compared to the other 
quartiles, in particular Q1 (lowest gene expression). In addition, less than 50 % of patients 
assigned to Q4 suffered disease recurrence, therefore no median recurrence-free survival 
(RFS) was available. In a further comparison, the RFS of Q2+Q3 represents more than 
double the RFS of patients assigned to Q1. To further validate the predictive abilities of 
DPYSL3, the data was subjected to a univariate cox regression analysis, showing a 
significant association of DPYSL3 expression with time to relapse (Fig. 5.23C). Overall, 
these findings further support the previously detected changes of DPYSL3 in which the 
reduced expression was annotated with a poorer cancer phenotype (Fig. 5.22A and Fig. 
5.21A).  
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Figure 5.23: Gene expression of DPYSL3 in patient-derived whole transcriptome datasets of recurrent and 
non-recurrent PCa (Glinsky, Glinskii et al. 2004). The data was downloaded through the following website: 
http://web.bioinformatics.cicbiogune.es/CANCERTOOL/index.html (Cortazar, Ana R., Torrano et al. 
2018). The profiles were generated using Affymetrix U95Av2. The sample material was categorised, 
dependent on comparison. A: No recurrence n = 37, recurrence n = 42; B: sorted by expression from 
lowest to highest and then separated into quartiles (Q1: n = 20, Q2+Q3: n = 39, Q4: n = 20); C: Univariate 
Cox regression analysis using DPYSL3, here the cases were not categorised, and all cases were used.  
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Using SDPR, comparison of patients without and with relapse showed a significant 
decrease in the overall expression of this gene (Fig. 5.24A), however the Kaplan-Meier 
analysis of the 3 quartile groups was unable to show a significant difference (Fig. 5.24B). 
Despite this, the comparison of median RFS times showed strong variations; patients with 
a lower SDPR expression show a RFS of 50 months, compared to 82 months of Q2 and 
Q3. Less than 50 % of patients assigned to Q4 experienced disease recurrence, therefore, 
no median time could be defined. Furthermore, the univariate cox regression analysis 
highlighted a significant association of SDPR expression with RFS (Fig. 5.24C). However, 
this association was less significant compared to DPYSL3 (Fig. 5.23C).  
 
 
 
Figure 5.24: Gene expression of SDPR in patient-derived whole transcriptome datasets of recurrent and 
non-recurrent PCa (Glinsky, Glinskii et al. 2004). The data was downloaded through the following website: 
http://web.bioinformatics.cicbiogune.es/CANCERTOOL/index.html (Cortazar, Ana R., Torrano et al. 
2018). The profiles were generated using Affymetrix U95Av2. The sample material was categorised, 
dependent on comparison. A: No recurrence n = 37, recurrence n = 42; B: sorted by expression from 
lowest to highest and then separated into quartiles (Q1: n = 20, Q2+Q3: n = 39, Q4: n = 20); C: Univariate 
Cox regression analysis using SDPR, here the cases were not categorised, and all cases were used.  
  
210 
 
5.3 Discussion 
As previously mentioned, the generation of omic profiles commonly results in long lists 
of potential candidates. Here, the transcriptomic and proteomic profiles of both EMT 
models have resulted in large numbers of significant markers. The lists of genes and 
proteins have shown clear differences in their numbers (Tab. 5.1) and in total, a higher 
number of genes were significantly altered compared to proteins. This variation is mainly 
based on the detection and quantification limitations of proteomic approaches. 
Improvements in the technology and instrumentation over the last 5 years have enabled 
increases in the number of quantifiable proteins identified via mass spectrometry 
approaches (Shishkova, Hebert et al. 2016). A repeated analysis of the sample material 
generated in this PhD project using our more advanced mass spectrometry approaches, 
could most likely result in an increased number of quantified proteins.  
 
In this study, the chosen approach for the identification of key markers was the generation 
of a highly confident core set of deregulated markers. This resulted in the identification 
of 13 conserved markers, consistently detected in both models (Tab. 5.2). Out of this list, 
4 markers were selected for further studies, consisting of DPYL3, FBLI1, SDPR and 
P4HA2. The validation approaches for each potential novel biomarker were applied to 
cell line and patient-derived material.  
 
The analysis of FBLI1 has shown a consistent upregulation across both cell lines and omic 
levels, showing slightly stronger induction in DU145 (Tab. 5.3). The increased expression 
upon stimulation was also shown through the analysis of MCF10A in both a stimulated 
and unstimulated state (Fig. 5.1), confirming the induction through TGF-β.  Overall, in 
the analysis of cancer cell lines, FBLIM1 showed the highest expression of all 4 analysed 
markers (Fig. 5.1), however it also demonstrated a lower expression in BCa cell lines 
compared to PCa cell lines (Fig. 5.1). A similar observation was shown in the screening 
of healthy tissue, where the expression of FBLIM1 was the overall strongest compared to 
the other 4 markers. The in silico analysis of 5 additional EMT models have presented 
variable results in which 3 have shown an increased expression, whereas 2 have shown a 
reduced expression (Fig. 5.18). This inconsistency could potentially indicate a limited 
suitability of FBLI1 as a potential new biomarker for EMT. As mentioned previously, 
EMT is a highly conserved processed, and it would be expected that strongly associated 
markers present a strong consistency across multiple models. This might indicate that 
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FBLI1 is altered through EMT but is not directly associated to the activated pathway. 
These potential limitations were further supported through the comparison of the model 
expression with healthy prostate RNA, which indicated inverse results for both untreated 
cell lines, in which P5B3 was showing a higher expression, whereas DU145 showed a 
lower expression (Fig. 5.2). However, a significant increase, higher compared to healthy 
tissue, was shown in both cell lines upon stimulation (Fig. 5.2). Despite this increased 
expression in a healthy tissue RNA panel, the protein detected using IHC was very limited 
and the staining intensity ranged from low to not detected, which was also true for 
prostate cancer specimens (Fig. 5.10, Fig 5.14). Therefore, the analysis provided only 
limited information and no association with staining intensity and disease stage could be 
performed.  
 
The in silico analysis of the expression of FBLIM1 presented no significant difference 
between healthy and CRPC tissue, whereas primary PCa expressed a significantly lower 
expression compared to healthy and CRPC tissue (Fig. 5.21B). Also, the comparison of 
gene expression across the Gleason scores 6, 7, 8 and 9 showed limited significance (Fig. 
5.22B). Previous studies on FBLI1, the Filamin-binding LIM protein 1, were also 
published using the name “Migfilin”. It was shown that FBLI1 plays a role in cell adhesion, 
the actin cytoskeleton and as an integrin-activator (Das, M., Ithychanda et al. 2011, 
Ithychanda, Das et al. 2009). Research articles on the function and association of FBLI1 
with cancer have shown information on an increase in disease malignancy through an 
increased FBLI1 expression (He, H., Ding et al. 2014, Toeda, Kasamatsu et al. 2018). 
Studies in oesophageal squamous cell carcinoma (ESCC) and oral squamous cell 
carcinoma (OSCC) have shown a regulation of cell migration and invasion through FBLI1 
(He, H., Ding et al. 2014, Toeda, Kasamatsu et al. 2018). Also, the analysis of clinical 
specimens showed a significantly higher expression of FBLI1 in cancerous tissue 
compared to healthy specimens, confirming the here observed expression changes from 
primary PCa to CRPC (Fig. 5.21B), potentially highlighting an association of FBLI1 
expression with disease outcome and overall survival length (Ou, Ma et al. 2012). In ESCC, 
a nuclear-cytoplasmic translocation from healthy to diseased tissue was observed, 
however this observation could not be confirmed in the analysed prostate TMAs of this 
study, based on the limited staining intensity across all samples (Fig. 5.14). The study on 
OSCC has furthermore identified an association of FBLI1 expression and its promotion 
of cellular migration, invasiveness and transendothelial migration (Toeda, Kasamatsu et 
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al. 2018). A potential explanation for the malignant function of FBLI1 was supplied by 
Seguin et al., who have stated that the increased expression of certain integrins can 
enhance the metastatic potential of tumours (Seguin, Desgrosellier et al. 2015). At the 
same time, Das et al., have shown that FBLI1 is enriched at cell-cell and cell-ECM sites, 
promoting integrin-activation through the displacement of filamin from integrins (Das, 
M., Ithychanda et al. 2011) and therefore categorising FBLI1 as an integrin activator. 
Furthermore, the silencing of FBLIM1 resulted in a downregulation of FN1, a commonly 
known marker of EMT-induction (Das, M., Ithychanda et al. 2011).  
 
The analysis of P4HA2 (Prolyl 4-hydroxylase subunit alpha-2) identified a consistent 
upregulation of approximately 2.5-fold in both cell line models, with a slightly higher 
increase at the proteomic level (Tab. 5.3). The screening of various cell lines (Fig. 5.1) has 
highlighted an increase of P4HA2 expression in MCF10A upon stimulation with TGF-β, 
also P4B6B and SAOS presented elevated levels of P4HA2 expression. P4B6B (Harner-
Foreman, Vadakekolathu et al. 2017) is a highly mesenchymal cell type, potentially 
supporting the induction of P4HA2 through the development of a mesenchymal 
morphology upon stimulation. SAOS was shown to have a high expression of collagen 
IV (Pautke, Schieker et al. 2004), whereas P4HA2 is involved in the collagen synthesis. 
The in silico analysis of 5 cell line models (Fig. 5.20) has also presented a consistent increase 
of P4HA2 expression in all 4 cancer cell line models, whereas a reduced expression was 
detected in the healthy tissue cell line. This mimics the expression pattern previously 
shown in the comparison of different prostate cancer stages (Fig. 5.21D). In the 
comparison of healthy tissue and both cell line models, a consistent increase from healthy 
to unstimulated to treated cells was observed (Fig. 5.2D+H). Furthermore, the expression 
of P4HA2 in prostate tissue presented a lower expression compared to the majority of 
analysed tissue RNA (Fig. 5.6). The analysis of protein expression in healthy tissue could 
confirmed an elevated expression of P4HA2 in the kidney and an overall very low to no 
expression in the remaining analysed tissues (Fig. 5.12). The protein expression observed 
in the prostate cancer TMA has also shown a very low expression overall, but the use of 
fluorescently-tagged secondary antibody has shown indications of a reduced expression 
in advanced prostate cancer (Fig. 5.16), however based on the limited number of patients 
no firm conclusions could be made.  
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An improved understanding on the impact of P4HA2 on disease progression was possible 
through the in silico analysis of clinically-derived expression profiles. The expression of 
P4HA2 was slightly decreased comparing healthy with primary PCa tissue, followed by a 
strong increase from primary PCa to CRPC (Fig. 5.21D). However, no differences in the 
expression intensity could be observed across the Gleason scores 6, 7, 8 and 9, 
highlighting limitations of P4HA2 as a disease progression marker (Fig. 5.22D). A study 
by Xiang et al, has shown that silencing of P4HA2 decreases proliferation and 
invasiveness in 3D culture as well as impairment of collagen deposition (Xiong, Deng et 
al. 2014). Not only does the analysis of in vitro models highlight the association of P4HA2 
with cancer progression and survival, but also the analysis of patient material has shown 
that the expression of P4HA2 is increased in BCa compared to healthy tissue, and in 
addition, is correlated with a poor prognosis (Gilkes, Chaturvedi et al. 2013, Xiong, Deng 
et al. 2014). Gilkes et al, suggested an association of P4HA2 with the organisation of 
collagen fibres of the ECM (Gilkes, Chaturvedi et al. 2013). The alignment of collagen 
surrounding the tumour can function as a disease prognosticator in BCa. Fibres that are 
aligned in a 90˚ angle to the tumour, so called perpendicular collagen, have been shown 
to be associated with a worse outcome (Conklin, Eickhoff et al. 2011). A study on the 
function of P4HA2 in breast cancer has shown that knockdown of P4HA2 in MDA-MB-
231 cells results in an inhibition of tumour growth, as well as a reduction in tumour 
stiffness (Gilkes, Chaturvedi et al. 2013), which inhibits the migratory capabilities. 
Previous studies have shown that an elevated tumour stiffness can increase cell invasion 
and tumour metastasis (Reid, Kay et al. 2017). Such an increased expression of P4HA2 
with a high stage PCa might represent a preparation of the primary tumour, through the 
increase of tumour stiffness, to spread in surrounding tissue and to develop metastasis.  
 
The serum deprivation-response protein (SDPR), also known as caveolae-associated 
protein 2 (Cavin-2) was the only marker, out of the 4 analysed, that is downregulated upon 
stimulation with TGF-β; the downregulation was more intense in DU145 cells compared 
to P5B3 cells (Tab. 5.3). This downregulation was also documented in MCF10A cells 
upon stimulation with TGF-β (Fig. 5.1), as well as in the 5 in silico cell line models (Fig. 
5.19), with all demonstrating a reduction in expression upon stimulation.  
 
The comparison of SDPR expression in both cell line models with healthy prostate 
mRNA has shown a significant reduction in both models (Fig. 5.2C+G). Furthermore, 
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the validation using IHC has shown indications of a reduced expression with disease 
progression from stage II to stage IV PCa (Fig. 5.19), which was more apparent through 
the use of an IF-tagged secondary antibody on the same tissue sections (Fig. 5.19). The in 
silico analysis of patient-derived expression profiles further supported the SDPR-reduction 
associated with disease progression and EMT induction (Fig. 5.121C). In addition, a 
reduction of SDPR expression was correlated with increasing Gleason score (Fig. 5.22C), 
however SDPR did present limited capabilities for the prognosis of disease-recurrence 
(Fig. 5.24) based on a Kaplan-Meier analysis. Significantly lower expression levels of 
SDPR were measured in patients with disease-recurrence compared to patients without 
(Fig. 5.24B). Furthermore, the cox regression analysis has shown a significant association 
of SDPR expression with RFS (Fig. 5.24C). Previous studies have already proposed that 
a loss of SDPR could function as a marker for tumour progression in breast cancer 
(Ozturk, Papageorgis et al. 2016, Tian, Yu et al. 2016), and that SDPR is commonly 
silenced epigenetically by promotor DNA methylation (Tian, Yu et al. 2016). On the 
contrary, a depletion or SDPR loss was shown to enhance EMT induction and TGF-β 
pathway signalling activation (Tian, Yu et al. 2016). In general, the loss or reduction of 
SDPR was previously documented in various cancers, including bladder, colorectal, lung, 
pancreatic and ovarian cancers (Ozturk, Papageorgis et al. 2016), suggesting a conserved 
role across different tissue types in the inhibition of metastasis development through 
TGF-β signalling.  
 
The analysis of both EMT models has shown a significant upregulation of DPYL3 on a 
gene and protein level, whereas the expression was visibly more strongly induced in P5B3 
cells compared to DU145 cells (Tab. 5.2). This difference in the induction intensity could 
potentially be related to the nature of P5B3, being a single cell clone and showing a full 
response on the stimulation (Fig. 3.9), whereas DU145 is a heterogeneous cell line with a 
limited response to TGF-β, which is restricted to a subset of cells (Fig. 3.13). DU145 has 
shown responding and non-responding cells to the stimulation with TGF-β. Most likely, 
responding cells highlighted a strong deregulation of EMT-associated markers, whereas 
non-responding cells did not. The generated expression intensities of proteins and genes 
were therefore based on cells with a strong and a weak change of expression. The overall 
intensity must therefore be based on an averaged expression of a marker of interest. The 
mix of responding and non-responding cells might have resulted in a dilution of the 
mRNA/proteins and therefore resulted in a lower detected fold change.  
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The analysis of various cancer cell lines (Fig. 5.1) has not shown an association of 
DPYSL3 with specific cancer aggressiveness or EMT state. This was for example shown 
in the lack of expression in P4B6. This model was previously described as spontaneous 
EMT and increased migratory potential was documented (Harner-Foreman, 
Vadakekolathu et al. 2017), and also the expression in P4B6B, a highly mesenchymal cell 
line, was shown to be very low, potentially representing a limited association of DPYSL3 
with a mesenchymal cell state. The additional in silico analysis of 5 independent models of 
EMT, induced through TGF-β alone or in combination with TNF-α (Fig. 5.17), has 
shown a consistent induction of DPYSL3 upon stimulation, further supporting the 
measured expression changes of DPYSL3 in the studied EMT models of P5B3 and 
DU145. Despite the significant induction across 7 independent EMT models, the analysis 
of patient-derived sample material highlighted an inverse directionality of DPYSL3 
expression with progressive disease.  
 
Healthy tissue RNA has shown a higher expression when compared to the unstimulated 
cells of P5B3 (Fig. 5.2A+E), which was further supported by a strong protein expression 
measured in healthy prostate tissue (Fig. 5.8 and 5.9). Despite the measured upregulation 
of DPSYL3 with EMT induction, the analysis of healthy prostate tissue specimens has 
shown a reduction of its expression from healthy tissue to adjacent prostate tissue, 
followed by stage II PCa. The lowest expression was shown in advanced PCa (Stage IV) 
(Fig. 5.13, Tab. 5.5). These initial observations were further confirmed through the in silico 
analysis of patient-derived gene expression profiles (Fig. 5.21A), highlighting a progressive 
reduction with disease state, showing the lowest expression in patients with CRPC. An 
expression reduction was also shown with increased Gleason scoring (Fig. 5.22A). 
Furthermore, DPYSL3 showed predictive capabilities for disease-free survival (Fig. 5.23).   
 
A literature review on the functional analysis of DPYSL3 and its potential function as a 
cancer biomarker has also shown inconsistent results varying from cancer type to cancer 
type. The analysis of its function in hepatocellular carcinoma (HCC) has shown that 
DPYL3 suppresses cell proliferation and that knockdown of DPYSL3 results in increased 
migratory capability of HCC cells. It was also observed that the mean expression of 
DPYSL3 was reduced in HCC compared to healthy specimens (Oya, Kanda et al. 2015) 
and patients with a lower expression presented a significantly lower OS and RFS. An 
additional study on the methylation status of DPYL3 and its prognostic abilities for pelvic 
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lymph node metastasis in PCa has shown that DPYL3 promotor methylation of 15 % 
and above is highly predictive for lymph node metastasis (LNM) (Gao, X., Li et al. 2017). 
On the other hand, high expression in gastric cancer was associated with worse survival 
and a more malignant cancer phenotype. Furthermore, the expression positively correlates 
with a shorter recurrence-free survival (Kanda, Mitsuro, Nomoto et al. 2014). These 
results highlight the potential variation on the impact of DPYL3 on survival. A study by 
Matsunuma et al. on DPYL3 in claudin-low breast cancer has resulted in the hypothesis 
that DPYL3 functions as an EMT suppressor, which is activated by EMT regulators, 
resulting in a negative-feedback loop (Matsunuma, Chan et al. 2018). As previously 
discussed in the utility of biomarkers as therapeutic targets, markers need to be separated 
into “messengers” and “drivers” (Shen 2013). Messenger markers are changed as a 
consequence of activation, but do not cause effects such as tumour progression or 
metastasis. It might be the case that the upregulation of DPYL3 was driven as a response 
to EMT, which confirms the successful induction of the process in all analysed EMT 
models. On the other hand, the general function of DPYL3 would be the suppression of 
EMT, however this was not possible based on the continuous supply of stimulating and 
inducing cytokines, which overpowered the ability of DPYL3 to inhibit the process of 
EMT. In patients, the reduction of DPYL3 might result in a misbalance of EMT activity 
enabling a tumour to spread.  
 
In conclusion, it can be said that all four markers can be reliably associated with the 
process of disease progression. Two markers, DPYL3 and SDPR, presented more 
consistent and conclusive results compared to P4HA2 and FBLI1. Despite this, the 
integrative approach of combining the transcriptomic and proteomic profiles of two 
independent EMT models has successfully identified a key collection of markers affiliated 
with the process of EMT and metastasis. However, it should be noted that this selection 
approach does not represent an ultimate solution and other methods for the integration 
of multi-omics datasets could have resulted in other, potentially better disease-associated 
biomarkers.  
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6. Chapter VI - Final discussion, conclusions 
and future work 
6.1 General discussion 
6.1.1 Introduction 
Worldwide an estimated number of approximately 1.3 million men were diagnosed with 
prostate cancer in 2018, of whom about 500 000 were newly diagnosed in Europe (WHO, 
2019). This identifies prostate cancer as the most common cancer in men in Europe. More 
than 95 % of these cases were diagnosed in men over 55, whereby the frequency of 
advanced disease is increasing with patient age (Scosyrev, Messing et al. 2012). Aside from 
the high incidence rate of PCa in men, the disease is also the 3rd most common cause of 
cancer in men in Europe with an estimated number of 110 000 deaths through PCa in 
2018 alone (WHO, 2019a). Reduced chances of survival are correlated with the stage of 
prostate cancer at the time of diagnosis and increased mortality is mainly due to the 
development of metastasis (Chowdhury, Robinson et al. 2013). About 4 % of PCa patients 
will develop metastases, which reduces their 5-year survival rate to only 30 % (Thobe, 
Clark et al. 2011).  
 
Since the majority of cancer-related deaths, not only in PCa, but overall, are related to the 
development of metastasis (Taketo 2011, Mehlen, Puisieux 2006), markers associated with 
this process are likely to be of high clinical utility in the surveillance and treatment of 
cancer patients. Markers for this process would enable the improved treatment decisions 
of potential systemic treatment after surgical removal of the primary tumour. It has been 
shown that the present uncertainty results in overtreatment, for example in BCa patients 
with lymph node negative diagnosis (Pantel, Brakenhoff 2004), where approximately 20 
to 25 % of patients develop metastatic disease within 10 years, however 90 % of the 
patients within this category were subjected to chemotherapeutic treatment. 
 
A key process commonly associated with the development of metastasis is “epithelial-
mesenchymal transition”. In general, EMT is an evolutionary highly conserved process 
(Lim, J., Thiery 2012), which is implicated during embryonal development, wound healing 
and fibrosis (Kalluri, Weinberg 2009). However, during cancer this process is activated, 
resulting in a metastasis-initiating mechanism. Here, polarised epithelial cells, which are 
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attached to a basement membrane and the neighbouring cells, undergo multifactorial 
changes to acquire mesenchymal cell properties. These changes result in altered gene and 
protein expression, which leads to increased motility through the degradation of 
intracellular contacts, increased invasiveness, migratory potential and resistance to 
apoptotic signals (Kalluri, Weinberg 2009). On a molecular level these changes are shown 
through a reduction of epithelial gene expression and an increase in mesenchymal 
associated genes. These changes are based on multiple molecular alterations such as the 
activation of EMT specific transcription factors (SNAI1, SNAI2, TWIST1, TWIST2, 
ZEB1) and an altered expression of additional proteins, including VIME, FINC, CADH1 
and CADH2. This process is not unidirectional and it should be highlighted that the cells 
can reverse the process back into an epithelial morphology; this is called mesenchymal to 
epithelial transition (Lim, J., Thiery 2012). 
 
The focus of this study was on the use of an integrated multi-omics approach for the 
discovery of novel disease-associated biomarkers in PCa and markers indicative for the 
process of EMT. Based on this, the study could be separated into 3 major milestones; (1) 
the development of well-characterised EMT models, (2) the generation and validation of 
omic profiles and the use of those to further characterise the derived EMT models, and 
(3) the discovery and validation of novel disease-associated biomarkers in PCa 
6.1.2 TGF-β stimulation induces an EMT-like phenotype in the 
prostate cancer cell lines P5B3 and DU145 and alters EMT-associated 
signalling pathways 
Many studies on the use of in vitro models of EMT achieved the induction of this process 
using cytokines, such as epidermal growth factor (EGF) (Grassi, de Souza Palma et al. 
2017), tumour necrosis factor α (TNF-α) (Wang, H., Wang et al. 2013), as well as 
hepatocyte growth factor (HGF) (Liu, Fang, Song et al. 2017).  In addition, many studies 
also supported the use of TGF-β for the activation of the EMT program in cell line 
models of liver (Lin, X., Liu et al. 2018), breast (Melzer, von der Ohe et al. 2017) and 
gastric cancer (Zhang, H., Liu et al. 2013). However, despite these findings, many of them 
have based their validation and further characterisation on the analysis of single EMT-
associated genes and proteins (Zhau, Odero-Marah et al. 2008, Waldmeier, Meyer-Schaller 
et al. 2012, Liang, Fu et al. 2015), or the analysis of single omic levels. Furthermore, the 
generation of single omic data is often not used to its fullest potential and is mostly 
analysed for the identification of major deregulated markers (Katz, Dubois-Marshall et al. 
219 
 
2011, Lenferink, Cantin et al. 2010, Mikula, Rubel et al. 2011). Despite their infrequent 
use, the application of pathway analysis tools or systems biology approaches can harbour 
a more in-depth understanding of changes induced or present within the analysed sample 
cohort (Kim, Park et al. 2010, Kanda, M., Shimizu et al. 2016). In addition, the studies on 
EMT are commonly based on the selection of one single cell line. Such cell lines are 
commonly generated from the metastatic tumour site (Zhau, Odero-Marah et al. 2008, 
Lim, M., Chuong et al. 2011, Neal, Mckeithen et al. 2011).  
 
In this study however, two cell lines (P5B3 and DU145), of which one was derived from 
a primary tumour (P5B3), were selected for the generation of inducible models of EMT 
and both were characterised using an integrated multi-omics approach, analysing gene and 
protein expression profiles from sample material generated at the same time point. This 
enabled the validation of the suitability of both models, not only on a wet-lab based 
approach but also through the analysis of omic profiles using an in silico pathway analysis 
based on pathway topology.  
 
Both cell line models were treated with 10 ng/ml TGF-β over a period of 10 days, which 
has highlighted morphological changes indicative of a response to the stimulation with 
TGF-β, which presented itself with single, elongated cells of P5B3 (Fig. 3.9) and grouped, 
elongated cells of DU145 (Fig. 3.13). The analysis of molecular and proteomic EMT-
markers have correlated the changes induced through the stimulation with an increased 
mesenchymal cell state. This was confirmed through an upregulation of EMT markers, 
such as VIME and FINC, as well as the downregulation of CADH1. The comparison of 
time point expression measurements of both models with published EMT state profiling 
indicated the association of both models to an intermediate mesenchymal phenotype 
(Huang, R. Y., Wong et al. 2013).  
 
In addition, the migratory potential of both models was analysed using a scratch/wound 
healing assay. Stimulated P5B3 cells have shown a strong increase in their behaviour, 
enabling a complete wound closure after 24 hours, whereas untreated cells presented a 
closure of less than 10 % during the same time frame. This supports the findings of a 
successful induction of a mesenchymal cell state in P5B3 and its use as a model for EMT 
and potentially a proxy for metastasis. DU145, however, did not show any significant 
differences in its behaviour between untreated and treated cells. Nonetheless, it has been 
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shown that EMT and migration do not necessarily correlate and that sometimes pre-EMT 
cells present a higher migratory potential compared to post-EMT cells (Schaeffer, 
Somarelli et al. 2014).  
 
These results support the use of both models for the generation of omic profiles and the 
profiles generated led to an EMT-phenotype and furthermore achieved a more in-depth 
understanding of changes induced through the stimulation with TGF-β. The analysis of 
both models using their omics profiles have highlighted the induction of EMT through 
the stimulation with TGF-β was enabled through the activation of both, SMAD-
dependent and SMAD-independent, signalling pathways. This induction was shown, 
independent from the morphological changes, which were only limited in the cell line 
DU145. It also highlighted that a holistic approach, using multi-omic profiles, can explain 
the observed changes in cellular behaviour more accurately. Therefore, the use of these 
models highlights their potential for a better selection of novel biomarkers based on the 
targeted pathway. Overall, the generation of omic profiles have shown that both analysis 
methods and cell line models enable a characterisation of the desired and induced 
phenotype, whereas the proteomic analysis has shown an enrichment of cytoskeletal-
related changes. The strong enrichment of cytoskeletal-associated proteins detected 
through the proteomic analysis were shown to be strongly associated the induction of 
EMT and changes in cell motility and adhesion.  
6.1.3 The integration of transcriptomic and proteomic profiles can 
identify novel biomarkers associated with EMT and prostate cancer 
progression  
The majority of omic studies for the discovery of novel biomarkers focus on the study of 
single omic levels (Kafetzopoulou, Boocock et al. 2013, Hou, Lou et al. 2015, Cheng, Lei, 
Yang et al. 2012), commonly the transcriptome or genome, which are also frequently 
analysed together (Wang, L., Xiao et al. 2014). The proteome however, is commonly 
discussed as harbouring a great potential for biomarker discovery (Borrebaeck 2017, 
Jacobs, Adkins et al. 2005, McDonald, Yates 2002), but developed only more recently into 
a routinely analysed omics level for the discovery of novel disease-associated biomarker 
(Hou, Lou et al. 2015, Øverbye, Skotland et al. 2015, Beretov, Wasinger et al. 2015). A 
large proportion of multi-omic studies have used sample material that was mostly 
generated separately at different time points or is derived from publicly available sources 
(Gupta, Jayaram et al. 2015, Li, L., Wei et al. 2014, Wagner, Ball et al. 2018). 
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 In this study, matching transcriptomic (P5B3 n=10, DU145 n=9) and proteomic (P5B3 
n=10, DU145U n=9, DU145T n=8) profiles were generated from the same samples 
under the same conditions. In addition, the sample material was collected within 1 hour 
to reduce protein degradation. This number of replicates presents, based on current 
knowledge, one of the largest matching cancer cell-line derived datasets based on the 
proteome and transcriptome of two cell line models. The improved quality of this 
integrated time-correlated approach was highlighted through an improved association of 
genes and proteins in both cell line models. However, it needs to be noted that this 
information is based on a reduced number of markers due to the limited amount of 
confidently identified proteins (P5B3 n=84, DU145 n=38). This limited number of 
proteins can be attributed to the limitations of technologies at the time of sample 
generation. A potential repeat for the sample analysis would most likely result in an 
increased identification and quantitation of proteins of up to 5000 proteins (Hülsmann, 
Kravic et al. 2018, Shishkova, Hebert et al. 2016). 
 
The integration of both models and omic profiles enabled the identification of a core 
marker set of 13 genes and proteins, which were highly associated with the induced 
morphological and phenotypic changes. Four of these markers (DPYL3, FBLI1, SDPR 
and P4HA2) were subjected to further wet-lab and in silico validation approaches. The 
standard approach for the validation of a potential novel biomarker is the analysis of tissue 
microarrays (TMA) (Bubendorf, Lukas, Nocito et al. 2001). TMAs are glass slides spotted 
with small sections of tumour tissue of multiple patients. They commonly represent an 
easy route to obtain patient material for validation purposes. (Hassan, Ferrario et al. 2008). 
Despite this, as it was also the case here, the validation is not always successful and shows 
only limited differences between desired clinical parameters (De Matos, Trufelli et al. 2010, 
O’Hurley, Sjöstedt et al. 2014), especially in biomarkers that are proposed to be specific 
to certain cells. It has been suggested that the use of TMAs is more suitable for 
homogeneously distributed biomarkers (Merseburger, Kuczyk et al. 2003), whereas the 
process of EMT is most likely focussed on a subpopulation of cells, which are potentially 
not represented on this particular tumour section. Certainly, the possibility that a marker 
is not suitable always exists and is commonly the reason for a lack of validation. However, 
many other factors can influence the validation process, such as antibody specificity and 
the tumour sections present on the TMA themselves, since these sections only represent 
a snapshot of the tumour (Quagliata, Schlageter et al. 2014). 
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Based on the above-mentioned limitations of TMAs, an alternative method using patient 
derived transcriptomic profiles, which are publicly available, can enable a more in-depth 
study and characterisation of potentially novel biomarkers across larger patient pools. 
Here, all four markers were analysed in previously developed EMT models of 
independent studies (Sun, Yuting, Daemen et al. 2014, Maupin, Sinha et al. 2010, 
Takahashi, Nagano et al. 2010), which has highlighted the significant change of all markers 
through the induction of EMT. In addition to the cell-line based EMT models, the 
samples were validated in patient-derived transcriptomic profiles, in regards to their 
association with disease stage (benign, primary PCa or CRPC) and Gleason score. This 
analysis has shown a consistent and significant correlation of DPYSL3 and SDPR. For 
this reason, these two markers were additionally analysed for their impact on disease-
recurrence and disease-free survival. Despite the lack of detection or identified 
correlations with clinical information based on the TMAs used, the results have 
highlighted that all markers are strongly associated with EMT and PCa. The most 
significant results were achieved for DPYSL3 and SDPR, of which their loss was shown 
to be highly associated with disease progression and recurrence in patient-derived data of 
PCa patients.  
 
Studies have shown a significant association of a reduced DPYSL3 expression with 
metastasis development, disease progression and migration. This was presented in studies 
of lung (Yang, Jiang et al. 2018), prostate (Gao, X., Li et al. 2017, Li, B., Li 2017) and liver 
cancer (Oya, Kanda et al. 2015). Overall, a large proportion of publications have identified 
DPYSL3 as a metastasis-inhibitor and that a reduced expression has a negative impact on 
clinical outcome. The work of Gao et al has highlighted a potential link between the 
changed DPYSL3 expression and its promotor methylation (Gao, X., Li et al. 2017). In 
this study, the expression of DPYSL3 was shown to be increased in both cell line models, 
which could be explained by the work of Matsunuma and colleagues, which have 
proposed that DPYSL3 functions as EMT suppressor regulating the EMT activation 
through a negative feedback loop (Matsunuma, Chan et al. 2018).  
 
The tumour suppressor gene SDPR was shown to be reduced in this study. Previous 
studies have shown concordant results in a study on BCa, which has suggested that SDPR 
could be of potential use as clinical biomarker in BCa (Ozturk, Papageorgis et al. 2016). 
Its clinical applicability for the prognosis of disease progression was further supported 
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through a study in hepatocellular carcinoma, where the expression of SDPR was 
significantly associated with tumour differentiation and TNM stage. Furthermore, a lower 
expression of SDPR was associated with poorer survival (Jing, Luo et al. 2016).  
 
In conclusion, it can be said that the integration of multi-omic profiles, derived from two 
independent cell line models, has enabled the identification of potential novel disease-
associated biomarkers in PCa, which was supported through previously conducted studies 
highlighting the suitability of DPYL3 and SDPR in a clinical setting.  
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6.2 Conclusion 
This study has generated two inducible models of EMT and successfully applied these to 
a novel pipeline describing a process from model to biomarker. This approach resulted in 
the identification of SDPR and DPYL3 as potential novel biomarkers for disease-
progression in PCa. In addition to this, the generation of the matching omic datasets of 
two independent cell lines was able to contribute to the understanding of gene and protein 
expression correlation, highlighting the improvements in the correlation that can be made 
through connected sample collection with minimal time difference. In addition to the 
novel findings and discoveries made in this study, using the generated data, the potential 
of this dataset is not yet exhausted and can be used for future studies, for example in a 
more in-depth study on changes upon stimulation and EMT.  
 
However, despite the successful use of this data, potential limitations need to be 
highlighted, such as the use of cell line models for the discovery of disease-associated 
biomarkers. Here, in this case, the discovered biomarkers could be successfully validated, 
however, it is crucial to select the model of choice carefully. Cell lines are highly artificial 
systems and it is of crucial importance to generate meaningful output, whereas their 
artificial nature can be overcome partially through the use of multiple models.  
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6.3 Future work 
This study has highlighted the development of two inducible EMT models and their 
successful application in a multi-omics approach for the discovery of markers associated 
with the process of EMT and the progression of prostate cancer. This study has identified 
13 markers of particular interest, of which 4 were characterised through the use of in vitro 
experiments and further validated using wet-lab approaches on clinically-derived 
specimens and in silico analyses. This process has shown an association of all 4 markers 
with EMT and disease progression, whereas SDPR and DPYL3 have presented a stronger 
potential in their function as novel candidates in the prediction of disease progression and 
recurrence in prostate cancer (see Chapter V). Additional work should be focussed on 
multiple aspects of this study, regarding technical advances, model characterisation and 
the function of selected markers, and furthermore the evaluation of both markers for the 
use as routine biomarkers.   
 
To further understand the biological association of induced changes and identified 
markers, a more in-depth characterisation of both developed EMT models is necessary. 
Studies have shown that cells that underwent EMT commonly present an increased 
resistance to therapy (Shibue, Weinberg 2017) in association with a reduced proliferation 
rate (Tsai, Yang 2013). For this reason, assays to define therapy resistance of both models 
to standard care therapeutics, such as Docetaxel or Dabazitaxel, as well as proliferation 
rate, are important for the development of a more in-depth understanding. In this study, 
scratch assays were performed and gave first insights in changes of migratory behaviour 
of both cell line models, however for a better understanding a more advanced and realistic 
approach should be chosen. Such an approach could be the use of a migration assay based 
on Transwell plates, which characterises the migration of cells through their capability to 
move from an upper layer through a permeable membrane.  
 
As mentioned previously, advances in mass spectrometry analysis and data processing 
enables the routine identification and quantitation of a higher number of proteins (up to 
5000) within 90 min, compared to the number identified in this study (~2000). For this 
reason, a repeated analysis of the sample material for the generation of an improved library 
could deliver important information on potential newly identified proteins associated with 
EMT, as well as information on the correlation of gene and protein expression.  
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Aside from the use of advances in the instrumentation, the study of the biological function 
and potential associated interactions of DPYL3 and SDPR should be performed. As 
mentioned in Chapter V, published studies have postulated an association of changes in 
the methylation of the promoter region of SDPR (Tian, Yu et al. 2016) and DPYL3 (Gao, 
X., Li et al. 2017) with the induced changes in gene expression. Based on these results, 
future work should be focussed on the study of the methylation status of SDPR and 
DPYL3 in the generated cell line models and downstream in clinical specimens. The 
identification of altered methylation intensities of promoter regions associated with 
DPYLS3 and SDPR and their function in disease progression could support the treatment 
decision of clinicians for the use of demethylating agents as alternative treatment options 
(Howell, Liu et al. 2010).  
 
The generation and integration of the transcriptomic and proteomic datasets has 
highlighted two potential new biomarkers for the use in a clinical setting, mainly based on 
the in silico analysis of clinically-derived transcriptomic profiles. However, the suitability 
of both markers for the prediction of disease-progression in PCa has to be further 
evaluated. A biomarker predictive for disease progression should present certain 
capabilities, such as the detection in easily obtained and mini-invasive sample material. 
Most-routinely used sources are blood and urine samples.  
 
For this reason, an initial evaluation step could be the analysis of gene and protein 
expression of both markers in the secretomes of both cell line models. A successful 
detection of either of the two, or both markers, in the secretomes of the cell line model, 
could be followed by the analysis of urine and blood samples of healthy, early stage and 
advanced prostate cancer. The screening of these different tissues would help collecting 
information on the presence/absence of these markers and also the potential variation in 
the expression across different disease stages.  
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Appendix 
 
A1 Unmodified images of Western blot analyses used in 
Chapter III 
 
A1.1 Western blot analysis of fibronectin, vimentin and CYCA 
(Loading Control) in P5B3 
 
 
A1.2 Western blot analysis of E-cadherin and CYCA (Loading 
Control) in P5B3 
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A1.3 Western blot analysis of N-cadherin and CYCA (Loading 
Control) in P5B3. A = optimised exposure for loading control, B = 
Extended exposure for detection of N-cadherin 
 
 
 
A1.4 Western blot analysis of fibronectin and CYCA (Loading 
Control) in DU145 
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A1.5 Western blot analysis of E-cadherin, vimentin and CYCA 
(Loading Control) in DU145, A = optimised exposure for loading 
control and vimentin, B = increased exposure for E-cadherin.  
 
 
A1.6 Western blot analysis of N-cadherin and CYCA (Loading 
Control) in DU145  
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A2 Electropherogram of sample material used in RNA-
sequencing experiment generated in Chapter IV 
 
A2.1 Electropherogram of RNA extracted from untreated and treated 
P5B3 
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A2.2 Electropherogram of RNA extracted from treated P5B3 and 
untreated DU145 
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A2.3 Electropherogram of RNA extracted from untreated and treated 
DU145 
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A2.4 Electropherogram of RNA extracted from treated DU145 
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A3 Significant altered markers  
 
A3.1 Genes not detected in P5B3 untreated or P5B3 treated after 
stimulation with TGF-β 
 
Rank Gene Bonferroni FC 
1 LOC102724279 0.00000 Not detected in P5B3U 
2 MSC-AS1 0.00000 Not detected in P5B3U 
3 LINC01583 0.00000 Not detected in P5B3U 
4 CADPS 0.00001 Not detected in P5B3U 
5 FBXL7 0.00001 Not detected in P5B3U 
6 CLEC18B 0.00001 Not detected in P5B3U 
7 CACNG7 0.00002 Not detected in P5B3U 
8 KLHDC8A 0.00007 Not detected in P5B3U 
9 NTRK3 0.00008 Not detected in P5B3U 
10 JAKMIP2-AS1 0.00012 Not detected in P5B3U 
11 RTL1 0.00040 Not detected in P5B3U 
12 COL22A1 0.00085 Not detected in P5B3U 
13 COL5A3 0.00179 Not detected in P5B3U 
14 IGFBP5 0.00548 Not detected in P5B3U 
15 MYCT1 0.00604 Not detected in P5B3U 
16 JAKMIP2 0.00631 Not detected in P5B3U 
17 DEC1 0.01190 Not detected in P5B3U 
18 MEG9 0.01798 Not detected in P5B3U 
19 NAP1L3 0.02233 Not detected in P5B3U 
20 SHANK1 0.03151 Not detected in P5B3U 
21 BPIFB1 0.00167 Not detected in P5B3T 
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A3.2 Significantly deregulated genes in P5B3 upon stimulation with 
TGF-β 
 
Rank Gene 
Corrected 
p-value 
FC Rank Gene 
Corrected 
p-value 
FC 
22 MSC 0.00000 1494.53 78 SERPINE1 0.00000 60.27 
23 DIO3 0.00000 594.44 79 ZEB1 0.00085 60.04 
24 MEG3 0.00001 483.72 80 KCNJ8 0.00002 59.97 
25 GDF6 0.00002 456.82 81 TMEM119 0.00000 59.69 
26 DGKI 0.00000 438.41 82 HMCN1 0.00000 59.26 
27 GPC4 0.00000 433.11 83 CPED1 0.00040 58.23 
28 NKAIN4 0.00858 418.27 84 RBP1 0.00000 55.13 
29 TRPM2 0.00000 402.27 85 TLL1 0.00000 53.02 
30 ITGB3 0.00000 375.01 86 AGTR1 0.04355 52.60 
31 HS3ST3A1 0.00000 328.71 87 TNS1 0.00000 51.89 
32 CDH11 0.00000 303.39 88 EPHA5-AS1 0.02757 51.03 
33 PPAPDC1A 0.00004 264.20 89 SIRPA 0.00000 50.58 
34 SPARC 0.00000 258.11 90 CRTAC1 0.00012 47.39 
35 BGN 0.00470 248.56 91 ZC4H2 0.00000 45.50 
36 POSTN 0.00001 235.44 92 NLRP1 0.00000 44.74 
37 VCAN 0.00000 214.21 93 CBLN2 0.00000 44.28 
38 CNN1 0.00000 203.77 94 SIRPB1 0.02057 43.77 
39 LOC728392 0.00000 192.20 95 IGLON5 0.00005 41.72 
40 TWIST2 0.00000 178.19 96 BIRC7 0.00124 41.55 
41 MARCH4 0.00000 175.12 97 MMP9 0.00000 41.32 
42 SLC28A3 0.00084 157.07 98 FGF1 0.00000 40.55 
43 MEDAG 0.00991 156.78 99 FOXS1 0.00000 39.87 
44 CTTNBP2 0.00001 150.16 100 LZTS1 0.00080 39.80 
45 VIM 0.00000 141.81 101 TSHZ3 0.01452 39.76 
46 ADAM12 0.00000 135.63 102 MMP10 0.00000 39.28 
47 PTPRN 0.00000 126.54 103 CCIN 0.00000 38.53 
48 CASC15 0.00002 122.86 104 CDH2 0.00000 37.98 
49 GLI2 0.00000 122.85 105 EPHA3 0.00001 37.07 
50 HHIP 0.00000 121.59 106 LDLRAD4 0.00001 36.13 
51 SNHG24 0.00000 116.76 107 NCF2 0.00000 35.97 
52 DCHS1 0.00000 102.49 108 FGF5 0.00000 34.82 
53 CREB3L1 0.00000 93.77 109 IL11 0.00000 34.58 
54 GBP5 0.00002 87.98 110 PRRX1 0.00002 34.16 
55 ADAMTS12 0.00000 85.07 111 SCN8A 0.00000 34.14 
56 APCDD1L-AS1 0.00000 84.98 112 CGB5 0.00552 33.83 
57 CHST10 0.00000 82.44 113 RNF182 0.00000 33.27 
58 IGF2 0.00000 80.08 114 MMP1 0.00141 32.92 
59 SUSD4 0.00000 80.00 115 MAP1B 0.00002 32.90 
60 RASSF10 0.00000 79.84 116 LOC101448202 0.02821 32.77 
61 SLC16A2 0.00145 78.80 117 CSDC2 0.00001 32.57 
62 MMP2 0.00000 76.91 118 ELN 0.00025 32.45 
63 FBLL1 0.00062 74.57 119 MOV10L1 0.00000 31.88 
64 CDH12 0.00001 73.38 120 MYH16 0.00000 31.77 
65 NLRP3 0.00001 73.15 121 APCDD1L 0.00000 31.76 
66 PDPN 0.00717 72.20 122 GFRA1 0.01958 31.36 
67 FBXL21 0.00000 70.49 123 ADAMTS10 0.00004 31.31 
68 ANXA6 0.00000 70.48 124 LTB 0.00000 30.73 
69 CCDC85A 0.00028 70.19 125 COL3A1 0.01797 30.54 
70 CSF2 0.00799 68.37 126 PGBD5 0.00002 30.44 
71 DKK2 0.00129 66.22 127 FXYD6 0.00006 30.14 
72 MEX3B 0.00000 62.92 128 RBMS3 0.00000 29.63 
73 CGB8 0.00000 62.75 129 GPR68 0.00000 29.43 
74 KCNH1 0.00000 62.39 130 CCNJL 0.00000 29.10 
75 DACT1 0.00000 61.99 131 SHC2 0.00002 29.06 
76 VIM-AS1 0.00004 61.77 132 SERPINA1 0.00511 28.76 
77 MGC12916 0.00073 60.67 133 KCNG1 0.00000 28.02 
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Rank Gene 
Corrected 
p-value 
FC Rank Gene 
Corrected 
p-value 
FC 
134 COL8A1 0.00000 27.95 190 KRTAP2-3 0.00086 18.97 
135 HAPLN3 0.00000 27.83 191 KIF1A 0.00000 18.92 
136 COL1A1 0.00001 27.48 192 TNFRSF19 0.00000 18.85 
137 PCDH10 0.00000 27.42 193 SDK2 0.03831 18.80 
138 FRMPD4 0.00000 27.20 194 LAPTM5 0.00000 18.78 
139 C5orf46 0.00059 27.18 195 FAM101A 0.00000 18.77 
140 C4orf26 0.00000 27.09 196 DIXDC1 0.00000 18.43 
141 RGS7 0.00005 26.17 197 ZP4 0.04097 18.33 
142 ADAM19 0.00000 26.16 198 HHIP-AS1 0.00000 18.09 
143 MYOZ1 0.00000 26.05 199 ADAMTS9 0.00053 18.07 
144 EPHA5 0.00000 26.02 200 GOLGA7B 0.00000 17.79 
145 LOC79160 0.00000 25.83 201 ADD2 0.00101 17.73 
146 XYLT1 0.00000 25.82 202 EGOT 0.00585 17.68 
147 ACTC1 0.00000 25.70 203 S1PR1 0.00000 17.65 
148 SDK1 0.00000 25.25 204 TMSB15A 0.00000 17.60 
149 DLX2 0.00001 25.18 205 EDIL3 0.00000 17.47 
150 ZDHHC22 0.01213 25.10 206 SCN2A 0.00000 17.45 
151 SLIT3 0.00000 25.05 207 SYT11 0.00000 17.31 
152 IGF2BP1 0.03813 24.68 208 DPYSL4 0.00000 17.26 
153 SENCR 0.00022 24.51 209 KCNK3 0.00006 17.24 
154 FLRT2 0.00000 24.26 210 COL27A1 0.00000 17.23 
155 PMP22 0.00060 24.17 211 IGFBP7 0.00000 17.22 
156 COL5A1 0.00000 23.96 212 SRPX 0.00000 17.20 
157 GLIPR2 0.00000 23.95 213 NAV3 0.00008 17.14 
158 ROBO3 0.00000 23.93 214 F2R 0.00000 17.09 
159 PALM2 0.00013 23.78 215 NSG1 0.00000 16.97 
160 ZCCHC12 0.00170 23.77 216 CLDN14 0.00000 16.91 
161 BEST3 0.00016 23.67 217 NCALD 0.00000 16.91 
162 FILIP1L 0.00000 23.61 218 IGFBP7-AS1 0.00000 16.89 
163 RCN3 0.00000 23.33 219 FMN2 0.00405 16.83 
164 C6orf15 0.00017 23.01 220 TOX 0.00000 16.83 
165 LOC101928370 0.04371 22.95 221 KCNMA1 0.00035 16.82 
166 RFTN1 0.00000 22.91 222 TNFRSF9 0.00001 16.82 
167 ARL4C 0.00000 22.86 223 CABP7 0.00006 16.80 
168 ADRA1D 0.00000 22.77 224 ADAMTS6 0.00000 16.79 
169 TUBA1A 0.00000 22.66 225 THBS2 0.00000 16.55 
170 MYOM3 0.00000 21.76 226 GUCY1A2 0.00000 16.55 
171 DPYSL3 0.00000 21.51 227 RGS4 0.00227 16.43 
172 COL6A3 0.00000 21.21 228 G0S2 0.00007 16.42 
173 COL6A2 0.00000 21.14 229 NTRK1 0.00332 16.37 
174 DLX1 0.00001 21.14 230 ITGA11 0.00332 16.14 
175 FIBIN 0.00002 20.88 231 NFATC2 0.00000 16.04 
176 CACNA1H 0.03038 20.78 232 C1QTNF2 0.00000 16.02 
177 ELFN1 0.00000 20.43 233 CHI3L2 0.02396 16.00 
178 FAM172BP 0.00003 20.42 234 MYH15 0.00057 15.97 
179 PALM2-AKAP2 0.00000 20.39 235 DACT3 0.00589 15.92 
180 FAP 0.00000 20.33 236 LOC541472 0.00000 15.88 
181 OSCAR 0.00001 20.32 237 LOC100507431 0.00000 15.87 
182 P2RY6 0.00000 20.25 238 SOGA3 0.00033 15.76 
183 AQP1 0.00000 20.12 239 DTNA 0.00666 15.69 
184 STEAP1B 0.00001 19.92 240 PAK3 0.03491 15.65 
185 POU3F1 0.00804 19.69 241 LTBP2 0.00000 15.64 
186 C14orf37 0.00169 19.45 242 SUN3 0.00000 15.63 
187 GPR176 0.00000 19.33 243 ACTBL2 0.00012 15.62 
188 FLI1 0.00046 19.26 244 TGFBI 0.00000 15.60 
189 MFGE8 0.00000 19.15 245 UCN2 0.00000 15.55 
190 KRTAP2-3 0.00086 18.97 246 STK32A 0.00136 15.49 
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Rank Gene 
Corrected 
p-value 
FC Rank Gene 
Corrected 
p-value 
FC 
247 PRR5L 0.00000 15.26 304 IL32 0.00000 11.85 
248 CNTNAP2 0.00762 15.25 305 MRAS 0.00000 11.75 
249 BICC1 0.00000 15.10 306 HRASLS 0.00062 11.66 
250 NEGR1 0.00856 15.07 307 GNG2 0.00000 11.57 
251 GAL3ST3 0.00003 15.05 308 NUAK1 0.00000 11.54 
252 LOC101929532 0.01484 14.98 309 KCNN1 0.04568 11.54 
253 RAI2 0.00000 14.78 310 OLFML3 0.01467 11.37 
254 PLAU 0.00000 14.76 311 JAM2 0.00000 11.31 
255 CYP24A1 0.00000 14.65 312 CWH43 0.00001 11.31 
256 BARX1 0.00000 14.56 313 IL6 0.00101 11.26 
257 PRR16 0.00013 14.56 314 MIA 0.00017 11.14 
258 HS3ST3B1 0.00493 14.50 315 ROS1 0.00106 11.13 
259 ANTXR2 0.00000 14.48 316 PSD 0.00000 10.98 
260 DIRAS1 0.00815 14.37 317 DCLK2 0.00000 10.95 
261 PCDHGC5 0.00014 14.32 318 SAMD14 0.00002 10.91 
262 KCNE4 0.00559 14.23 319 PDCD1LG2 0.00004 10.86 
263 ZNF474 0.00006 14.19 320 KALRN 0.00000 10.73 
264 LOC284581 0.00049 14.16 321 NPR3 0.00001 10.72 
265 FAM13C 0.00315 14.08 322 GUCY1A3 0.00007 10.68 
266 CAMK1D 0.00003 14.01 323 LINC00607 0.03900 10.62 
267 MFAP2 0.00000 14.00 324 LOX 0.00000 10.61 
268 MRC2 0.00000 13.94 325 LCK 0.00000 10.60 
269 PDE4C 0.00000 13.91 326 PRKAR2B 0.00000 10.59 
270 GBP6 0.00000 13.89 327 FRMD5 0.00000 10.56 
271 IL23A 0.00001 13.86 328 FBLN5 0.00000 10.56 
272 GJA1 0.00000 13.66 329 KCNA7 0.00218 10.54 
273 MSRB3 0.00001 13.62 330 KIF12 0.00000 10.51 
274 WNT7A 0.00000 13.60 331 GHR 0.00344 10.39 
275 ELMOD1 0.00016 13.50 332 IKZF3 0.00000 10.39 
276 TENM4 0.00000 13.50 333 FZD10-AS1 0.00000 10.32 
277 USP2 0.00000 13.36 334 ZDHHC8P1 0.00004 10.31 
278 TMEM98 0.00000 13.35 335 IRX4 0.00998 10.24 
279 KCND1 0.00499 13.25 336 EBI3 0.00000 10.21 
280 NTNG1 0.00000 13.18 337 NPBWR1 0.00000 10.20 
281 SNAI1 0.00075 13.05 338 LOC101928718 0.00052 10.16 
282 SH3GL3 0.00000 13.04 339 HOXB9 0.01307 10.13 
283 AEBP1 0.00000 13.03 340 PLA2G4C 0.00025 10.10 
284 EFNB3 0.00000 12.95 341 NIPAL4 0.00000 10.09 
285 MYO3B 0.00000 12.95 342 NUAK2 0.00002 10.06 
286 GAS6-AS2 0.00000 12.90 343 FAM110B 0.01726 10.02 
287 ADRA2C 0.00408 12.89 344 DPYSL5 0.00000 9.92 
288 CISH 0.00017 12.87 345 LRRTM3 0.01597 9.91 
289 ATP8B2 0.00000 12.77 346 PIK3AP1 0.00046 9.83 
290 SYT1 0.00000 12.76 347 DYSF 0.00000 9.83 
291 ZNF469 0.00000 12.68 348 CPQ 0.00007 9.82 
292 PLEKHO1 0.00000 12.66 349 TNC 0.00000 9.66 
293 MSX1 0.00786 12.61 350 MDGA1 0.00000 9.64 
294 ASGR1 0.00001 12.56 351 KIAA1549L 0.00000 9.63 
295 FN1 0.00000 12.51 352 RAI14 0.00000 9.62 
296 PNMA2 0.00776 12.39 353 TMCC2 0.00000 9.62 
297 PLAT 0.00000 12.36 354 LOC100506178 0.00000 9.59 
298 ADAMTS15 0.00000 12.32 355 ALPL 0.00276 9.51 
299 HTR7 0.00000 12.21 356 HAS2 0.00001 9.50 
300 KCNJ12 0.01067 12.14 357 EHD3 0.00000 9.48 
301 SERPINE2 0.00000 12.09 358 NXPH2 0.00868 9.45 
302 TAGLN 0.00000 12.04 359 CD74 0.00000 9.39 
303 PCDHB5 0.00002 11.85 360 GRASP 0.03258 9.38 
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Rank Gene 
Corrected 
p-value 
FC Rank Gene 
Corrected 
p-value 
FC 
361 SLC22A17 0.00001 9.35 418 PIK3CD 0.00000 8.02 
362 ACTG2 0.00019 9.34 419 NREP 0.00000 8.01 
363 NACAD 0.00000 9.32 420 KBTBD11 0.04797 7.98 
364 MAGEH1 0.00001 9.29 421 LOC101928710 0.00000 7.96 
365 CD83 0.00000 9.29 422 DHRS2 0.00000 7.88 
366 RPSAP52 0.00003 9.28 423 CYR61 0.00000 7.86 
367 SLC2A12 0.00000 9.27 424 XKR5 0.03171 7.83 
368 GABRB3 0.00107 9.23 425 IL1B 0.00001 7.83 
369 HAGLROS 0.00697 9.18 426 APBA2 0.00123 7.82 
370 ARHGAP22 0.00000 9.16 427 L1CAM 0.00000 7.80 
371 SMAD7 0.00000 9.10 428 KRT33B 0.02168 7.78 
372 KLF2 0.00000 9.07 429 IL4I1 0.00001 7.74 
373 PCSK1N 0.00000 9.06 430 PAPPA 0.00000 7.73 
374 PLEKHG1 0.00000 9.00 431 C10orf55 0.00000 7.69 
375 SEMA7A 0.00000 8.98 432 RASSF9 0.00066 7.67 
376 NOX5 0.00001 8.94 433 RAB3B 0.00029 7.63 
377 PARP11 0.00053 8.90 434 SOBP 0.01386 7.62 
378 SCARF1 0.00926 8.87 435 ANGPTL2 0.00003 7.60 
379 CHRNB4 0.00002 8.86 436 MAP6 0.00088 7.58 
380 LBH 0.00000 8.85 437 JAG1 0.00000 7.57 
381 THBS1 0.00000 8.84 438 TRPC4 0.00000 7.56 
382 BATF3 0.00000 8.83 439 PODNL1 0.00021 7.56 
383 CXCL1 0.00001 8.81 440 APOE 0.00000 7.52 
384 P4HA3 0.00000 8.81 441 CHST11 0.00000 7.52 
385 CTGF 0.00000 8.80 442 LOC729683 0.00000 7.49 
386 TM4SF19 0.00000 8.76 443 DYRK3 0.00001 7.46 
387 C15orf48 0.00000 8.65 444 CNGB1 0.00000 7.45 
388 CSMD3 0.00005 8.65 445 FAM171A1 0.00000 7.40 
389 SLC29A4 0.00000 8.64 446 BEX4 0.03512 7.38 
390 SHOX2 0.00056 8.62 447 IFI6 0.00598 7.37 
391 TSPAN5 0.00000 8.60 448 TRAF1 0.00000 7.36 
392 SNCB 0.00000 8.60 449 KIAA1644 0.00002 7.36 
393 MIR100HG 0.00359 8.55 450 AMIGO2 0.00000 7.34 
394 LYL1 0.00000 8.54 451 CHRNA3 0.00001 7.32 
395 PROC 0.00000 8.50 452 CCDC184 0.00510 7.31 
396 MN1 0.00000 8.50 453 NPTX1 0.00000 7.31 
397 ATP10A 0.01549 8.47 454 SOX4 0.00000 7.29 
398 CCDC69 0.00000 8.38 455 SARDH 0.00974 7.28 
399 PNMAL1 0.00082 8.37 456 CD274 0.00095 7.27 
400 OAS2 0.00001 8.32 457 CNTN1 0.00371 7.22 
401 ZFP57 0.02673 8.28 458 TG 0.00031 7.22 
402 TAGLN3 0.00004 8.26 459 COL7A1 0.00000 7.20 
403 NKILA 0.00000 8.25 460 ISM1 0.02118 7.15 
404 LHB 0.00002 8.22 461 IRAK2 0.00000 7.12 
405 FAM171A2 0.00000 8.21 462 POU2F2 0.03129 7.11 
406 CRMP1 0.00000 8.21 463 MICAL2 0.00000 7.11 
407 SLC27A6 0.00000 8.20 464 NKX3-1 0.00000 7.10 
408 RNF150 0.00000 8.19 465 TNFAIP3 0.00000 7.09 
409 RND1 0.00144 8.16 466 IFFO1 0.00000 7.06 
410 PODXL 0.00000 8.15 467 FLNC 0.00000 7.04 
411 FBXO32 0.00000 8.13 468 SNCAIP 0.00005 6.99 
412 FRMD6 0.00000 8.12 469 TMEFF1 0.00051 6.98 
413 IL31RA 0.00000 8.12 470 PMEPA1 0.00000 6.98 
414 DKK3 0.00000 8.11 471 PID1 0.00000 6.92 
415 RAB39B 0.00000 8.09 472 LINC00623 0.00000 6.85 
416 SH2D2A 0.00000 8.06 473 KRT34 0.00035 6.76 
417 CCDC136 0.00000 8.03 474 ARMCX2 0.00000 6.75 
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475 PRICKLE2 0.00000 6.75 532 TPM1 0.00000 5.98 
476 PDZD4 0.00000 6.74 533 TMEM92 0.00000 5.98 
477 ZNF697 0.00000 6.74 534 RASGRP3 0.00001 5.97 
478 FNDC4 0.00000 6.73 535 FAM131B 0.00008 5.94 
479 GPRC5B 0.00000 6.72 536 KRT6B 0.00000 5.93 
480 LAMC2 0.00000 6.66 537 GREM1 0.00018 5.93 
481 CCDC8 0.00000 6.66 538 PLCB4 0.00145 5.93 
482 GPSM3 0.00000 6.65 539 TRPC3 0.04051 5.92 
483 LIPG 0.00000 6.63 540 LIMD2 0.00000 5.91 
484 PRRT4 0.00005 6.62 541 LOC102724094 0.03915 5.90 
485 LRRC71 0.00446 6.59 542 CTHRC1 0.00000 5.87 
486 LOC101059948 0.00000 6.58 543 MLLT11 0.00000 5.87 
487 CAPN5 0.00000 6.55 544 LINC00704 0.00000 5.87 
488 GEM 0.00000 6.54 545 LOC100129940 0.02743 5.85 
489 PRCD 0.00000 6.51 546 PAPPA-AS1 0.00208 5.84 
490 CYTH4 0.00535 6.49 547 KRT81 0.00000 5.81 
491 FERMT1 0.00000 6.47 548 PDGFB 0.00000 5.81 
492 CNIH3 0.00539 6.45 549 MEX3A 0.00000 5.80 
493 COL6A1 0.00000 6.45 550 LPAR3 0.00000 5.79 
494 LOC389332 0.03911 6.44 551 SLC4A8 0.00000 5.78 
495 ATP2A3 0.00000 6.42 552 PGF 0.00000 5.77 
496 STARD4-AS1 0.00000 6.39 553 DUSP8 0.00000 5.75 
497 CYGB 0.00000 6.38 554 DISC1 0.00004 5.74 
498 TM4SF19-AS1 0.00055 6.38 555 TMEM178A 0.00017 5.73 
499 EDNRA 0.00145 6.37 556 KDR 0.03055 5.71 
500 LARGE 0.00033 6.34 557 GAB3 0.00004 5.71 
501 FOXD1 0.00000 6.33 558 MMP24 0.00000 5.70 
502 SOCS2-AS1 0.00000 6.33 559 SPRED3 0.00000 5.69 
503 MFAP5 0.00001 6.32 560 CHRM4 0.00000 5.68 
504 CNTNAP1 0.00000 6.31 561 C1QTNF5 0.00000 5.68 
505 EFR3B 0.00013 6.30 562 SNAI3-AS1 0.00004 5.68 
506 RHOB 0.00000 6.30 563 CAMK4 0.00019 5.67 
507 SYNE1 0.00001 6.29 564 FBN2 0.00000 5.66 
508 PIWIL2 0.03397 6.29 565 COL25A1 0.03135 5.63 
509 NCR3LG1 0.00000 6.28 566 LRRN4 0.00663 5.63 
510 COL4A1 0.00000 6.28 567 ARHGEF40 0.00000 5.63 
511 GRB10 0.00000 6.26 568 TGM2 0.00000 5.63 
512 GLIPR1 0.00000 6.26 569 CACNA1G 0.00011 5.61 
513 CREB5 0.03005 6.26 570 ARHGAP31 0.00000 5.59 
514 HMGA2 0.00238 6.25 571 SALL4 0.00001 5.59 
515 SERPINB2 0.04672 6.22 572 KCNE5 0.00001 5.59 
516 RELB 0.00000 6.21 573 PKIA 0.00000 5.58 
517 TLN2 0.00000 6.18 574 ALOX5AP 0.00000 5.57 
518 SLC46A3 0.00223 6.16 575 UGT3A2 0.00186 5.56 
519 ADAMTS1 0.00000 6.16 576 DNAJB5 0.00000 5.56 
520 SEPT5 0.00000 6.16 577 TMEM74B 0.00001 5.55 
521 SPHK1 0.00000 6.15 578 PDLIM3 0.00028 5.55 
522 PHYHIPL 0.02815 6.14 579 NEXN 0.00199 5.54 
523 LOC100130476 0.01275 6.12 580 FAM20C 0.00000 5.52 
524 SOCS2 0.00000 6.12 581 IFI27 0.00002 5.52 
525 LINC00941 0.00000 6.10 582 SHROOM4 0.00000 5.51 
526 SCNN1D 0.01256 6.10 583 LRP1 0.00024 5.49 
527 IRS1 0.00000 6.08 584 TUBB2B 0.00000 5.46 
528 PLXNA4 0.00000 6.06 585 ATP6V0A4 0.00101 5.46 
529 C1S 0.00230 6.02 586 EMP3 0.00000 5.45 
530 SHC3 0.00000 6.02 587 FAXC 0.00000 5.45 
531 MEIS3 0.00001 5.99 588 GIPC3 0.03571 5.43 
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589 DSE 0.00000 5.41 646 LINC00960 0.00087 4.84 
590 GRIP1 0.00011 5.41 647 DLL1 0.00000 4.83 
591 CALD1 0.00010 5.41 648 RAMP1 0.00000 4.82 
592 PIK3IP1 0.00000 5.41 649 TRIM36 0.00318 4.81 
593 PLEK2 0.00000 5.40 650 IL1RAPL2 0.00004 4.79 
594 NGF 0.00000 5.39 651 KCNJ15 0.00000 4.79 
595 INHBA 0.00000 5.38 652 AZIN2 0.00004 4.79 
596 CACHD1 0.00000 5.36 653 CRYAB 0.00026 4.79 
597 ADRB1 0.02587 5.36 654 TRHDE-AS1 0.00000 4.79 
598 CDK5R1 0.00000 5.35 655 SH3PXD2A 0.00000 4.77 
599 REEP2 0.00000 5.33 656 BAMBI 0.00000 4.77 
600 CCL5 0.00000 5.32 657 PRDM8 0.00001 4.76 
601 ZCCHC24 0.00000 5.32 658 FAM231D 0.01606 4.76 
602 RIMS3 0.00000 5.31 659 FUT8 0.00000 4.75 
603 ITGA5 0.00000 5.29 660 TMEM86A 0.00008 4.75 
604 HTRA3 0.00028 5.28 661 KIAA1324 0.00000 4.73 
605 TUBB3 0.00000 5.28 662 PRR29 0.00947 4.72 
606 PLXDC2 0.00000 5.27 663 IFI44L 0.00000 4.72 
607 PDGFA 0.00000 5.27 664 DCLK1 0.00001 4.71 
608 DCBLD1 0.00000 5.25 665 SH3KBP1 0.00000 4.70 
609 ZFPM2 0.00007 5.25 666 NT5E 0.00004 4.68 
610 GPNMB 0.00001 5.24 667 OVCH2 0.00073 4.68 
611 EGF 0.04375 5.20 668 SPON2 0.01278 4.67 
612 NEDD9 0.00000 5.16 669 RAET1K 0.00016 4.67 
613 SLITRK6 0.00001 5.16 670 CERS4 0.03456 4.67 
614 MURC 0.04706 5.16 671 NRIP3 0.00000 4.67 
615 RBM24 0.00000 5.15 672 ARID3B 0.00000 4.66 
616 PCDHGA6 0.04675 5.12 673 EML1 0.00008 4.66 
617 PALLD 0.00000 5.12 674 GPR173 0.00084 4.62 
618 SV2A 0.00000 5.09 675 POPDC3 0.00000 4.61 
619 PTHLH 0.00000 5.08 676 CAPRIN2 0.00000 4.60 
620 PITX3 0.00412 5.08 677 LMBR1L 0.00000 4.59 
621 FZD10 0.00000 5.07 678 SAP30L-AS1 0.00000 4.58 
622 APLP1 0.00000 5.04 679 SLC6A17 0.03089 4.57 
623 AXL 0.00000 5.04 680 ZNF135 0.00016 4.57 
624 CYP1A1 0.00000 5.03 681 TCF4 0.00000 4.55 
625 PCDH18 0.00000 5.03 682 PARD6G 0.00000 4.52 
626 DPYSL2 0.00000 5.02 683 TBX3 0.00000 4.52 
627 SLC8A1 0.00000 5.01 684 SOX6 0.00000 4.51 
628 HUNK 0.04879 5.01 685 KSR1 0.00000 4.49 
629 SPANXD 0.00001 5.00 686 MYL9 0.00000 4.48 
630 MYO10 0.00000 5.00 687 KIF5C 0.00008 4.48 
631 WNT5B 0.00000 5.00 688 HIC1 0.00000 4.47 
632 HOXB2 0.00000 5.00 689 NR5A2 0.00000 4.46 
633 MKX 0.00604 5.00 690 COL4A2 0.00000 4.45 
634 RNF122 0.00000 4.99 691 CYP26B1 0.00000 4.44 
635 HTR1D 0.00000 4.98 692 SCARF2 0.00000 4.43 
636 ETS1 0.00000 4.98 693 MX2 0.00838 4.43 
637 COL18A1 0.00000 4.93 694 SLC22A1 0.00006 4.42 
638 NES 0.00003 4.93 695 SPATA4 0.00211 4.41 
639 BOC 0.00000 4.93 696 TRHDE 0.00000 4.40 
640 MSANTD3-TMEFF1 0.00066 4.93 697 LINC01137 0.00000 4.40 
641 CHN1 0.00000 4.92 698 CNKSR2 0.01203 4.39 
642 PCDHB14 0.00052 4.89 699 SMIM3 0.00000 4.37 
643 CXCL11 0.00096 4.88 700 SP5 0.00000 4.37 
644 KIAA0226L 0.00002 4.86 701 MATN3 0.00000 4.37 
645 DCHS2 0.00000 4.85 702 SPRR1B 0.00054 4.36 
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703 BACH2 0.00000 4.36 760 POU6F1 0.00000 3.91 
704 TM6SF2 0.00015 4.36 761 ADGRL2 0.00000 3.91 
705 UNC5C 0.00016 4.33 762 LINC01605 0.00000 3.90 
706 LRRC75B 0.00000 4.32 763 ENC1 0.00000 3.90 
707 CXCL3 0.00484 4.32 764 MAGEE1 0.00136 3.90 
708 ST6GALNAC5 0.00003 4.31 765 KIAA1614 0.00125 3.89 
709 SRSF12 0.00082 4.29 766 MSANTD3 0.00000 3.89 
710 SHF 0.00000 4.26 767 FHL1 0.00001 3.88 
711 DOK1 0.00000 4.25 768 BATF2 0.00965 3.87 
712 KRT17 0.00016 4.24 769 TXK 0.00196 3.87 
713 BDNF 0.00007 4.22 770 FKBP7 0.00000 3.86 
714 LOC642366 0.00158 4.21 771 MX1 0.00184 3.85 
715 PCDHGB2 0.01376 4.19 772 CDON 0.00000 3.84 
716 FAM101B 0.00000 4.19 773 MCAM 0.00000 3.84 
717 GALNT10 0.00000 4.18 774 OCIAD2 0.00000 3.84 
718 OMP 0.00283 4.17 775 MTSS1 0.00000 3.84 
719 BVES 0.00000 4.16 776 MCOLN3 0.00001 3.84 
720 RUNDC3A-AS1 0.00003 4.16 777 PEAR1 0.00003 3.83 
721 DOCK4 0.00024 4.16 778 GADD45G 0.00004 3.81 
722 SCN1B 0.00116 4.15 779 MIR31HG 0.00000 3.81 
723 CLDN6 0.00000 4.14 780 PCNX 0.00000 3.81 
724 GUCY1B3 0.00000 4.13 781 SOCS1 0.00000 3.81 
725 KPNA7 0.00000 4.12 782 GAS6 0.00000 3.80 
726 EFEMP2 0.00000 4.12 783 LRRC3 0.00000 3.79 
727 RBAKDN 0.01702 4.11 784 SNPH 0.00000 3.79 
728 UCHL1 0.00000 4.11 785 STARD9 0.00003 3.79 
729 APLN 0.00060 4.11 786 MB21D2 0.00000 3.79 
730 ITGA2 0.00003 4.10 787 LMCD1 0.00000 3.77 
731 B4GALNT1 0.00000 4.10 788 FAM225A 0.00854 3.77 
732 HHAT 0.00000 4.10 789 ASPHD2 0.00000 3.77 
733 RNF130 0.00000 4.09 790 HHIPL1 0.00242 3.77 
734 TRIM46 0.00000 4.09 791 CPA4 0.00000 3.76 
735 TRPV3 0.00701 4.08 792 HES2 0.00000 3.76 
736 NFKBIE 0.00000 4.08 793 HOXD13 0.01691 3.74 
737 GNAZ 0.02798 4.04 794 MGAT3 0.00105 3.72 
738 MME 0.00000 4.04 795 SCUBE3 0.00001 3.70 
739 DOCK10 0.00075 4.03 796 GPR161 0.00000 3.70 
740 TMEM121 0.00000 4.01 797 OPRL1 0.00266 3.69 
741 IKBKE 0.00000 4.00 798 CUBN 0.03728 3.69 
742 C16orf45 0.00000 3.98 799 LINC01436 0.01126 3.68 
743 GPRASP2 0.00001 3.97 800 TEK 0.00000 3.67 
744 PRDM11 0.01883 3.96 801 TEAD2 0.00000 3.67 
745 CSF1 0.00000 3.96 802 MARCKSL1 0.00000 3.66 
746 SERPING1 0.00364 3.96 803 CEP170 0.00089 3.66 
747 CLSTN3 0.00000 3.95 804 CNTNAP3P2 0.00001 3.66 
748 XAF1 0.00028 3.95 805 ABR 0.00000 3.66 
749 EPHB2 0.00000 3.94 806 CLIP2 0.00000 3.65 
750 GADD45A 0.00001 3.94 807 PCDH9 0.00020 3.65 
751 LOC103091866 0.00012 3.94 808 PXDC1 0.00000 3.64 
752 GBP1 0.00160 3.93 809 LARP6 0.00000 3.64 
753 KCTD11 0.00000 3.93 810 MIR181A2HG 0.00035 3.64 
754 H2AFY2 0.00012 3.93 811 PARM1 0.00005 3.64 
755 NANOS3 0.00824 3.92 812 NFIX 0.00000 3.63 
756 ULBP3 0.00002 3.92 813 S1PR5 0.00000 3.63 
757 LRRN2 0.00005 3.92 814 MMP11 0.02510 3.62 
758 CARD11 0.00000 3.92 815 DIO2 0.00802 3.62 
759 HSPA12A 0.00009 3.92 816 CSRP2 0.00000 3.62 
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817 CST6 0.00001 3.61 874 LOC101060542 0.00000 3.36 
818 ADTRP 0.00000 3.61 875 TEPP 0.04241 3.35 
819 HDAC9 0.00003 3.60 876 LAMA3 0.00000 3.35 
820 DZIP1L 0.00000 3.59 877 PDLIM7 0.00000 3.35 
821 SPOCK1 0.00000 3.58 878 NLGN2 0.00003 3.34 
822 RASL11B 0.02042 3.57 879 HOXB4 0.00000 3.34 
823 NXPH3 0.00010 3.56 880 CGNL1 0.00001 3.33 
824 RASGEF1A 0.00026 3.55 881 CRYGC 0.00368 3.33 
825 FAT4 0.00294 3.55 882 PHLDB1 0.00000 3.32 
826 CACNB1 0.00000 3.54 883 DNAJB2 0.00000 3.32 
827 LOXL1 0.00000 3.54 884 TMEM132A 0.00000 3.32 
828 ISL1 0.00000 3.54 885 CDO1 0.04652 3.32 
829 CYTH1 0.00000 3.54 886 SLC6A15 0.00045 3.32 
830 LAYN 0.00000 3.54 887 KCTD15 0.00000 3.32 
831 C17orf51 0.00000 3.54 888 RWDD2A 0.00000 3.31 
832 ARHGEF25 0.00123 3.53 889 KIF3C 0.00000 3.30 
833 CCDC71L 0.00000 3.53 890 FOXL1 0.00110 3.30 
834 SYNPO 0.00000 3.52 891 TMEM2 0.00000 3.29 
835 CYFIP2 0.00075 3.52 892 TET1 0.00000 3.29 
836 S1PR2 0.00001 3.52 893 BNC2 0.00000 3.28 
837 FAM196B 0.00025 3.51 894 CDKN2B 0.00000 3.28 
838 LPCAT2 0.00000 3.51 895 SMURF2 0.01083 3.27 
839 FRAS1 0.00012 3.51 896 FAM214B 0.00000 3.26 
840 SOX9-AS1 0.00085 3.51 897 TRAF5 0.00000 3.26 
841 MUM1L1 0.00778 3.51 898 TMEM171 0.00129 3.26 
842 CXCL6 0.00509 3.50 899 TMCC1 0.00000 3.25 
843 BASP1 0.00000 3.50 900 CDC42EP2 0.00000 3.25 
844 ATP2C2 0.00000 3.49 901 FBN1 0.00004 3.25 
845 ALDH1A2 0.00000 3.49 902 MFSD2A 0.00000 3.25 
846 EVC 0.00000 3.49 903 FMNL3 0.00000 3.24 
847 DOCK2 0.01809 3.48 904 TP53I3 0.00000 3.24 
848 STMN3 0.00000 3.48 905 SIPA1L1 0.00000 3.24 
849 CBX2 0.00000 3.47 906 P3H3 0.00000 3.23 
850 MYO7B 0.00000 3.47 907 FOSL1 0.00000 3.23 
851 PTPN21 0.00000 3.46 908 FSTL1 0.00000 3.23 
852 DYNC1I1 0.01215 3.46 909 LOC654342 0.00000 3.23 
853 PDGFC 0.00000 3.46 910 ELL2 0.00002 3.23 
854 SMIM10L2B 0.00132 3.45 911 IFI44 0.00002 3.22 
855 LHX5 0.00505 3.45 912 SPRY4 0.00000 3.22 
856 FZD2 0.00000 3.45 913 GPR153 0.00000 3.21 
857 CCBE1 0.00000 3.44 914 TOX2 0.00000 3.21 
858 ETV5 0.00000 3.43 915 APLF 0.00008 3.20 
859 CTIF 0.00000 3.42 916 OTUB2 0.00000 3.20 
860 HAS2-AS1 0.00147 3.42 917 IER3 0.00000 3.20 
861 SATB2 0.00000 3.42 918 SYDE1 0.00000 3.20 
862 DAB2 0.00000 3.39 919 TBXA2R 0.00168 3.19 
863 MT1M 0.00000 3.39 920 TGFB2 0.00000 3.17 
864 PACERR 0.01694 3.38 921 GPR143 0.00000 3.16 
865 SFXN3 0.00000 3.38 922 KCNQ5 0.02279 3.16 
866 PDGFRL 0.00001 3.37 923 UBA6-AS1 0.00000 3.16 
867 RBP7 0.00000 3.37 924 LHX6 0.00000 3.16 
868 MTCL1 0.00000 3.37 925 A1BG-AS1 0.02642 3.16 
869 HERC3 0.00000 3.37 926 FOXN3 0.00000 3.15 
870 WIPF1 0.00000 3.36 927 VASH1 0.00912 3.15 
871 C10orf25 0.00001 3.36 928 CAP2 0.00059 3.14 
872 PHTF1 0.00000 3.36 929 MICAL1 0.00000 3.14 
873 TNNT1 0.00000 3.36 930 ACTG1 0.00000 3.14 
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931 SERPINB8 0.00000 3.14 988 RAB30 0.00051 2.97 
932 PTPRK 0.00000 3.13 989 RNF152 0.00001 2.97 
933 MEGF9 0.00000 3.13 990 MSI1 0.00000 2.97 
934 HCN2 0.00000 3.13 991 RECK 0.00210 2.96 
935 ISM2 0.00152 3.12 992 BCAS4 0.00000 2.96 
936 C2CD4C 0.00000 3.12 993 HSF2BP 0.00000 2.96 
937 P3H1 0.00000 3.12 994 DPY19L2P1 0.00034 2.96 
938 MTMR9LP 0.00024 3.12 995 DCBLD2 0.00054 2.96 
939 LOC100506844 0.00000 3.12 996 STX1B 0.00000 2.96 
940 HBEGF 0.00455 3.12 997 USB1 0.00000 2.96 
941 TBC1D2B 0.00000 3.11 998 AFAP1L2 0.00000 2.96 
942 PEA15 0.00000 3.11 999 ADGRA2 0.00000 2.96 
943 CD44 0.00000 3.10 1000 MAP1LC3A 0.00000 2.96 
944 NCF1C 0.00195 3.10 1001 SMARCD3 0.00001 2.96 
945 NGFR 0.00474 3.10 1002 ZFP69B 0.00669 2.95 
946 SDC3 0.00000 3.10 1003 ACHE 0.00003 2.94 
947 IL7R 0.00005 3.10 1004 DNAH17 0.00030 2.94 
948 PLSCR3 0.00000 3.09 1005 ABL2 0.00000 2.94 
949 LINC00883 0.00126 3.09 1006 ARSI 0.00000 2.94 
950 SKIL 0.00000 3.08 1007 SALL2 0.00004 2.93 
951 RAMP2 0.00057 3.08 1008 FZD1 0.00000 2.93 
952 GADD45B 0.00000 3.08 1009 KCTD17 0.00000 2.93 
953 TTPAL 0.00000 3.08 1010 LIX1L 0.00000 2.92 
954 JARID2 0.00000 3.07 1011 NLGN4X 0.04480 2.92 
955 SETBP1 0.00000 3.07 1012 HYI 0.00000 2.92 
956 SIRT4 0.00007 3.07 1013 SERPINB9 0.00023 2.91 
957 WDR66 0.00005 3.07 1014 RASSF4 0.00000 2.91 
958 RGL1 0.00000 3.07 1015 SCAMP5 0.00197 2.91 
959 TCHH 0.02729 3.05 1016 IL27RA 0.00000 2.91 
960 ANGPTL4 0.00001 3.05 1017 TIAM2 0.00000 2.91 
961 MAP3K7CL 0.00007 3.05 1018 ZNF503-AS2 0.00015 2.89 
962 PDZD2 0.00000 3.04 1019 DNAJC18 0.00000 2.89 
963 ZNF528-AS1 0.00231 3.04 1020 THEMIS2 0.00637 2.89 
964 MMP14 0.00000 3.03 1021 ARHGEF28 0.00000 2.89 
965 MMD 0.00003 3.03 1022 TSPAN9 0.00000 2.89 
966 LCP1 0.00183 3.02 1023 CDK6 0.01343 2.89 
967 SP110 0.00000 3.02 1024 FOXO3B 0.00000 2.89 
968 HCP5 0.00212 3.02 1025 FZD7 0.00000 2.88 
969 GPR132 0.00002 3.02 1026 DDIT4L 0.00594 2.88 
970 RASD2 0.00239 3.02 1027 SLC26A2 0.00024 2.88 
971 ACAP1 0.00048 3.02 1028 KLHL25 0.00000 2.88 
972 MICALCL 0.00067 3.01 1029 CCDC102A 0.00000 2.88 
973 NAGK 0.00000 3.01 1030 KLF7 0.00000 2.87 
974 TPST1 0.00000 3.01 1031 PLCG1 0.00000 2.87 
975 SPANXB1 0.00000 3.01 1032 ANKRD44 0.00036 2.87 
976 MVB12B 0.00000 3.00 1033 GDF11 0.00000 2.87 
977 TNFSF15 0.00000 3.00 1034 ARL15 0.00250 2.87 
978 DPF1 0.00001 3.00 1035 PCDHGB5 0.00000 2.86 
979 IER5L 0.00000 3.00 1036 ADGRG1 0.00000 2.86 
980 CNTNAP3B 0.00000 2.99 1037 LOC644554 0.00001 2.86 
981 AASS 0.00004 2.99 1038 NXPE3 0.00001 2.86 
982 BPGM 0.00000 2.98 1039 ITGB6 0.00000 2.86 
983 EVA1A 0.00000 2.98 1040 IRF9 0.00000 2.86 
984 DSEL 0.00007 2.98 1041 BRSK1 0.00000 2.86 
985 MAPK8IP2 0.00000 2.98 1042 PDE2A 0.00000 2.85 
986 AKAP2 0.00005 2.97 1043 FHOD3 0.00000 2.85 
987 DBN1 0.00000 2.97 1044 GRK5 0.00000 2.85 
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1159 LYPD1 0.00000 2.61 1216 NECAP2 0.00000 2.48 
1160 FUT8-AS1 0.00018 2.61 1217 CAMK2N2 0.00522 2.48 
1161 LOC283299 0.02383 2.61 1218 WDR91 0.00000 2.48 
1162 SHROOM2 0.00000 2.61 1219 LOXL1-AS1 0.00019 2.48 
1163 FAM43B 0.00329 2.61 1220 AKR1B1 0.00000 2.48 
1164 DLC1 0.00000 2.60 1221 ZSCAN2 0.00000 2.48 
1165 PPP2R5B 0.00000 2.60 1222 EPSTI1 0.00000 2.48 
1166 SERTAD4-AS1 0.03021 2.60 1223 USPL1 0.00002 2.48 
1167 COL9A2 0.00053 2.59 1224 SLC45A3 0.00000 2.48 
1168 LDOC1 0.00000 2.58 1225 BTN2A2 0.00000 2.47 
1169 MAP3K12 0.00000 2.57 1226 TTYH3 0.00000 2.47 
1170 DOCK11 0.00129 2.57 1227 CIB2 0.00000 2.47 
1171 MYO7A 0.00990 2.57 1228 GPRIN1 0.00000 2.46 
1172 KANK4 0.00000 2.57 1229 CACNA2D1 0.01294 2.46 
1173 ACVR1 0.00000 2.56 1230 ZNF365 0.00000 2.46 
1174 KRT5 0.00008 2.56 1231 DDAH2 0.00000 2.46 
1175 SMURF1 0.00000 2.56 1232 CSRNP2 0.00146 2.45 
1176 RUNX1 0.00000 2.55 1233 ISG15 0.00233 2.45 
1177 C1orf106 0.00000 2.55 1234 LIFR 0.00062 2.45 
1178 LINC01124 0.00025 2.55 1235 GHET1 0.03193 2.45 
1179 MT1F 0.00084 2.55 1236 PBXIP1 0.00004 2.45 
1180 AGPAT4 0.00000 2.55 1237 NRGN 0.00000 2.45 
1181 ORMDL3 0.00000 2.54 1238 SHANK3 0.00000 2.44 
1182 ANKRD37 0.00010 2.54 1239 ZNF532 0.00000 2.44 
1183 PPP1R18 0.00000 2.54 1240 PLA2R1 0.00011 2.44 
1184 SPRN 0.00008 2.54 1241 NBPF1 0.00002 2.44 
1185 XDH 0.00639 2.54 1242 SLC2A6 0.00000 2.44 
1186 DAPK3 0.00000 2.53 1243 PCSK6 0.01310 2.44 
1187 SACS 0.03267 2.53 1244 FYN 0.00000 2.43 
1188 PACS1 0.00000 2.53 1245 HERC5 0.00000 2.43 
1189 DLG4 0.00000 2.52 1246 PSMD2 0.00000 2.43 
1190 TPST2 0.00000 2.52 1247 CCDC85B 0.00002 2.43 
1191 GABBR1 0.00852 2.52 1248 AKR1C3 0.02756 2.43 
1192 C8orf46 0.00057 2.52 1249 GLS 0.00346 2.43 
1193 CLDN11 0.00004 2.52 1250 LRCH3 0.00000 2.43 
1194 CROCC 0.00000 2.52 1251 RIPK2 0.00001 2.43 
1195 SLC39A13 0.00000 2.52 1252 SH3BGRL3 0.00000 2.43 
1196 CERKL 0.00031 2.52 1253 LINC01138 0.00079 2.43 
1197 SRC 0.00000 2.52 1254 NXN 0.00000 2.43 
1198 USP18 0.02214 2.51 1255 NLRC5 0.00298 2.43 
1199 KDELR3 0.00000 2.51 1256 SYNGR3 0.00000 2.42 
1200 GAREML 0.00001 2.51 1257 SAA1 0.00076 2.41 
1201 LPAR5 0.00001 2.51 1258 EID2B 0.01450 2.41 
1202 C3orf18 0.00003 2.50 1259 LOC101929128 0.00702 2.41 
1203 ZC3H12A 0.00000 2.50 1260 RASA3 0.00000 2.41 
1204 CHST15 0.00000 2.50 1261 PCDHGC3 0.00003 2.41 
1205 COL16A1 0.00000 2.50 1262 KATNAL1 0.00187 2.41 
1206 GXYLT2 0.00111 2.50 1263 KCTD12 0.00003 2.40 
1207 PANX1 0.00000 2.49 1264 MYADM 0.00000 2.40 
1208 NFKB2 0.00000 2.49 1265 IGFBP4 0.00000 2.40 
1209 ABCA13 0.00170 2.49 1266 DLGAP4 0.00000 2.40 
1210 SLC4A4 0.00702 2.49 1267 MT2A 0.00000 2.40 
1211 MYB 0.00380 2.49 1268 FJX1 0.00000 2.40 
1212 ZNF385B 0.00045 2.49 1269 ZNF618 0.00000 2.40 
1213 OAS3 0.00057 2.49 1270 ICAM1 0.00005 2.40 
1214 MEF2C 0.00031 2.48 1271 EVC2 0.00000 2.40 
1215 FAM95C 0.00087 2.48 1272 P4HA2 0.00000 2.39 
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1273 SNCA 0.00050 2.39 1330 SP100 0.00000 2.31 
1274 GPX7 0.00000 2.39 1331 SLC22A3 0.00000 2.31 
1275 CCDC74A 0.00001 2.39 1332 TNIP1 0.00000 2.31 
1276 ZNF329 0.00000 2.39 1333 HSPB1 0.00002 2.31 
1277 FAM89B 0.00000 2.39 1334 HIC2 0.01228 2.31 
1278 IDS 0.00000 2.39 1335 MYH9 0.00000 2.30 
1279 KIAA0930 0.00000 2.39 1336 SMO 0.00000 2.30 
1280 RGS20 0.00062 2.38 1337 ARHGEF17 0.00000 2.30 
1281 MRGPRF 0.00007 2.38 1338 MSN 0.00000 2.30 
1282 APBB1 0.00000 2.38 1339 FBXO2 0.00000 2.30 
1283 SCARA3 0.00000 2.38 1340 SORCS2 0.00059 2.30 
1284 SLC25A37 0.00000 2.38 1341 FAM65C 0.03115 2.29 
1285 ISG20 0.00000 2.38 1342 FKBP1A 0.00000 2.29 
1286 MMP17 0.00000 2.38 1343 ZSCAN31 0.00218 2.29 
1287 TAX1BP3 0.00000 2.38 1344 SHISA4 0.00005 2.29 
1288 FRY 0.00491 2.38 1345 DCUN1D3 0.00001 2.29 
1289 CPAMD8 0.00156 2.37 1346 ZEB2 0.00211 2.29 
1290 LOC642852 0.00001 2.37 1347 CYLD 0.00097 2.29 
1291 ABCA1 0.00000 2.37 1348 ZNF821 0.00007 2.28 
1292 NFATC1 0.00541 2.37 1349 MRAP2 0.00023 2.28 
1293 ARFGAP1 0.00000 2.37 1350 VEGFC 0.00000 2.28 
1294 ENDOD1 0.00000 2.37 1351 IGSF3 0.00000 2.28 
1295 VOPP1 0.00000 2.37 1352 ULBP2 0.00000 2.28 
1296 SLC9A7 0.00000 2.36 1353 CORO1A 0.00000 2.28 
1297 FGF2 0.02218 2.36 1354 BBC3 0.00001 2.28 
1298 APBA1 0.00000 2.36 1355 FAM13A-AS1 0.02023 2.28 
1299 SELM 0.00000 2.36 1356 PRKD1 0.00799 2.28 
1300 CLSTN1 0.00000 2.36 1357 GUSBP4 0.00000 2.27 
1301 PARVA 0.00000 2.36 1358 SLC30A4 0.00022 2.27 
1302 IVL 0.00014 2.36 1359 FARP1 0.00000 2.27 
1303 EPG5 0.00001 2.36 1360 HELZ2 0.00376 2.27 
1304 ZNF699 0.00004 2.35 1361 MARVELD1 0.00000 2.27 
1305 BMP2 0.00000 2.35 1362 NXPH4 0.04986 2.27 
1306 TCF12 0.00120 2.35 1363 ETV4 0.00014 2.26 
1307 LOC100507053 0.00001 2.35 1364 ACTRT3 0.00000 2.26 
1308 PTPRB 0.00000 2.35 1365 NBPF3 0.00000 2.26 
1309 KIRREL 0.00000 2.34 1366 STEAP3 0.00000 2.25 
1310 TMEM255B 0.00001 2.34 1367 IFI27L2 0.00000 2.25 
1311 LETM2 0.00000 2.34 1368 ARHGAP44 0.00048 2.25 
1312 FHL3 0.00000 2.33 1369 WIPI1 0.00000 2.25 
1313 GOPC 0.00747 2.33 1370 TJP1 0.00002 2.25 
1314 FBLIM1 0.00000 2.33 1371 CCDC93 0.00028 2.25 
1315 ZNF319 0.00000 2.33 1372 NAV1 0.00025 2.24 
1316 OLFML2A 0.00352 2.32 1373 STEAP3-AS1 0.00000 2.24 
1317 LOC100499489 0.00023 2.32 1374 ZNF154 0.00072 2.24 
1318 ZNF713 0.00171 2.32 1375 TRIM8 0.00000 2.24 
1319 CNN2 0.00000 2.32 1376 C10orf35 0.00010 2.24 
1320 GATA6 0.00000 2.32 1377 ATP9A 0.00000 2.24 
1321 EXTL2 0.00001 2.32 1378 UBE2Q2P1 0.00030 2.23 
1322 RNF144A 0.00001 2.32 1379 LUZP1 0.00000 2.23 
1323 PGBD1 0.00048 2.32 1380 BMP4 0.00003 2.23 
1324 ZNF561-AS1 0.00000 2.32 1381 C17orf97 0.00590 2.23 
1325 BFSP1 0.00799 2.32 1382 RHOBTB1 0.00000 2.23 
1326 ABL1 0.00000 2.32 1383 INPP5F 0.00012 2.23 
1327 TMSB10 0.00000 2.31 1384 KIF21B 0.00005 2.23 
1328 PDZD7 0.00025 2.31 1385 MSRA 0.00005 2.23 
1329 ARHGEF10 0.00003 2.31 1386 PLEKHG5 0.00000 2.22 
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1387 COL17A1 0.00000 2.22 1444 SNURF 0.00000 2.15 
1388 MAPK11 0.00000 2.22 1445 FOXL2NB 0.00290 2.15 
1389 ZNF582-AS1 0.00238 2.22 1446 TGFB1 0.00000 2.15 
1390 TNFRSF12A 0.00000 2.22 1447 SMC5-AS1 0.00016 2.15 
1391 CNN3 0.00000 2.22 1448 MAP4K4 0.00021 2.15 
1392 BMPR2 0.00002 2.22 1449 FRMD6-AS1 0.00000 2.15 
1393 C3orf52 0.00000 2.22 1450 TGFB3 0.00329 2.15 
1394 RBMS2 0.00000 2.21 1451 ENTPD7 0.00000 2.14 
1395 NLK 0.00001 2.21 1452 NTAN1 0.00000 2.14 
1396 MTMR11 0.00003 2.21 1453 ADPRH 0.00000 2.14 
1397 ARL10 0.01396 2.21 1454 GFOD1 0.00005 2.14 
1398 S100A3 0.00831 2.21 1455 LUZP2 0.01721 2.14 
1399 ZFP90 0.00021 2.21 1456 SEPT6 0.00000 2.14 
1400 TUBB2A 0.00001 2.21 1457 PCDHGB6 0.00039 2.14 
1401 TLE1 0.00000 2.21 1458 ARHGEF18 0.00000 2.13 
1402 PPP4R1L 0.00003 2.21 1459 LINC01224 0.00000 2.13 
1403 VDR 0.00000 2.20 1460 STK10 0.00000 2.13 
1404 PI4KAP1 0.00735 2.20 1461 NCKAP5L 0.00000 2.13 
1405 TMEM198 0.00000 2.20 1462 TCF7 0.00000 2.13 
1406 ZFAND2A 0.00000 2.20 1463 PALD1 0.00160 2.13 
1407 VANGL2 0.00000 2.20 1464 JUN 0.03680 2.13 
1408 PCDHGA9 0.02415 2.20 1465 FGF11 0.00000 2.13 
1409 PTCHD4 0.00020 2.19 1466 PHF21A 0.00003 2.13 
1410 CDK17 0.00093 2.19 1467 PAX8 0.00000 2.13 
1411 KIFC3 0.00000 2.19 1468 SMYD2 0.00195 2.12 
1412 HVCN1 0.03339 2.19 1469 C19orf66 0.02386 2.12 
1413 BHLHB9 0.03061 2.19 1470 PAPL 0.03552 2.12 
1414 CNTNAP3 0.00000 2.18 1471 PRKAB2 0.00000 2.12 
1415 THBS3 0.00006 2.18 1472 KIAA1161 0.00001 2.12 
1416 RNF121 0.00000 2.18 1473 ATXN7L2 0.01283 2.12 
1417 ZNF853 0.00000 2.18 1474 HDX 0.02216 2.12 
1418 LRRC49 0.00112 2.18 1475 RAB43 0.00000 2.12 
1419 ANKLE2 0.00000 2.18 1476 TICAM1 0.00000 2.12 
1420 SPRED1 0.01215 2.17 1477 SRRM3 0.00027 2.12 
1421 GPR137B 0.00037 2.17 1478 TRIM3 0.00000 2.12 
1422 ARTN 0.00007 2.17 1479 L3MBTL3 0.00000 2.12 
1423 ANXA8 0.00000 2.17 1480 TNFRSF25 0.00074 2.11 
1424 OPTN 0.00329 2.17 1481 EVL 0.00000 2.11 
1425 TTLL7 0.00765 2.17 1482 P4HA2-AS1 0.00685 2.11 
1426 IVNS1ABP 0.00000 2.16 1483 CDKN1A 0.00000 2.11 
1427 ARHGAP32 0.00000 2.16 1484 STK38L 0.03873 2.11 
1428 SERPINB7 0.00000 2.16 1485 ITGAV 0.00306 2.11 
1429 ITGA6 0.01002 2.16 1486 GSTM3 0.00000 2.11 
1430 SEMA3A 0.00038 2.16 1487 ANKRD65 0.00027 2.11 
1431 SCD5 0.00033 2.16 1488 GNAI2 0.00000 2.11 
1432 C8orf48 0.00246 2.16 1489 A1BG 0.00003 2.11 
1433 SUPT3H 0.00040 2.16 1490 ZBED2 0.00000 2.10 
1434 ATP1B1 0.00000 2.16 1491 LIMS1 0.00442 2.10 
1435 TMEM156 0.00365 2.16 1492 IFFO2 0.00001 2.10 
1436 ABCC9 0.00244 2.16 1493 FUT4 0.00000 2.10 
1437 SNX25 0.00000 2.16 1494 ATP10D 0.00001 2.10 
1438 CYP27C1 0.00009 2.16 1495 PI4KAP2 0.00138 2.10 
1439 CDC14A 0.00012 2.16 1496 FOXL2 0.00586 2.10 
1440 CELSR3 0.00001 2.15 1497 MIR22HG 0.00038 2.09 
1441 CD3EAP 0.00000 2.15 1498 YPEL5 0.00000 2.09 
1442 SUSD5 0.00007 2.15 1499 MXRA7 0.00000 2.09 
1443 AGAP2-AS1 0.00000 2.15 1500 ZSCAN26 0.02564 2.09 
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1501 LCAT 0.00336 2.09 1558 ZNF281 0.00533 2.01 
1502 RTN4R 0.00000 2.09 1559 TBC1D16 0.00004 2.01 
1503 IL11RA 0.00010 2.09 1560 STX2 0.00187 2.01 
1504 PUS10 0.00155 2.09 1561 THSD1 0.01510 2.01 
1505 GAS1 0.00023 2.09 1562 NBPF12 0.00637 2.01 
1506 TTC7B 0.00001 2.09 1563 NATD1 0.00000 2.01 
1507 MYO1D 0.00000 2.09 1564 LONRF1 0.02422 2.01 
1508 KLC1 0.00000 2.09 1565 TNFRSF6B 0.00002 2.01 
1509 VCL 0.00000 2.09 1566 SEL1L3 0.00000 2.01 
1510 CDSN 0.00040 2.09 1567 TTTY14 0.00197 2.00 
1511 FBXO10 0.00005 2.09 1568 AVEN 0.00000 2.00 
1512 MIR205HG 0.00322 2.08 1569 SH3PXD2B 0.00000 2.00 
1513 TPM2 0.00000 2.08 1570 NBPF15 0.00000 2.00 
1514 MAP7D1 0.00000 2.08 1571 ZNF669 0.00000 2.00 
1515 EXT2 0.00000 2.07 1572 SLC16A4 0.00501 2.00 
1516 MOXD1 0.00000 2.07 1573 PARP8 0.00000 2.00 
1517 CCDC92 0.00032 2.07 1574 CSRNP1 0.00062 2.00 
1518 PRRX2 0.03290 2.07 1575 ACTB 0.00000 2.00 
1519 ZHX3 0.00001 2.07 1576 TCONS_00029157 0.00167 2.00 
1520 MDFI 0.00000 2.07 1577 SLC38A7 0.00000 2.00 
1521 CCND1 0.00723 2.06 1578 PPFIBP1 0.00410 2.00 
1522 GJB2 0.00000 2.06 1579 CDC42EP5 0.00000 2.00 
1523 RAPGEF2 0.00220 2.06 1580 E2F7 0.00026 2.00 
1524 LYPD6 0.01757 2.06 1581 MARK1 0.00210 1.99 
1525 DDX58 0.00005 2.06 1582 ZNF827 0.00000 1.99 
1526 TLE4 0.00000 2.06 1583 GOLT1A 0.00584 1.99 
1527 ZNF850 0.00713 2.05 1584 VLDLR 0.00000 1.99 
1528 AADAT 0.00022 2.05 1585 DFNA5 0.00000 1.99 
1529 FAXDC2 0.02958 2.05 1586 HN1 0.00000 1.99 
1530 NUMBL 0.00001 2.05 1587 CDH4 0.01237 1.99 
1531 DNMBP-AS1 0.00151 2.05 1588 IFI16 0.00054 1.99 
1532 GAD1 0.00000 2.05 1589 ADAMTSL5 0.02783 1.99 
1533 ACTA2 0.00640 2.05 1590 FCHSD1 0.00000 1.99 
1534 NPR2 0.01520 2.05 1591 IFIT1 0.00144 1.99 
1535 TRAF3 0.00000 2.05 1592 SPOCD1 0.00035 1.98 
1536 PIK3CD-AS2 0.04945 2.05 1593 MAPK8IP1 0.00000 1.98 
1537 PBX3 0.00003 2.05 1594 BTBD11 0.00000 1.98 
1538 INAFM2 0.00002 2.05 1595 AREL1 0.00000 1.98 
1539 CDC42SE1 0.00000 2.04 1596 PLEKHO2 0.00009 1.98 
1540 ANXA5 0.00000 2.04 1597 HERC6 0.00000 1.98 
1541 MSANTD2 0.00045 2.04 1598 GLCE 0.00007 1.98 
1542 BCL11B 0.02837 2.04 1599 MAPKAPK2 0.00000 1.98 
1543 NF2 0.00000 2.04 1600 ZFP64 0.00000 1.98 
1544 CYP2U1 0.03162 2.04 1601 NOCT 0.00000 1.98 
1545 NOL4L 0.00001 2.04 1602 C4orf48 0.00085 1.97 
1546 CEACAM19 0.00058 2.04 1603 KIFC2 0.00001 1.97 
1547 KIAA0754 0.00009 2.04 1604 C17orf67 0.00052 1.97 
1548 ZSCAN9 0.00019 2.03 1605 LOC101927027 0.00093 1.97 
1549 SPNS2 0.00067 2.03 1606 FURIN 0.00000 1.97 
1550 ZFP36L1 0.00607 2.03 1607 GRINA 0.00000 1.97 
1551 EVA1B 0.00001 2.03 1608 FTL 0.00000 1.97 
1552 ADGRB2 0.00000 2.03 1609 HIP1 0.00000 1.97 
1553 PRKY 0.00001 2.03 1610 AMZ1 0.01094 1.97 
1554 CTXN1 0.00002 2.02 1611 MDK 0.00002 1.97 
1555 HTRA1 0.00225 2.02 1612 FADS3 0.00003 1.97 
1556 TRIM16L 0.00000 2.02 1613 LIMK2 0.00000 1.96 
1557 ZBTB38 0.00250 2.02 1614 WTIP 0.00012 1.96 
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1615 PKP1 0.00000 1.96 1672 CCDC28B 0.00000 1.90 
1616 PCNXL2 0.00000 1.96 1673 MSL3 0.00000 1.90 
1617 LAT2 0.02892 1.96 1674 VASN 0.00067 1.90 
1618 DUSP22 0.00000 1.96 1675 FAM127C 0.00000 1.90 
1619 ZIK1 0.00001 1.96 1676 KCNS3 0.00012 1.90 
1620 GABARAPL1 0.00000 1.96 1677 PFN4 0.00033 1.90 
1621 ZNF641 0.00002 1.96 1678 ZNF542P 0.00257 1.90 
1622 RUNX2 0.00026 1.96 1679 AP5Z1 0.00000 1.90 
1623 NET1 0.00175 1.95 1680 DENND5A 0.00000 1.90 
1624 PRKCA 0.00001 1.95 1681 NME7 0.00520 1.89 
1625 UAP1L1 0.00001 1.95 1682 TANGO6 0.00000 1.89 
1626 MAPK8IP3 0.00002 1.95 1683 KIAA1211 0.00062 1.89 
1627 C20orf194 0.00000 1.95 1684 SLFN5 0.00007 1.89 
1628 FLJ23867 0.00000 1.95 1685 STARD4 0.02780 1.89 
1629 PLK2 0.00013 1.94 1686 ZFYVE1 0.00045 1.89 
1630 TGIF2 0.00000 1.94 1687 ZNF462 0.00028 1.89 
1631 C1orf74 0.00000 1.94 1688 NAB2 0.00000 1.89 
1632 ZBTB46 0.00009 1.94 1689 PIP4K2C 0.00000 1.89 
1633 FOXN3-AS1 0.04877 1.94 1690 TTTY15 0.00004 1.89 
1634 SLMO1 0.02943 1.94 1691 TNFAIP1 0.00000 1.89 
1635 MLXIP 0.00009 1.94 1692 CYP2J2 0.01915 1.89 
1636 HOMER3 0.00000 1.94 1693 DHRSX 0.00000 1.89 
1637 SUGCT 0.00000 1.94 1694 SKI 0.00002 1.88 
1638 SSC4D 0.00400 1.94 1695 CAND2 0.00002 1.88 
1639 PRAF2 0.00011 1.94 1696 AKAP12 0.00173 1.88 
1640 ATP13A2 0.00000 1.93 1697 ANOS1 0.00012 1.88 
1641 MMP24-AS1 0.00000 1.93 1698 KCTD7 0.00002 1.88 
1642 PORCN 0.00002 1.93 1699 IGF1R 0.00012 1.88 
1643 SNX29 0.00000 1.93 1700 PKIG 0.00000 1.88 
1644 LINC00842 0.00063 1.93 1701 FAAP100 0.00000 1.88 
1645 STX1A 0.00001 1.93 1702 FGD6 0.00000 1.88 
1646 NRP1 0.00000 1.93 1703 DNMT3A 0.00000 1.88 
1647 ZNF486 0.00005 1.92 1704 HABP4 0.00007 1.87 
1648 SERTAD4 0.00000 1.92 1705 MYO9B 0.00000 1.87 
1649 SVIL-AS1 0.00001 1.92 1706 FAM65A 0.00293 1.87 
1650 STAT5A 0.00000 1.92 1707 CORO1C 0.00001 1.87 
1651 ARL16 0.00000 1.92 1708 MKL1 0.00000 1.87 
1652 SLC35F2 0.00001 1.92 1709 TRNP1 0.00000 1.87 
1653 INSIG1 0.00000 1.92 1710 SLC37A2 0.00001 1.87 
1654 FST 0.00113 1.92 1711 FAM26F 0.00225 1.86 
1655 PDLIM4 0.00000 1.92 1712 SPEG 0.00073 1.86 
1656 CPE 0.00002 1.92 1713 SH2B3 0.00001 1.86 
1657 GCNT1 0.00002 1.92 1714 TRIB2 0.00002 1.86 
1658 ZFAND5 0.00000 1.92 1715 SEZ6L2 0.00002 1.86 
1659 MAFK 0.00000 1.92 1716 ZDHHC17 0.04738 1.86 
1660 TP53INP2 0.00825 1.91 1717 CHPF 0.00001 1.86 
1661 TSPYL4 0.00000 1.91 1718 GALNT14 0.00001 1.86 
1662 ZYX 0.00000 1.91 1719 DNAH5 0.00013 1.86 
1663 MESDC1 0.00007 1.91 1720 RRBP1 0.00034 1.86 
1664 PXDN 0.00001 1.91 1721 ITGB1 0.03724 1.86 
1665 LEF1 0.03517 1.91 1722 ATXN1 0.00006 1.86 
1666 FKRP 0.00002 1.91 1723 TATDN2 0.00000 1.85 
1667 CHST3 0.00001 1.91 1724 CALCOCO1 0.00000 1.85 
1668 CAMKK1 0.00002 1.91 1725 GOLIM4 0.00705 1.85 
1669 WNT9A 0.00004 1.91 1726 RGS12 0.00000 1.85 
1670 DNMBP 0.00000 1.90 1727 TVP23C 0.02451 1.85 
1671 SLC31A2 0.00000 1.90 1728 STAT2 0.00020 1.85 
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1729 SLC19A2 0.00002 1.85 1786 CDH24 0.00000 1.80 
1730 SLITRK5 0.00304 1.85 1787 KLHL5 0.02780 1.80 
1731 UPP1 0.00000 1.85 1788 LPIN2 0.00000 1.80 
1732 NR2F1-AS1 0.00155 1.84 1789 KIAA1549 0.00882 1.80 
1733 RNF44 0.00001 1.84 1790 FAM219A 0.00000 1.80 
1734 SIK1 0.00025 1.84 1791 PTTG1IP 0.00000 1.80 
1735 SLC36A1 0.00567 1.84 1792 GOSR2 0.00000 1.79 
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1868 IRGQ 0.00020 1.75 1925 HDAC7 0.00000 1.71 
1869 ABTB2 0.00005 1.75 1926 FANK1 0.00014 1.71 
1870 PTRF 0.00000 1.75 1927 MGAT5B 0.01760 1.71 
1871 ECM1 0.02373 1.75 1928 PLK3 0.00312 1.71 
1872 RIC8A 0.00000 1.75 1929 TMEM8A 0.00000 1.71 
1873 IGFBP6 0.00006 1.75 1930 ZNF408 0.00009 1.71 
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1879 IFI27L1 0.00043 1.74 1936 RAP1GAP2 0.00000 1.71 
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1881 MFHAS1 0.00000 1.74 1938 FAM109A 0.00001 1.71 
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1883 PLEKHG2 0.00010 1.74 1940 VAT1 0.00000 1.71 
1884 CD2BP2 0.00000 1.74 1941 USP11 0.00000 1.70 
1885 TTL 0.00022 1.74 1942 KLHL18 0.00036 1.70 
1886 IFNLR1 0.00051 1.74 1943 EXOG 0.01999 1.70 
1887 C1orf216 0.00000 1.74 1944 PLOD1 0.00016 1.70 
1888 CADM4 0.00016 1.74 1945 ACOT9 0.00000 1.70 
1889 DTX3 0.00251 1.74 1946 GNA12 0.00000 1.70 
1890 ITPKB 0.00011 1.74 1947 C14orf159 0.00138 1.70 
1891 EXT1 0.00000 1.74 1948 THOC5 0.00000 1.70 
1892 MGAT5 0.00000 1.74 1949 C9orf91 0.00000 1.70 
1893 TRAF6 0.00000 1.74 1950 ARF4 0.00002 1.69 
1894 SLC12A4 0.00000 1.74 1951 TULP4 0.00252 1.69 
1895 ATF5 0.00001 1.74 1952 SEMA4F 0.00000 1.69 
1896 TMEM265 0.00002 1.73 1953 ZNF3 0.00002 1.69 
1897 MICAL3 0.00001 1.73 1954 CACNB3 0.00005 1.69 
1898 SPSB1 0.00006 1.73 1955 PTK7 0.00019 1.69 
1899 IFNGR2 0.00000 1.73 1956 RRAS 0.00000 1.69 
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1957 RELT 0.00017 1.69 2014 KLHL21 0.00000 1.65 
1958 EIF2AK4 0.01048 1.69 2015 ZSWIM8 0.00000 1.65 
1959 ULK1 0.00138 1.69 2016 MEAF6 0.01901 1.65 
1960 GLIS2 0.00839 1.69 2017 ZNF516 0.00000 1.65 
1961 TIMP4 0.00002 1.69 2018 LOC389831 0.00255 1.65 
1962 DGKD 0.00000 1.69 2019 CSGALNACT2 0.01355 1.65 
1963 MANBA 0.00002 1.69 2020 KANK2 0.00000 1.65 
1964 ARMC5 0.00008 1.68 2021 TBCB 0.00000 1.65 
1965 ZNRF3 0.00154 1.68 2022 RIN2 0.00039 1.64 
1966 CTSC 0.00000 1.68 2023 TCEA2 0.00004 1.64 
1967 RPS6KC1 0.00012 1.68 2024 GDAP1 0.03738 1.64 
1968 ATL1 0.00567 1.68 2025 SETMAR 0.00037 1.64 
1969 TRAPPC10 0.00000 1.68 2026 SPTB 0.00005 1.64 
1970 HIVEP1 0.00208 1.68 2027 ABHD4 0.00749 1.64 
1971 POMT2 0.00001 1.68 2028 SNAPC4 0.00004 1.64 
1972 MAP1S 0.00003 1.68 2029 ZNF140 0.00054 1.64 
1973 HNRNPA1P33 0.00299 1.68 2030 PROCR 0.00000 1.64 
1974 SLC35B4 0.00079 1.68 2031 SRF 0.00090 1.64 
1975 VPS18 0.00031 1.68 2032 CAP1 0.00000 1.64 
1976 MEX3D 0.00004 1.67 2033 ACTR1A 0.00000 1.64 
1977 CDH3 0.00003 1.67 2034 PSTPIP2 0.00218 1.63 
1978 PHLDA2 0.00005 1.67 2035 ELMO2 0.00000 1.63 
1979 COMMD9 0.00000 1.67 2036 TMEM206 0.00020 1.63 
1980 TMEM110 0.00025 1.67 2037 ADCY7 0.00024 1.63 
1981 DRAP1 0.00000 1.67 2038 TMEM25 0.00000 1.63 
1982 CD59 0.00000 1.67 2039 LIMK1 0.00000 1.63 
1983 S100A2 0.00077 1.67 2040 CFL1 0.00000 1.63 
1984 CYP27B1 0.03986 1.67 2041 CERS5 0.00030 1.63 
1985 LTBP1 0.00012 1.67 2042 CERS6 0.00163 1.63 
1986 SEC61A1 0.00000 1.67 2043 SESN2 0.00870 1.63 
1987 CBX1 0.00013 1.66 2044 TFIP11 0.00000 1.63 
1988 CRCP 0.00000 1.66 2045 TCF3 0.00001 1.62 
1989 YKT6 0.00000 1.66 2046 IFIT3 0.03285 1.62 
1990 ATP6V1B2 0.00000 1.66 2047 TTBK2 0.00890 1.62 
1991 KRT16 0.00034 1.66 2048 SFN 0.00000 1.62 
1992 SEC31A 0.00000 1.66 2049 BAG3 0.00002 1.62 
1993 ATOX1 0.00000 1.66 2050 GNG4 0.00030 1.62 
1994 MAPK7 0.00178 1.66 2051 TJP2 0.00404 1.62 
1995 KDM5B 0.00061 1.66 2052 CD276 0.00001 1.62 
1996 ZNF668 0.00000 1.66 2053 RCAN1 0.00038 1.62 
1997 BHLHE40 0.00008 1.66 2054 ZC3H7B 0.00000 1.62 
1998 KIF13A 0.02979 1.66 2055 CLIP4 0.00062 1.62 
1999 HILPDA 0.00001 1.66 2056 RABAC1 0.00005 1.61 
2000 CIC 0.00002 1.66 2057 AP4M1 0.00000 1.61 
2001 PTBP2 0.01924 1.66 2058 MYL6 0.00000 1.61 
2002 CDK14 0.00527 1.66 2059 NBPF8 0.00719 1.61 
2003 CLTB 0.00002 1.65 2060 ZBTB47 0.00016 1.61 
2004 ORAI2 0.00008 1.65 2061 SVIL 0.00029 1.61 
2005 POFUT2 0.00003 1.65 2062 CEP170B 0.00000 1.61 
2006 NT5DC2 0.00001 1.65 2063 UBE2F 0.00000 1.61 
2007 CMTM3 0.00000 1.65 2064 TP53INP1 0.04134 1.61 
2008 HOXA11 0.00003 1.65 2065 SNN 0.00002 1.61 
2009 MT1E 0.00000 1.65 2066 ZPR1 0.00000 1.61 
2010 TP63 0.00606 1.65 2067 UBTD1 0.00000 1.61 
2011 OBSL1 0.00035 1.65 2068 PAK1 0.00000 1.61 
2012 PPP1R14B 0.00000 1.65 2069 RAC2 0.00000 1.61 
2013 B3GNT9 0.00001 1.65 2070 SEC14L1 0.00000 1.61 
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1991 KRT16 0.00034 1.66 2048 SFN 0.00000 1.62 
1992 SEC31A 0.00000 1.66 2049 BAG3 0.00002 1.62 
1993 ATOX1 0.00000 1.66 2050 GNG4 0.00030 1.62 
1994 MAPK7 0.00178 1.66 2051 TJP2 0.00404 1.62 
1995 KDM5B 0.00061 1.66 2052 CD276 0.00001 1.62 
1996 ZNF668 0.00000 1.66 2053 RCAN1 0.00038 1.62 
1997 BHLHE40 0.00008 1.66 2054 ZC3H7B 0.00000 1.62 
1998 KIF13A 0.02979 1.66 2055 CLIP4 0.00062 1.62 
1999 HILPDA 0.00001 1.66 2056 RABAC1 0.00005 1.61 
2000 CIC 0.00002 1.66 2057 AP4M1 0.00000 1.61 
2001 PTBP2 0.01924 1.66 2058 MYL6 0.00000 1.61 
2002 CDK14 0.00527 1.66 2059 NBPF8 0.00719 1.61 
2003 CLTB 0.00002 1.65 2060 ZBTB47 0.00016 1.61 
2004 ORAI2 0.00008 1.65 2061 SVIL 0.00029 1.61 
2005 POFUT2 0.00003 1.65 2062 CEP170B 0.00000 1.61 
2006 NT5DC2 0.00001 1.65 2063 UBE2F 0.00000 1.61 
2007 CMTM3 0.00000 1.65 2064 TP53INP1 0.04134 1.61 
2008 HOXA11 0.00003 1.65 2065 SNN 0.00002 1.61 
2009 MT1E 0.00000 1.65 2066 ZPR1 0.00000 1.61 
2010 TP63 0.00606 1.65 2067 UBTD1 0.00000 1.61 
2011 OBSL1 0.00035 1.65 2068 PAK1 0.00000 1.61 
2012 PPP1R14B 0.00000 1.65 2069 RAC2 0.00000 1.61 
2013 B3GNT9 0.00001 1.65 2070 SEC14L1 0.00000 1.61 
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1957 RELT 0.00017 1.69 2014 KLHL21 0.00000 1.65 
1958 EIF2AK4 0.01048 1.69 2015 ZSWIM8 0.00000 1.65 
1959 ULK1 0.00138 1.69 2016 MEAF6 0.01901 1.65 
1960 GLIS2 0.00839 1.69 2017 ZNF516 0.00000 1.65 
1961 TIMP4 0.00002 1.69 2018 LOC389831 0.00255 1.65 
1962 DGKD 0.00000 1.69 2019 CSGALNACT2 0.01355 1.65 
1963 MANBA 0.00002 1.69 2020 KANK2 0.00000 1.65 
1964 ARMC5 0.00008 1.68 2021 TBCB 0.00000 1.65 
1965 ZNRF3 0.00154 1.68 2022 RIN2 0.00039 1.64 
1966 CTSC 0.00000 1.68 2023 TCEA2 0.00004 1.64 
1967 RPS6KC1 0.00012 1.68 2024 GDAP1 0.03738 1.64 
1968 ATL1 0.00567 1.68 2025 SETMAR 0.00037 1.64 
1969 TRAPPC10 0.00000 1.68 2026 SPTB 0.00005 1.64 
1970 HIVEP1 0.00208 1.68 2027 ABHD4 0.00749 1.64 
1971 POMT2 0.00001 1.68 2028 SNAPC4 0.00004 1.64 
1972 MAP1S 0.00003 1.68 2029 ZNF140 0.00054 1.64 
1973 HNRNPA1P33 0.00299 1.68 2030 PROCR 0.00000 1.64 
1974 SLC35B4 0.00079 1.68 2031 SRF 0.00090 1.64 
1975 VPS18 0.00031 1.68 2032 CAP1 0.00000 1.64 
1976 MEX3D 0.00004 1.67 2033 ACTR1A 0.00000 1.64 
1977 CDH3 0.00003 1.67 2034 PSTPIP2 0.00218 1.63 
1978 PHLDA2 0.00005 1.67 2035 ELMO2 0.00000 1.63 
1979 COMMD9 0.00000 1.67 2036 TMEM206 0.00020 1.63 
1980 TMEM110 0.00025 1.67 2037 ADCY7 0.00024 1.63 
1981 DRAP1 0.00000 1.67 2038 TMEM25 0.00000 1.63 
1982 CD59 0.00000 1.67 2039 LIMK1 0.00000 1.63 
1983 S100A2 0.00077 1.67 2040 CFL1 0.00000 1.63 
1984 CYP27B1 0.03986 1.67 2041 CERS5 0.00030 1.63 
1985 LTBP1 0.00012 1.67 2042 CERS6 0.00163 1.63 
1986 SEC61A1 0.00000 1.67 2043 SESN2 0.00870 1.63 
1987 CBX1 0.00013 1.66 2044 TFIP11 0.00000 1.63 
1988 CRCP 0.00000 1.66 2045 TCF3 0.00001 1.62 
1989 YKT6 0.00000 1.66 2046 IFIT3 0.03285 1.62 
1990 ATP6V1B2 0.00000 1.66 2047 TTBK2 0.00890 1.62 
1991 KRT16 0.00034 1.66 2048 SFN 0.00000 1.62 
1992 SEC31A 0.00000 1.66 2049 BAG3 0.00002 1.62 
1993 ATOX1 0.00000 1.66 2050 GNG4 0.00030 1.62 
1994 MAPK7 0.00178 1.66 2051 TJP2 0.00404 1.62 
1995 KDM5B 0.00061 1.66 2052 CD276 0.00001 1.62 
1996 ZNF668 0.00000 1.66 2053 RCAN1 0.00038 1.62 
1997 BHLHE40 0.00008 1.66 2054 ZC3H7B 0.00000 1.62 
1998 KIF13A 0.02979 1.66 2055 CLIP4 0.00062 1.62 
1999 HILPDA 0.00001 1.66 2056 RABAC1 0.00005 1.61 
2000 CIC 0.00002 1.66 2057 AP4M1 0.00000 1.61 
2001 PTBP2 0.01924 1.66 2058 MYL6 0.00000 1.61 
2002 CDK14 0.00527 1.66 2059 NBPF8 0.00719 1.61 
2003 CLTB 0.00002 1.65 2060 ZBTB47 0.00016 1.61 
2004 ORAI2 0.00008 1.65 2061 SVIL 0.00029 1.61 
2005 POFUT2 0.00003 1.65 2062 CEP170B 0.00000 1.61 
2006 NT5DC2 0.00001 1.65 2063 UBE2F 0.00000 1.61 
2007 CMTM3 0.00000 1.65 2064 TP53INP1 0.04134 1.61 
2008 HOXA11 0.00003 1.65 2065 SNN 0.00002 1.61 
2009 MT1E 0.00000 1.65 2066 ZPR1 0.00000 1.61 
2010 TP63 0.00606 1.65 2067 UBTD1 0.00000 1.61 
2011 OBSL1 0.00035 1.65 2068 PAK1 0.00000 1.61 
2012 PPP1R14B 0.00000 1.65 2069 RAC2 0.00000 1.61 
2013 B3GNT9 0.00001 1.65 2070 SEC14L1 0.00000 1.61 
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2071 FAM201A 0.02880 1.61 2128 CDKN2A 0.00261 1.57 
2072 ZSWIM4 0.00623 1.61 2129 ADRA1B 0.00027 1.57 
2073 SAMHD1 0.00391 1.61 2130 RAB38 0.01084 1.57 
2074 RBFOX2 0.00003 1.61 2131 UBE2E3 0.00662 1.57 
2075 MTURN 0.01928 1.61 2132 CKB 0.00002 1.57 
2076 NINJ1 0.00066 1.61 2133 ZBTB9 0.00102 1.57 
2077 KRT6A 0.03810 1.61 2134 TOMM34 0.00000 1.57 
2078 TFPT 0.00000 1.61 2135 ILK 0.00000 1.57 
2079 PNP 0.00000 1.60 2136 FAM83G 0.00000 1.57 
2080 CACNG4 0.03064 1.60 2137 WDR45 0.00000 1.57 
2081 CHPF2 0.00001 1.60 2138 NFIL3 0.00030 1.57 
2082 GS1-124K5.11 0.00000 1.60 2139 GZF1 0.01916 1.57 
2083 TSPAN17 0.00000 1.60 2140 KIAA0226 0.00007 1.57 
2084 SNX21 0.00000 1.60 2141 NDEL1 0.00003 1.57 
2085 GPR39 0.00005 1.60 2142 THRA 0.00042 1.57 
2086 WDR81 0.00166 1.60 2143 BNIP3 0.04579 1.57 
2087 SIPA1L3 0.00003 1.60 2144 C3orf38 0.00503 1.57 
2088 TNFRSF10D 0.00001 1.60 2145 TOM1 0.00008 1.57 
2089 HARS2 0.00000 1.60 2146 NME4 0.00000 1.57 
2090 NISCH 0.00032 1.60 2147 RHOC 0.00000 1.56 
2091 B4GALT7 0.00000 1.60 2148 FBXO41 0.04018 1.56 
2092 RPL23AP82 0.03696 1.60 2149 RIPK1 0.00000 1.56 
2093 HMGXB3 0.00002 1.60 2150 KIF1C 0.00000 1.56 
2094 TOMM40L 0.00005 1.60 2151 RAB11FIP5 0.00001 1.56 
2095 NSFL1C 0.00000 1.60 2152 COMMD3 0.00000 1.56 
2096 PHC1 0.00062 1.60 2153 IGF2BP2 0.04858 1.56 
2097 TMEM57 0.00018 1.60 2154 MEA1 0.00000 1.56 
2098 CTNNB1 0.00011 1.59 2155 GAB2 0.00020 1.56 
2099 GPR156 0.03661 1.59 2156 SSR3 0.04065 1.56 
2100 KLHDC8B 0.00337 1.59 2157 HERPUD1 0.00026 1.56 
2101 MPV17L2 0.00005 1.59 2158 ARL4A 0.00029 1.56 
2102 ABRACL 0.00000 1.59 2159 FMNL1 0.00260 1.56 
2103 SLC29A1 0.00029 1.59 2160 DIEXF 0.00006 1.56 
2104 CHSY1 0.00368 1.59 2161 HOMER2 0.00080 1.56 
2105 CLCN7 0.00027 1.59 2162 GATAD2A 0.00000 1.56 
2106 RRAGC 0.00977 1.59 2163 CDR2 0.00067 1.55 
2107 WBP1L 0.00002 1.59 2164 ARHGAP17 0.00000 1.55 
2108 GDI1 0.00000 1.59 2165 CENPO 0.00020 1.55 
2109 BRD9 0.00000 1.58 2166 KRBA1 0.00999 1.55 
2110 CD40 0.00000 1.58 2167 MGAT1 0.00000 1.55 
2111 RIMKLB 0.00775 1.58 2168 RAB42 0.00020 1.55 
2112 NTRK2 0.01620 1.58 2169 EIF1AD 0.00000 1.55 
2113 CDYL 0.00000 1.58 2170 FBXL19 0.00023 1.55 
2114 TXLNA 0.00000 1.58 2171 FOXP4 0.00243 1.55 
2115 TCP11L1 0.00448 1.58 2172 ASB1 0.00000 1.55 
2116 CD151 0.00000 1.58 2173 CXorf40B 0.00085 1.55 
2117 SGPL1 0.00000 1.58 2174 TBC1D1 0.00003 1.55 
2118 HMOX2 0.00000 1.58 2175 METTL1 0.00002 1.55 
2119 LRP3 0.01570 1.57 2176 MYO1C 0.00000 1.55 
2120 TP73-AS1 0.00006 1.57 2177 FZD4 0.00655 1.55 
2121 ZFYVE26 0.00066 1.57 2178 CNPY4 0.01638 1.55 
2122 SUSD6 0.02107 1.57 2179 PQLC2 0.00086 1.55 
2123 C8orf58 0.00034 1.57 2180 PHF23 0.00210 1.55 
2124 LOC101929709 0.00022 1.57 2181 NYNRIN 0.01986 1.55 
2125 AJUBA 0.00003 1.57 2182 FLCN 0.00034 1.55 
2126 CCDC137 0.00004 1.57 2183 CNP 0.00005 1.55 
2127 CARD10 0.00004 1.57 2184 ATP2C1 0.01134 1.55 
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2185 ZNF460 0.03624 1.55 2242 LYPLA2 0.00020 1.52 
2186 ARHGAP1 0.00016 1.55 2243 KDM3A 0.02738 1.52 
2187 CYTH2 0.00191 1.55 2244 LPXN 0.00931 1.52 
2188 RNF187 0.00002 1.55 2245 SLC9A3R2 0.00298 1.52 
2189 FAM168A 0.00003 1.55 2246 CDYL2 0.00004 1.52 
2190 ZNF358 0.00004 1.55 2247 DCAF5 0.00037 1.52 
2191 PHF1 0.00000 1.55 2248 ENTHD2 0.01109 1.52 
2192 INA 0.00270 1.54 2249 CLN5 0.00067 1.52 
2193 ARPC1B 0.00000 1.54 2250 B3GLCT 0.00932 1.52 
2194 GPAT4 0.00002 1.54 2251 SSH1 0.00014 1.51 
2195 HN1L 0.00000 1.54 2252 CDK13 0.00000 1.51 
2196 RBM15B 0.00000 1.54 2253 BBS4 0.00009 1.51 
2197 ZNF561 0.00513 1.54 2254 VAMP3 0.00030 1.51 
2198 MTMR3 0.00001 1.54 2255 ACAT2 0.00546 1.51 
2199 ZNF587 0.00032 1.54 2256 DUOXA1 0.00035 1.51 
2200 TUBB6 0.00000 1.54 2257 ZNF79 0.00216 1.51 
2201 LOXL3 0.00054 1.54 2258 HGSNAT 0.00004 1.51 
2202 SAT1 0.00001 1.54 2259 EXO5 0.00023 1.51 
2203 ZNF608 0.00421 1.54 2260 VGLL4 0.00611 1.51 
2204 TSC22D1 0.00109 1.53 2261 BRF2 0.00126 1.51 
2205 VMP1 0.00004 1.53 2262 GNB1 0.00003 1.51 
2206 TOR1B 0.00000 1.53 2263 HJURP 0.04337 1.51 
2207 CERK 0.00047 1.53 2264 FZR1 0.00287 1.51 
2208 BACE1 0.00080 1.53 2265 OAZ2 0.00000 1.51 
2209 ST6GALNAC6 0.00286 1.53 2266 B4GALNT4 0.00790 1.51 
2210 MAP2 0.04992 1.53 2267 SRGAP2 0.00035 1.50 
2211 PPIF 0.00025 1.53 2268 SAP30L 0.02210 1.50 
2212 FAM118B 0.00000 1.53 2269 TP53BP1 0.00486 1.50 
2213 ZNF8 0.00013 1.53 2270 RRP36 0.00000 1.50 
2214 VPS39 0.00000 1.53 2271 IL18BP 0.01033 1.50 
2215 SQSTM1 0.00000 1.53 2272 TEX10 0.04067 1.50 
2216 PDE6D 0.00001 1.53 2273 INO80C 0.01586 1.50 
2217 TMEM102 0.00187 1.53 2274 TM2D2 0.00001 1.50 
2218 FLYWCH1 0.00075 1.53 2275 NGFRAP1 0.00000 1.50 
2219 ZFAND3 0.00101 1.53 2276 DNLZ 0.00588 1.50 
2220 SNX33 0.00059 1.53 2277 QSOX1 0.00007 1.50 
2221 TVP23C-CDRT4 0.01578 1.53 2278 TIMM22 0.00000 1.50 
2222 POLR3A 0.00041 1.53 2279 NIPSNAP1 0.00002 1.50 
2223 ETV6 0.00033 1.53 2280 UBE2Z 0.00000 1.50 
2224 ANKS3 0.03136 1.53 2281 RAB11FIP3 0.00149 1.50 
2225 PNMA1 0.00005 1.53 2282 ISY1-RAB43 0.00000 1.50 
2226 ANXA2 0.00000 1.53 2283 ESYT1 0.00000 1.50 
2227 PGRMC2 0.00025 1.53 2284 MLPH 0.00000 1.49 
2228 ZBTB4 0.00001 1.53 2285 JUND 0.00330 1.49 
2229 HGS 0.00000 1.53 2286 TIMM23B 0.00130 1.49 
2230 RUSC2 0.00000 1.53 2287 MAP4 0.00037 1.49 
2231 STX4 0.00447 1.53 2288 MGST3 0.00003 1.49 
2232 IQCK 0.00003 1.52 2289 CHD3 0.02483 1.49 
2233 KIAA0355 0.00068 1.52 2290 C1orf50 0.00043 1.49 
2234 EHBP1L1 0.00015 1.52 2291 TRAM2 0.00045 1.49 
2235 DPP9 0.00005 1.52 2292 DDX60L 0.00080 1.49 
2236 DSTYK 0.00014 1.52 2293 DIABLO 0.00002 1.49 
2237 ATAT1 0.00206 1.52 2294 ZSWIM6 0.00012 1.49 
2238 TECPR1 0.00023 1.52 2295 YRDC 0.00151 1.49 
2239 CASP2 0.00313 1.52 2296 FKBP1B 0.00390 1.49 
2240 PLEKHM2 0.00000 1.52 2297 WDYHV1 0.00000 1.49 
2241 LRIG3 0.01923 1.52 2298 DCAF4 0.00000 1.49 
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2299 ELF4 0.00078 1.49 2356 TESK1 0.00571 1.47 
2300 MANF 0.00147 1.49 2357 NRBP1 0.00000 1.46 
2301 CRYBB2P1 0.00357 1.49 2358 RBM4B 0.03293 1.46 
2302 DCTN5 0.00000 1.49 2359 DGCR8 0.00018 1.46 
2303 REXO2 0.01009 1.49 2360 CENPB 0.00001 1.46 
2304 POLR3D 0.02013 1.49 2361 SUSD1 0.00530 1.46 
2305 NCOA5 0.00000 1.49 2362 ARPC1A 0.00000 1.46 
2306 TMEM234 0.00060 1.49 2363 ANXA2P2 0.01215 1.46 
2307 ARPC4 0.00002 1.49 2364 PIAS3 0.00039 1.46 
2308 INPPL1 0.00001 1.49 2365 PINX1 0.00066 1.46 
2309 HYAL2 0.02124 1.49 2366 FUNDC2 0.00004 1.46 
2310 HRAS 0.00005 1.49 2367 RIT1 0.00141 1.46 
2311 APBB3 0.02116 1.49 2368 FAM21A 0.00369 1.46 
2312 SLC39A14 0.00001 1.49 2369 FAM50B 0.00034 1.46 
2313 FUT11 0.00074 1.49 2370 TBC1D25 0.00025 1.46 
2314 NFKB1 0.00002 1.49 2371 OST4 0.00000 1.45 
2315 RANGAP1 0.00000 1.49 2372 SMARCD1 0.00004 1.45 
2316 TBC1D17 0.00001 1.48 2373 IL17RA 0.01767 1.45 
2317 CCDC109B 0.00011 1.48 2374 CRAMP1L 0.00002 1.45 
2318 GNG5 0.00000 1.48 2375 CHST14 0.00053 1.45 
2319 SNAP47 0.00001 1.48 2376 TMEM189 0.00014 1.45 
2320 BRK1 0.00000 1.48 2377 C7orf49 0.00000 1.45 
2321 CPNE2 0.00000 1.48 2378 BSDC1 0.00000 1.45 
2322 TMEM242 0.01259 1.48 2379 PFN1 0.00000 1.45 
2323 TRAPPC1 0.00000 1.48 2380 OSBPL3 0.02321 1.45 
2324 ATXN1L 0.00063 1.48 2381 SZRD1 0.00000 1.45 
2325 TMEM185A 0.00085 1.48 2382 ZNF512 0.01215 1.45 
2326 SEPW1 0.00000 1.48 2383 GABARAP 0.00000 1.45 
2327 LLGL1 0.00042 1.48 2384 MARK4 0.00012 1.45 
2328 PTPRF 0.00250 1.48 2385 RAPGEF1 0.01381 1.45 
2329 EIF2B2 0.00000 1.48 2386 ASL 0.00002 1.45 
2330 KDM6A 0.00107 1.48 2387 TSPAN6 0.00000 1.45 
2331 ATAD3B 0.04511 1.48 2388 CDC16 0.00119 1.45 
2332 TPM3 0.00000 1.48 2389 CASP6 0.00000 1.45 
2333 BTN2A1 0.00104 1.48 2390 LAMTOR1 0.00000 1.45 
2334 SLC13A3 0.00042 1.48 2391 DCTN1 0.00003 1.45 
2335 ATG13 0.00000 1.48 2392 JMJD4 0.00168 1.45 
2336 C15orf57 0.00027 1.48 2393 TRIM27 0.00077 1.45 
2337 PFKP 0.00000 1.48 2394 BUD31 0.00000 1.45 
2338 SMYD3 0.00000 1.47 2395 LDOC1L 0.01798 1.45 
2339 FTSJ1 0.00000 1.47 2396 AQP11 0.04264 1.44 
2340 STX3 0.00989 1.47 2397 SUPT5H 0.00000 1.44 
2341 EXOC7 0.00000 1.47 2398 ADD1 0.00000 1.44 
2342 TRIM21 0.01113 1.47 2399 ZNF707 0.00075 1.44 
2343 SRR 0.00534 1.47 2400 CLCN6 0.02617 1.44 
2344 TAGLN2 0.00000 1.47 2401 C1orf52 0.03364 1.44 
2345 PML 0.00569 1.47 2402 ARMC9 0.00068 1.44 
2346 ST5 0.00534 1.47 2403 RELA 0.00000 1.44 
2347 GAS2L1 0.03242 1.47 2404 LOC389906 0.01191 1.44 
2348 KANSL3 0.00128 1.47 2405 B3GALT6 0.01658 1.44 
2349 TAOK2 0.00279 1.47 2406 STRADA 0.00000 1.44 
2350 CMTM7 0.00158 1.47 2407 PANK2 0.00083 1.44 
2351 TUBB 0.00000 1.47 2408 NPLOC4 0.00014 1.44 
2352 TEP1 0.02708 1.47 2409 TECPR2 0.00390 1.44 
2353 CMTR1 0.00185 1.47 2410 MGEA5 0.01989 1.44 
2354 BRPF3 0.03586 1.47 2411 BAX 0.00001 1.44 
2355 PPM1M 0.00044 1.47 2412 GABPB1 0.00458 1.44 
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2413 BTBD9 0.00077 1.44 2470 SYS1 0.00000 1.41 
2414 GFOD2 0.01231 1.44 2471 PWP1 0.00000 1.41 
2415 RNF40 0.00000 1.44 2472 FAM131A 0.02562 1.41 
2416 TM2D3 0.04091 1.44 2473 FAM53C 0.00243 1.41 
2417 LPPR2 0.00668 1.44 2474 SIPA1 0.00001 1.41 
2418 VPS53 0.00315 1.44 2475 KNOP1 0.00000 1.41 
2419 FADD 0.00033 1.44 2476 ARF3 0.00000 1.41 
2420 KDM4A 0.00312 1.44 2477 PCYT1A 0.00091 1.41 
2421 ATG101 0.00006 1.44 2478 TSR2 0.00002 1.41 
2422 AGTRAP 0.00015 1.44 2479 ME3 0.00266 1.41 
2423 TMEM51 0.01132 1.44 2480 PDXK 0.03422 1.41 
2424 C7orf43 0.03540 1.44 2481 TRPC4AP 0.00000 1.41 
2425 FHOD1 0.00020 1.44 2482 FAM50A 0.00001 1.41 
2426 GSTO1 0.00003 1.44 2483 HSD17B7 0.04408 1.41 
2427 GPAM 0.00309 1.44 2484 GPN2 0.00506 1.41 
2428 ENTPD4 0.00003 1.44 2485 MSTO1 0.01229 1.41 
2429 GOLGA3 0.00344 1.43 2486 AMMECR1L 0.02856 1.41 
2430 ORMDL2 0.00001 1.43 2487 USP35 0.00004 1.41 
2431 CCT2 0.00074 1.43 2488 TNFRSF10B 0.00085 1.41 
2432 SSR2 0.00000 1.43 2489 MED20 0.00000 1.41 
2433 PTPRJ 0.00035 1.43 2490 LPIN3 0.00524 1.41 
2434 ERCC3 0.00000 1.43 2491 RASSF1 0.00194 1.41 
2435 SH3BP5L 0.00284 1.43 2492 ZDHHC18 0.02147 1.41 
2436 RNF215 0.01873 1.43 2493 CYTH3 0.00000 1.41 
2437 IRF2BP2 0.00020 1.43 2494 CENPBD1 0.00662 1.41 
2438 ITGA3 0.00015 1.43 2495 PDE4DIP 0.00123 1.41 
2439 GNL1 0.00000 1.43 2496 SAP30BP 0.00010 1.40 
2440 CUTA 0.00004 1.43 2497 MICA 0.04038 1.40 
2441 PLD3 0.02924 1.43 2498 TOLLIP 0.01828 1.40 
2442 ENG 0.01868 1.43 2499 RING1 0.02789 1.40 
2443 FBXL12 0.00124 1.43 2500 RAD54L2 0.02557 1.40 
2444 SLC37A3 0.00001 1.43 2501 SNF8 0.00008 1.40 
2445 P3H4 0.00051 1.43 2502 ETNK2 0.00003 1.40 
2446 SLC35E1 0.00078 1.43 2503 CDC34 0.00009 1.40 
2447 WDR82 0.00000 1.43 2504 TARBP2 0.00485 1.40 
2448 NOSIP 0.00032 1.43 2505 TWF2 0.00003 1.40 
2449 TSTD2 0.01877 1.43 2506 COMMD5 0.00001 1.40 
2450 MOAP1 0.00047 1.43 2507 TP53RK 0.00086 1.40 
2451 MTCH1 0.00001 1.43 2508 PINK1 0.00032 1.40 
2452 MAST2 0.00002 1.43 2509 EMC10 0.00015 1.40 
2453 WDR1 0.00000 1.43 2510 MSRB2 0.00007 1.40 
2454 DMTF1 0.03617 1.43 2511 LAMTOR2 0.00046 1.40 
2455 C17orf49 0.00323 1.43 2512 CENPV 0.01545 1.40 
2456 B4GALT2 0.00041 1.42 2513 SLC2A1 0.03237 1.40 
2457 FGFRL1 0.00474 1.42 2514 ARPC2 0.00017 1.39 
2458 NARF 0.00113 1.42 2515 FKBP9 0.00381 1.39 
2459 CDCA7L 0.00008 1.42 2516 FBRS 0.00607 1.39 
2460 UROS 0.00005 1.42 2517 ATXN7L3B 0.00008 1.39 
2461 JUP 0.00180 1.42 2518 UBXN7 0.04919 1.39 
2462 ACLY 0.00191 1.42 2519 TRMT12 0.00020 1.39 
2463 SCRN1 0.04685 1.42 2520 POLM 0.00188 1.39 
2464 SERPINH1 0.00298 1.42 2521 MAPRE1 0.00030 1.39 
2465 STRIP1 0.00000 1.42 2522 ZNF282 0.00213 1.39 
2466 USP22 0.00004 1.42 2523 TAF7 0.00062 1.39 
2467 AKT1 0.00005 1.42 2524 NOP14-AS1 0.00583 1.39 
2468 E2F3 0.02288 1.41 2525 FAM120B 0.01361 1.39 
2469 AP2B1 0.00179 1.41 2526 DBNL 0.00001 1.39 
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2527 NINL 0.01965 1.39 2584 CXXC1 0.00340 1.36 
2528 DTD1 0.00177 1.39 2585 KANSL1 0.00023 1.36 
2529 FAM32A 0.00000 1.39 2586 PPP1R12C 0.00411 1.36 
2530 SERINC3 0.00760 1.39 2587 PHACTR4 0.00402 1.36 
2531 PDZD11 0.00000 1.39 2588 FXYD5 0.00001 1.36 
2532 EBP 0.00048 1.39 2589 PFDN1 0.00756 1.36 
2533 SNAPC2 0.00007 1.38 2590 ATP6V0A2 0.01253 1.36 
2534 CAPZB 0.00000 1.38 2591 TMEM14C 0.00000 1.36 
2535 TOR1A 0.00001 1.38 2592 SHKBP1 0.00421 1.36 
2536 PFN2 0.00000 1.38 2593 RTCB 0.00000 1.36 
2537 MAP3K4 0.00231 1.38 2594 RPP30 0.00025 1.36 
2538 WIPI2 0.00000 1.38 2595 GBF1 0.00467 1.36 
2539 ERC1 0.00451 1.38 2596 APOPT1 0.00909 1.36 
2540 CMIP 0.00187 1.38 2597 GMIP 0.01767 1.36 
2541 DVL1 0.00176 1.38 2598 RFX5 0.00053 1.36 
2542 TNKS1BP1 0.02269 1.38 2599 PRDM4 0.00700 1.36 
2543 BRMS1 0.00008 1.38 2600 PPP2R2D 0.00075 1.36 
2544 ERF 0.00594 1.38 2601 FBXL5 0.03263 1.36 
2545 TBC1D13 0.00013 1.38 2602 HEATR6 0.00024 1.36 
2546 TBCC 0.00214 1.37 2603 SLC15A4 0.00233 1.36 
2547 TRIM25 0.00104 1.37 2604 ADAR 0.01523 1.36 
2548 MIR4435-2HG 0.02124 1.37 2605 DCTN2 0.00000 1.35 
2549 PPRC1 0.00125 1.37 2606 DNAJC9 0.01097 1.35 
2550 GRAMD1A 0.00313 1.37 2607 NUP62 0.00070 1.35 
2551 ARFRP1 0.00058 1.37 2608 PVRL2 0.00028 1.35 
2552 STX8 0.00891 1.37 2609 TES 0.00866 1.35 
2553 SLC35E2B 0.02874 1.37 2610 TMEM173 0.00149 1.35 
2554 AEN 0.00018 1.37 2611 COX19 0.00925 1.35 
2555 MAD2L2 0.00005 1.37 2612 BIN3 0.00023 1.35 
2556 RTKN 0.00016 1.37 2613 KBTBD2 0.00195 1.35 
2557 DEXI 0.00022 1.37 2614 PDCD11 0.03775 1.35 
2558 PBX2 0.00088 1.37 2615 NOL9 0.01192 1.35 
2559 OS9 0.03367 1.37 2616 GPN1 0.00000 1.35 
2560 TADA3 0.00084 1.37 2617 PELO 0.00000 1.35 
2561 ACOT7 0.00007 1.37 2618 GRIPAP1 0.01870 1.35 
2562 FDX1L 0.01983 1.37 2619 SURF4 0.00000 1.35 
2563 TMEM208 0.00003 1.37 2620 S100A11 0.00001 1.35 
2564 CAMSAP1 0.00000 1.37 2621 NUDCD3 0.00001 1.35 
2565 ANO10 0.00093 1.37 2622 PRMT2 0.00000 1.35 
2566 SNX12 0.00000 1.37 2623 BPHL 0.00000 1.35 
2567 SQRDL 0.00002 1.37 2624 SDHAF2 0.00282 1.35 
2568 FBXO44 0.00448 1.37 2625 TRAF2 0.02894 1.35 
2569 PTPN1 0.00000 1.37 2626 EXOSC6 0.00313 1.35 
2570 ZNF513 0.03891 1.37 2627 ADAT1 0.00001 1.35 
2571 METTL22 0.00034 1.37 2628 IKBKG 0.02768 1.35 
2572 CSNK1G1 0.03209 1.37 2629 MBD3 0.00268 1.34 
2573 C12orf43 0.00000 1.37 2630 STK39 0.02536 1.34 
2574 DAD1 0.00000 1.37 2631 TIMM10B 0.00006 1.34 
2575 UBE2R2 0.00000 1.37 2632 RRAGA 0.00000 1.34 
2576 PI4K2A 0.00005 1.37 2633 CASC3 0.00079 1.34 
2577 PGS1 0.00049 1.37 2634 TNIP2 0.01089 1.34 
2578 TNFRSF21 0.00007 1.36 2635 NTMT1 0.01728 1.34 
2579 ANKRD11 0.00327 1.36 2636 CHD4 0.04903 1.34 
2580 PYCARD 0.00403 1.36 2637 DEDD 0.00104 1.34 
2581 EIF4EBP1 0.03087 1.36 2638 FOCAD 0.00061 1.34 
2582 RNF19B 0.00672 1.36 2639 DUSP3 0.00092 1.34 
2583 HIVEP2 0.03897 1.36 2640 CTBP1-AS2 0.00225 1.34 
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2641 IP6K2 0.02825 1.34 2698 DDX24 0.00000 1.30 
2642 MORF4L1 0.00649 1.34 2699 AP3S2 0.01270 1.30 
2643 POMGNT2 0.00017 1.34 2700 SNIP1 0.04128 1.30 
2644 PNPLA6 0.01182 1.34 2701 PARD3 0.00042 1.30 
2645 STAG3L4 0.00233 1.34 2702 ZNF304 0.00430 1.30 
2646 ARHGDIA 0.00311 1.34 2703 S100A13 0.00013 1.30 
2647 AGAP3 0.00648 1.34 2704 GNAS 0.00012 1.30 
2648 RNASEH2C 0.00001 1.33 2705 ASB6 0.00096 1.30 
2649 FAM134A 0.00258 1.33 2706 ZNF496 0.01425 1.30 
2650 HLA-E 0.00001 1.33 2707 CENPT 0.00455 1.30 
2651 ZC3HC1 0.00036 1.33 2708 CALM2 0.03566 1.30 
2652 EVI5L 0.00122 1.33 2709 ZHX2 0.00617 1.30 
2653 BOK 0.04219 1.33 2710 NRSN2 0.00143 1.30 
2654 ISCA2 0.01587 1.33 2711 REXO4 0.01895 1.30 
2655 GUSBP1 0.03645 1.33 2712 SLC39A7 0.00054 1.30 
2656 HCCS 0.00001 1.33 2713 RPL39L 0.00550 1.30 
2657 BAIAP2L1 0.00001 1.33 2714 UROD 0.00012 1.30 
2658 RDH11 0.00673 1.33 2715 HOXD11 0.00798 1.30 
2659 RAB34 0.00281 1.33 2716 KLC2 0.00554 1.30 
2660 CIAPIN1 0.00044 1.33 2717 ZNF622 0.00001 1.30 
2661 CLASP1 0.02046 1.33 2718 GUK1 0.02456 1.29 
2662 ELOVL1 0.00003 1.33 2719 MAX 0.00419 1.29 
2663 MAP3K11 0.01277 1.33 2720 JOSD1 0.00004 1.29 
2664 TDP1 0.00255 1.33 2721 WDR37 0.01752 1.29 
2665 CDK2 0.00004 1.32 2722 DNAJC8 0.00144 1.29 
2666 STARD3 0.00011 1.32 2723 PHPT1 0.00775 1.29 
2667 SRSF8 0.00109 1.32 2724 TMEM230 0.01746 1.29 
2668 SF3B4 0.01132 1.32 2725 PMM2 0.00001 1.29 
2669 TMEM199 0.00166 1.32 2726 YIPF3 0.00048 1.29 
2670 SRP14 0.00747 1.32 2727 SLC35B2 0.02642 1.29 
2671 CREB3 0.00003 1.32 2728 TUSC2 0.00305 1.29 
2672 DDA1 0.00000 1.32 2729 PTPN9 0.00017 1.29 
2673 SMG9 0.03239 1.32 2730 MCM7 0.00153 1.29 
2674 LINC00094 0.04701 1.32 2731 SWI5 0.04182 1.29 
2675 EHD4 0.00000 1.32 2732 CLTA 0.00001 1.29 
2676 PREP 0.00191 1.32 2733 URB1 0.00822 1.29 
2677 B4GALT3 0.00277 1.32 2734 CDK9 0.00370 1.29 
2678 RNF216 0.00053 1.32 2735 SDF2 0.04215 1.29 
2679 PDRG1 0.00047 1.32 2736 DAXX 0.00006 1.28 
2680 DDX31 0.00625 1.32 2737 IST1 0.00037 1.28 
2681 SMG6 0.01898 1.32 2738 WHSC1 0.00198 1.28 
2682 BMS1P6 0.02988 1.32 2739 B3GAT3 0.03861 1.28 
2683 COPS7B 0.01686 1.31 2740 BMS1P20 0.03775 1.28 
2684 CDCA4 0.01252 1.31 2741 MBD1 0.00361 1.28 
2685 C19orf12 0.00156 1.31 2742 ARHGEF7 0.00019 1.28 
2686 VPS25 0.00148 1.31 2743 YWHAQ 0.00000 1.28 
2687 ATXN7L3 0.03109 1.31 2744 GNB5 0.00024 1.28 
2688 DCTD 0.00009 1.31 2745 PPP4R1 0.00022 1.28 
2689 MXD4 0.00599 1.31 2746 SEC24C 0.04527 1.28 
2690 OCRL 0.03815 1.31 2747 CDA 0.01677 1.28 
2691 DPH7 0.00020 1.31 2748 SLC2A4RG 0.00834 1.28 
2692 SHC1 0.00003 1.31 2749 CCNI 0.00005 1.28 
2693 SLC25A38 0.04340 1.31 2750 NUTF2 0.00395 1.28 
2694 PRRC2B 0.04074 1.31 2751 ZMIZ2 0.04813 1.28 
2695 TMEM120B 0.00169 1.31 2752 COPA 0.00435 1.28 
2696 KDM2B 0.00149 1.31 2753 CCNE1 0.02809 1.28 
2697 ELOF1 0.00383 1.30 2754 LSG1 0.00275 1.28 
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2755 TMEM39B 0.02279 1.28 2812 UBL5 0.00239 1.24 
2756 BOD1 0.00303 1.28 2813 SRPRB 0.00002 1.24 
2757 TMEM256 0.01619 1.28 2814 PIP5K1A 0.00857 1.24 
2758 NGRN 0.00007 1.28 2815 NUDT1 0.02515 1.24 
2759 SGTA 0.02029 1.28 2816 GON4L 0.01220 1.24 
2760 LCMT1 0.00070 1.28 2817 DGKA 0.04669 1.24 
2761 BCL7B 0.01885 1.28 2818 TMED9 0.02639 1.23 
2762 TUBA1B 0.00012 1.28 2819 ACAA2 0.00057 1.23 
2763 ERCC1 0.03076 1.28 2820 WDR45B 0.00470 1.23 
2764 VPS33A 0.00086 1.28 2821 DDX23 0.00760 1.23 
2765 HYOU1 0.01993 1.27 2822 TSR3 0.03138 1.23 
2766 YTHDF1 0.02896 1.27 2823 EIF4A1 0.00297 1.23 
2767 ZNF263 0.01992 1.27 2824 CPSF7 0.04129 1.23 
2768 RBM4 0.00091 1.27 2825 TP53 0.03237 1.23 
2769 SERF2 0.00390 1.27 2826 ISCU 0.00365 1.23 
2770 MTMR14 0.00877 1.27 2827 ABCF2 0.00959 1.23 
2771 RBM19 0.01570 1.27 2828 EHD1 0.00945 1.23 
2772 WDR54 0.02954 1.27 2829 HK1 0.01558 1.23 
2773 DDX19A 0.00022 1.27 2830 PHF19 0.02929 1.23 
2774 SORBS3 0.00760 1.27 2831 AK1 0.00291 1.23 
2775 MTHFD1L 0.01195 1.27 2832 SLC35D2 0.03950 1.23 
2776 TMSB4X 0.00000 1.27 2833 NEDD8 0.00323 1.23 
2777 MYEOV2 0.00015 1.27 2834 NUP93 0.04568 1.22 
2778 NEK6 0.00146 1.27 2835 PGAM1 0.04551 1.22 
2779 RTFDC1 0.00000 1.27 2836 GTF3C4 0.00069 1.22 
2780 KIAA0391 0.00002 1.27 2837 SF3A3 0.00000 1.22 
2781 AP2M1 0.00039 1.27 2838 PRPF4 0.00073 1.22 
2782 RAF1 0.00003 1.27 2839 IRF5 0.02769 1.22 
2783 FEN1 0.00139 1.27 2840 ACIN1 0.00235 1.22 
2784 CBR1 0.00021 1.26 2841 SDC4 0.01387 1.22 
2785 PI4KB 0.00036 1.26 2842 FAM134C 0.01689 1.22 
2786 IFT52 0.00030 1.26 2843 C14orf119 0.00427 1.22 
2787 MRPL14 0.02210 1.26 2844 NONO 0.02998 1.22 
2788 RALY 0.00339 1.26 2845 RABIF 0.03593 1.21 
2789 MPZL1 0.01963 1.26 2846 EZR 0.00690 1.21 
2790 ASH2L 0.00868 1.26 2847 UBE2Q1 0.01446 1.21 
2791 CLP1 0.02369 1.26 2848 MAEA 0.03081 1.21 
2792 IPO9 0.00341 1.26 2849 GTF2F1 0.02364 1.21 
2793 TOX4 0.00000 1.26 2850 MTFR1L 0.02221 1.21 
2794 POLE3 0.00004 1.26 2851 PPP3CC 0.03546 1.20 
2795 KIAA1191 0.00013 1.26 2852 UBE2J2 0.01930 1.20 
2796 POLR2C 0.00001 1.25 2853 TPD52L2 0.00033 1.20 
2797 ATP6V0E1 0.00003 1.25 2854 SF3B2 0.00017 1.20 
2798 MICB 0.01138 1.25 2855 HNRNPAB 0.00141 1.20 
2799 E2F6 0.01059 1.25 2856 GINS3 0.00486 1.20 
2800 COA3 0.00218 1.25 2857 SAE1 0.00060 1.20 
2801 BFAR 0.00987 1.25 2858 S100A10 0.03389 1.19 
2802 CTSZ 0.02507 1.25 2859 LSM14B 0.03112 1.19 
2803 MED8 0.00738 1.25 2860 SUPT4H1 0.00938 1.19 
2804 SUMO3 0.00001 1.25 2861 DHDDS 0.02384 1.19 
2805 MAPKAP1 0.00189 1.25 2862 ARPC5L 0.00515 1.19 
2806 TMEM185B 0.01243 1.25 2863 GUCD1 0.01693 1.19 
2807 KXD1 0.03701 1.25 2864 TANGO2 0.00275 1.19 
2808 BRD2 0.01048 1.25 2865 DNAJC5 0.04598 1.19 
2809 FAF2 0.00183 1.25 2866 ILF2 0.01515 1.18 
2810 IPPK 0.00152 1.25 2867 TIMELESS 0.02162 1.17 
2811 ADIPOR2 0.01265 1.25 2868 CTNNBL1 0.01972 1.17 
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2869 ECD 0.02571 1.17 2926 GOT1 0.00186 -1.25 
2870 RAN 0.00315 1.16 2927 TXNDC5 0.01948 -1.25 
2871 DDX47 0.00854 1.16 2928 PMPCB 0.00011 -1.25 
2872 EWSR1 0.03637 1.16 2929 TMEM69 0.01468 -1.25 
2873 INTS4 0.02745 1.16 2930 MRPS27 0.00003 -1.25 
2874 BUB3 0.02053 1.15 2931 MPRIP 0.00583 -1.25 
2875 DERL1 0.02916 1.14 2932 MRPL37 0.01910 -1.25 
2876 TLDC1 0.04691 1.13 2933 RPS15 0.04967 -1.25 
2877 RHOA 0.04571 1.12 2934 RPS14 0.00761 -1.25 
2878 SEC13 0.02105 1.12 2935 TMEM106C 0.00836 -1.25 
2879 FBXO7 0.03641 1.12 2936 RPL12 0.00094 -1.25 
2880 NDUFB4 0.02287 -1.14 2937 PRCP 0.00078 -1.25 
2881 RPL15 0.00020 -1.15 2938 NUDT5 0.00000 -1.25 
2882 PEX19 0.03314 -1.16 2939 SNRPD3 0.01077 -1.25 
2883 EIF3D 0.02430 -1.17 2940 CCT7 0.00139 -1.25 
2884 RPN1 0.03674 -1.17 2941 CAPN1 0.04256 -1.26 
2885 RFC5 0.00004 -1.17 2942 RPL10A 0.00002 -1.26 
2886 FUCA2 0.02180 -1.17 2943 EIF2D 0.00047 -1.26 
2887 AK2 0.00128 -1.18 2944 ALG9 0.01392 -1.26 
2888 EIF3K 0.04902 -1.18 2945 AMFR 0.00028 -1.26 
2889 MTCH2 0.00013 -1.18 2946 KIF22 0.02011 -1.26 
2890 ATP5H 0.00064 -1.18 2947 EIF2B5 0.00007 -1.26 
2891 RPL3 0.00220 -1.19 2948 RBFA 0.00570 -1.26 
2892 ALAS1 0.03248 -1.19 2949 PITRM1 0.00175 -1.26 
2893 RPRD1B 0.00122 -1.19 2950 ECH1 0.00285 -1.26 
2894 NUP88 0.00305 -1.19 2951 RPS11 0.01145 -1.27 
2895 NDUFV3 0.02876 -1.19 2952 RPS18 0.00368 -1.27 
2896 EIF4A3 0.00039 -1.19 2953 ATRAID 0.01206 -1.27 
2897 CRTAP 0.01952 -1.19 2954 BRE 0.00056 -1.27 
2898 EEF1D 0.02280 -1.19 2955 MRPL34 0.00048 -1.27 
2899 GART 0.00052 -1.19 2956 DYNLT1 0.00010 -1.27 
2900 CDK5RAP1 0.04036 -1.20 2957 WIBG 0.00311 -1.27 
2901 GRPEL1 0.01396 -1.20 2958 CKLF 0.00177 -1.27 
2902 ATP5L 0.00208 -1.20 2959 SUCLG1 0.00052 -1.27 
2903 PRPS1 0.03055 -1.20 2960 UQCRFS1 0.00000 -1.27 
2904 ECHS1 0.03458 -1.20 2961 NDUFAB1 0.00817 -1.27 
2905 GATB 0.00290 -1.21 2962 TUBG1 0.03827 -1.28 
2906 NHP2 0.00334 -1.21 2963 TIAM1 0.00560 -1.28 
2907 MRPL21 0.04137 -1.21 2964 GTF3A 0.02346 -1.28 
2908 C1orf43 0.00239 -1.22 2965 RPL19 0.00003 -1.28 
2909 NDUFA9 0.00427 -1.22 2966 SLC39A9 0.00222 -1.28 
2910 RPL27A 0.00019 -1.22 2967 DAZAP1 0.00001 -1.28 
2911 TOMM7 0.03421 -1.22 2968 LAPTM4B 0.00657 -1.28 
2912 CHMP4A 0.03954 -1.22 2969 ADI1 0.00144 -1.28 
2913 RPL39 0.00022 -1.22 2970 RPL35A 0.00000 -1.28 
2914 PCID2 0.00037 -1.22 2971 ERGIC3 0.01969 -1.28 
2915 VPS37B 0.04643 -1.23 2972 CCNB2 0.02446 -1.28 
2916 NIF3L1 0.00269 -1.23 2973 RPL13A 0.00258 -1.28 
2917 AHCY 0.00244 -1.24 2974 DNAJA3 0.00444 -1.28 
2918 CCDC85C 0.02404 -1.24 2975 ICT1 0.00854 -1.29 
2919 NAA38 0.00904 -1.24 2976 NADSYN1 0.00042 -1.29 
2920 NDUFB9 0.00000 -1.24 2977 APOA1BP 0.00029 -1.29 
2921 NELFA 0.04971 -1.24 2978 EEF1G 0.00010 -1.29 
2922 TUBGCP4 0.04553 -1.25 2979 COQ5 0.01243 -1.30 
2923 SPCS1 0.00450 -1.25 2980 LHFPL2 0.04754 -1.30 
2924 IQCE 0.02128 -1.25 2981 MRPL38 0.03147 -1.30 
2925 MRPL53 0.03021 -1.25 2982 OXA1L 0.02706 -1.30 
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2983 UBE2T 0.00094 -1.30 3040 KDF1 0.00106 -1.34 
2984 RPS19 0.00123 -1.30 3041 GHITM 0.01629 -1.34 
2985 RHOF 0.01390 -1.30 3042 LINC00493 0.03249 -1.34 
2986 HIGD2A 0.00032 -1.30 3043 NDUFA10 0.00000 -1.34 
2987 FAM162A 0.00479 -1.30 3044 NDUFV1 0.00155 -1.34 
2988 PTTG1 0.00112 -1.31 3045 AKR1A1 0.00054 -1.34 
2989 RPL27 0.00000 -1.31 3046 MYBL2 0.02924 -1.34 
2990 MFF 0.00263 -1.31 3047 DPCD 0.04815 -1.34 
2991 ATP5A1 0.00334 -1.31 3048 ARHGAP8 0.01725 -1.34 
2992 SBNO2 0.00542 -1.31 3049 SNX8 0.00001 -1.34 
2993 PA2G4 0.00000 -1.31 3050 JAGN1 0.00273 -1.34 
2994 RPL13 0.02022 -1.31 3051 PMS2P1 0.02128 -1.34 
2995 DDB2 0.02726 -1.31 3052 PSMG2 0.02087 -1.35 
2996 RFT1 0.00853 -1.32 3053 TMEM59 0.04022 -1.35 
2997 NENF 0.00101 -1.32 3054 MKNK1 0.01186 -1.35 
2998 BLCAP 0.00129 -1.32 3055 PXMP2 0.01565 -1.35 
2999 SCMH1 0.00889 -1.32 3056 FAH 0.00005 -1.35 
3000 SYNGR2 0.00592 -1.32 3057 SOX17 0.00969 -1.35 
3001 GLE1 0.00004 -1.32 3058 STOML2 0.00434 -1.35 
3002 PDCD6 0.00007 -1.32 3059 PROSER2 0.00000 -1.35 
3003 S100A6 0.01711 -1.32 3060 RBKS 0.00011 -1.35 
3004 SLC25A5 0.00000 -1.32 3061 RPS3 0.00002 -1.35 
3005 COQ9 0.00066 -1.32 3062 COQ7 0.00810 -1.35 
3006 PMS2 0.04016 -1.32 3063 NDUFS2 0.00026 -1.35 
3007 MRPL22 0.00093 -1.32 3064 RPS4X 0.00000 -1.35 
3008 RPS8 0.00000 -1.32 3065 DUS2 0.00000 -1.35 
3009 PYCR2 0.00000 -1.32 3066 KAT8 0.01370 -1.35 
3010 PGM1 0.00044 -1.32 3067 SP1 0.01335 -1.35 
3011 RPS21 0.00036 -1.32 3068 RPL4 0.00001 -1.36 
3012 PGAM5 0.00037 -1.32 3069 CUX1 0.02233 -1.36 
3013 TMED4 0.00018 -1.32 3070 GSTK1 0.00506 -1.36 
3014 VAMP8 0.00001 -1.32 3071 CLPP 0.03442 -1.36 
3015 ACO2 0.00236 -1.32 3072 LOC81691 0.03995 -1.36 
3016 PNKD 0.00240 -1.32 3073 MRPS18B 0.00000 -1.36 
3017 RPS12 0.00003 -1.32 3074 TECR 0.02710 -1.36 
3018 RPS6 0.00000 -1.32 3075 ATP5G3 0.00000 -1.36 
3019 QSOX2 0.00348 -1.33 3076 CDC42BPG 0.00971 -1.36 
3020 MED11 0.01589 -1.33 3077 MCU 0.00048 -1.36 
3021 RPS9 0.00005 -1.33 3078 RPL32 0.00000 -1.36 
3022 RPS4Y1 0.00000 -1.33 3079 VWDE 0.00079 -1.36 
3023 BBS1 0.04241 -1.33 3080 PRDX1 0.00267 -1.36 
3024 TPD52L1 0.00060 -1.33 3081 ADCK4 0.00309 -1.36 
3025 ZNF395 0.01391 -1.33 3082 EED 0.00411 -1.36 
3026 VDAC1 0.00003 -1.33 3083 DPAGT1 0.00139 -1.36 
3027 RPLP0 0.00022 -1.33 3084 TMCO4 0.00072 -1.37 
3028 CISD3 0.04148 -1.33 3085 FARSB 0.00500 -1.37 
3029 NOP56 0.01126 -1.33 3086 NOA1 0.00111 -1.37 
3030 UQCC3 0.01212 -1.33 3087 ITM2C 0.02919 -1.37 
3031 MDH2 0.00000 -1.33 3088 RPSA 0.00003 -1.37 
3032 PLEKHA2 0.00512 -1.33 3089 RPL18 0.00014 -1.37 
3033 LTBR 0.00013 -1.33 3090 RPS2 0.00074 -1.37 
3034 NDUFS8 0.01252 -1.33 3091 ATP5C1 0.00001 -1.37 
3035 MID1 0.00252 -1.33 3092 NPM3 0.00377 -1.37 
3036 LITAF 0.01429 -1.34 3093 CLDND1 0.00517 -1.37 
3037 MPI 0.00092 -1.34 3094 LRPAP1 0.00008 -1.37 
3038 RPS28 0.00025 -1.34 3095 RPS23 0.00000 -1.37 
3039 KRTCAP2 0.01061 -1.34 3096 C6orf106 0.00000 -1.37 
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3097 RPL35 0.00001 -1.37 3154 ERBB2 0.00067 -1.41 
3098 RREB1 0.00322 -1.38 3155 EFEMP1 0.00004 -1.41 
3099 RPL38 0.00047 -1.38 3156 GALK1 0.00126 -1.41 
3100 QPCTL 0.01569 -1.38 3157 ATP5G2 0.00001 -1.41 
3101 SLC43A3 0.00515 -1.38 3158 RPS27A 0.00198 -1.41 
3102 CYC1 0.00030 -1.38 3159 TMEM231 0.00332 -1.41 
3103 CSRP2BP 0.01244 -1.38 3160 ERGIC1 0.00003 -1.41 
3104 SMARCD2 0.00005 -1.38 3161 CHCHD7 0.00174 -1.41 
3105 NADK 0.00381 -1.38 3162 IGSF8 0.01447 -1.41 
3106 GRHPR 0.00000 -1.38 3163 AGFG2 0.00582 -1.42 
3107 CIB1 0.00001 -1.38 3164 PDHX 0.02303 -1.42 
3108 TUFM 0.00001 -1.38 3165 SLC16A1 0.02190 -1.42 
3109 SLC50A1 0.00018 -1.38 3166 CSTB 0.00000 -1.42 
3110 MCAT 0.00117 -1.38 3167 PYGL 0.00080 -1.42 
3111 MTHFD1 0.00159 -1.39 3168 GUSB 0.00152 -1.42 
3112 COX5A 0.00000 -1.39 3169 ITPK1 0.00207 -1.42 
3113 OBFC1 0.00005 -1.39 3170 RPL37A 0.00000 -1.42 
3114 TMED3 0.00017 -1.39 3171 CDC25C 0.00005 -1.42 
3115 PPIP5K1 0.00451 -1.39 3172 IFRD2 0.04105 -1.42 
3116 ZDHHC12 0.01180 -1.39 3173 RMDN3 0.00021 -1.42 
3117 MPC1 0.01047 -1.39 3174 MARVELD3 0.00166 -1.42 
3118 HAX1 0.00341 -1.39 3175 ABHD11 0.00050 -1.42 
3119 RPSAP58 0.00194 -1.39 3176 RPL37 0.00000 -1.42 
3120 SCARNA12 0.00073 -1.39 3177 RTN4IP1 0.00004 -1.42 
3121 SNRPF 0.00006 -1.39 3178 CTDSPL 0.00019 -1.42 
3122 PDHA1 0.01424 -1.39 3179 CAPG 0.00013 -1.42 
3123 TMEM186 0.01207 -1.39 3180 ECSIT 0.00409 -1.42 
3124 PAICS 0.00558 -1.39 3181 RTN3 0.00354 -1.42 
3125 ANAPC16 0.00153 -1.39 3182 MROH6 0.00705 -1.42 
3126 TANC1 0.03461 -1.39 3183 MRPL45 0.00091 -1.42 
3127 JTB 0.00010 -1.39 3184 SLC37A4 0.00621 -1.42 
3128 PRMT7 0.00380 -1.40 3185 LDLRAD3 0.00284 -1.42 
3129 EPS8L1 0.00065 -1.40 3186 ZADH2 0.00763 -1.42 
3130 TSEN54 0.00947 -1.40 3187 ATP5G1 0.00001 -1.43 
3131 PACSIN3 0.00006 -1.40 3188 PIGV 0.00162 -1.43 
3132 RNPEPL1 0.02843 -1.40 3189 RPL14 0.00000 -1.43 
3133 FAM96B 0.00004 -1.40 3190 TMTC2 0.00802 -1.43 
3134 AP1M2 0.00079 -1.40 3191 ELMO3 0.00003 -1.43 
3135 DARS2 0.00008 -1.40 3192 G6PD 0.02936 -1.43 
3136 PRKAG2 0.01307 -1.40 3193 RUVBL2 0.00405 -1.43 
3137 SLC25A15 0.00053 -1.40 3194 BCKDHA 0.00104 -1.43 
3138 TBCD 0.00009 -1.40 3195 DENND3 0.00061 -1.43 
3139 ENKD1 0.00400 -1.40 3196 UQCRC2 0.00000 -1.43 
3140 RPL29 0.00000 -1.40 3197 CEP72 0.00001 -1.43 
3141 TAF4 0.01454 -1.40 3198 NUP37 0.00022 -1.43 
3142 TOE1 0.00111 -1.40 3199 TXN 0.00669 -1.43 
3143 ENOSF1 0.00000 -1.40 3200 LTA4H 0.01456 -1.43 
3144 CDKN2C 0.00418 -1.40 3201 LOC554223 0.00269 -1.43 
3145 ACAA1 0.00001 -1.41 3202 ELL3 0.00054 -1.44 
3146 MRPL35 0.00068 -1.41 3203 SOD2 0.02729 -1.44 
3147 KDSR 0.00287 -1.41 3204 RNPEP 0.00004 -1.44 
3148 SLC48A1 0.00167 -1.41 3205 TALDO1 0.00009 -1.44 
3149 GCN1 0.03436 -1.41 3206 FKBP4 0.00000 -1.44 
3150 SNX5 0.00612 -1.41 3207 AFG3L2 0.00000 -1.44 
3151 ARHGEF16 0.00038 -1.41 3208 NUDT19 0.01285 -1.44 
3152 MTFMT 0.00989 -1.41 3209 HSPE1 0.00416 -1.44 
3153 CRISPLD1 0.01398 -1.41 3210 FAM83A 0.00002 -1.44 
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3211 IQSEC2 0.01956 -1.44 3268 LPCAT3 0.01175 -1.48 
3212 PIH1D1 0.00009 -1.44 3269 RPS13 0.00000 -1.48 
3213 ASCC1 0.00001 -1.44 3270 CCHCR1 0.00440 -1.48 
3214 GFM1 0.04715 -1.45 3271 PCCB 0.00017 -1.48 
3215 TSC22D2 0.00120 -1.45 3272 COQ4 0.00023 -1.48 
3216 PDLIM2 0.01558 -1.45 3273 TMEM143 0.03069 -1.48 
3217 SDHB 0.00000 -1.45 3274 IL10RB 0.00004 -1.48 
3218 RPL21 0.00004 -1.45 3275 H2AFJ 0.00004 -1.48 
3219 GPX4 0.00271 -1.45 3276 TYSND1 0.00069 -1.49 
3220 TMEM179B 0.00615 -1.45 3277 WBSCR22 0.00000 -1.49 
3221 GBAS 0.00052 -1.45 3278 SPAG16 0.01056 -1.49 
3222 CCDC47 0.04777 -1.45 3279 PWWP2B 0.04210 -1.49 
3223 HAGHL 0.00072 -1.45 3280 COL9A3 0.00412 -1.49 
3224 RPS3A 0.00000 -1.45 3281 CEBPZOS 0.01540 -1.49 
3225 PNPO 0.00000 -1.45 3282 COG7 0.00002 -1.49 
3226 BTBD2 0.00303 -1.45 3283 HIST1H4C 0.00919 -1.49 
3227 ANXA11 0.00000 -1.45 3284 RPS16 0.00779 -1.49 
3228 CALHM2 0.00274 -1.45 3285 SLC25A10 0.00260 -1.49 
3229 CCDC134 0.01394 -1.46 3286 C1orf116 0.00004 -1.49 
3230 NACA 0.00020 -1.46 3287 NDUFA7 0.00009 -1.49 
3231 RIBC2 0.01823 -1.46 3288 RPS10 0.00000 -1.49 
3232 RPL30 0.00000 -1.46 3289 MID2 0.00044 -1.49 
3233 WDR19 0.00166 -1.46 3290 LPCAT4 0.00117 -1.49 
3234 RPL36 0.00001 -1.46 3291 NGEF 0.00087 -1.50 
3235 R3HDM2 0.00368 -1.46 3292 STK24 0.00001 -1.50 
3236 ISYNA1 0.02051 -1.46 3293 SELO 0.01018 -1.50 
3237 C1orf210 0.00037 -1.46 3294 NUBPL 0.02088 -1.50 
3238 NDUFS1 0.00001 -1.46 3295 SLC3A2 0.00003 -1.50 
3239 RPL7A 0.00009 -1.46 3296 SIL1 0.00149 -1.50 
3240 SEH1L 0.00161 -1.46 3297 MADD 0.00031 -1.50 
3241 FOXRED1 0.00042 -1.46 3298 PCBD1 0.00001 -1.50 
3242 RPS5 0.00033 -1.46 3299 ARID5B 0.02975 -1.50 
3243 CHID1 0.00036 -1.46 3300 D2HGDH 0.00542 -1.50 
3244 MAPK3 0.00010 -1.46 3301 METTL5 0.02464 -1.50 
3245 CRELD2 0.00035 -1.46 3302 TCIRG1 0.00249 -1.50 
3246 ASF1B 0.00008 -1.47 3303 NECAB3 0.02523 -1.50 
3247 DGAT1 0.00193 -1.47 3304 RPL22 0.03948 -1.51 
3248 RAD23A 0.00000 -1.47 3305 HAGH 0.00231 -1.51 
3249 RPL18A 0.00003 -1.47 3306 RPP25L 0.00848 -1.51 
3250 PITPNM1 0.01229 -1.47 3307 PTPRR 0.00024 -1.51 
3251 PIGO 0.00106 -1.47 3308 DEGS1 0.00096 -1.51 
3252 RBPMS 0.04372 -1.47 3309 CDH1 0.00016 -1.51 
3253 PLCE1 0.00470 -1.47 3310 LRRC45 0.00122 -1.51 
3254 NANS 0.00001 -1.47 3311 TMEM170A 0.00200 -1.51 
3255 ERMARD 0.00459 -1.47 3312 MRPL24 0.00000 -1.51 
3256 RPS25 0.00017 -1.47 3313 RMND5B 0.00002 -1.51 
3257 PAN2 0.00780 -1.47 3314 HSPA9 0.00009 -1.51 
3258 NAAA 0.00005 -1.47 3315 EEF1B2 0.00000 -1.52 
3259 RPL8 0.00001 -1.47 3316 RNF103 0.01439 -1.52 
3260 CD109 0.02362 -1.47 3317 SCRN2 0.00131 -1.52 
3261 PXMP4 0.00005 -1.47 3318 GRTP1 0.00137 -1.52 
3262 MAPK13 0.00000 -1.48 3319 SORD 0.00000 -1.52 
3263 TTC19 0.00022 -1.48 3320 MTSS1L 0.00044 -1.52 
3264 SLC25A39 0.00420 -1.48 3321 COA6 0.03875 -1.52 
3265 TMX2 0.00001 -1.48 3322 ST3GAL1 0.00000 -1.52 
3266 AIFM1 0.00835 -1.48 3323 ANKRD13C 0.00195 -1.52 
3267 RAB25 0.00000 -1.48 3324 ATP5B 0.00000 -1.52 
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3325 NQO2 0.00108 -1.53 3382 ZNF552 0.00246 -1.57 
3326 LDHB 0.03348 -1.53 3383 ILVBL 0.00003 -1.57 
3327 HIST1H4A 0.02177 -1.53 3384 PCDH1 0.00007 -1.57 
3328 TACC2 0.00003 -1.53 3385 CYSRT1 0.00347 -1.57 
3329 CLDN7 0.00000 -1.53 3386 CENPP 0.00912 -1.57 
3330 CMBL 0.00963 -1.53 3387 IMMP2L 0.00488 -1.58 
3331 TSEN2 0.03560 -1.53 3388 VAPA 0.00257 -1.58 
3332 COQ6 0.00004 -1.53 3389 BAIAP2 0.00001 -1.58 
3333 ARSJ 0.00419 -1.53 3390 HSD17B12 0.00849 -1.58 
3334 SLC27A3 0.00012 -1.53 3391 PECR 0.00186 -1.58 
3335 VSIG10 0.00094 -1.53 3392 LONP1 0.00011 -1.58 
3336 XPNPEP3 0.00001 -1.54 3393 SLC27A5 0.00433 -1.58 
3337 LGR4 0.00432 -1.54 3394 EBPL 0.00001 -1.59 
3338 RAB11FIP1 0.00009 -1.54 3395 DLEU1 0.00540 -1.59 
3339 C9orf142 0.00334 -1.54 3396 GSTO2 0.00000 -1.59 
3340 METTL10 0.00579 -1.54 3397 DHRS13 0.01080 -1.59 
3341 COQ2 0.01855 -1.54 3398 CASC8 0.00181 -1.59 
3342 CAPS 0.01371 -1.54 3399 ARHGEF10L 0.00000 -1.59 
3343 ABCD1 0.00188 -1.54 3400 ESRP2 0.00000 -1.59 
3344 LDLRAP1 0.00002 -1.54 3401 LYAR 0.01286 -1.59 
3345 RPLP2 0.00003 -1.54 3402 SH3GLB2 0.00010 -1.59 
3346 RPS29 0.00000 -1.54 3403 BDH1 0.00005 -1.59 
3347 PTPRU 0.00218 -1.54 3404 RELL1 0.00677 -1.59 
3348 TMEM184A 0.00082 -1.55 3405 NDUFV2 0.00000 -1.59 
3349 PGAP2 0.00011 -1.55 3406 NCAPD3 0.00001 -1.59 
3350 DSG2 0.02474 -1.55 3407 SKP2 0.00000 -1.59 
3351 PPT2 0.00000 -1.55 3408 ADGRE5 0.01860 -1.59 
3352 PDSS2 0.00953 -1.55 3409 ABHD15 0.00000 -1.60 
3353 RPPH1 0.00002 -1.55 3410 CASP7 0.00351 -1.60 
3354 COMT 0.00002 -1.55 3411 SIGMAR1 0.00264 -1.60 
3355 GAN 0.00620 -1.55 3412 CD9 0.00000 -1.60 
3356 AKAP13 0.00078 -1.55 3413 C1QBP 0.00000 -1.60 
3357 NR2F6 0.00574 -1.55 3414 GNAL 0.00085 -1.60 
3358 TMEM246 0.00000 -1.55 3415 CHEK2 0.00000 -1.60 
3359 SPATS2L 0.00119 -1.55 3416 TKT 0.00006 -1.60 
3360 TST 0.00026 -1.56 3417 CLUH 0.00020 -1.60 
3361 RPL23A 0.00000 -1.56 3418 TTC30B 0.00524 -1.61 
3362 GDE1 0.00000 -1.56 3419 SNORA70 0.00994 -1.61 
3363 DANCR 0.00000 -1.56 3420 SMIM22 0.00002 -1.61 
3364 SHTN1 0.02832 -1.56 3421 KRT8 0.00000 -1.61 
3365 FAM53B 0.00002 -1.56 3422 FGFR3 0.02268 -1.61 
3366 RCC1 0.00000 -1.56 3423 ZNF431 0.03106 -1.61 
3367 ERVMER34-1 0.04671 -1.56 3424 MSH5 0.01909 -1.61 
3368 PPP1R15B 0.00456 -1.56 3425 JAK3 0.03382 -1.61 
3369 ZCCHC2 0.02275 -1.56 3426 FAM46B 0.00021 -1.61 
3370 ATP1A1 0.00001 -1.56 3427 TMEM205 0.00000 -1.61 
3371 CCDC51 0.00000 -1.56 3428 EXOSC5 0.00060 -1.61 
3372 SLC1A5 0.02205 -1.56 3429 HIST1H2AB 0.02061 -1.61 
3373 ATP5D 0.01226 -1.56 3430 SCARNA17 0.00069 -1.62 
3374 EPHA1 0.00025 -1.56 3431 PAIP2B 0.01828 -1.62 
3375 TCF25 0.00001 -1.56 3432 LRPPRC 0.01741 -1.62 
3376 CRB3 0.03630 -1.57 3433 PHYH 0.00663 -1.62 
3377 SLC37A1 0.00000 -1.57 3434 GPHN 0.00093 -1.62 
3378 ESRRA 0.00000 -1.57 3435 SARS2 0.00007 -1.62 
3379 PNPLA2 0.00141 -1.57 3436 MSLN 0.00044 -1.62 
3380 NAB1 0.00000 -1.57 3437 DNAJC19 0.01239 -1.62 
3381 GSTCD 0.01505 -1.57 3438 KLF3 0.00635 -1.62 
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3439 HIST1H2BI 0.03207 -1.62 3496 PRDX6 0.00000 -1.67 
3440 NDUFC1 0.00000 -1.62 3497 PSME1 0.00000 -1.67 
3441 MAN2A2 0.00095 -1.63 3498 TMEM147 0.00000 -1.67 
3442 DLAT 0.00691 -1.63 3499 DENND2D 0.00000 -1.68 
3443 CXCL16 0.00013 -1.63 3500 ESYT2 0.00001 -1.68 
3444 FUK 0.00512 -1.63 3501 PHF10 0.00140 -1.68 
3445 HIBADH 0.00210 -1.63 3502 CSGALNACT1 0.00031 -1.68 
3446 MEIS2 0.00784 -1.63 3503 AK4 0.00020 -1.68 
3447 EFNA5 0.00767 -1.63 3504 MIF4GD 0.00016 -1.68 
3448 SH3BP2 0.00003 -1.63 3505 LRP8 0.02610 -1.68 
3449 FBXW9 0.00019 -1.63 3506 ABLIM3 0.00038 -1.69 
3450 TMC6 0.00000 -1.63 3507 LOC100288181 0.00000 -1.69 
3451 HDAC4 0.00018 -1.63 3508 SNORA24 0.00953 -1.69 
3452 NAA25 0.00463 -1.64 3509 PXN-AS1 0.02838 -1.69 
3453 COASY 0.00000 -1.64 3510 CAMKMT 0.00086 -1.69 
3454 DAPK1 0.01066 -1.64 3511 DSC3 0.01399 -1.69 
3455 CAMK2G 0.00000 -1.64 3512 ZFP36 0.00002 -1.69 
3456 PVRL1 0.01481 -1.64 3513 RALGDS 0.00002 -1.70 
3457 ADCY6 0.00118 -1.64 3514 ACSF2 0.00021 -1.70 
3458 DNM2 0.00000 -1.64 3515 TOP2A 0.02859 -1.70 
3459 CBR4 0.00884 -1.64 3516 ADRBK1 0.00001 -1.70 
3460 IARS2 0.00211 -1.64 3517 ATXN10 0.00000 -1.70 
3461 RAB15 0.00006 -1.64 3518 GALM 0.00427 -1.70 
3462 USP24 0.03602 -1.64 3519 TLCD1 0.00206 -1.70 
3463 C21orf59 0.00358 -1.64 3520 NBEAL2 0.04412 -1.70 
3464 PARS2 0.04761 -1.65 3521 MUTYH 0.00106 -1.70 
3465 SCARNA22 0.00247 -1.65 3522 GK5 0.03449 -1.70 
3466 NDUFAF2 0.00017 -1.65 3523 LOC113230 0.04795 -1.70 
3467 MRPL39 0.00004 -1.65 3524 TKFC 0.00017 -1.70 
3468 ATE1 0.00447 -1.65 3525 RNY1 0.00419 -1.71 
3469 SCARNA13 0.00010 -1.65 3526 PLEKHA6 0.00003 -1.71 
3470 CELSR1 0.01012 -1.65 3527 FARP2 0.00005 -1.71 
3471 ADAM15 0.00000 -1.65 3528 TMEM241 0.00000 -1.71 
3472 HDDC3 0.00224 -1.65 3529 RFFL 0.00000 -1.71 
3473 SCARNA6 0.00047 -1.65 3530 PPARG 0.00000 -1.71 
3474 SCARNA2 0.00049 -1.65 3531 OXCT1 0.02872 -1.71 
3475 ADAT2 0.00584 -1.66 3532 MYH14 0.00159 -1.71 
3476 HSBP1L1 0.00000 -1.66 3533 UCA1 0.00000 -1.71 
3477 LRRC1 0.00933 -1.66 3534 TPCN1 0.00000 -1.71 
3478 TXNRD1 0.00198 -1.66 3535 BRI3BP 0.00011 -1.72 
3479 ATP7B 0.00259 -1.66 3536 TMEM141 0.00000 -1.72 
3480 TAOK3 0.00161 -1.66 3537 NMI 0.04951 -1.73 
3481 HEXB 0.00001 -1.66 3538 ACSL3 0.00117 -1.73 
3482 RPUSD3 0.00009 -1.66 3539 MAOA 0.02625 -1.73 
3483 BSCL2 0.00002 -1.66 3540 SLC17A5 0.00125 -1.73 
3484 TIGD2 0.01395 -1.67 3541 FZD5 0.00199 -1.73 
3485 B9D2 0.03499 -1.67 3542 SFXN4 0.00001 -1.73 
3486 VARS 0.01234 -1.67 3543 ETFB 0.00001 -1.73 
3487 ZDHHC23 0.00181 -1.67 3544 HOXA1 0.00010 -1.74 
3488 TMEM99 0.00002 -1.67 3545 NR6A1 0.01041 -1.74 
3489 IQCH 0.00435 -1.67 3546 PHKA1 0.00000 -1.74 
3490 SLC22A18 0.00004 -1.67 3547 PLD1 0.01000 -1.74 
3491 L2HGDH 0.02069 -1.67 3548 PIAS1 0.00206 -1.74 
3492 PIGP 0.00041 -1.67 3549 NDC1 0.00001 -1.74 
3493 RIPK4 0.00000 -1.67 3550 LRP11 0.00887 -1.74 
3494 RPL36A 0.00000 -1.67 3551 SEMA4B 0.00000 -1.74 
3495 MFSD6 0.00006 -1.67 3552 COQ3 0.00000 -1.74 
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3553 NDRG1 0.00890 -1.74 3610 DNAAF3 0.00497 -1.80 
3554 IBTK 0.01112 -1.74 3611 HIST1H2BE 0.00053 -1.80 
3555 CCDC6 0.00019 -1.75 3612 PIM3 0.00012 -1.80 
3556 AIM1 0.00366 -1.75 3613 ARHGAP42 0.04018 -1.80 
3557 YBX3 0.00000 -1.75 3614 ACAT1 0.00235 -1.80 
3558 OIP5 0.00105 -1.75 3615 CHAC2 0.01137 -1.81 
3559 SYPL1 0.01799 -1.75 3616 CCDC106 0.00066 -1.81 
3560 NEK2 0.02386 -1.75 3617 TCAF2 0.00352 -1.81 
3561 ELMSAN1 0.00009 -1.75 3618 HR 0.00049 -1.81 
3562 ECHDC3 0.00000 -1.75 3619 BCKDHB 0.00000 -1.81 
3563 LOC154761 0.00226 -1.75 3620 EGFR 0.00002 -1.81 
3564 AKAP1 0.00000 -1.75 3621 FAM43A 0.03370 -1.81 
3565 KLF9 0.00030 -1.75 3622 SFXN2 0.00002 -1.81 
3566 ATP1B3 0.00000 -1.75 3623 KIAA1804 0.00078 -1.81 
3567 KCTD3 0.01343 -1.75 3624 BLVRA 0.00000 -1.82 
3568 DAG1 0.00346 -1.75 3625 POLD2 0.00000 -1.82 
3569 PTPRS 0.00612 -1.76 3626 RABGGTA 0.00000 -1.82 
3570 OSBPL5 0.00000 -1.76 3627 OSTF1 0.00002 -1.82 
3571 TMEM182 0.01058 -1.76 3628 PPP1R3G 0.01687 -1.82 
3572 APRT 0.00000 -1.76 3629 PIK3R1 0.00102 -1.82 
3573 RETSAT 0.00000 -1.76 3630 CPNE7 0.00000 -1.82 
3574 SYTL1 0.01973 -1.76 3631 TSPAN15 0.00000 -1.82 
3575 NSUN7 0.03244 -1.76 3632 DPH6 0.00013 -1.82 
3576 FRAT2 0.00000 -1.76 3633 NABP1 0.03161 -1.82 
3577 FTH1 0.00000 -1.76 3634 MAP7 0.00005 -1.83 
3578 ZMYND8 0.00000 -1.77 3635 RHPN1 0.00073 -1.83 
3579 DLGAP1-AS1 0.00043 -1.77 3636 CBX7 0.00227 -1.83 
3580 IRAK1BP1 0.01605 -1.77 3637 LAMA5 0.00325 -1.83 
3581 DENND4C 0.04203 -1.77 3638 CHP1 0.00000 -1.83 
3582 RPARP-AS1 0.00717 -1.77 3639 CHKA 0.00000 -1.83 
3583 PLEKHF1 0.00027 -1.77 3640 C3 0.00025 -1.83 
3584 PRSS21 0.00434 -1.77 3641 UBXN8 0.00011 -1.83 
3585 NT5C3A 0.03836 -1.78 3642 IMPDH2 0.00000 -1.83 
3586 RNF141 0.00373 -1.78 3643 HAUS4 0.00000 -1.83 
3587 IPO4 0.00417 -1.78 3644 HIST1H4D 0.00019 -1.83 
3588 PGAP3 0.01057 -1.78 3645 TCEAL1 0.00036 -1.83 
3589 CDC42SE2 0.00038 -1.78 3646 AHNAK 0.00397 -1.84 
3590 SNORA67 0.01817 -1.78 3647 TFRC 0.00002 -1.84 
3591 DHTKD1 0.00000 -1.78 3648 ABCB6 0.00000 -1.84 
3592 FDX1 0.01196 -1.78 3649 SNX2 0.04582 -1.84 
3593 NUSAP1 0.00088 -1.78 3650 SEMA3F 0.00432 -1.84 
3594 OSR2 0.00042 -1.78 3651 WDR34 0.00001 -1.84 
3595 PPT1 0.00000 -1.78 3652 DTWD2 0.00005 -1.84 
3596 TMEM165 0.00000 -1.78 3653 MPZL3 0.00000 -1.84 
3597 CPT2 0.00000 -1.78 3654 HIST1H2BB 0.00505 -1.85 
3598 MTL5 0.00000 -1.79 3655 NMU 0.00002 -1.85 
3599 GNE 0.00089 -1.79 3656 CHMP2B 0.02563 -1.85 
3600 ICK 0.01626 -1.79 3657 HOXA5 0.00028 -1.85 
3601 MAP3K1 0.00051 -1.79 3658 C11orf71 0.00540 -1.85 
3602 ECHDC2 0.01705 -1.79 3659 ACTR3C 0.00980 -1.85 
3603 MYO1B 0.01510 -1.79 3660 FAM83H-AS1 0.00046 -1.85 
3604 CRYZL1 0.00000 -1.79 3661 DTX4 0.00000 -1.85 
3605 MCCC1 0.00005 -1.80 3662 SPA17 0.00002 -1.85 
3606 TTLL12 0.00002 -1.80 3663 ROR1 0.00001 -1.85 
3607 SLC22A5 0.00000 -1.80 3664 CYB5A 0.00000 -1.85 
3608 GPI 0.00001 -1.80 3665 TRAPPC9 0.00000 -1.86 
3609 CRACR2B 0.03747 -1.80 3666 HOXA9 0.00000 -1.86 
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3667 LINC01588 0.00026 -1.86 3724 OMA1 0.00332 -1.91 
3668 PTGR2 0.00184 -1.86 3725 ANXA4 0.00125 -1.92 
3669 CALML4 0.00266 -1.86 3726 SSH3 0.00000 -1.92 
3670 PAG1 0.01381 -1.86 3727 LOC101927811 0.02121 -1.92 
3671 MYO18A 0.00001 -1.86 3728 WDR90 0.00024 -1.92 
3672 SLC25A19 0.00003 -1.86 3729 SH3BP5-AS1 0.00146 -1.92 
3673 FAM86C2P 0.02767 -1.86 3730 MARCH1 0.00000 -1.92 
3674 APEH 0.00000 -1.86 3731 ACYP1 0.01743 -1.92 
3675 NEIL1 0.03239 -1.86 3732 GCLC 0.00191 -1.92 
3676 TRERF1 0.00000 -1.87 3733 C10orf54 0.00000 -1.92 
3677 ELOVL6 0.00608 -1.87 3734 TERC 0.00001 -1.93 
3678 GCHFR 0.00001 -1.87 3735 CBLC 0.00001 -1.93 
3679 LEO1 0.01722 -1.87 3736 ST6GALNAC2 0.01679 -1.93 
3680 UBXN11 0.00062 -1.87 3737 SMPD2 0.00004 -1.93 
3681 ABHD12 0.00001 -1.87 3738 CEACAM1 0.00294 -1.93 
3682 C9orf116 0.00000 -1.87 3739 CRABP2 0.00002 -1.93 
3683 MND1 0.01690 -1.87 3740 SAMD12 0.01401 -1.93 
3684 CA2 0.00000 -1.87 3741 GLUD1 0.00000 -1.93 
3685 ACBD4 0.00592 -1.88 3742 PARD6A 0.00000 -1.93 
3686 E2F8 0.00033 -1.88 3743 ETFDH 0.00013 -1.93 
3687 ARHGEF4 0.00010 -1.88 3744 FAM98C 0.00034 -1.93 
3688 MIER3 0.02783 -1.88 3745 SNORA43 0.00009 -1.93 
3689 BHLHE41 0.00453 -1.88 3746 KLK6 0.01085 -1.93 
3690 SFI1 0.00215 -1.88 3747 GPD2 0.00232 -1.94 
3691 EMP2 0.00000 -1.88 3748 ADAMTSL3 0.00458 -1.94 
3692 SEMA5A 0.03211 -1.88 3749 PPTC7 0.00246 -1.94 
3693 LAMA4 0.00000 -1.88 3750 FER1L4 0.00059 -1.94 
3694 SNORA17 0.01517 -1.88 3751 ZBTB7B 0.00017 -1.94 
3695 ARRB1 0.00000 -1.89 3752 FAM63B 0.01381 -1.94 
3696 SNORA84 0.00060 -1.89 3753 CREG1 0.00021 -1.95 
3697 SDHA 0.00000 -1.89 3754 DHRS11 0.00000 -1.95 
3698 HIBCH 0.04692 -1.89 3755 PPP1R3D 0.00000 -1.95 
3699 NTHL1 0.00000 -1.89 3756 CARS2 0.00000 -1.95 
3700 C15orf62 0.00114 -1.89 3757 MIPEP 0.00000 -1.95 
3701 FAM49A 0.03975 -1.89 3758 CLDN4 0.00000 -1.96 
3702 KAZN 0.01779 -1.89 3759 GATA3 0.00035 -1.96 
3703 SLC52A3 0.00017 -1.89 3760 ACSS2 0.00000 -1.96 
3704 PTPRH 0.00000 -1.89 3761 SYK 0.00000 -1.96 
3705 ECI1 0.00000 -1.89 3762 GPSM2 0.00060 -1.96 
3706 TMEM30B 0.00030 -1.89 3763 CAMK2N1 0.00000 -1.96 
3707 SMCHD1 0.02803 -1.89 3764 NANOS1 0.00007 -1.97 
3708 RNASET2 0.00000 -1.89 3765 LMTK2 0.00000 -1.97 
3709 PLCD1 0.00067 -1.90 3766 ERICH5 0.04034 -1.97 
3710 PSMB10 0.00000 -1.90 3767 SCARNA10 0.00001 -1.97 
3711 HSDL2 0.00001 -1.90 3768 FAM213A 0.00002 -1.97 
3712 ZNF341 0.00028 -1.90 3769 IL17RB 0.00065 -1.97 
3713 GALNT13 0.00190 -1.90 3770 IL15RA 0.00000 -1.97 
3714 WFDC2 0.00000 -1.90 3771 SOX13 0.00000 -1.97 
3715 HCAR2 0.04179 -1.90 3772 PROSER2-AS1 0.00000 -1.97 
3716 BCAT2 0.00001 -1.90 3773 SNORA71D 0.00002 -1.98 
3717 CPD 0.00048 -1.90 3774 MOCOS 0.00001 -1.98 
3718 PTPN13 0.00170 -1.91 3775 ASCL2 0.01032 -1.98 
3719 PLEKHA7 0.00000 -1.91 3776 NOV 0.01626 -1.98 
3720 PROM2 0.00001 -1.91 3777 PPP1R3C 0.00014 -1.98 
3721 MCCC2 0.00001 -1.91 3778 SAPCD2 0.00061 -1.98 
3722 TCTN1 0.00003 -1.91 3779 TSPAN1 0.00000 -1.98 
3723 NUDT16P1 0.00013 -1.91 3780 HS6ST1 0.00000 -1.99 
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3781 RDM1 0.00206 -1.99 3838 ARRDC1 0.00000 -2.07 
3782 SLC35E4 0.00048 -1.99 3839 MARVELD2 0.00003 -2.08 
3783 SLK 0.01402 -1.99 3840 IL18 0.00577 -2.08 
3784 HIST1H2BM 0.01678 -1.99 3841 GGCT 0.00018 -2.08 
3785 PAXIP1-AS1 0.02080 -2.00 3842 OGDHL 0.04495 -2.08 
3786 PLEKHG6 0.00000 -2.00 3843 FOXD2 0.02476 -2.08 
3787 SLC7A5 0.00000 -2.00 3844 TMEM38B 0.00111 -2.08 
3788 PIGN 0.00004 -2.00 3845 CCDC57 0.00001 -2.08 
3789 IDH3A 0.00000 -2.00 3846 COMTD1 0.00020 -2.08 
3790 LOC101927181 0.00781 -2.00 3847 C6orf132 0.00000 -2.09 
3791 ASAH1 0.00008 -2.00 3848 F12 0.00018 -2.09 
3792 LYPD5 0.00002 -2.00 3849 LY6K 0.00000 -2.09 
3793 FAR1 0.00519 -2.00 3850 PDE9A 0.00002 -2.09 
3794 CIPC 0.00013 -2.01 3851 SNORA10 0.00253 -2.09 
3795 COBLL1 0.00650 -2.01 3852 SIAE 0.00015 -2.09 
3796 SUCLG2 0.00050 -2.01 3853 NR3C1 0.00001 -2.10 
3797 UPK3B 0.01175 -2.01 3854 PPA1 0.00253 -2.10 
3798 LOC100505666 0.00432 -2.01 3855 LYRM7 0.00078 -2.10 
3799 MKNK2 0.00001 -2.01 3856 SPEF2 0.02247 -2.10 
3800 SNORA71B 0.01057 -2.01 3857 CRYBG3 0.00446 -2.11 
3801 NAPRT 0.00001 -2.02 3858 ABHD17C 0.00000 -2.11 
3802 PPP1R12B 0.00000 -2.02 3859 EPN3 0.00004 -2.11 
3803 ACY1 0.00001 -2.02 3860 SNORA47 0.01824 -2.11 
3804 RAC3 0.00001 -2.02 3861 PPP2R5A 0.00017 -2.11 
3805 OPLAH 0.00000 -2.02 3862 PKN2 0.00059 -2.11 
3806 EVPL 0.00008 -2.02 3863 TLE2 0.00000 -2.12 
3807 FAM111B 0.00254 -2.02 3864 KLHDC4 0.00000 -2.12 
3808 PARD6B 0.00704 -2.03 3865 LRRC16A 0.00000 -2.12 
3809 ZFYVE28 0.00532 -2.03 3866 TMEM53 0.00004 -2.12 
3810 TMEM106B 0.01878 -2.03 3867 HDHD3 0.00001 -2.12 
3811 RIMS4 0.00030 -2.03 3868 RXRA 0.00000 -2.12 
3812 GALNT7 0.00004 -2.03 3869 MARCH1 0.00451 -2.12 
3813 HINT3 0.02303 -2.03 3870 MIPOL1 0.00002 -2.12 
3814 ZNF488 0.01148 -2.03 3871 ASAP3 0.00000 -2.12 
3815 CASP4 0.00014 -2.03 3872 FAM86B1 0.00239 -2.12 
3816 LOC646762 0.00017 -2.03 3873 SNORA74B 0.00115 -2.13 
3817 MACC1 0.00576 -2.04 3874 BZW2 0.00000 -2.13 
3818 ALDH3A2 0.00001 -2.04 3875 NALCN 0.00000 -2.13 
3819 LINC01550 0.00173 -2.04 3876 PITX1 0.00001 -2.13 
3820 RBP4 0.00000 -2.04 3877 KCNK1 0.00001 -2.13 
3821 BLVRB 0.00000 -2.04 3878 CFAP36 0.00164 -2.13 
3822 LGALS3 0.00000 -2.04 3879 TRIM2 0.03377 -2.14 
3823 MORN1 0.00014 -2.04 3880 CASKIN2 0.00001 -2.14 
3824 ATP2B4 0.00037 -2.04 3881 EGFR-AS1 0.00000 -2.14 
3825 RHOV 0.00028 -2.04 3882 HIST1H1A 0.00083 -2.14 
3826 BANK1 0.00682 -2.04 3883 SNORA44 0.00942 -2.14 
3827 FAM84B 0.00068 -2.05 3884 TOB1 0.00360 -2.15 
3828 STAC 0.00000 -2.05 3885 GMDS 0.00000 -2.15 
3829 DCPS 0.00000 -2.05 3886 IRX2 0.00000 -2.15 
3830 UHRF1BP1 0.00001 -2.06 3887 TESK2 0.00001 -2.15 
3831 TRIML2 0.03072 -2.06 3888 THRIL 0.00000 -2.16 
3832 FGD3 0.00001 -2.06 3889 UNC93B1 0.00000 -2.16 
3833 ACADS 0.00004 -2.06 3890 KLHL2 0.00001 -2.16 
3834 HES5 0.01396 -2.06 3891 RNF149 0.00000 -2.16 
3835 DBP 0.00309 -2.06 3892 MAP3K8 0.00230 -2.16 
3836 LACTB2 0.00007 -2.07 3893 GMPR 0.00000 -2.16 
3837 TMCO6 0.00000 -2.07 3894 PITPNC1 0.00000 -2.16 
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3895 IFI30 0.00000 -2.17 3952 B4GALT4 0.00000 -2.26 
3896 ABCC3 0.00000 -2.17 3953 GRHL3 0.00005 -2.27 
3897 NFIA 0.00006 -2.17 3954 SERINC5 0.00120 -2.27 
3898 SLC45A4 0.00000 -2.17 3955 IQCD 0.00006 -2.27 
3899 PXYLP1 0.00000 -2.17 3956 ZSCAN12P1 0.00262 -2.28 
3900 AGMAT 0.00000 -2.18 3957 ZNRF2 0.00000 -2.28 
3901 ABCB10 0.00014 -2.18 3958 CPEB3 0.00001 -2.28 
3902 ANKRD33B 0.00005 -2.18 3959 TBX6 0.00417 -2.29 
3903 C1GALT1 0.00315 -2.18 3960 RASAL1 0.00000 -2.29 
3904 LYNX1 0.00002 -2.18 3961 AP1AR 0.00928 -2.29 
3905 NMNAT2 0.00956 -2.18 3962 HPCAL1 0.00000 -2.29 
3906 TTC39A 0.00000 -2.18 3963 KCNQ1OT1 0.00461 -2.29 
3907 HADH 0.00000 -2.18 3964 SNORA71A 0.00007 -2.29 
3908 B4GALNT3 0.00191 -2.18 3965 SNORA23 0.00188 -2.29 
3909 UPK3BL 0.00031 -2.18 3966 RHPN2 0.00000 -2.29 
3910 SNORD89 0.02726 -2.19 3967 PLAC8 0.00000 -2.29 
3911 PER2 0.00001 -2.19 3968 TMEM135 0.00091 -2.29 
3912 CNNM4 0.00001 -2.19 3969 DMPK 0.00030 -2.30 
3913 INPP5J 0.00779 -2.19 3970 FAM151A 0.00000 -2.30 
3914 RARG 0.00000 -2.19 3971 EGLN3 0.00000 -2.30 
3915 STOM 0.00001 -2.19 3972 BCL2L10 0.03545 -2.30 
3916 PADI1 0.00114 -2.19 3973 WNT2B 0.00184 -2.30 
3917 SPTSSA 0.01138 -2.19 3974 PCGF5 0.00001 -2.30 
3918 MCMDC2 0.00115 -2.21 3975 PBK 0.00084 -2.31 
3919 LMTK3 0.00000 -2.21 3976 OLMALINC 0.00003 -2.31 
3920 SNORA38 0.00464 -2.21 3977 ACOT11 0.00000 -2.31 
3921 GPR78 0.00063 -2.21 3978 HID1 0.00000 -2.31 
3922 GCSH 0.00026 -2.21 3979 TTC6 0.00416 -2.32 
3923 RNFT2 0.03856 -2.21 3980 KTN1-AS1 0.00058 -2.32 
3924 HSPB11 0.00001 -2.22 3981 LINC00707 0.00001 -2.32 
3925 FAM8A1 0.00410 -2.22 3982 CHN2 0.00013 -2.34 
3926 ADGRV1 0.00018 -2.22 3983 RMND5A 0.00003 -2.34 
3927 LRRC8B 0.00010 -2.22 3984 VGLL1 0.00000 -2.34 
3928 NAALADL2 0.01713 -2.22 3985 ARHGAP26 0.00000 -2.34 
3929 WDR31 0.00080 -2.22 3986 SCARNA16 0.02443 -2.34 
3930 CCNO 0.00378 -2.22 3987 ACADM 0.01009 -2.35 
3931 PDIK1L 0.00005 -2.22 3988 SEMA3B 0.00000 -2.36 
3932 SCARNA9L 0.00006 -2.22 3989 B3GNT7 0.00000 -2.36 
3933 TFAP2C 0.00000 -2.22 3990 POR 0.00000 -2.36 
3934 RARRES3 0.00002 -2.23 3991 SNORA71C 0.00096 -2.37 
3935 SNORA68 0.00042 -2.23 3992 SRGAP3 0.00133 -2.37 
3936 KRT19 0.00000 -2.23 3993 ILDR1 0.00282 -2.37 
3937 TRAFD1 0.00014 -2.24 3994 NUDT8 0.00000 -2.37 
3938 TMEM61 0.03938 -2.24 3995 IFIT2 0.00611 -2.37 
3939 CDC42EP4 0.00000 -2.25 3996 UPK2 0.01491 -2.37 
3940 SULT2B1 0.00000 -2.25 3997 TMEM144 0.00000 -2.37 
3941 DSG3 0.00787 -2.25 3998 EEF2K 0.00000 -2.38 
3942 LOC100294362 0.00006 -2.25 3999 TFPI 0.00003 -2.39 
3943 SNORD3A 0.00078 -2.25 4000 CES2 0.00000 -2.39 
3944 SREBF1 0.00000 -2.25 4001 PADI2 0.00917 -2.39 
3945 RNF144B 0.03785 -2.25 4002 HLA-DMA 0.00532 -2.39 
3946 SYNE2 0.00003 -2.25 4003 PDLIM1 0.00000 -2.40 
3947 STC1 0.01679 -2.25 4004 PDE4D 0.00068 -2.40 
3948 QTRT1 0.00009 -2.26 4005 ARHGDIB 0.00000 -2.40 
3949 NFIB 0.00040 -2.26 4006 SNORA26 0.00045 -2.40 
3950 ATP7A 0.00045 -2.26 4007 SLC29A2 0.00000 -2.40 
3951 ACSL1 0.00000 -2.26 4008 MACROD1 0.00008 -2.40 
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4009 HPSE 0.00000 -2.41 4066 BTG2 0.01781 -2.58 
4010 FAM102A 0.00000 -2.41 4067 FAM102B 0.02333 -2.58 
4011 DPP7 0.00000 -2.41 4068 RHOBTB3 0.00000 -2.59 
4012 HTATIP2 0.00000 -2.41 4069 B3GNT3 0.00000 -2.59 
4013 AVPI1 0.00001 -2.41 4070 KRTCAP3 0.00000 -2.59 
4014 ENPP4 0.00310 -2.42 4071 TCEA3 0.00000 -2.59 
4015 TMEM123 0.01493 -2.42 4072 SEMA3E 0.00003 -2.59 
4016 SKAP2 0.01917 -2.42 4073 LMO7 0.00003 -2.59 
4017 PEPD 0.00000 -2.42 4074 TRAP1 0.00000 -2.59 
4018 SNORA45A 0.00095 -2.42 4075 SLC1A6 0.00000 -2.60 
4019 PRMT3 0.00000 -2.42 4076 PIK3C2B 0.00000 -2.60 
4020 NTN4 0.00011 -2.42 4077 FAM195A 0.00000 -2.61 
4021 SLC16A14 0.00000 -2.43 4078 NPW 0.02834 -2.61 
4022 CPT1A 0.00000 -2.43 4079 LIPE 0.00000 -2.61 
4023 STS 0.00509 -2.43 4080 IFITM2 0.00000 -2.61 
4024 FOXA1 0.00000 -2.45 4081 SNORA64 0.00098 -2.62 
4025 SPON1 0.00401 -2.45 4082 PITPNM3 0.00000 -2.62 
4026 SPTLC3 0.00054 -2.45 4083 ITGB8 0.00028 -2.63 
4027 RHOBTB2 0.00000 -2.45 4084 FRMD4B 0.00139 -2.63 
4028 CDKL1 0.00022 -2.45 4085 LOC101927954 0.00051 -2.64 
4029 LIPH 0.00000 -2.46 4086 DAPK2 0.00018 -2.64 
4030 GRAMD4 0.00000 -2.46 4087 ABCC5 0.00000 -2.64 
4031 ANO1 0.00000 -2.46 4088 FGFBP1 0.00000 -2.65 
4032 PRTG 0.02292 -2.47 4089 RASEF 0.00001 -2.65 
4033 SNORA52 0.01994 -2.47 4090 KIAA0040 0.00002 -2.65 
4034 STARD8 0.00012 -2.47 4091 FOXC1 0.00001 -2.66 
4035 PPP1R9A 0.00672 -2.49 4092 LRRC8D 0.00001 -2.66 
4036 STAT4 0.00272 -2.49 4093 TNIK 0.00000 -2.67 
4037 EHF 0.00004 -2.49 4094 KCNS1 0.00000 -2.67 
4038 NRP2 0.00002 -2.49 4095 MGAT4A 0.00050 -2.67 
4039 MATN2 0.00004 -2.49 4096 MEGF6 0.00087 -2.67 
4040 EML2 0.00000 -2.50 4097 ANKRD22 0.00008 -2.68 
4041 KLHDC9 0.00001 -2.50 4098 ARHGEF3 0.00000 -2.68 
4042 RFESD 0.01286 -2.50 4099 RBM47 0.00000 -2.69 
4043 ERP27 0.00001 -2.50 4100 C5orf38 0.00001 -2.69 
4044 WDR89 0.00006 -2.50 4101 CMTM4 0.00000 -2.70 
4045 HK2 0.00000 -2.51 4102 ID3 0.00000 -2.71 
4046 GEMIN8P4 0.00000 -2.51 4103 WNT3A 0.03229 -2.71 
4047 CEBPD 0.00022 -2.52 4104 TEX15 0.00842 -2.71 
4048 ZNF652 0.00117 -2.52 4105 ATP8B1 0.00007 -2.71 
4049 EXPH5 0.00011 -2.52 4106 APOL6 0.00002 -2.71 
4050 FNBP1 0.00000 -2.52 4107 EAF2 0.00447 -2.71 
4051 KLHL29 0.00000 -2.52 4108 HOOK1 0.00124 -2.72 
4052 RBPMS-AS1 0.01187 -2.53 4109 LLGL2 0.00000 -2.72 
4053 PA2G4P4 0.00429 -2.53 4110 KIZ 0.00012 -2.73 
4054 DCXR 0.00000 -2.54 4111 VAV3 0.00006 -2.73 
4055 AHR 0.00169 -2.54 4112 DNAH11 0.00000 -2.73 
4056 TNFAIP2 0.00000 -2.54 4113 OAF 0.00000 -2.73 
4057 RALGPS2 0.00003 -2.55 4114 RNLS 0.00000 -2.73 
4058 LRP5 0.00000 -2.55 4115 EMP1 0.00000 -2.74 
4059 CEBPA 0.00523 -2.56 4116 SMAD6 0.00000 -2.74 
4060 CHPT1 0.00000 -2.56 4117 SNORA21 0.01380 -2.75 
4061 KIF13B 0.00000 -2.56 4118 CTH 0.02133 -2.76 
4062 PLCD3 0.00000 -2.56 4119 SPATA13 0.00000 -2.77 
4063 TTC22 0.00002 -2.57 4120 SULT1A1 0.00000 -2.77 
4064 PIR 0.00001 -2.57 4121 ERMP1 0.00000 -2.77 
4065 PLIN2 0.00000 -2.58 4122 CLMN 0.00000 -2.78 
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4123 SH3YL1 0.00004 -2.79 4180 PLA2G16 0.00000 -3.03 
4124 GPT 0.01312 -2.79 4181 RAPGEF5 0.00000 -3.03 
4125 CCSER1 0.00001 -2.80 4182 ADORA2B 0.00000 -3.03 
4126 PTGER4 0.00460 -2.80 4183 CSPG4 0.00003 -3.03 
4127 DPYD 0.00000 -2.80 4184 SYNE4 0.00000 -3.04 
4128 LYPD6B 0.00000 -2.81 4185 TMPRSS2 0.00000 -3.04 
4129 REEP6 0.00003 -2.81 4186 CABLES1 0.00000 -3.04 
4130 KIAA1958 0.00000 -2.81 4187 PBX1 0.00000 -3.05 
4131 SHMT1 0.00000 -2.82 4188 ITPR1 0.00002 -3.05 
4132 WNK2 0.00028 -2.82 4189 AP1S3 0.00000 -3.06 
4133 ALDH1A3 0.00000 -2.82 4190 PRRG4 0.00000 -3.06 
4134 QRFPR 0.00447 -2.82 4191 MGST1 0.00000 -3.06 
4135 NUP210 0.00001 -2.83 4192 SCNN1A 0.00000 -3.07 
4136 KAT2B 0.00002 -2.83 4193 LOC100130987 0.00001 -3.08 
4137 FAM46A 0.00000 -2.84 4194 MBOAT1 0.00000 -3.08 
4138 LPIN1 0.00000 -2.84 4195 DLK2 0.00000 -3.09 
4139 DDIT4 0.00000 -2.85 4196 OCLN 0.00000 -3.10 
4140 CASQ2 0.02123 -2.85 4197 TFPI2 0.00000 -3.10 
4141 RHOU 0.00543 -2.86 4198 FTCDNL1 0.02232 -3.10 
4142 A4GALT 0.00000 -2.86 4199 RAB20 0.00000 -3.11 
4143 RAB27B 0.00326 -2.86 4200 RAB11FIP4 0.00000 -3.11 
4144 TMEM52 0.01123 -2.87 4201 MAFB 0.00002 -3.11 
4145 SLC25A45 0.00000 -2.87 4202 NR2F2 0.00000 -3.12 
4146 SH3TC2 0.00000 -2.89 4203 WBSCR27 0.00500 -3.13 
4147 CA9 0.03209 -2.89 4204 SASH1 0.00001 -3.13 
4148 FAM134B 0.00005 -2.89 4205 NR1H3 0.00000 -3.13 
4149 GPD1L 0.00075 -2.89 4206 UGT1A6 0.00000 -3.15 
4150 CFAP43 0.00537 -2.89 4207 C4orf32 0.00143 -3.16 
4151 PRICKLE4 0.00000 -2.90 4208 MAP3K5 0.00000 -3.17 
4152 LOC100506271 0.04977 -2.91 4209 AREG 0.01738 -3.18 
4153 SGPP2 0.01129 -2.91 4210 TNFRSF11A 0.00000 -3.19 
4154 SH3TC1 0.00000 -2.91 4211 ESR1 0.00000 -3.19 
4155 SECTM1 0.00000 -2.91 4212 ABCA5 0.00013 -3.20 
4156 SLC16A7 0.00008 -2.92 4213 LOC100128770 0.03572 -3.21 
4157 CFB 0.00023 -2.92 4214 SMPDL3A 0.00003 -3.26 
4158 ST6GALNAC4 0.00000 -2.92 4215 SNORD14B 0.02578 -3.27 
4159 S100A4 0.00000 -2.92 4216 PTPRO 0.03234 -3.27 
4160 TC2N 0.00025 -2.93 4217 PLA2G10 0.00012 -3.27 
4161 BAG1 0.00000 -2.95 4218 PPL 0.00000 -3.27 
4162 DKFZP586I1420 0.00000 -2.95 4219 S100A9 0.00001 -3.29 
4163 EPB41L4A-AS2 0.00024 -2.95 4220 ISPD 0.00000 -3.30 
4164 PRR15 0.00000 -2.96 4221 CYP3A7 0.00013 -3.31 
4165 PRKCD 0.00000 -2.96 4222 TH 0.00000 -3.32 
4166 LRRC32 0.00691 -2.98 4223 CKMT1A 0.00000 -3.33 
4167 ACER2 0.00090 -2.98 4224 CXADR 0.00000 -3.34 
4168 ANK3 0.00003 -2.98 4225 CHCHD10 0.00000 -3.34 
4169 BIRC3 0.00065 -2.99 4226 NOS1AP 0.00000 -3.34 
4170 KLF5 0.00002 -2.99 4227 PLS1 0.00073 -3.34 
4171 ARNT2 0.00114 -2.99 4228 GAREM 0.00000 -3.38 
4172 TMEM238 0.00000 -2.99 4229 RASSF5 0.00000 -3.38 
4173 FOXQ1 0.00006 -2.99 4230 RGCC 0.00445 -3.40 
4174 HOXC13 0.00000 -3.00 4231 SNCG 0.00000 -3.41 
4175 P4HTM 0.00000 -3.00 4232 CAMK2D 0.00001 -3.43 
4176 TMEM91 0.00000 -3.01 4233 SORL1 0.00000 -3.43 
4177 EPB41L1 0.00000 -3.02 4234 OVOL2 0.00000 -3.44 
4178 PEX11A 0.00000 -3.02 4235 GRAMD1C 0.01933 -3.44 
4179 BTBD3 0.00000 -3.02 4236 OLR1 0.00000 -3.44 
 
 
 
307 
 
 
Rank Gene 
Corrected 
p-value 
FC Rank Gene 
Corrected 
p-value 
FC 
4237 PDCD4 0.00030 -3.45 4294 CD55 0.00003 -3.97 
4238 C6orf165 0.00068 -3.48 4295 GLUL 0.00000 -4.04 
4239 SYT8 0.00002 -3.49 4296 GSTA4 0.00000 -4.04 
4240 PLCXD3 0.00002 -3.49 4297 ABHD11-AS1 0.00000 -4.04 
4241 BSPRY 0.00000 -3.51 4298 MUC20 0.00003 -4.05 
4242 PRSS12 0.00000 -3.52 4299 LOC102723373 0.00347 -4.07 
4243 MYZAP 0.00000 -3.53 4300 COBL 0.00000 -4.07 
4244 EPAS1 0.00000 -3.53 4301 IGSF11 0.00729 -4.09 
4245 RNF223 0.00128 -3.54 4302 IL1RN 0.00000 -4.09 
4246 ANKDD1A 0.00000 -3.54 4303 TGFBR3 0.00001 -4.10 
4247 RHBDL1 0.02801 -3.55 4304 MRPL23-AS1 0.03742 -4.11 
4248 C11orf70 0.00000 -3.55 4305 ARFGEF3 0.00000 -4.11 
4249 SUSD2 0.00016 -3.55 4306 PLLP 0.00000 -4.14 
4250 FAAH 0.00002 -3.55 4307 RARRES2 0.00019 -4.14 
4251 EPS8 0.00000 -3.55 4308 THEM6 0.00000 -4.14 
4252 C5orf66-AS1 0.00354 -3.55 4309 ERBB4 0.00005 -4.15 
4253 MPV17L 0.00000 -3.56 4310 RINL 0.00000 -4.16 
4254 PCDH20 0.01153 -3.57 4311 GRHL1 0.00000 -4.17 
4255 IMPA2 0.00000 -3.57 4312 KLHL30 0.00000 -4.20 
4256 ID1 0.00000 -3.58 4313 PLIN4 0.00003 -4.23 
4257 ABCA12 0.00000 -3.58 4314 MAL2 0.00000 -4.23 
4258 CKMT1B 0.00001 -3.58 4315 ACPP 0.00000 -4.23 
4259 RGS11 0.00000 -3.59 4316 PSG4 0.00045 -4.23 
4260 CASP10 0.00001 -3.61 4317 SLC9A3R1 0.00000 -4.23 
4261 TNNI2 0.00008 -3.62 4318 FREM2 0.00333 -4.23 
4262 SLC9A2 0.00032 -3.62 4319 SULT1A2 0.00000 -4.25 
4263 LRRC4 0.00000 -3.62 4320 FLVCR2 0.00000 -4.25 
4264 CXXC5 0.00001 -3.65 4321 PTGES 0.00000 -4.25 
4265 PHACTR3 0.01293 -3.67 4322 SRD5A3 0.00000 -4.26 
4266 EXOC3L4 0.00826 -3.68 4323 KLK5 0.00000 -4.32 
4267 MAP2K6 0.00006 -3.69 4324 LOC101927934 0.00000 -4.33 
4268 GSR 0.00000 -3.69 4325 ECEL1P2 0.00000 -4.34 
4269 ARHGAP20 0.00001 -3.72 4326 MITF 0.00000 -4.35 
4270 ID4 0.00045 -3.73 4327 PC 0.00000 -4.36 
4271 KIF26A 0.00000 -3.73 4328 PHLPP1 0.00000 -4.37 
4272 CMAHP 0.00000 -3.74 4329 COLCA2 0.00183 -4.38 
4273 FKBP5 0.00000 -3.74 4330 ALDH3B2 0.00009 -4.38 
4274 TNFRSF18 0.00000 -3.76 4331 GAL 0.00000 -4.43 
4275 MYO5C 0.00000 -3.77 4332 FA2H 0.00000 -4.45 
4276 C1orf226 0.00000 -3.77 4333 IL12A 0.00001 -4.45 
4277 NAGA 0.00000 -3.77 4334 PDE8B 0.00001 -4.47 
4278 TMPRSS3 0.00002 -3.78 4335 CLDN3 0.00354 -4.50 
4279 MCF2L 0.00912 -3.79 4336 TLR3 0.00411 -4.52 
4280 PPM1H 0.00000 -3.80 4337 SGPP1 0.00001 -4.53 
4281 TMPRSS13 0.00001 -3.80 4338 FRMD3 0.00000 -4.53 
4282 ZG16B 0.00000 -3.80 4339 ST3GAL4-AS1 0.00000 -4.54 
4283 IL6R 0.00054 -3.83 4340 FAM3B 0.04917 -4.59 
4284 ADRB2 0.00000 -3.83 4341 GRAMD2 0.00000 -4.65 
4285 RGS9BP 0.00103 -3.84 4342 SLC25A25-AS1 0.00000 -4.66 
4286 MXRA5 0.00000 -3.84 4343 SLC27A2 0.00000 -4.67 
4287 NRG4 0.00002 -3.86 4344 ASS1 0.00000 -4.67 
4288 C4orf19 0.00001 -3.88 4345 HS6ST2 0.00000 -4.67 
4289 E2F2 0.00000 -3.88 4346 ST3GAL4 0.00000 -4.69 
4290 AIM1L 0.00000 -3.89 4347 NPNT 0.00000 -4.69 
4291 XK 0.00000 -3.90 4348 TFCP2L1 0.00000 -4.71 
4292 ADAP1 0.00000 -3.93 4349 ALDH3B1 0.00000 -4.72 
4293 SYBU 0.00000 -3.96 4350 TMC5 0.00000 -4.72 
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4351 PPM1L 0.00005 -4.76 4408 BCAS1 0.00004 -6.21 
4352 FOXO6 0.00027 -4.77 4409 HPDL 0.00000 -6.24 
4353 MPZL2 0.00000 -4.77 4410 UNC5B-AS1 0.00001 -6.24 
4354 LINC01133 0.00017 -4.79 4411 FAM174B 0.00000 -6.28 
4355 TCN1 0.04962 -4.79 4412 BEST2 0.01963 -6.29 
4356 TBC1D8 0.00000 -4.80 4413 ADGRE2 0.00000 -6.31 
4357 MAG 0.00000 -4.80 4414 KLK8 0.00000 -6.31 
4358 CREG2 0.00000 -4.81 4415 PTGS1 0.00000 -6.40 
4359 RSPH1 0.01389 -4.82 4416 ACSL5 0.00000 -6.40 
4360 ENPP1 0.00000 -4.82 4417 GPX2 0.03780 -6.42 
4361 TNFSF10 0.00196 -4.84 4418 SCARB1 0.00000 -6.45 
4362 LOC100506834 0.03013 -4.89 4419 ABCB1 0.00102 -6.50 
4363 LIPA 0.00000 -4.89 4420 CD22 0.00001 -6.56 
4364 BCL6 0.00000 -4.89 4421 RAPGEFL1 0.00000 -6.58 
4365 ZNF114 0.00000 -4.92 4422 EPB41L4A 0.00000 -6.58 
4366 LOC101928738 0.03180 -4.94 4423 MB 0.00000 -6.69 
4367 IRX3 0.00000 -4.95 4424 SPOCK2 0.00000 -6.74 
4368 SCEL 0.00000 -4.97 4425 LIMCH1 0.00000 -6.76 
4369 ANXA9 0.00001 -4.98 4426 CDKN1C 0.00003 -6.80 
4370 ALPPL2 0.01005 -4.99 4427 KRT15 0.00000 -6.82 
4371 WDR86-AS1 0.00000 -5.01 4428 ZNF503-AS1 0.00001 -6.83 
4372 SMIM5 0.00000 -5.02 4429 TINCR 0.00000 -6.85 
4373 CFD 0.00000 -5.03 4430 EVA1C 0.00000 -6.91 
4374 LRG1 0.00000 -5.04 4431 HRASLS2 0.00000 -6.94 
4375 EVPLL 0.00047 -5.05 4432 RASL11A 0.00000 -6.96 
4376 KCNQ3 0.00000 -5.06 4433 DHRS9 0.00063 -6.98 
4377 FUT9 0.00026 -5.10 4434 TMPRSS11E 0.00014 -7.07 
4378 MMRN2 0.00000 -5.14 4435 DOCK8 0.00000 -7.10 
4379 ATP8A1 0.00006 -5.15 4436 HPGD 0.02030 -7.18 
4380 CCDC64B 0.00000 -5.20 4437 POU2F3 0.00118 -7.27 
4381 UPK1B 0.00000 -5.26 4438 ELF3 0.00000 -7.35 
4382 SPINK5 0.00005 -5.30 4439 KLK10 0.00000 -7.39 
4383 PNMT 0.00000 -5.30 4440 ANKRD2 0.00000 -7.40 
4384 SIDT1 0.00000 -5.34 4441 KCNK5 0.00000 -7.42 
4385 POU5F1 0.00000 -5.35 4442 FAM65B 0.00000 -7.42 
4386 IKZF2 0.00000 -5.39 4443 DLX3 0.00008 -7.44 
4387 IL20RA 0.00000 -5.41 4444 ADGRF1 0.00000 -7.55 
4388 ANGPT1 0.00015 -5.43 4445 KCNK15 0.00000 -7.56 
4389 RTN4RL1 0.00000 -5.44 4446 ADAMTSL4 0.00000 -7.64 
4390 PSORS1C3 0.00000 -5.45 4447 EDN2 0.00001 -7.71 
4391 SLC16A5 0.00000 -5.46 4448 GATA2 0.00000 -7.72 
4392 S100A14 0.00000 -5.49 4449 LXN 0.00001 -7.79 
4393 PSG1 0.01603 -5.52 4450 TRIM29 0.00000 -7.80 
4394 SPTSSB 0.00004 -5.57 4451 MMP28 0.00000 -7.86 
4395 GATA2-AS1 0.00000 -5.68 4452 CYP26A1 0.00000 -7.97 
4396 SLC6A11 0.00000 -5.73 4453 TJP3 0.00000 -7.97 
4397 FFAR4 0.00901 -5.74 4454 KLK7 0.00000 -8.03 
4398 LOC284344 0.00021 -5.81 4455 MYPN 0.00000 -8.07 
4399 EDAR 0.00000 -5.82 4456 ALDH3A1 0.00000 -8.08 
4400 ID2 0.00000 -5.97 4457 ZBTB16 0.00000 -8.10 
4401 SDPR 0.00000 -5.99 4458 CLIC5 0.00000 -8.22 
4402 CNR1 0.00002 -5.99 4459 CD14 0.00000 -8.26 
4403 C5AR1 0.00006 -5.99 4460 VEPH1 0.00000 -8.26 
4404 SLC29A3 0.00000 -6.00 4461 SP6 0.00000 -8.28 
4405 LRRC26 0.00692 -6.08 4462 LINC01085 0.00063 -8.36 
4406 PTGDS 0.00020 -6.16 4463 GCNT3 0.00599 -8.37 
4407 PIK3C2G 0.00001 -6.17 4464 HSD11B2 0.00000 -8.41 
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4465 PDK4 0.00164 -8.62 4522 TMEM45B 0.00000 -15.42 
4466 CALHM3 0.00000 -8.70 4523 PKDCC 0.00111 -15.70 
4467 ANKRD20A5P 0.01155 -8.90 4524 OSBP2 0.00000 -15.79 
4468 SLC25A21 0.00000 -8.94 4525 ADIRF 0.00000 -15.90 
4469 MUC13 0.01139 -9.01 4526 TMPRSS4 0.00000 -16.00 
4470 BCO1 0.00782 -9.01 4527 VILL 0.00000 -16.12 
4471 ALDH1L1 0.00000 -9.03 4528 PADI4 0.00048 -16.16 
4472 TGM1 0.00000 -9.06 4529 ALOX5 0.00000 -16.27 
4473 EPGN 0.00000 -9.26 4530 NCCRP1 0.00000 -16.44 
4474 TLE6 0.00035 -9.30 4531 SLURP1 0.00000 -16.75 
4475 SCNN1G 0.00000 -9.55 4532 WFDC12 0.02774 -16.87 
4476 PPARGC1B 0.00002 -9.70 4533 KLK11 0.00000 -16.88 
4477 CAPN8 0.00000 -9.86 4534 B3GALT5 0.00015 -17.76 
4478 DSG4 0.00013 -9.94 4535 HRK 0.00000 -17.95 
4479 GRAMD1B 0.00118 -10.08 4536 CYP4X1 0.00000 -18.20 
4480 ABCG2 0.00000 -10.16 4537 CDH23 0.00000 -18.65 
4481 SMOC2 0.00000 -10.28 4538 MUC1 0.00000 -18.69 
4482 S100A5 0.00986 -10.34 4539 PRR15L 0.00000 -18.95 
4483 LY6D 0.00000 -10.42 4540 TRIM31 0.00000 -19.33 
4484 CYP4B1 0.00003 -10.69 4541 SOX21-AS1 0.00000 -20.07 
4485 TSPAN8 0.00000 -10.70 4542 AGR2 0.00000 -20.18 
4486 PROM1 0.02362 -10.77 4543 KCNQ1 0.00000 -21.03 
4487 METTL7A 0.00000 -10.95 4544 PAX9 0.00000 -21.35 
4488 AMN 0.00000 -10.98 4545 WISP2 0.00000 -22.65 
4489 ARHGEF38 0.02655 -10.99 4546 LDLRAD1 0.00914 -23.02 
4490 FOLR1 0.00000 -10.99 4547 SCNN1B 0.00000 -23.07 
4491 S100P 0.00000 -11.13 4548 PI3 0.00001 -24.97 
4492 UPK3A 0.00005 -11.22 4549 BMP3 0.00001 -25.29 
4493 SGSM1 0.00000 -11.35 4550 LCN2 0.00010 -25.65 
4494 SLCO4A1 0.00000 -11.42 4551 SOX21 0.00000 -26.63 
4495 SSTR1 0.00002 -11.67 4552 UNC5B 0.00000 -26.68 
4496 SLCO4A1-AS1 0.00000 -11.70 4553 CLDN8 0.00005 -27.24 
4497 PCSK5 0.00000 -11.82 4554 PPFIBP2 0.00027 -29.16 
4498 MMP7 0.00000 -11.88 4555 PDE3B 0.00061 -29.45 
4499 MGP 0.00011 -11.91 4556 CEACAM5 0.00000 -30.41 
4500 UBXN10 0.00007 -12.06 4557 MSMB 0.02101 -30.90 
4501 LINC01559 0.00000 -12.78 4558 KRT13 0.00000 -32.31 
4502 SCARA5 0.00031 -12.96 4559 MGAM 0.00027 -36.26 
4503 RARRES1 0.00000 -13.08 4560 GKN1 0.00002 -36.78 
4504 TNXB 0.00000 -13.09 4561 C10orf105 0.00120 -37.62 
4505 FBP1 0.00000 -13.22 4562 CDH5 0.00000 -37.64 
4506 GDPD3 0.00000 -13.24 4563 CEACAM6 0.00000 -38.61 
4507 SEMA6D 0.00000 -13.40 4564 CYP4F12 0.00000 -38.72 
4508 AOC1 0.00002 -13.44 4565 PPP1R16B 0.00000 -39.34 
4509 ALPP 0.00000 -13.78 4566 CRISP3 0.00001 -50.88 
4510 EREG 0.00051 -14.02 4567 CYP4F29P 0.02164 -55.30 
4511 H19 0.00000 -14.13 4568 INHBB 0.00000 -57.80 
4512 FXYD3 0.00000 -14.15 4569 SLC12A3 0.00006 -65.71 
4513 PPEF1 0.01523 -14.43 4570 KRT4 0.00000 -89.42 
4514 SYT12 0.00000 -14.54 4571 LYPD2 0.00797 -99.94 
4515 CYP4F3 0.00000 -14.70 4572 RERG 0.00000 -102.87 
4516 LOC729966 0.00000 -14.86 4573 PSCA 0.00000 -103.70 
4517 DEGS2 0.00002 -14.88 4574 GKN2 0.00000 -118.65 
4518 GLB1L2 0.00000 -14.91 4575 C11orf86 0.00000 -120.44 
4519 AQP3 0.00000 -15.18 
4520 LINC00974 0.00001 -15.22 
4521 SLPI 0.00000 -15.24 
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1 BMP2 0.00000 84.71 56 TPM1 0.00000 11.63 
2 DOCK2 0.00002 77.30 57 FRMD6 0.00000 11.48 
3 SPOCK1 0.00000 70.63 58 KIAA1614 0.00000 11.48 
4 C4orf26 0.00000 67.91 59 P4HA3 0.00000 11.40 
5 MYOCD 0.03454 63.42 60 NIPAL4 0.00000 11.21 
6 LPAR5 0.00013 56.57 61 ADAMTS6 0.00000 11.16 
7 COL20A1 0.00000 46.29 62 BCL11A 0.00002 11.07 
8 R3HDML 0.00228 43.91 63 SORCS2 0.00042 10.54 
9 GDF6 0.04188 41.02 64 MPP4 0.00197 10.54 
10 CRLF1 0.00000 38.49 65 PADI2 0.00000 10.53 
11 CCR1 0.00029 37.79 66 TGFBI 0.00000 10.50 
12 ITGA11 0.00003 35.57 67 TAGLN 0.00000 10.48 
13 ROS1 0.00003 31.85 68 GPR87 0.00000 10.45 
14 LBH 0.00000 30.86 69 ADGRF4 0.00000 10.44 
15 COL4A1 0.00015 30.53 70 CPED1 0.02424 10.42 
16 SGCG 0.00644 29.28 71 FAM198B 0.03761 10.20 
17 LOC100507431 0.00417 28.47 72 CASC15 0.00600 10.11 
18 ADGRF2 0.03797 27.75 73 RASGRF2 0.00000 10.05 
19 KLHDC8A 0.00000 27.52 74 DACT1 0.00083 9.81 
20 NRP2 0.00000 27.23 75 LCP1 0.00000 9.64 
21 CHRNA4 0.00009 26.35 76 THBS1 0.00004 9.61 
22 FOXS1 0.00009 24.95 77 NCF2 0.00000 9.56 
23 ADAM19 0.00000 24.73 78 BMF 0.00000 9.55 
24 PLXNA4 0.00040 23.99 79 GRID1 0.00324 9.54 
25 MC5R 0.01355 22.71 80 BAAT 0.00007 9.40 
26 SAP30L-AS1 0.00002 21.75 81 C1orf106 0.00000 9.35 
27 CD300C 0.00002 21.49 82 COL1A1 0.00015 9.07 
28 RASGRP3 0.00001 21.37 83 TP53I3 0.00000 9.06 
29 ALPK2 0.00000 20.88 84 LINC00704 0.00019 8.97 
30 GNA14 0.00002 20.75 85 FLRT2 0.00203 8.91 
31 GALNT10 0.00000 19.22 86 MSC 0.00000 8.61 
32 COL4A2 0.00007 19.00 87 LDLRAD4 0.00143 8.47 
33 GPR183 0.00002 18.76 88 JAM2 0.00000 8.44 
34 PMEPA1 0.00000 18.71 89 LOC79160 0.00167 8.40 
35 RASGRP1 0.00000 18.66 90 FAM26E 0.01653 8.38 
36 NKAIN4 0.00000 17.33 91 ITGAV 0.00000 8.37 
37 IGF2 0.00000 17.06 92 LAMC2 0.00004 8.21 
38 MYO7B 0.01624 17.06 93 CLDN14 0.00000 8.18 
39 NKILA 0.00000 16.48 94 ISM2 0.00000 8.15 
40 SLAMF9 0.00285 15.74 95 ARHGAP31 0.00000 8.05 
41 ACTBL2 0.00564 15.60 96 CCDC80 0.00000 7.79 
42 COL5A1 0.00001 14.98 97 WNT5B 0.00000 7.71 
43 TMEM59L 0.00000 14.54 98 CTGF 0.00004 7.58 
44 CLEC19A 0.00181 14.16 99 LTBP2 0.00001 7.54 
45 ESM1 0.04853 13.99 100 ANXA8L1 0.00002 7.52 
46 SERPINE1 0.00061 13.98 101 GPR132 0.00001 7.51 
47 AMIGO2 0.00000 13.79 102 PPP1R14C 0.00000 7.44 
48 PIK3IP1 0.00000 13.59 103 PCDH1 0.00000 7.39 
49 SEMA5B 0.00348 13.51 104 MSC-AS1 0.00000 7.37 
50 GLIPR1 0.00001 12.99 105 LMCD1 0.00000 7.36 
51 ESAM 0.00000 12.82 106 CYP24A1 0.00000 7.24 
52 LINC01279 0.00170 12.71 107 PKP1 0.00000 7.09 
53 ACKR3 0.00000 12.36 108 HS3ST3B1 0.00082 7.01 
54 NEDD9 0.00000 11.98 109 AQP1 0.00009 6.90 
55 SERPINE2 0.00000 11.65 110 RNF152 0.01339 6.90 
 
 
311 
 
Rank Gene 
Corrected 
p-value 
FC Rank Gene 
Corrected 
p-value 
FC 
111 MBOAT2 0.00000 6.77 168 STK32A 0.00000 4.96 
112 LINC01561 0.01299 6.68 169 SCN2A 0.00001 4.96 
113 SYT11 0.00000 6.61 170 PHLDB1 0.00000 4.94 
114 LINC01537 0.03804 6.48 171 LMO1 0.00035 4.90 
115 AFAP1L2 0.00000 6.40 172 LTBP1 0.00211 4.88 
116 ZCCHC18 0.01586 6.37 173 SMAD7 0.00000 4.87 
117 SYT13 0.00033 6.36 174 DSE 0.00009 4.85 
118 DCBLD1 0.00000 6.33 175 IFFO1 0.00003 4.83 
119 KLF7 0.00000 6.29 176 TFPI2 0.00001 4.83 
120 COL7A1 0.00027 6.27 177 DHRS2 0.00001 4.77 
121 LINC00842 0.00004 6.26 178 TP53INP1 0.00934 4.77 
122 PTPRK 0.00000 6.26 179 TSPAN2 0.00016 4.75 
123 STK38L 0.00003 6.17 180 FSTL1 0.00034 4.74 
124 VASN 0.00000 6.14 181 ADAMTS15 0.00000 4.73 
125 ANPEP 0.00035 6.10 182 LZTS1 0.00000 4.71 
126 LINC00623 0.00000 6.06 183 FGF1 0.00821 4.71 
127 PGM2L1 0.00165 6.05 184 PTHLH 0.00000 4.69 
128 PRUNE2 0.00001 6.01 185 FOXP1 0.00000 4.65 
129 RAI14 0.00005 6.00 186 FBN1 0.01403 4.64 
130 CPNE4 0.02539 5.90 187 ARL15 0.00004 4.62 
131 PIK3AP1 0.00170 5.89 188 C14orf37 0.00025 4.61 
132 PGBD5 0.00015 5.88 189 MEX3B 0.00061 4.53 
133 COL27A1 0.00000 5.80 190 PKIA 0.00006 4.51 
134 NRG1 0.00003 5.77 191 PPAPDC1A 0.00000 4.50 
135 QPCT 0.00026 5.76 192 EVA1A 0.00105 4.49 
136 LAMB1 0.00002 5.76 193 TARSL2 0.00001 4.47 
137 WNT7A 0.00015 5.74 194 MFAP2 0.00000 4.47 
138 LIMS2 0.00006 5.73 195 C18orf25 0.00014 4.46 
139 INPP4B 0.00000 5.66 196 TCEAL1 0.00009 4.45 
140 DNAH7 0.04635 5.65 197 MRC2 0.00001 4.43 
141 ENG 0.00001 5.64 198 XPR1 0.00001 4.42 
142 LOC100128288 0.03848 5.61 199 MATN3 0.00002 4.42 
143 CDKN2B 0.00059 5.57 200 ACTC1 0.00011 4.40 
144 NLRP1 0.00000 5.55 201 BEAN1 0.00000 4.38 
145 FKBP7 0.00043 5.54 202 PRR5L 0.00000 4.37 
146 CACNA1G 0.00000 5.52 203 FHOD3 0.00000 4.37 
147 CHST11 0.00000 5.52 204 SLC35F3 0.00047 4.36 
148 NAV1 0.00080 5.52 205 ITGA2 0.00004 4.36 
149 DOCK10 0.00012 5.51 206 BAMBI 0.00000 4.33 
150 PROC 0.00002 5.49 207 MOB3B 0.00001 4.32 
151 LFNG 0.00000 5.40 208 ANGPTL4 0.00000 4.32 
152 ZNF365 0.00136 5.37 209 CFAP54 0.00002 4.27 
153 SKIL 0.00053 5.31 210 EPHB2 0.00000 4.24 
154 RCAN2 0.00006 5.27 211 IL18BP 0.00165 4.23 
155 SOX4 0.00003 5.23 212 PITX2 0.00013 4.22 
156 LOC729683 0.00073 5.23 213 ZNF697 0.00683 4.22 
157 LRRN2 0.00000 5.18 214 SHC3 0.00526 4.20 
158 MACRH4 0.00050 5.17 215 NR2F1-AS1 0.00017 4.20 
159 FSTL3 0.00000 5.15 216 MVB12B 0.00000 4.20 
160 TNFRSF19 0.00050 5.13 217 NOG 0.00000 4.20 
161 CACHD1 0.00043 5.08 218 PTPRB 0.00482 4.19 
162 HNRNPA1P33 0.00054 5.03 219 TMEM45A 0.00002 4.19 
163 MAML2 0.00310 5.03 220 SNAI2 0.01168 4.16 
164 DNAJC22 0.00069 5.03 221 FERMT2 0.00064 4.15 
165 FBXO32 0.00000 5.02 222 NEURL1B 0.00000 4.15 
166 CORO2B 0.00006 5.00 223 WIPF1 0.00011 4.12 
167 KIAA1549L 0.00056 4.98 224 DPY19L1 0.00001 4.12 
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225 TUBA4A 0.00000 4.11 282 STK33 0.00801 3.61 
226 SGK1 0.00000 4.11 283 BVES 0.04019 3.61 
227 PLS3 0.00812 4.10 284 IL11 0.00123 3.60 
228 HTR1D 0.00000 4.07 285 PLA2R1 0.00745 3.60 
229 FST 0.01065 4.06 286 TMEM2 0.00187 3.58 
230 GALNT16 0.00002 4.05 287 VSTM4 0.00507 3.57 
231 GNG2 0.00228 4.04 288 MYO10 0.00011 3.57 
232 JARID2 0.00000 4.03 289 EFR3B 0.00000 3.57 
233 LIMS1 0.00140 4.03 290 GPRC5B 0.00000 3.57 
234 FZD2 0.00000 4.03 291 GLIPR2 0.00000 3.56 
235 MATK 0.00050 4.02 292 CALD1 0.01101 3.56 
236 MN1 0.00159 3.99 293 WNT5A 0.00029 3.55 
237 LOC643072 0.00009 3.98 294 F2R 0.00001 3.52 
238 DOCK4 0.00000 3.98 295 DPYSL3 0.00000 3.52 
239 GBP1 0.00004 3.96 296 CNTNAP2 0.01026 3.52 
240 MLLT11 0.00000 3.95 297 BST1 0.00004 3.50 
241 LINC01138 0.00000 3.95 298 CDKN1C 0.00000 3.50 
242 KCTD11 0.00000 3.94 299 MME 0.02216 3.48 
243 UNC5CL 0.00005 3.94 300 CLUL1 0.01930 3.48 
244 CADM1 0.00001 3.94 301 PGRMC2 0.00003 3.46 
245 YPEL2 0.00001 3.94 302 HLA-DPA1 0.00022 3.46 
246 EFNA2 0.00000 3.94 303 GOPC 0.00245 3.46 
247 BPGM 0.00000 3.92 304 SLC19A2 0.00051 3.44 
248 SUSD6 0.00000 3.92 305 EDN1 0.00000 3.43 
249 MIR503HG 0.00281 3.90 306 CDK14 0.00006 3.42 
250 ACTG2 0.01424 3.90 307 GPC4 0.02720 3.42 
251 FAM228B 0.00003 3.89 308 RAB3B 0.03706 3.42 
252 DNAJB2 0.00000 3.89 309 ST5 0.00000 3.39 
253 HSD17B6 0.01463 3.88 310 ECM1 0.00000 3.38 
254 IGFBP3 0.01741 3.88 311 MARCKSL1 0.00000 3.38 
255 ZCCHC12 0.00274 3.86 312 FRMD6-AS1 0.00000 3.38 
256 COL4A4 0.00106 3.85 313 TSPAN18 0.00000 3.38 
257 KALRN 0.00096 3.83 314 ABAT 0.00000 3.38 
258 FZD1 0.00001 3.83 315 PFN4 0.00012 3.37 
259 EEPD1 0.00000 3.82 316 FBLIM1 0.00000 3.37 
260 ANOS1 0.00002 3.82 317 ARHGEF40 0.00000 3.36 
261 S1PR3 0.00714 3.81 318 GLI1 0.00474 3.36 
262 NTN1 0.00001 3.81 319 SUSD4 0.00007 3.36 
263 PCDHB15 0.00101 3.81 320 ELK3 0.00214 3.35 
264 LRCH2 0.01425 3.81 321 DYNC1I1 0.03052 3.34 
265 MAMDC2 0.00057 3.79 322 PBX1 0.00253 3.33 
266 MMP14 0.00000 3.79 323 MEX3A 0.02578 3.31 
267 SLC22A3 0.00001 3.78 324 OCIAD2 0.00000 3.31 
268 RAPGEF2 0.00506 3.77 325 NREP 0.00000 3.31 
269 TAPT1 0.00000 3.76 326 ZNF112 0.02019 3.29 
270 TLN2 0.00006 3.76 327 GABRQ 0.00010 3.29 
271 ST8SIA6 0.00359 3.75 328 TMEM92 0.00122 3.27 
272 LINC00869 0.00000 3.74 329 TMEM65 0.00550 3.25 
273 COL4A3 0.00796 3.74 330 RAP2A 0.00421 3.25 
274 LRRC8C 0.00005 3.73 331 SUSD5 0.00006 3.24 
275 PXDN 0.00307 3.73 332 HLX 0.00002 3.24 
276 NPC2 0.00000 3.73 333 RASSF2 0.00002 3.24 
277 TNFAIP8 0.00051 3.70 334 LPCAT2 0.00001 3.24 
278 EML1 0.00000 3.69 335 TGFB1I1 0.00000 3.23 
279 PDGFC 0.00059 3.68 336 APCDD1 0.00043 3.21 
280 KDM7A 0.00259 3.67 337 HBEGF 0.00002 3.21 
281 LRP4 0.00018 3.66 338 BMPR1B 0.03023 3.20 
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339 SEMA7A 0.00000 3.19 396 PLEKHG4B 0.00000 2.96 
340 FAM105A 0.00224 3.19 397 ARHGAP32 0.00026 2.96 
341 C4orf19 0.00008 3.19 398 ADAMTSL3 0.00013 2.96 
342 LINC00941 0.01609 3.18 399 TSPAN12 0.01099 2.94 
343 ARNTL2 0.00004 3.18 400 EPB41L2 0.00206 2.94 
344 RGL1 0.00131 3.18 401 PTPN21 0.00006 2.93 
345 FERMT1 0.00033 3.16 402 ARHGEF18 0.00000 2.92 
346 ZNF185 0.00000 3.16 403 EMB 0.00290 2.92 
347 SERTAD4 0.00000 3.15 404 FNDC3B 0.00001 2.91 
348 C14orf132 0.00009 3.14 405 IGF2BP1 0.01044 2.90 
349 SLC26A2 0.00260 3.14 406 LIPG 0.00241 2.89 
350 MYB 0.03136 3.13 407 PCDHB2 0.00003 2.89 
351 RFTN1 0.00030 3.13 408 SH3PXD2A 0.00015 2.89 
352 PID1 0.00000 3.13 409 ZNF532 0.00015 2.88 
353 NR2F1 0.00604 3.12 410 SMIM3 0.00004 2.87 
354 RNF121 0.00000 3.11 411 PPP1R12A 0.00465 2.87 
355 LOC730101 0.00001 3.11 412 ETS1 0.00090 2.87 
356 BMPR2 0.00026 3.11 413 RECK 0.00014 2.86 
357 CDYL2 0.00101 3.11 414 MRAS 0.00002 2.85 
358 SLC2A10 0.00005 3.11 415 ULK1 0.00000 2.85 
359 PDZD2 0.00085 3.10 416 SLAMF7 0.00005 2.85 
360 FUT8 0.00009 3.08 417 SERPINB5 0.00012 2.84 
361 FAM214B 0.00000 3.08 418 RNF182 0.00155 2.84 
362 PCDHB9 0.04642 3.07 419 PLEK2 0.00000 2.84 
363 P4HA1 0.01728 3.07 420 FAXDC2 0.00000 2.83 
364 BEST3 0.00066 3.07 421 ZNF827 0.00000 2.82 
365 TUFT1 0.00000 3.06 422 RBMS3 0.00046 2.81 
366 LINC00673 0.00000 3.06 423 KRBA2 0.00289 2.80 
367 CEP170 0.00171 3.05 424 MAP7 0.00045 2.80 
368 MAP3K2 0.03094 3.05 425 CCM2L 0.03419 2.79 
369 FNBP1L 0.01295 3.04 426 EFEMP2 0.01569 2.79 
370 SPOCD1 0.00000 3.04 427 SPDL1 0.03838 2.78 
371 PALLD 0.00004 3.03 428 NFASC 0.00123 2.78 
372 TMCC1 0.00001 3.03 429 TSPAN14 0.00000 2.78 
373 OLFM2 0.00000 3.03 430 NEBL 0.00198 2.77 
374 SEMA3C 0.00138 3.02 431 LOC103091866 0.00003 2.76 
375 ATP7A 0.00489 3.02 432 ELL2 0.04939 2.75 
376 KCNH1 0.00000 3.01 433 TGFB3 0.00009 2.74 
377 CD44 0.00001 3.01 434 PEAR1 0.03533 2.74 
378 PDGFA 0.00061 3.01 435 PIK3CD 0.00000 2.73 
379 LRP12 0.00270 3.01 436 TNFRSF25 0.04894 2.73 
380 SERTAD4-AS1 0.00001 3.00 437 BLOC1S2 0.00212 2.72 
381 ACSL4 0.03111 3.00 438 RHOB 0.00001 2.72 
382 PPP3CA 0.00041 3.00 439 PALM2 0.01814 2.71 
383 SYT1 0.00042 2.99 440 CYP26B1 0.00010 2.71 
384 CFH 0.04510 2.99 441 SYCE1L 0.00114 2.71 
385 ATP13A2 0.00000 2.99 442 FAM189A2 0.00458 2.71 
386 LINC01137 0.00000 2.99 443 SGCB 0.00004 2.71 
387 IGF2BP3 0.01190 2.98 444 SORT1 0.00288 2.71 
388 IL17RD 0.01330 2.98 445 FAM168A 0.00006 2.71 
389 PAX6 0.00021 2.98 446 PDIA3P1 0.00002 2.70 
390 CHSY3 0.01427 2.98 447 NXPH3 0.00034 2.70 
391 MYL9 0.00000 2.98 448 MAFA 0.01426 2.70 
392 GLI2 0.00012 2.97 449 ZDHHC17 0.01347 2.70 
393 ATP10D 0.00065 2.97 450 GADD45B 0.00001 2.70 
394 SBK1 0.04527 2.97 451 PRKAB2 0.00029 2.70 
395 PLOD2 0.00064 2.96 452 WWP1 0.01856 2.70 
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453 PLEKHA8P1 0.01444 2.69 510 ARMCX2 0.00003 2.56 
454 ITGB1 0.00438 2.69 511 CPEB2 0.00581 2.56 
455 ZNF260 0.03529 2.69 512 MAP1B 0.02637 2.55 
456 PCDHB13 0.00254 2.67 513 RNF165 0.01702 2.55 
457 HLA-DQB1 0.00602 2.67 514 LUZP1 0.00012 2.55 
458 CBX2 0.00016 2.67 515 CARD11 0.00467 2.55 
459 TPM4 0.00013 2.67 516 BCAT1 0.01322 2.55 
460 GPNMB 0.00010 2.67 517 FAM231D 0.02900 2.55 
461 CTSV 0.00003 2.66 518 CLSTN1 0.00004 2.55 
462 DSC2 0.01842 2.66 519 AKT3 0.01203 2.55 
463 DFNB31 0.00000 2.66 520 RAB30 0.00016 2.55 
464 GPR161 0.00542 2.65 521 ZFP36L1 0.00096 2.55 
465 TSPAN13 0.00055 2.65 522 ACVR1 0.00024 2.54 
466 TRAM1 0.02573 2.65 523 MIR22HG 0.00000 2.54 
467 PLAC1 0.00395 2.65 524 SLC4A7 0.00079 2.54 
468 NDST1 0.00039 2.65 525 SLC16A2 0.00475 2.54 
469 EFR3A 0.00288 2.64 526 GALNT1 0.04169 2.54 
470 PACS1 0.00200 2.64 527 MFSD7 0.00010 2.53 
471 GAS6-AS2 0.00004 2.64 528 FXYD6 0.00083 2.53 
472 LOC728392 0.00583 2.62 529 ABCA1 0.00035 2.53 
473 MOXD1 0.00581 2.61 530 DLC1 0.00438 2.52 
474 CTHRC1 0.00132 2.61 531 P2RY2 0.00013 2.52 
475 LIMA1 0.00391 2.61 532 HIVEP1 0.01008 2.52 
476 F2RL1 0.00000 2.61 533 IL13RA1 0.00440 2.51 
477 TRIB1 0.00049 2.61 534 LGR6 0.00091 2.51 
478 KIAA1211 0.00194 2.61 535 CMTM3 0.00000 2.51 
479 PBX3 0.00002 2.60 536 SIK1 0.00009 2.51 
480 TANC2 0.02026 2.60 537 KIDINS220 0.01440 2.51 
481 PTGES3L 0.02293 2.60 538 TTC3 0.00398 2.51 
482 APLP1 0.00171 2.60 539 UBTD2 0.00066 2.50 
483 AGPAT4 0.00073 2.60 540 MAP3K7CL 0.00022 2.50 
484 ARNTL 0.00001 2.60 541 EXTL2 0.01960 2.50 
485 KDELC1 0.00021 2.60 542 ITGB3 0.00024 2.49 
486 STXBP5 0.00004 2.60 543 MORF4L2 0.00002 2.49 
487 SDC2 0.02157 2.60 544 FRS2 0.04053 2.49 
488 SMURF2 0.00012 2.60 545 PCDHB6 0.00783 2.49 
489 ANO6 0.00035 2.59 546 HSD17B8 0.01602 2.49 
490 APAF1 0.00797 2.59 547 CALU 0.00016 2.48 
491 RBPJ 0.03847 2.59 548 TNRC6C 0.02639 2.48 
492 TRAM2 0.00001 2.59 549 GOLIM4 0.00333 2.48 
493 BMP6 0.00109 2.58 550 SEC24D 0.00349 2.48 
494 TRPS1 0.00866 2.58 551 EFEMP1 0.00143 2.48 
495 SLC45A3 0.00007 2.58 552 APBB2 0.00000 2.48 
496 HTRA3 0.00040 2.58 553 ZC4H2 0.00775 2.48 
497 NKX3-1 0.00018 2.58 554 ZBED2 0.00002 2.47 
498 CSRP2 0.00002 2.58 555 YPEL5 0.00030 2.47 
499 FAM114A1 0.00060 2.57 556 HLA-DRB1 0.00011 2.47 
500 SNAP23 0.00109 2.57 557 PCDHB5 0.00095 2.47 
501 SARAF 0.00214 2.57 558 CD59 0.00000 2.47 
502 MLLT3 0.00089 2.57 559 EDIL3 0.00056 2.46 
503 CTTNBP2NL 0.01569 2.57 560 YIPF5 0.00008 2.46 
504 USP2 0.00013 2.57 561 RBP1 0.00330 2.46 
505 ANKLE2 0.00000 2.56 562 JUNB 0.00000 2.46 
506 TFEB 0.00007 2.56 563 MATN2 0.02941 2.46 
507 VANGL2 0.03451 2.56 564 SOWAHC 0.02071 2.46 
508 BHLHE40 0.00003 2.56 565 HECW2 0.00796 2.45 
509 KIAA1211L 0.01900 2.56 566 PPP1R13L 0.00308 2.45 
 
 
 
315 
 
 
Rank Gene 
Corrected 
p-value 
FC Rank Gene 
Corrected 
p-value 
FC 
567 PLCXD2 0.00009 2.45 624 PRKD3 0.00057 2.34 
568 SUSD1 0.00017 2.45 625 C2CD4C 0.00035 2.34 
569 SWAP70 0.01451 2.45 626 PLAGL1 0.02586 2.34 
570 CACNA1H 0.00071 2.44 627 CDK17 0.00181 2.33 
571 CDKN1A 0.00001 2.44 628 ITGB5 0.00043 2.33 
572 TIPARP 0.00588 2.44 629 KIAA1161 0.00049 2.33 
573 ITPRIPL2 0.01589 2.44 630 SLC2A12 0.00135 2.33 
574 CLTCL1 0.00000 2.44 631 IPW 0.02061 2.33 
575 RNFT1 0.02088 2.44 632 ERAP2 0.00894 2.33 
576 CAPRIN2 0.00266 2.43 633 STT3B 0.02399 2.33 
577 RCAN1 0.00398 2.43 634 PRKAA2 0.03740 2.32 
578 MIR181A2HG 0.02415 2.43 635 PDGFB 0.00103 2.32 
579 ATP1B1 0.00151 2.43 636 PGRMC1 0.00205 2.32 
580 SLC29A1 0.00000 2.43 637 PHTF1 0.00740 2.32 
581 MKL1 0.00000 2.43 638 LOC100507487 0.00243 2.32 
582 CCPG1 0.00626 2.42 639 STARD13 0.00068 2.32 
583 MIR31HG 0.00020 2.42 640 DNAJC3 0.00302 2.32 
584 NRCAM 0.00277 2.42 641 CHRNB1 0.00002 2.32 
585 GPR137C 0.02394 2.41 642 B4GALT1 0.00537 2.32 
586 HSP90B1 0.02699 2.41 643 TAB2 0.00421 2.31 
587 KLHL24 0.01856 2.41 644 CECR2 0.00217 2.31 
588 IFI16 0.02494 2.41 645 FGF11 0.00036 2.31 
589 HHAT 0.00043 2.41 646 AOX1 0.00055 2.31 
590 FNDC3A 0.01635 2.41 647 ADAM9 0.00759 2.31 
591 ST6GAL1 0.00002 2.41 648 ATL1 0.02570 2.31 
592 EIF2AK3 0.01567 2.41 649 HS2ST1 0.03729 2.31 
593 SLC35D1 0.00176 2.41 650 ELF1 0.00026 2.30 
594 FAM101B 0.00235 2.40 651 IL31RA 0.00037 2.30 
595 PLEKHO1 0.00000 2.40 652 CACNG4 0.00000 2.30 
596 ADTRP 0.01074 2.40 653 SH2D4A 0.00000 2.30 
597 TES 0.00053 2.40 654 AREL1 0.00005 2.30 
598 ETS2 0.00048 2.40 655 KCNN4 0.00002 2.30 
599 WWC2 0.00299 2.40 656 ENTPD7 0.00166 2.30 
600 TBC1D19 0.00607 2.39 657 ERICH5 0.01185 2.30 
601 BDH2 0.01107 2.39 658 IGF1R 0.00951 2.29 
602 AHNAK2 0.01819 2.39 659 CAP2 0.00007 2.29 
603 ASPHD2 0.00007 2.39 660 TMEM57 0.00015 2.29 
604 CYTH1 0.00000 2.38 661 UBA6-AS1 0.00003 2.28 
605 EPHA4 0.00711 2.38 662 CCDC74B 0.00077 2.28 
606 SLFN12 0.00373 2.37 663 P4HA2-AS1 0.04429 2.28 
607 FAM177A1 0.00033 2.37 664 KLHL26 0.00624 2.28 
608 EHBP1 0.00068 2.36 665 CGN 0.00323 2.28 
609 P4HA2 0.00066 2.36 666 RAB5A 0.02058 2.28 
610 CCSER2 0.03227 2.36 667 HOXC8 0.02648 2.27 
611 TPD52 0.00443 2.36 668 RBM27 0.04440 2.27 
612 PFKFB3 0.00024 2.36 669 KLHL25 0.00000 2.27 
613 PTK7 0.00004 2.36 670 KCNQ5 0.04276 2.27 
614 LHFP 0.00691 2.36 671 ITGA5 0.00000 2.27 
615 STC1 0.02228 2.35 672 LAMP2 0.00230 2.27 
616 FEZ2 0.02747 2.35 673 FURIN 0.00004 2.26 
617 KIAA0922 0.00142 2.35 674 PADI1 0.00230 2.26 
618 GPX8 0.00003 2.35 675 ERV3-1 0.00006 2.26 
619 TSC22D3 0.00004 2.35 676 MAGT1 0.00478 2.26 
620 WNT3 0.00122 2.35 677 BEND4 0.01835 2.26 
621 CAMSAP2 0.02082 2.35 678 TMEM117 0.00275 2.26 
622 KDM5B 0.00031 2.35 679 CNPY4 0.00002 2.26 
623 PELI1 0.01402 2.35 680 ARFGAP1 0.00000 2.25 
 
 
 
316 
 
 
Rank Gene 
Corrected 
p-value 
FC Rank Gene 
Corrected 
p-value 
FC 
681 CITED4 0.00117 2.25 738 SH3BGRL 0.01027 2.16 
682 ZNF618 0.01376 2.25 739 CHST7 0.00003 2.16 
683 LMO4 0.00342 2.25 740 TNFSF9 0.00000 2.16 
684 LRP11 0.00791 2.24 741 IGFBP4 0.00003 2.16 
685 DOCK9 0.00335 2.24 742 LAMC1 0.02064 2.16 
686 KDELC2 0.00259 2.24 743 ZNF627 0.00155 2.15 
687 TNFAIP8L3 0.00640 2.24 744 MPZL3 0.03492 2.15 
688 GADD45G 0.00002 2.24 745 WBP5 0.00316 2.15 
689 PICALM 0.00054 2.23 746 ZNF570 0.04719 2.15 
690 ZNF853 0.01391 2.23 747 PDLIM7 0.00000 2.15 
691 DMRTA2 0.02313 2.23 748 KIRREL 0.00020 2.14 
692 KIF3C 0.00001 2.23 749 NEXN 0.02497 2.14 
693 PRKACB 0.03055 2.23 750 RTN4 0.00092 2.14 
694 C3orf52 0.00537 2.22 751 INPPL1 0.00102 2.14 
695 PROS1 0.01801 2.22 752 SOCS6 0.02504 2.14 
696 EXT1 0.00038 2.22 753 PBXIP1 0.00142 2.14 
697 MFAP3 0.00673 2.22 754 PLD1 0.00083 2.14 
698 LOXL4 0.00200 2.22 755 C5orf24 0.00211 2.14 
699 KLF10 0.00658 2.22 756 SDCCAG8 0.00082 2.13 
700 BTG1 0.00225 2.21 757 DDX6 0.00718 2.13 
701 FOCAD 0.00000 2.21 758 DAB2 0.00985 2.13 
702 ZNF93 0.02161 2.21 759 SLC16A1 0.01064 2.13 
703 RSPRY1 0.00184 2.21 760 BMPR1A 0.00652 2.12 
704 SHC2 0.00065 2.21 761 TUBA1A 0.00022 2.12 
705 SIPA1L1 0.00266 2.20 762 PXDC1 0.00116 2.12 
706 AFF4 0.04205 2.20 763 GALNT6 0.01060 2.12 
707 KCNQ2 0.00388 2.20 764 ITSN2 0.01712 2.12 
708 SNAI1 0.00060 2.19 765 SCARB2 0.00152 2.12 
709 SPATS2 0.00003 2.19 766 APLF 0.03075 2.11 
710 UBASH3B 0.00010 2.19 767 FUT8-AS1 0.00137 2.11 
711 SLC35F2 0.00020 2.19 768 KIF16B 0.00813 2.11 
712 TMSB4X 0.00000 2.19 769 CCDC50 0.00088 2.11 
713 MT1L 0.00000 2.18 770 TTYH3 0.00010 2.11 
714 SLC22A17 0.00237 2.18 771 ACTR2 0.00891 2.11 
715 VWA1 0.00004 2.18 772 PDIA3 0.01953 2.11 
716 PVRL3 0.00248 2.18 773 GABARAPL1 0.00502 2.11 
717 PLAUR 0.00000 2.18 774 IER3 0.00000 2.11 
718 CGNL1 0.03804 2.18 775 SSR3 0.00460 2.11 
719 PRR15 0.00050 2.18 776 SLC41A2 0.00025 2.10 
720 ITGA1 0.01093 2.18 777 AAMDC 0.00006 2.10 
721 TMEM237 0.01845 2.18 778 PAWR 0.00375 2.10 
722 ULBP1 0.00299 2.17 779 ARHGEF28 0.00340 2.10 
723 JADE3 0.01122 2.17 780 NKD1 0.00330 2.09 
724 WTIP 0.01745 2.17 781 TMCC2 0.00003 2.09 
725 ANO4 0.00864 2.17 782 MFHAS1 0.04354 2.09 
726 YTHDF1 0.00005 2.17 783 OPRL1 0.00931 2.09 
727 VDR 0.00003 2.17 784 ADAM23 0.01802 2.09 
728 PWWP2A 0.00092 2.17 785 KANSL1L 0.00621 2.09 
729 ECE1 0.00067 2.17 786 RNF170 0.01349 2.09 
730 ITPR2 0.04546 2.16 787 HSF2BP 0.00003 2.09 
731 MAML3 0.00364 2.16 788 SLC17A5 0.00545 2.09 
732 KHDRBS3 0.00002 2.16 789 SERINC3 0.00795 2.08 
733 CPT1C 0.00015 2.16 790 CCNJL 0.00002 2.08 
734 TSPYL4 0.00004 2.16 791 PRRC1 0.03556 2.08 
735 TMEM165 0.00000 2.16 792 NRBF2 0.03001 2.08 
736 PEA15 0.00000 2.16 793 C5orf15 0.00036 2.08 
737 CHRNA5 0.00027 2.16 794 EPHB3 0.00018 2.08 
 
 
 
317 
 
 
Rank Gene 
Corrected 
p-value 
FC Rank Gene 
Corrected 
p-value 
FC 
795 ACTN1 0.00002 2.08 852 TCP11L1 0.00001 2.00 
796 SEL1L 0.00552 2.07 853 ZBTB47 0.00002 2.00 
797 DNAJC10 0.01555 2.07 854 FKBP9 0.03660 2.00 
798 MANSC1 0.00821 2.07 855 MMP17 0.00005 2.00 
799 WIPI1 0.00002 2.07 856 DBN1 0.00000 1.99 
800 FAM200B 0.00441 2.07 857 ADAM10 0.04147 1.99 
801 SPSB1 0.00018 2.07 858 ZNRF2P1 0.01312 1.99 
802 AMACR 0.00015 2.07 859 C9orf91 0.00001 1.99 
803 CTNNB1 0.00052 2.06 860 RAB1A 0.01410 1.99 
804 PKIG 0.00002 2.06 861 JAM3 0.00026 1.99 
805 ARL3 0.03695 2.06 862 PHTF2 0.01695 1.99 
806 CPE 0.04987 2.06 863 PLSCR4 0.01014 1.98 
807 STIM2 0.00151 2.06 864 ARMCX3 0.00505 1.98 
808 GLCE 0.03966 2.06 865 FAM171A2 0.00035 1.98 
809 LOC344887 0.00006 2.05 866 ABR 0.00000 1.98 
810 PGBD1 0.01579 2.05 867 IMPAD1 0.04600 1.98 
811 SPIN1 0.00619 2.05 868 GDF11 0.00103 1.98 
812 RAP1B 0.03106 2.05 869 ORAI2 0.00458 1.98 
813 CAMKK1 0.00904 2.05 870 ME1 0.00095 1.98 
814 RBFOX2 0.00332 2.05 871 LRCH1 0.01061 1.98 
815 LINC00294 0.00243 2.04 872 LIMK2 0.00059 1.97 
816 PTPRE 0.00140 2.04 873 DNAH17-AS1 0.03611 1.97 
817 MEF2A 0.04740 2.04 874 CNN3 0.00210 1.97 
818 JAK1 0.03132 2.04 875 ERAP1 0.04828 1.97 
819 LOC541472 0.03679 2.03 876 TMCO1 0.02853 1.97 
820 SEC14L2 0.00297 2.03 877 RAB23 0.04448 1.97 
821 OSBPL1A 0.01181 2.03 878 VCL 0.00485 1.97 
822 ACTR3 0.03040 2.03 879 PPIC 0.00314 1.97 
823 HSD17B12 0.01203 2.03 880 ATP6V1G1 0.02128 1.97 
824 CTXN1 0.00041 2.03 881 SIRPA 0.00253 1.97 
825 ATP6AP2 0.00363 2.03 882 UNC5A 0.00687 1.97 
826 ARID2 0.02821 2.03 883 PCSK7 0.00037 1.97 
827 VLDLR 0.03854 2.02 884 TMSB4Y 0.03990 1.97 
828 LOC284454 0.00406 2.02 885 TBKBP1 0.00115 1.96 
829 RSU1 0.00001 2.02 886 GNAQ 0.02317 1.96 
830 GAS6 0.00007 2.02 887 NXPE3 0.00219 1.96 
831 CCNE1 0.00685 2.02 888 LAPTM4A 0.00241 1.96 
832 CERS6 0.00632 2.02 889 PCDHA6 0.01841 1.96 
833 HSPB8 0.00009 2.02 890 NOTCH2 0.00741 1.96 
834 SGPL1 0.00111 2.02 891 UBXN4 0.00954 1.95 
835 ABI1 0.01963 2.02 892 CARD6 0.00032 1.95 
836 TCF12 0.03606 2.01 893 PALM 0.00053 1.95 
837 POMT2 0.00021 2.01 894 B4GALT4 0.01572 1.95 
838 CHMP4C 0.00709 2.01 895 LRRC49 0.02170 1.95 
839 NOL4L 0.00015 2.01 896 BEND7 0.00058 1.94 
840 HACD1 0.00004 2.01 897 TPST1 0.00001 1.94 
841 TMEM41B 0.01276 2.01 898 LRRC8A 0.00018 1.94 
842 DNAL1 0.02609 2.01 899 MR1 0.00037 1.94 
843 RASA1 0.02085 2.01 900 RWDD2A 0.00111 1.93 
844 DCAF5 0.00001 2.00 901 FAM161B 0.03804 1.93 
845 TAF9B 0.00526 2.00 902 MAP1LC3A 0.00024 1.93 
846 ARPC5 0.00462 2.00 903 PPM1A 0.04035 1.93 
847 CHN1 0.01858 2.00 904 RNASE4 0.01653 1.93 
848 MMP11 0.00512 2.00 905 FHL3 0.00001 1.93 
849 RAP1GDS1 0.00006 2.00 906 TGOLN2 0.02938 1.93 
850 NCOA1 0.01276 2.00 907 IGSF3 0.03779 1.93 
851 NPTN 0.00182 2.00 908 FOXD1 0.04367 1.93 
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909 ARID1B 0.00386 1.92 966 DSC3 0.04310 1.85 
910 NCKAP5L 0.00096 1.92 967 CD70 0.00000 1.85 
911 VPS54 0.01981 1.92 968 ARCN1 0.01956 1.85 
912 SGCE 0.03802 1.92 969 ITSN1 0.00274 1.85 
913 TMEM50B 0.03731 1.92 970 PON2 0.00015 1.85 
914 DIP2B 0.01656 1.91 971 OSTC 0.04346 1.84 
915 BACE1 0.00057 1.91 972 SLC39A7 0.00205 1.84 
916 AFF1 0.01438 1.91 973 LOC100506071 0.00230 1.84 
917 CRTC1 0.00023 1.91 974 MORF4L1 0.00680 1.84 
918 FARP1 0.00010 1.91 975 OLFM1 0.00009 1.84 
919 KLF12 0.02802 1.91 976 MARK1 0.03339 1.84 
920 SLC44A1 0.02902 1.91 977 PLAU 0.00064 1.83 
921 LOC642852 0.02848 1.91 978 EFHC1 0.00198 1.83 
922 HFE 0.00042 1.91 979 ITM2B 0.00004 1.83 
923 ATG12 0.00757 1.90 980 NCOA4 0.00461 1.83 
924 DNAJB6 0.00078 1.90 981 DDX26B 0.03110 1.83 
925 SLC39A13 0.00000 1.90 982 LGMN 0.00048 1.83 
926 SLC22A4 0.00207 1.90 983 SAMD11 0.00075 1.83 
927 ABHD4 0.00011 1.89 984 PAPPA2 0.02941 1.83 
928 JUN 0.02173 1.89 985 MBD5 0.03022 1.83 
929 TM2D3 0.00064 1.89 986 AMOTL1 0.00491 1.83 
930 CCDC93 0.00253 1.88 987 KCNK6 0.01686 1.83 
931 PPFIA1 0.00095 1.88 988 TFDP2 0.01582 1.82 
932 S1PR5 0.00147 1.88 989 ZFC3H1 0.02143 1.82 
933 COL6A2 0.00043 1.88 990 TBC1D1 0.01505 1.82 
934 FBXL3 0.04885 1.88 991 HOMER1 0.01642 1.82 
935 MED13L 0.01526 1.88 992 LINC00648 0.00706 1.82 
936 JADE1 0.01217 1.88 993 ZC3H12A 0.00001 1.81 
937 CLN5 0.00062 1.88 994 LRRC16A 0.00516 1.81 
938 KIF26B 0.03668 1.88 995 EHHADH 0.01442 1.81 
939 PARD6G 0.00450 1.88 996 ATXN1 0.00683 1.81 
940 CTIF 0.00012 1.88 997 PCGF3 0.01452 1.81 
941 CROCC 0.01223 1.88 998 FAM43A 0.01935 1.81 
942 LOC389831 0.02837 1.88 999 MBNL1-AS1 0.04020 1.81 
943 NATD1 0.00014 1.87 1000 YWHAZ 0.04301 1.81 
944 TMEM200B 0.04029 1.87 1001 CDC42SE1 0.00011 1.81 
945 ATRNL1 0.04619 1.87 1002 POFUT2 0.00019 1.81 
946 PCNXL4 0.04932 1.87 1003 TCAF1 0.00980 1.81 
947 ZNF821 0.00063 1.87 1004 RNASEL 0.03264 1.80 
948 STAU2 0.00731 1.87 1005 TAOK3 0.01575 1.80 
949 MAN2A1 0.00795 1.87 1006 ERC1 0.00749 1.80 
950 TMEM132A 0.00093 1.87 1007 PCED1B 0.00130 1.80 
951 APP 0.01461 1.87 1008 RPS6KC1 0.01825 1.80 
952 SPICE1 0.04980 1.87 1009 STX2 0.01322 1.80 
953 HDX 0.00312 1.87 1010 ICAM1 0.01705 1.80 
954 TXNDC15 0.00077 1.86 1011 HSPB1 0.00002 1.80 
955 TRIO 0.00145 1.86 1012 TM7SF3 0.02699 1.79 
956 CD46 0.00799 1.86 1013 SRC 0.00016 1.79 
957 MSL3 0.00344 1.86 1014 PCNX 0.00081 1.79 
958 B3GLCT 0.01755 1.86 1015 BBS9 0.00006 1.79 
959 TMX4 0.01879 1.85 1016 ZFAND5 0.04114 1.79 
960 GRAMD3 0.03010 1.85 1017 NLK 0.00001 1.79 
961 SH3PXD2B 0.02060 1.85 1018 PDLIM3 0.00001 1.79 
962 MT1X 0.00021 1.85 1019 PLSCR3 0.00527 1.79 
963 WDR11 0.01067 1.85 1020 OSBPL10 0.00265 1.78 
964 PHF21A 0.00553 1.85 1021 PSMD2 0.00025 1.78 
965 SP100 0.01456 1.85 1022 SMURF1 0.00153 1.78 
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1023 VMP1 0.01821 1.78 1080 DLG5 0.01201 1.72 
1024 SV2A 0.00318 1.78 1081 DNMBP 0.01132 1.72 
1025 IL11RA 0.01191 1.78 1082 MYO1E 0.02679 1.72 
1026 GALNT2 0.01100 1.78 1083 AVL9 0.00549 1.72 
1027 EVC2 0.00219 1.78 1084 TRAK2 0.01289 1.72 
1028 PNMA1 0.01070 1.78 1085 BCAR3 0.02964 1.72 
1029 RASA3 0.00033 1.78 1086 MAGED1 0.00956 1.72 
1030 HOXB2 0.04536 1.78 1087 SPPL2A 0.03668 1.72 
1031 FGD4 0.01036 1.77 1088 GSN 0.00075 1.72 
1032 PLCG1 0.00037 1.77 1089 KCNMA1 0.00082 1.71 
1033 ZNF561 0.04950 1.77 1090 BBS4 0.00000 1.71 
1034 ABL1 0.00024 1.77 1091 SLC38A9 0.02791 1.71 
1035 ADAMTS7 0.03069 1.77 1092 ABTB2 0.00039 1.71 
1036 CDYL 0.00001 1.77 1093 LMBRD1 0.02935 1.71 
1037 KIAA1841 0.00290 1.77 1094 ELOVL5 0.00457 1.71 
1038 AP5M1 0.03769 1.77 1095 PLXNB1 0.00012 1.71 
1039 MAP1LC3B 0.01791 1.77 1096 HCG18 0.00254 1.71 
1040 DNAJB5 0.00000 1.77 1097 KLHL20 0.00320 1.71 
1041 HDAC7 0.00001 1.77 1098 PRSS23 0.03126 1.70 
1042 SPATS2L 0.02866 1.76 1099 SLC6A8 0.04355 1.70 
1043 SEPT2 0.00914 1.76 1100 FEZ1 0.00024 1.70 
1044 SDC3 0.00210 1.76 1101 SEC31A 0.00195 1.70 
1045 AP3B1 0.02501 1.76 1102 GPR176 0.02187 1.70 
1046 XXYLT1 0.00605 1.76 1103 P3H1 0.02245 1.70 
1047 FAM126B 0.04070 1.76 1104 PRKD1 0.02187 1.70 
1048 MEX3D 0.02735 1.76 1105 ZYX 0.00039 1.70 
1049 ERCC6-PGBD3 0.00918 1.76 1106 SMTN 0.00296 1.70 
1050 LOC101927204 0.03383 1.75 1107 ZNF319 0.00138 1.69 
1051 C9orf3 0.00006 1.75 1108 TCTN2 0.00854 1.69 
1052 CCDC92 0.00237 1.75 1109 MARCH5 0.00352 1.69 
1053 CCDC109B 0.00249 1.75 1110 APH1B 0.00990 1.69 
1054 PTK2 0.00092 1.75 1111 GLIS3 0.00002 1.69 
1055 FBXL5 0.00175 1.75 1112 ORMDL3 0.00033 1.68 
1056 GPC2 0.00897 1.75 1113 CD40 0.00204 1.68 
1057 NDRG4 0.04772 1.74 1114 RALB 0.02418 1.68 
1058 FCHSD2 0.00003 1.74 1115 RAB3GAP2 0.04655 1.68 
1059 ENO3 0.00046 1.74 1116 PARP8 0.01375 1.68 
1060 CAPN5 0.00381 1.74 1117 SUMF1 0.00935 1.68 
1061 TM2D2 0.00042 1.74 1118 S1PR2 0.01706 1.68 
1062 SYNPO 0.00248 1.74 1119 IRAK4 0.01465 1.68 
1063 FOSL2 0.02506 1.74 1120 TRAPPC10 0.02350 1.68 
1064 LAPTM4B 0.01477 1.74 1121 MEIS3 0.00977 1.67 
1065 VOPP1 0.00047 1.74 1122 CAP1 0.00064 1.67 
1066 CADM4 0.03641 1.74 1123 BMP1 0.00493 1.67 
1067 ZSCAN30 0.04695 1.74 1124 TUSC3 0.01948 1.67 
1068 CSGALNACT2 0.01112 1.74 1125 FRMD5 0.01385 1.67 
1069 BTN2A2 0.00513 1.74 1126 AKTIP 0.04109 1.67 
1070 SETD7 0.01327 1.73 1127 DEGS1 0.00054 1.67 
1071 UBE2J1 0.02266 1.73 1128 SERP1 0.03864 1.67 
1072 MESDC2 0.00652 1.73 1129 TINAGL1 0.01032 1.67 
1073 SBDS 0.00946 1.73 1130 FANCF 0.03363 1.66 
1074 CNOT4 0.00079 1.73 1131 TSPAN9 0.02150 1.66 
1075 MTMR3 0.00007 1.73 1132 TCTEX1D2 0.02011 1.66 
1076 PDCD6IP 0.01720 1.73 1133 COG3 0.00688 1.66 
1077 HBP1 0.01562 1.73 1134 FIBCD1 0.00548 1.66 
1078 ENY2 0.00637 1.73 1135 WSB1 0.01302 1.66 
1079 USP54 0.00041 1.73 1136 SMAP1 0.00093 1.66 
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1137 CSNK1G3 0.01876 1.66 1194 MT2A 0.00311 1.58 
1138 DNAH5 0.00541 1.66 1195 HERPUD2 0.02346 1.58 
1139 B3GNT9 0.01431 1.66 1196 PAPSS1 0.01466 1.58 
1140 AZI2 0.02527 1.66 1197 UBE2K 0.02795 1.58 
1141 DSTN 0.00286 1.66 1198 STXBP4 0.00615 1.58 
1142 PEX2 0.04158 1.66 1199 VIM 0.00182 1.58 
1143 SCPEP1 0.02767 1.65 1200 LEPROT 0.04245 1.57 
1144 GOLPH3L 0.02816 1.65 1201 C11orf30 0.02790 1.57 
1145 HLA-DMB 0.03160 1.65 1202 MAPK7 0.00361 1.57 
1146 LTBP4 0.00912 1.65 1203 NGF 0.00065 1.57 
1147 VTI1A 0.00586 1.65 1204 TMEM59 0.00593 1.57 
1148 SSBP3 0.00065 1.65 1205 FAM219B 0.01608 1.56 
1149 MAPKBP1 0.00018 1.65 1206 IRF2BPL 0.04650 1.56 
1150 FMNL3 0.00022 1.65 1207 OCIAD1 0.00642 1.56 
1151 CLDND1 0.02297 1.65 1208 NUTM2B-AS1 0.00541 1.56 
1152 MPZL1 0.00512 1.65 1209 PSD3 0.04071 1.56 
1153 TMED9 0.01710 1.64 1210 DDAH2 0.00143 1.56 
1154 SIK2 0.04044 1.64 1211 BFAR 0.00038 1.55 
1155 ZMYM4 0.01632 1.64 1212 TTC30A 0.00015 1.55 
1156 C7orf73 0.01282 1.64 1213 C15orf57 0.00234 1.55 
1157 DHX32 0.00977 1.64 1214 CALM2 0.01498 1.55 
1158 USP35 0.00043 1.64 1215 SH3KBP1 0.03938 1.55 
1159 PPP3CB 0.00369 1.63 1216 ZDHHC6 0.02076 1.55 
1160 RUFY1 0.01465 1.63 1217 STEAP3 0.00015 1.55 
1161 ATP1B3 0.02918 1.63 1218 ARPC2 0.03536 1.54 
1162 DGCR8 0.00148 1.63 1219 KDELR3 0.00083 1.54 
1163 TMEM50A 0.00316 1.63 1220 TAF7 0.03481 1.54 
1164 BTBD10 0.04671 1.63 1221 PCYT1A 0.00219 1.54 
1165 SLC29A4 0.02121 1.63 1222 LIPA 0.03606 1.54 
1166 SVIL-AS1 0.01353 1.62 1223 UBE2F 0.01997 1.54 
1167 LIMD2 0.00005 1.62 1224 BASP1 0.00507 1.53 
1168 TTC8 0.01102 1.62 1225 LMBR1L 0.03551 1.53 
1169 MLPH 0.00146 1.62 1226 NMB 0.02143 1.53 
1170 FUBP1 0.03377 1.62 1227 CHCHD7 0.00448 1.53 
1171 COCH 0.00807 1.62 1228 PLOD1 0.02671 1.53 
1172 LEPROTL1 0.00658 1.61 1229 TFG 0.01189 1.52 
1173 CTDSP2 0.00589 1.61 1230 CAPZB 0.00008 1.52 
1174 PHACTR4 0.00050 1.61 1231 KCTD10 0.03441 1.52 
1175 MSN 0.00023 1.61 1232 GALNT18 0.03514 1.52 
1176 AFAP1 0.00385 1.61 1233 GNAS 0.00339 1.52 
1177 DFNA5 0.00868 1.61 1234 ZNF706 0.04575 1.52 
1178 FAAP100 0.00000 1.61 1235 ABCC5 0.00552 1.52 
1179 ACO1 0.00742 1.61 1236 EVL 0.00898 1.52 
1180 TBC1D2B 0.02526 1.61 1237 ADORA1 0.01199 1.52 
1181 MAP7D1 0.00017 1.60 1238 MANBA 0.04460 1.51 
1182 SLC25A37 0.00007 1.60 1239 GALNT11 0.00192 1.51 
1183 SERPINH1 0.02243 1.60 1240 WBP1L 0.00238 1.51 
1184 GLT8D1 0.02662 1.60 1241 APPL2 0.02222 1.51 
1185 DGKD 0.00845 1.60 1242 CD151 0.00167 1.50 
1186 MAN1A2 0.00123 1.60 1243 CMIP 0.03898 1.50 
1187 STK24 0.00182 1.60 1244 ADCY6 0.00862 1.50 
1188 SEPT15 0.02952 1.60 1245 ZSWIM6 0.03321 1.49 
1189 CTNNA1 0.03597 1.59 1246 FHL1 0.03759 1.49 
1190 NDEL1 0.00224 1.59 1247 KLC4 0.00612 1.49 
1191 FLNA 0.04853 1.59 1248 MFSD11 0.01478 1.49 
1192 PTPRA 0.02996 1.59 1249 ALS2 0.03601 1.49 
1193 SPHK1 0.00184 1.58 1250 TNFAIP1 0.01899 1.49 
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1251 NDFIP1 0.01127 1.49 1308 DOK4 0.02404 1.35 
1252 TAF1B 0.02219 1.49 1309 RBM4B 0.02646 1.35 
1253 IFNGR2 0.00072 1.49 1310 FAM32A 0.02772 1.35 
1254 STX12 0.00234 1.49 1311 RBM4 0.03585 1.34 
1255 CCAR1 0.02328 1.48 1312 HOMER3 0.00826 1.33 
1256 RBL2 0.03152 1.48 1313 RARA 0.01170 1.33 
1257 DGKA 0.01121 1.48 1314 SMYD3 0.01228 1.33 
1258 CDC23 0.00507 1.48 1315 ICA1 0.01172 1.32 
1259 CERCAM 0.00354 1.48 1316 LINC00152 0.00839 1.31 
1260 CERK 0.01141 1.48 1317 PDE6D 0.00182 1.31 
1261 PTPN9 0.01323 1.48 1318 TRIM16L 0.03597 1.30 
1262 CTPS1 0.01987 1.48 1319 TSPAN15 0.02433 1.30 
1263 CALCOCO1 0.00114 1.47 1320 SNX1 0.01356 1.27 
1264 PLA2G15 0.00325 1.47 1321 CETN2 0.04094 1.27 
1265 ATG9A 0.03711 1.47 1322 ERCC3 0.03520 1.25 
1266 RNF14 0.00276 1.47 1323 FUNDC2 0.02693 1.22 
1267 AP3M2 0.01588 1.47 1324 REEP5 0.04121 1.20 
1268 IRF7 0.00008 1.47 1325 MRPS15 0.03257 -1.23 
1269 TRAF3 0.03432 1.46 1326 MRPL43 0.01586 -1.23 
1270 PACSIN2 0.00932 1.46 1327 PNKP 0.02443 -1.24 
1271 HLA-E 0.03840 1.46 1328 PPAP2C 0.01119 -1.24 
1272 ATG16L1 0.00631 1.45 1329 DHX30 0.01783 -1.24 
1273 KIFC3 0.00090 1.45 1330 KRTCAP2 0.01602 -1.24 
1274 SYDE1 0.00017 1.45 1331 COX5A 0.00503 -1.24 
1275 LDB1 0.00002 1.45 1332 RPL19 0.02029 -1.25 
1276 SFXN3 0.00272 1.45 1333 SNRPA 0.01751 -1.25 
1277 ATP8B2 0.04536 1.45 1334 C19orf43 0.00755 -1.25 
1278 ZSWIM4 0.01764 1.44 1335 THAP4 0.02035 -1.25 
1279 SNURF 0.01367 1.44 1336 HCFC1R1 0.00566 -1.25 
1280 PAFAH1B1 0.04647 1.44 1337 COMMD4 0.00882 -1.25 
1281 CHPF2 0.03349 1.44 1338 RPL13A 0.00800 -1.26 
1282 TWF2 0.00067 1.44 1339 COX8A 0.01377 -1.26 
1283 TMTC4 0.03144 1.44 1340 SH3GLB2 0.03471 -1.26 
1284 CACFD1 0.00303 1.44 1341 COQ9 0.02244 -1.26 
1285 FSCN1 0.00250 1.44 1342 FADS3 0.02254 -1.26 
1286 WWC3 0.04937 1.44 1343 TRMT2A 0.01970 -1.26 
1287 TMEM44 0.00037 1.43 1344 TOMM22 0.03149 -1.26 
1288 GRN 0.04885 1.43 1345 ELP5 0.03170 -1.26 
1289 PIAS3 0.01023 1.43 1346 SMYD5 0.01925 -1.26 
1290 RFWD2 0.01116 1.43 1347 RANGRF 0.00101 -1.26 
1291 CEP68 0.00035 1.42 1348 RAC3 0.02790 -1.26 
1292 RNF215 0.03179 1.41 1349 FIS1 0.02617 -1.26 
1293 NPLOC4 0.03103 1.41 1350 POR 0.03129 -1.26 
1294 UBTD1 0.00867 1.41 1351 RPS26 0.02686 -1.27 
1295 STX1A 0.03749 1.41 1352 FBL 0.04886 -1.27 
1296 PPP1R21 0.03812 1.40 1353 ATRAID 0.02200 -1.27 
1297 DNASE1L1 0.00424 1.40 1354 POLR2H 0.04792 -1.27 
1298 PPP1R18 0.00056 1.40 1355 EBP 0.03841 -1.27 
1299 MAGED2 0.02023 1.40 1356 PSME2 0.00461 -1.27 
1300 ANXA2R 0.00144 1.39 1357 E4F1 0.01253 -1.27 
1301 ACOX3 0.00134 1.38 1358 ADRM1 0.01500 -1.27 
1302 ABCD4 0.00927 1.37 1359 PSMB3 0.02432 -1.27 
1303 RRAS 0.00744 1.37 1360 RPL32 0.02295 -1.27 
1304 RUSC2 0.00026 1.37 1361 MRPS11 0.01387 -1.28 
1305 RXRB 0.01045 1.36 1362 FIBP 0.01299 -1.28 
1306 LOC220729 0.04024 1.36 1363 CPNE1 0.00827 -1.28 
1307 PROCR 0.02743 1.35 1364 POLR2E 0.02142 -1.28 
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1365 UQCC1 0.01928 -1.28 1422 HIGD2A 0.00011 -1.33 
1366 C11orf98 0.01838 -1.28 1423 NIT1 0.02995 -1.33 
1367 NSMCE1 0.02638 -1.28 1424 RPS10 0.04319 -1.33 
1368 NADSYN1 0.01797 -1.28 1425 SLC37A4 0.00166 -1.33 
1369 RPS13 0.01611 -1.28 1426 TRIM11 0.00728 -1.33 
1370 MTFP1 0.03826 -1.28 1427 NDUFB10 0.03450 -1.33 
1371 TRAF7 0.00643 -1.28 1428 DAGLB 0.01784 -1.33 
1372 NOP56 0.01432 -1.28 1429 FLII 0.01764 -1.33 
1373 DEF8 0.01951 -1.29 1430 NR1H2 0.01100 -1.33 
1374 CPSF4 0.03446 -1.29 1431 COQ4 0.00814 -1.33 
1375 IMPDH2 0.00640 -1.29 1432 ASPSCR1 0.00809 -1.33 
1376 C19orf48 0.00285 -1.29 1433 ZDHHC12 0.00161 -1.33 
1377 ADSL 0.00285 -1.29 1434 PMS2P1 0.04644 -1.33 
1378 MRPL27 0.03886 -1.29 1435 SLC25A39 0.00145 -1.33 
1379 GAPDH 0.01147 -1.29 1436 ARPC1B 0.01220 -1.33 
1380 HAUS5 0.02383 -1.29 1437 ZNRD1 0.00042 -1.33 
1381 EIF2D 0.02435 -1.29 1438 SEPT9 0.00886 -1.33 
1382 RANGAP1 0.04355 -1.29 1439 NCAPH2 0.01489 -1.33 
1383 SURF1 0.04252 -1.29 1440 NTMT1 0.00447 -1.33 
1384 PLEKHJ1 0.01375 -1.29 1441 MYO19 0.00061 -1.34 
1385 ANAPC2 0.01269 -1.30 1442 ECHS1 0.01662 -1.34 
1386 ABHD14B 0.03406 -1.30 1443 FUK 0.03960 -1.34 
1387 PHB2 0.00084 -1.30 1444 BTBD2 0.00534 -1.34 
1388 METTL22 0.02239 -1.30 1445 GLTSCR2 0.04560 -1.34 
1389 UBE2M 0.02058 -1.30 1446 DALRD3 0.01976 -1.34 
1390 GEMIN4 0.04158 -1.30 1447 TACO1 0.00248 -1.34 
1391 OAZ1 0.00613 -1.30 1448 CAMK1 0.01223 -1.34 
1392 PNKD 0.00845 -1.31 1449 CDK4 0.01214 -1.34 
1393 IDH3G 0.02200 -1.31 1450 RPL29 0.03241 -1.34 
1394 TEX264 0.01142 -1.31 1451 SLC25A1 0.00252 -1.34 
1395 UBQLN4 0.02520 -1.31 1452 SHPK 0.00581 -1.34 
1396 EIF3G 0.02782 -1.31 1453 DUS2 0.02829 -1.34 
1397 RPL38 0.01892 -1.31 1454 SSNA1 0.01203 -1.34 
1398 PSMG3 0.00450 -1.31 1455 DHPS 0.00451 -1.34 
1399 ALAS1 0.01127 -1.31 1456 NSMF 0.01128 -1.34 
1400 HINT2 0.01102 -1.31 1457 C9orf142 0.02079 -1.35 
1401 ORAI3 0.00852 -1.31 1458 PCID2 0.00872 -1.35 
1402 MRPL24 0.01009 -1.31 1459 CISD3 0.01301 -1.35 
1403 FDX1L 0.00313 -1.32 1460 VPS52 0.00143 -1.35 
1404 TRIM47 0.02275 -1.32 1461 MGMT 0.04381 -1.35 
1405 FBXW5 0.01081 -1.32 1462 HS1BP3 0.00925 -1.35 
1406 CSNK2B 0.03908 -1.32 1463 CDA 0.00040 -1.35 
1407 PGM1 0.01176 -1.32 1464 KIF22 0.00067 -1.35 
1408 DBNDD1 0.00039 -1.32 1465 RRNAD1 0.00118 -1.35 
1409 TSPO 0.00259 -1.32 1466 RPS6KB2 0.00865 -1.35 
1410 BOLA1 0.01743 -1.32 1467 TUBGCP2 0.00182 -1.35 
1411 NOC2L 0.02508 -1.32 1468 C19orf70 0.04811 -1.35 
1412 EIF3K 0.00256 -1.32 1469 CHMP2A 0.00126 -1.35 
1413 FDPS 0.01237 -1.32 1470 NUBP2 0.02131 -1.35 
1414 MRPL2 0.00007 -1.32 1471 RUSC1 0.00141 -1.35 
1415 RPUSD2 0.01054 -1.32 1472 DESI1 0.03891 -1.35 
1416 ADAM15 0.00065 -1.32 1473 SRM 0.04586 -1.35 
1417 POLD1 0.00673 -1.32 1474 FAU 0.00820 -1.36 
1418 ACADVL 0.02278 -1.32 1475 ALDH16A1 0.03987 -1.36 
1419 EEF2 0.01449 -1.32 1476 PPP2R4 0.00014 -1.36 
1420 LCMT1 0.04241 -1.32 1477 NOP2 0.00757 -1.36 
1421 LTBR 0.04867 -1.32 1478 CDC20 0.02180 -1.36 
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1479 HAGH 0.00029 -1.36 1536 MTG2 0.00015 -1.39 
1480 TEAD4 0.00830 -1.36 1537 ITPA 0.00454 -1.39 
1481 ATP5B 0.00019 -1.36 1538 FANCG 0.00218 -1.39 
1482 OXLD1 0.00161 -1.36 1539 RPS21 0.00088 -1.39 
1483 DANCR 0.04243 -1.36 1540 SARS2 0.00002 -1.39 
1484 ATAD3A 0.00880 -1.36 1541 PAQR7 0.00822 -1.39 
1485 TPRA1 0.01553 -1.36 1542 PGP 0.04258 -1.39 
1486 MED11 0.00660 -1.36 1543 RPSA 0.02348 -1.39 
1487 SLC25A6 0.00059 -1.36 1544 STOML2 0.00022 -1.39 
1488 CEP72 0.00899 -1.36 1545 MRPL10 0.00438 -1.39 
1489 WDR34 0.00241 -1.36 1546 GRWD1 0.00241 -1.39 
1490 CLIC1 0.00079 -1.36 1547 TIMM17B 0.00120 -1.39 
1491 DNAJA3 0.02993 -1.36 1548 AAAS 0.00046 -1.39 
1492 NDOR1 0.00222 -1.36 1549 TMEM141 0.01340 -1.39 
1493 VARS2 0.00390 -1.36 1550 CUL9 0.03677 -1.39 
1494 ZMYND19 0.03685 -1.36 1551 COA4 0.01438 -1.39 
1495 DVL2 0.00206 -1.36 1552 OGDH 0.00004 -1.39 
1496 GPX4 0.00172 -1.36 1553 C20orf27 0.00157 -1.39 
1497 LSM2 0.02333 -1.37 1554 PMM1 0.03821 -1.40 
1498 RPLP0 0.01325 -1.37 1555 TAP1 0.00410 -1.40 
1499 DCAF7 0.00071 -1.37 1556 UBE2S 0.03172 -1.40 
1500 TKFC 0.00963 -1.37 1557 DPM2 0.00247 -1.40 
1501 RRP1 0.04394 -1.37 1558 ECSIT 0.01667 -1.40 
1502 ANXA5 0.00059 -1.37 1559 MVD 0.00141 -1.40 
1503 SUV39H1 0.01142 -1.37 1560 RFC2 0.02307 -1.40 
1504 NR2C2AP 0.01344 -1.37 1561 MRPL41 0.00056 -1.40 
1505 EIF3D 0.03428 -1.37 1562 POLR2L 0.00047 -1.40 
1506 RNH1 0.00126 -1.37 1563 PHGDH 0.02581 -1.40 
1507 RPL7A 0.00402 -1.37 1564 TSPAN4 0.00040 -1.40 
1508 SMPD2 0.02399 -1.37 1565 BCKDHA 0.00021 -1.40 
1509 ACOT8 0.01335 -1.37 1566 POLDIP2 0.00004 -1.40 
1510 AURKAIP1 0.00032 -1.37 1567 QTRT1 0.00701 -1.40 
1511 RPL18 0.00371 -1.37 1568 GPI 0.01291 -1.40 
1512 RAB40C 0.01415 -1.37 1569 OGFOD2 0.00006 -1.40 
1513 SNX17 0.01970 -1.37 1570 POLRMT 0.01626 -1.40 
1514 MRPL17 0.00138 -1.37 1571 IFRD2 0.00038 -1.40 
1515 PPP2R3B 0.00756 -1.37 1572 NINJ1 0.00651 -1.40 
1516 SIVA1 0.00387 -1.37 1573 TRAPPC2L 0.01682 -1.40 
1517 ENO1 0.00112 -1.37 1574 MRPL37 0.00005 -1.40 
1518 MPG 0.00239 -1.37 1575 RECQL4 0.00143 -1.40 
1519 DUSP9 0.01406 -1.37 1576 PLEKHH3 0.00035 -1.40 
1520 GPX1 0.00217 -1.38 1577 ANKRD13D 0.00298 -1.40 
1521 CSTB 0.00019 -1.38 1578 C14orf80 0.00075 -1.40 
1522 GINS2 0.01500 -1.38 1579 RPS9 0.01391 -1.40 
1523 TTC9C 0.04758 -1.38 1580 PHF19 0.01582 -1.41 
1524 GPANK1 0.00082 -1.38 1581 PELP1 0.01321 -1.41 
1525 TBC1D2 0.00277 -1.38 1582 NELFE 0.00196 -1.41 
1526 APOA1BP 0.00355 -1.38 1583 WDR74 0.00057 -1.41 
1527 ARHGAP27 0.01328 -1.38 1584 FLOT2 0.00102 -1.41 
1528 SLC9A3R2 0.02325 -1.38 1585 SNX21 0.00267 -1.41 
1529 PYCR2 0.00003 -1.38 1586 RPL35 0.01852 -1.41 
1530 NUDT22 0.00041 -1.38 1587 TMEM147 0.00064 -1.41 
1531 MRPS26 0.00498 -1.38 1588 NOB1 0.00513 -1.41 
1532 WDR54 0.00046 -1.38 1589 MRPL38 0.00087 -1.41 
1533 PPAN 0.00367 -1.38 1590 IPO4 0.00090 -1.41 
1534 MROH1 0.00344 -1.38 1591 MYBL2 0.00115 -1.41 
1535 NOC4L 0.01824 -1.38 1592 IGFBP2 0.00188 -1.41 
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1593 SNX8 0.00301 -1.42 1650 YDJC 0.00958 -1.46 
1594 FOXRED1 0.00671 -1.42 1651 PSMB10 0.01360 -1.46 
1595 RNASEK 0.00012 -1.42 1652 HAUS7 0.00465 -1.46 
1596 CHCHD5 0.00591 -1.42 1653 COQ6 0.00097 -1.46 
1597 GALM 0.01672 -1.42 1654 CARD10 0.00896 -1.46 
1598 TMCO6 0.03786 -1.42 1655 SHROOM3 0.02183 -1.46 
1599 RTEL1 0.00015 -1.42 1656 SLC50A1 0.00001 -1.46 
1600 CCDC86 0.00780 -1.42 1657 APRT 0.00008 -1.46 
1601 SDHAF1 0.00579 -1.42 1658 SRI 0.00002 -1.46 
1602 CST3 0.00013 -1.42 1659 VRK3 0.00095 -1.46 
1603 MRPL54 0.01171 -1.43 1660 FAH 0.01882 -1.46 
1604 MEPCE 0.00001 -1.43 1661 CALHM2 0.00080 -1.46 
1605 ARL2 0.00505 -1.43 1662 NAPRT 0.00432 -1.46 
1606 ACD 0.00131 -1.43 1663 PMPCA 0.00013 -1.46 
1607 RPS16 0.01155 -1.43 1664 AKR7A2 0.00064 -1.46 
1608 GTPBP6 0.00398 -1.43 1665 TRUB2 0.00013 -1.46 
1609 UQCC3 0.00203 -1.43 1666 IMP3 0.00047 -1.47 
1610 DRAP1 0.00334 -1.43 1667 SELO 0.01264 -1.47 
1611 CYC1 0.00072 -1.43 1668 ARRDC1 0.00002 -1.47 
1612 ATP5G1 0.00056 -1.43 1669 RPL18A 0.00165 -1.47 
1613 C16orf59 0.04394 -1.43 1670 SDCCAG3 0.00393 -1.47 
1614 MMP24 0.00619 -1.43 1671 ADPRHL1 0.02405 -1.47 
1615 C19orf60 0.02894 -1.44 1672 AIMP2 0.00003 -1.47 
1616 MRPS24 0.00237 -1.44 1673 RPS18 0.00625 -1.47 
1617 TIMM50 0.00056 -1.44 1674 DDX41 0.00001 -1.47 
1618 TRMT112 0.00005 -1.44 1675 DDX56 0.00011 -1.47 
1619 HGH1 0.00050 -1.44 1676 IRF3 0.00133 -1.47 
1620 PIM2 0.00484 -1.44 1677 NMRAL1 0.00001 -1.47 
1621 TUBB4B 0.00049 -1.44 1678 WBP2 0.00150 -1.47 
1622 RPS28 0.00011 -1.44 1679 MYBBP1A 0.00336 -1.47 
1623 RPS19 0.00360 -1.44 1680 ZBTB48 0.00083 -1.47 
1624 DBNDD2 0.00486 -1.44 1681 THAP7 0.00027 -1.47 
1625 LSM4 0.00003 -1.44 1682 RBKS 0.00397 -1.47 
1626 SURF2 0.02123 -1.44 1683 ICT1 0.00271 -1.47 
1627 FAM64A 0.00498 -1.44 1684 MAPK11 0.03404 -1.47 
1628 RPS6KA1 0.00082 -1.44 1685 ADCK2 0.00305 -1.47 
1629 MRPL4 0.00197 -1.44 1686 SNU13 0.00000 -1.48 
1630 CIB1 0.00010 -1.44 1687 FANCA 0.00083 -1.48 
1631 C19orf24 0.00328 -1.45 1688 RGS3 0.00008 -1.48 
1632 MAD2L2 0.00009 -1.45 1689 ETFB 0.00225 -1.48 
1633 NDUFV1 0.00006 -1.45 1690 INF2 0.00236 -1.48 
1634 RNF31 0.00077 -1.45 1691 CRAT 0.00001 -1.48 
1635 MRPS12 0.00047 -1.45 1692 EMG1 0.00084 -1.48 
1636 C17orf53 0.00097 -1.45 1693 NSUN5 0.00885 -1.48 
1637 RBP7 0.04121 -1.45 1694 PGAM5 0.00014 -1.48 
1638 KLHDC4 0.00004 -1.45 1695 POLD2 0.00004 -1.48 
1639 PCBD1 0.00110 -1.45 1696 EIF4EBP1 0.00129 -1.48 
1640 SFXN4 0.00091 -1.45 1697 CECR5 0.00152 -1.48 
1641 BCAS4 0.00377 -1.45 1698 RPL13 0.00042 -1.48 
1642 SHMT2 0.00056 -1.45 1699 CDT1 0.00462 -1.48 
1643 C8orf82 0.01210 -1.45 1700 SMARCD2 0.00010 -1.48 
1644 PGD 0.00236 -1.45 1701 AHCY 0.00001 -1.49 
1645 PRMT7 0.00577 -1.45 1702 TST 0.00075 -1.49 
1646 RPL37A 0.00026 -1.45 1703 BOP1 0.00378 -1.49 
1647 RRP9 0.00723 -1.45 1704 INPP5B 0.00007 -1.49 
1648 TUFM 0.00003 -1.46 1705 VARS 0.00034 -1.49 
1649 STUB1 0.00536 -1.46 1706 MCM7 0.00017 -1.49 
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1707 RPL36 0.00100 -1.49 1764 RABGGTA 0.00004 -1.54 
1708 RUVBL2 0.00003 -1.49 1765 MRPS18B 0.00045 -1.54 
1709 ZP3 0.00016 -1.49 1766 CLPP 0.00010 -1.54 
1710 HAX1 0.00011 -1.49 1767 MRPL12 0.00021 -1.54 
1711 ACBD4 0.00311 -1.49 1768 ABHD12 0.00005 -1.54 
1712 LIME1 0.00132 -1.49 1769 THOC6 0.00002 -1.54 
1713 HSD3B7 0.01781 -1.50 1770 PTRH1 0.00253 -1.54 
1714 METTL12 0.02788 -1.50 1771 B3GNTL1 0.03439 -1.54 
1715 CLU 0.00223 -1.50 1772 HECW1 0.03426 -1.54 
1716 PNPLA2 0.00267 -1.50 1773 COASY 0.00014 -1.55 
1717 RPLP2 0.00003 -1.50 1774 TRAF4 0.00189 -1.55 
1718 FANCE 0.00316 -1.50 1775 KCNJ11 0.03942 -1.55 
1719 PHLDB3 0.01705 -1.50 1776 FARSA 0.00001 -1.55 
1720 QPCTL 0.00103 -1.50 1777 KIAA0319 0.00010 -1.55 
1721 ACSF3 0.00132 -1.50 1778 UBE2O 0.00110 -1.55 
1722 NDUFAF3 0.00009 -1.50 1779 RPL23A 0.00000 -1.55 
1723 RNASEH2A 0.00004 -1.50 1780 SPC24 0.00535 -1.55 
1724 GTPBP3 0.00440 -1.50 1781 IMP4 0.00007 -1.56 
1725 CABYR 0.00016 -1.50 1782 DPP7 0.00001 -1.56 
1726 METTL1 0.00021 -1.50 1783 SLC25A22 0.00498 -1.56 
1727 C19orf33 0.00004 -1.50 1784 TMC6 0.01095 -1.56 
1728 MOCOS 0.00419 -1.51 1785 CEBPB 0.00220 -1.56 
1729 FMNL1 0.03285 -1.51 1786 THAP7-AS1 0.00001 -1.56 
1730 IRF5 0.00020 -1.51 1787 ZNHIT2 0.00063 -1.56 
1731 NLE1 0.00863 -1.51 1788 KHK 0.00001 -1.56 
1732 SLC27A3 0.00556 -1.51 1789 FAM83A 0.00016 -1.56 
1733 PKMYT1 0.00619 -1.51 1790 SLC25A11 0.00010 -1.57 
1734 HERC4 0.00321 -1.51 1791 TACC2 0.00145 -1.57 
1735 MDH2 0.00001 -1.51 1792 MIF4GD 0.00025 -1.57 
1736 NOL6 0.00150 -1.51 1793 WDR62 0.00003 -1.57 
1737 SNHG15 0.04632 -1.51 1794 NANS 0.00073 -1.57 
1738 LONP1 0.00346 -1.51 1795 LINC00116 0.00007 -1.57 
1739 TARS2 0.00595 -1.51 1796 RPS5 0.00281 -1.57 
1740 TLCD1 0.00069 -1.51 1797 FBXO2 0.03998 -1.58 
1741 NDUFA7 0.00000 -1.52 1798 TPRN 0.00015 -1.58 
1742 MFSD3 0.00168 -1.52 1799 OSGIN1 0.01070 -1.58 
1743 STRA13 0.00403 -1.52 1800 EXOSC4 0.00283 -1.58 
1744 OVCA2 0.00000 -1.52 1801 ALKBH2 0.00022 -1.58 
1745 FKBP4 0.02259 -1.52 1802 PDXP 0.00000 -1.58 
1746 ACO2 0.00000 -1.52 1803 NECAB3 0.00002 -1.58 
1747 C9orf114 0.00000 -1.52 1804 UBE2C 0.00033 -1.58 
1748 ANXA11 0.00000 -1.52 1805 PSMB8 0.00082 -1.58 
1749 RPL8 0.00019 -1.52 1806 ETHE1 0.00817 -1.58 
1750 NQO2 0.00050 -1.53 1807 CTU2 0.00036 -1.58 
1751 EIF6 0.00012 -1.53 1808 DPM3 0.00007 -1.59 
1752 PLCD3 0.00098 -1.53 1809 MRPS34 0.00001 -1.59 
1753 SCARB1 0.00068 -1.53 1810 E2F1 0.00030 -1.59 
1754 DUS1L 0.00004 -1.53 1811 TK1 0.00071 -1.59 
1755 RPP25 0.03033 -1.53 1812 SAC3D1 0.00001 -1.59 
1756 TNS3 0.00941 -1.53 1813 STK16 0.00000 -1.59 
1757 CCDC51 0.00275 -1.53 1814 HDDC3 0.00073 -1.59 
1758 FAM96B 0.00000 -1.53 1815 SFXN2 0.00093 -1.60 
1759 DHDH 0.02378 -1.53 1816 PDCD2L 0.00053 -1.60 
1760 TBRG4 0.00029 -1.53 1817 F12 0.00046 -1.60 
1761 RIMS4 0.00018 -1.54 1818 SYTL1 0.00497 -1.60 
1762 BRI3 0.00001 -1.54 1819 ZNF593 0.00019 -1.60 
1763 RILP 0.00128 -1.54 1820 CCDC85C 0.01004 -1.60 
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1821 PSME1 0.00014 -1.60 1878 SQRDL 0.00013 -1.68 
1822 CDC45 0.00112 -1.60 1879 HIST2H2AC 0.04016 -1.68 
1823 TTLL12 0.00000 -1.60 1880 RAD23A 0.00000 -1.68 
1824 IFI35 0.01523 -1.61 1881 CRACR2B 0.02851 -1.68 
1825 BIN1 0.00006 -1.61 1882 GSTO2 0.00000 -1.69 
1826 MVP 0.00000 -1.61 1883 ISG15 0.00355 -1.69 
1827 ITPK1 0.00014 -1.61 1884 NME3 0.00006 -1.69 
1828 BAIAP2 0.00005 -1.61 1885 PCYT2 0.00001 -1.69 
1829 NUDT14 0.00003 -1.61 1886 ELFN2 0.00826 -1.70 
1830 HIST2H2AB 0.04245 -1.62 1887 MST1R 0.00012 -1.70 
1831 RPL12 0.00010 -1.62 1888 ARHGEF16 0.00192 -1.70 
1832 NDRG1 0.01397 -1.62 1889 REPIN1 0.00095 -1.70 
1833 DDX28 0.00063 -1.62 1890 MRM1 0.00055 -1.70 
1834 MLX 0.00010 -1.62 1891 DAGLA 0.02320 -1.70 
1835 RPS2 0.00001 -1.62 1892 GHDC 0.02538 -1.71 
1836 ESRRA 0.00028 -1.62 1893 TTC39C 0.00000 -1.71 
1837 MUTYH 0.00069 -1.63 1894 MSH5 0.00000 -1.71 
1838 LMTK3 0.04097 -1.63 1895 PITX1 0.00007 -1.71 
1839 FAM207A 0.00011 -1.63 1896 LAMA5 0.03966 -1.71 
1840 ZNF524 0.00993 -1.63 1897 PAM16 0.00043 -1.72 
1841 GREB1L 0.03545 -1.63 1898 DTX2 0.00002 -1.72 
1842 DCXR 0.00263 -1.63 1899 MCTP2 0.00675 -1.72 
1843 AGFG2 0.01782 -1.63 1900 CHEK2 0.00000 -1.72 
1844 MCM2 0.00003 -1.63 1901 FLOT1 0.00000 -1.73 
1845 JADE2 0.00614 -1.63 1902 A4GALT 0.00083 -1.73 
1846 CCDC85B 0.00136 -1.63 1903 TERC 0.02303 -1.73 
1847 CENPM 0.00011 -1.64 1904 PTP4A3 0.00016 -1.73 
1848 PUSL1 0.00052 -1.64 1905 RPARP-AS1 0.02728 -1.73 
1849 TYSND1 0.00004 -1.64 1906 HIST1H1C 0.00674 -1.74 
1850 XRCC3 0.00002 -1.64 1907 BCL3 0.00089 -1.74 
1851 CLIP2 0.00003 -1.64 1908 ADRBK1 0.00001 -1.74 
1852 APEH 0.00000 -1.64 1909 C9orf89 0.00001 -1.74 
1853 E2F2 0.02004 -1.64 1910 HPSE 0.00111 -1.74 
1854 TSEN34 0.00000 -1.64 1911 ARRB2 0.00000 -1.74 
1855 CYB5A 0.00071 -1.64 1912 IGFLR1 0.01817 -1.74 
1856 BLVRB 0.00051 -1.65 1913 COTL1 0.00001 -1.74 
1857 PDE9A 0.00060 -1.65 1914 STON2 0.00451 -1.74 
1858 ECI1 0.00001 -1.65 1915 ACY1 0.00010 -1.74 
1859 HIST1H4C 0.02845 -1.66 1916 NDUFC2-KCTD14 0.02746 -1.75 
1860 MYO18A 0.00010 -1.66 1917 TNFSF13 0.01660 -1.75 
1861 UCP2 0.00402 -1.66 1918 MRPS2 0.00001 -1.76 
1862 SSH3 0.00001 -1.66 1919 C16orf13 0.00000 -1.76 
1863 MPP1 0.00184 -1.66 1920 PKN1 0.00000 -1.77 
1864 ALDH4A1 0.00035 -1.66 1921 PARD6A 0.00004 -1.77 
1865 POC1A 0.00024 -1.66 1922 CARS2 0.00327 -1.77 
1866 TSEN54 0.00010 -1.67 1923 BIK 0.00000 -1.78 
1867 ST6GALNAC4 0.00000 -1.67 1924 LMNA 0.00000 -1.78 
1868 SLC25A10 0.00010 -1.67 1925 TRAP1 0.00000 -1.78 
1869 PPARGC1B 0.00083 -1.67 1926 PYGB 0.00000 -1.78 
1870 DUS3L 0.00014 -1.67 1927 SBNO2 0.00000 -1.78 
1871 RPP25L 0.00029 -1.67 1928 SH2D5 0.02872 -1.78 
1872 SGSM3 0.00001 -1.67 1929 LDOC1 0.00060 -1.79 
1873 TYMSOS 0.03198 -1.67 1930 ARMC7 0.00055 -1.79 
1874 HMBS 0.00000 -1.67 1931 VPS9D1-AS1 0.02401 -1.79 
1875 DHRS13 0.00579 -1.68 1932 TIGD3 0.01431 -1.79 
1876 MCM5 0.00001 -1.68 1933 LYPD3 0.00003 -1.80 
1877 ATP8B3 0.00004 -1.68 1934 TTC39A 0.00116 -1.80 
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1935 NOP14-AS1 0.00000 -1.80 1992 TRERF1 0.00044 -1.91 
1936 HIST1H1E 0.00376 -1.80 1993 CCDC103 0.00173 -1.91 
1937 MFI2 0.00014 -1.80 1994 LPAR1 0.00000 -1.91 
1938 TNFAIP2 0.00005 -1.81 1995 NOXA1 0.01636 -1.92 
1939 TMEM205 0.00004 -1.81 1996 PRRT3-AS1 0.02224 -1.92 
1940 HMGA1 0.00012 -1.81 1997 RIN1 0.01202 -1.92 
1941 ZNF511 0.00000 -1.81 1998 HIST1H1B 0.00096 -1.92 
1942 HIST1H3A 0.00254 -1.81 1999 HIST1H2AC 0.00187 -1.93 
1943 CYSRT1 0.00165 -1.81 2000 TPCN1 0.00003 -1.93 
1944 FBXO6 0.02392 -1.82 2001 HIST1H2BC 0.00194 -1.93 
1945 PPL 0.00327 -1.82 2002 ACADS 0.00003 -1.93 
1946 SPATA13 0.00004 -1.82 2003 HIST1H2AK 0.00250 -1.94 
1947 APOL6 0.00057 -1.82 2004 ARHGAP8 0.00045 -1.94 
1948 TMTC2 0.00214 -1.82 2005 ALDH3A1 0.01362 -1.94 
1949 SH3RF2 0.00002 -1.83 2006 GMPR 0.00016 -1.94 
1950 HIST1H4B 0.01004 -1.83 2007 STMN3 0.00344 -1.94 
1951 FAHD2B 0.00002 -1.83 2008 TRIM62 0.00024 -1.94 
1952 GCHFR 0.00003 -1.83 2009 HIST1H2AI 0.00111 -1.94 
1953 SCO2 0.00001 -1.84 2010 LRRC61 0.00000 -1.95 
1954 HIST1H2AM 0.00126 -1.84 2011 BCL2L1 0.00000 -1.95 
1955 AIF1L 0.00057 -1.84 2012 RPH3AL 0.00000 -1.96 
1956 MRPS6 0.00001 -1.84 2013 HSBP1L1 0.00023 -1.97 
1957 PARD6B 0.00426 -1.84 2014 ITGB2 0.00720 -1.97 
1958 LOC81691 0.00003 -1.84 2015 WSCD1 0.00005 -1.97 
1959 GAL3ST1 0.01345 -1.84 2016 HIST1H2AB 0.00041 -1.97 
1960 WNT10A 0.00795 -1.85 2017 CASP9 0.00000 -1.97 
1961 RHOF 0.00000 -1.85 2018 MSLN 0.00154 -1.97 
1962 ADAM11 0.00837 -1.85 2019 HIST1H4A 0.00065 -1.97 
1963 GALE 0.00002 -1.85 2020 ABALON 0.00000 -1.97 
1964 DNTTIP1 0.00000 -1.86 2021 PBX4 0.02333 -1.98 
1965 RGL3 0.00020 -1.86 2022 HIST1H2BL 0.00071 -1.98 
1966 HIST1H2AH 0.00071 -1.86 2023 HIST1H2AL 0.00929 -1.98 
1967 DDN 0.02301 -1.86 2024 CLDN7 0.00036 -1.98 
1968 GPRC5A 0.00000 -1.86 2025 PPP1R35 0.00000 -1.98 
1969 RAC2 0.00092 -1.87 2026 PIP5KL1 0.04207 -1.99 
1970 SERPINA1 0.00001 -1.87 2027 PKP3 0.00000 -2.00 
1971 SYT12 0.00171 -1.87 2028 FOXJ1 0.00000 -2.00 
1972 CRB3 0.00001 -1.87 2029 COMTD1 0.00011 -2.00 
1973 FOXN3-AS1 0.00209 -1.87 2030 TBL1X 0.00653 -2.00 
1974 TMEM61 0.04116 -1.87 2031 RITA1 0.00000 -2.00 
1975 HIST1H4D 0.00512 -1.87 2032 HIST1H2AD 0.00720 -2.01 
1976 FAM86DP 0.00556 -1.87 2033 BDH1 0.00007 -2.01 
1977 NXN 0.00000 -1.88 2034 MALL 0.00000 -2.01 
1978 PON3 0.01277 -1.88 2035 BTBD11 0.00007 -2.01 
1979 DENND3 0.00000 -1.88 2036 FLJ37035 0.00349 -2.02 
1980 FAM86EP 0.00449 -1.88 2037 GLS2 0.01743 -2.03 
1981 KRT19 0.00000 -1.89 2038 TNNT1 0.00000 -2.03 
1982 HIST1H3B 0.01141 -1.89 2039 ANKRD39 0.00001 -2.03 
1983 ITGB2-AS1 0.01961 -1.89 2040 PPIF 0.00000 -2.03 
1984 HIST1H4H 0.00050 -1.89 2041 ACSS2 0.00000 -2.04 
1985 IFITM2 0.00050 -1.89 2042 PPFIBP2 0.02615 -2.04 
1986 SEMA4B 0.00002 -1.90 2043 RBM47 0.00193 -2.04 
1987 ECH1 0.00000 -1.90 2044 CRYM 0.01124 -2.04 
1988 C16orf45 0.02399 -1.90 2045 TGM2 0.00000 -2.05 
1989 HIST2H3D 0.02298 -1.90 2046 TMC5 0.00058 -2.05 
1990 TFPI 0.00169 -1.90 2047 BAG1 0.00000 -2.06 
1991 ITPKA 0.00044 -1.91 2048 PSMB9 0.00018 -2.06 
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2049 LOC100288798 0.02995 -2.07 2106 ANKRD33B 0.01142 -2.35 
2050 HIST1H2BD 0.00023 -2.07 2107 PGM5P2 0.00038 -2.35 
2051 C1orf226 0.02919 -2.07 2108 EDN2 0.00624 -2.35 
2052 ARHGEF4 0.00580 -2.07 2109 FOSL1 0.00032 -2.36 
2053 THEM6 0.00000 -2.07 2110 APLN 0.00203 -2.36 
2054 OSBP2 0.00021 -2.07 2111 ARHGEF2 0.00000 -2.36 
2055 LY6E 0.00000 -2.08 2112 HIST3H2A 0.00042 -2.37 
2056 ENTPD6 0.00000 -2.08 2113 TMEM173 0.00000 -2.37 
2057 IL6R 0.03289 -2.08 2114 DEGS2 0.04337 -2.37 
2058 HIST1H2BJ 0.00021 -2.09 2115 TARID 0.00015 -2.38 
2059 CTSH 0.00004 -2.09 2116 PRKCG 0.04621 -2.39 
2060 RASGEF1A 0.00006 -2.09 2117 OTUD3 0.00000 -2.41 
2061 TRABD2A 0.00000 -2.10 2118 TRNP1 0.00001 -2.42 
2062 HIST1H2BO 0.00011 -2.11 2119 SYNE3 0.00737 -2.43 
2063 ISG20 0.00000 -2.11 2120 KRTCAP3 0.02349 -2.43 
2064 PHLPP1 0.00120 -2.11 2121 STAT4 0.00011 -2.43 
2065 IFI30 0.00070 -2.11 2122 HIST1H2AJ 0.02619 -2.43 
2066 HIST1H4L 0.00023 -2.12 2123 NR0B1 0.00321 -2.44 
2067 TMEM238 0.00015 -2.12 2124 GATA2 0.00031 -2.45 
2068 MX1 0.00001 -2.13 2125 HIST1H2BF 0.00012 -2.47 
2069 TMEM215 0.02183 -2.13 2126 MAP3K5 0.00023 -2.47 
2070 TNFRSF18 0.04657 -2.14 2127 S100A6 0.00000 -2.47 
2071 HIST1H3I 0.00194 -2.14 2128 ACSS1 0.04839 -2.49 
2072 TGFBR3 0.00174 -2.14 2129 CDC42EP4 0.00000 -2.49 
2073 ADAP1 0.00301 -2.15 2130 EML2 0.00000 -2.50 
2074 HIST3H2BB 0.00019 -2.15 2131 MAPKAPK3 0.00000 -2.51 
2075 RAB3IL1 0.00016 -2.16 2132 VWA7 0.00000 -2.51 
2076 BSPRY 0.00009 -2.17 2133 S100A3 0.00000 -2.52 
2077 VSTM2L 0.01780 -2.17 2134 PPARG 0.00000 -2.52 
2078 NTHL1 0.00000 -2.18 2135 HAS3 0.00359 -2.52 
2079 LLGL2 0.00000 -2.18 2136 CHCHD10 0.00000 -2.54 
2080 FNBP1 0.00006 -2.18 2137 ANKRD29 0.00008 -2.54 
2081 UNC93B1 0.00000 -2.19 2138 SULT1A1 0.00001 -2.54 
2082 C10orf95 0.01075 -2.19 2139 IRS2 0.00010 -2.55 
2083 GCAT 0.00000 -2.19 2140 HIST1H2BN 0.00006 -2.57 
2084 PRPH 0.00521 -2.20 2141 CPT1A 0.00000 -2.60 
2085 FJX1 0.00302 -2.20 2142 NKD2 0.00001 -2.60 
2086 ERBB3 0.00010 -2.20 2143 HIST1H2AE 0.00002 -2.60 
2087 PAG1 0.00097 -2.20 2144 CPNE7 0.00000 -2.63 
2088 KCNK5 0.00000 -2.21 2145 ANK1 0.00270 -2.63 
2089 MAPK12 0.00000 -2.21 2146 ADAM8 0.00033 -2.64 
2090 FBXO27 0.00000 -2.23 2147 KRT86 0.00001 -2.65 
2091 APOBEC3B 0.00292 -2.23 2148 HOXA3 0.00000 -2.67 
2092 SLC22A18 0.00002 -2.23 2149 PIM3 0.00000 -2.67 
2093 CDC25B 0.00000 -2.23 2150 HIST1H3G 0.00001 -2.67 
2094 P2RX5 0.00000 -2.24 2151 ABHD11 0.00000 -2.68 
2095 HIST2H2BF 0.04241 -2.24 2152 EML2-AS1 0.00014 -2.68 
2096 RAB26 0.02736 -2.24 2153 IGFBP6 0.00000 -2.68 
2097 GRB7 0.00000 -2.25 2154 EVA1C 0.00012 -2.69 
2098 PLA2G16 0.00000 -2.26 2155 PDLIM2 0.00003 -2.69 
2099 LONRF2 0.00046 -2.26 2156 TSPAN1 0.00002 -2.69 
2100 ZCCHC2 0.00001 -2.27 2157 ID1 0.00001 -2.70 
2101 HIST1H3D 0.00023 -2.29 2158 LINC01348 0.00688 -2.70 
2102 SDR16C5 0.00938 -2.31 2159 RAB17 0.00000 -2.71 
2103 HIST1H3H 0.00006 -2.32 2160 ADORA2B 0.00000 -2.72 
2104 TESC 0.00000 -2.33 2161 CPLX1 0.02503 -2.72 
2105 NPAS1 0.00144 -2.33 2162 MBP 0.00052 -2.76 
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2163 HIST1H2BG 0.00009 -2.77 2220 ALDH3B1 0.00000 -3.48 
2164 PDE4B 0.00005 -2.77 2221 CYP4F11 0.00000 -3.50 
2165 HPCAL1 0.00000 -2.79 2222 HIST1H2BI 0.00000 -3.51 
2166 UPP1 0.00013 -2.80 2223 KCNK3 0.00015 -3.52 
2167 AKR1B10 0.00005 -2.81 2224 S100A4 0.00001 -3.59 
2168 PSCA 0.00140 -2.81 2225 TACSTD2 0.00000 -3.60 
2169 HIST1H2BM 0.00002 -2.81 2226 ASS1 0.00000 -3.65 
2170 FAM195A 0.00000 -2.82 2227 MUC1 0.00001 -3.67 
2171 ADGRG2 0.00002 -2.82 2228 MTSS1L 0.00000 -3.68 
2172 IMPA2 0.00000 -2.83 2229 ANKRD2 0.00003 -3.69 
2173 SGPP2 0.00071 -2.83 2230 ZC3H12D 0.01523 -3.70 
2174 PC 0.00000 -2.84 2231 MPV17L 0.00000 -3.77 
2175 S1PR4 0.00091 -2.84 2232 OASL 0.00732 -3.78 
2176 HPDL 0.00000 -2.84 2233 WBSCR27 0.00000 -3.84 
2177 CKB 0.00000 -2.85 2234 MMP28 0.04081 -3.86 
2178 NALCN 0.00000 -2.86 2235 SECTM1 0.00000 -3.92 
2179 NLRP12 0.00002 -2.87 2236 PITPNM3 0.00000 -3.93 
2180 GFAP 0.00006 -2.87 2237 CEMIP 0.04870 -3.98 
2181 SLC16A5 0.00000 -2.88 2238 DUSP5 0.00098 -4.07 
2182 TBC1D8 0.00000 -2.88 2239 CYP2S1 0.00000 -4.09 
2183 GOLT1A 0.00000 -2.89 2240 WFDC21P 0.00116 -4.19 
2184 WFDC2 0.01320 -2.89 2241 LOC100288181 0.00000 -4.20 
2185 MROH6 0.00000 -2.92 2242 CXCL2 0.00000 -4.22 
2186 AVPI1 0.00000 -2.93 2243 SOCS2 0.00019 -4.24 
2187 LINC00346 0.00038 -2.93 2244 CLDN4 0.00000 -4.25 
2188 HMHA1 0.00000 -2.98 2245 TJP3 0.00001 -4.40 
2189 PCSK9 0.00044 -2.99 2246 CXCL8 0.00421 -4.40 
2190 TFAP2C 0.00017 -3.01 2247 RHOV 0.00000 -4.42 
2191 AREG 0.04056 -3.01 2248 DHX58 0.00139 -4.48 
2192 PLIN2 0.00002 -3.02 2249 FA2H 0.00000 -4.58 
2193 HIST1H1D 0.00215 -3.02 2250 SFTA1P 0.00004 -4.60 
2194 HIST1H2BE 0.02192 -3.02 2251 CITED2 0.00001 -4.61 
2195 CABLES1 0.00001 -3.02 2252 LOC100133669 0.00972 -4.68 
2196 RAB38 0.00000 -3.02 2253 GPAT3 0.00000 -4.72 
2197 CCDC64 0.00002 -3.04 2254 LAMA3 0.00000 -4.73 
2198 DBP 0.00091 -3.06 2255 FCMR 0.00000 -4.74 
2199 CCNA1 0.01418 -3.07 2256 TNFRSF1B 0.00001 -4.76 
2200 PLXNA2 0.00001 -3.07 2257 WDR86 0.00058 -4.82 
2201 ELMO3 0.00000 -3.07 2258 POM121L9P 0.00111 -4.87 
2202 RASD1 0.01265 -3.08 2259 WISP2 0.00000 -4.88 
2203 SRPX2 0.04008 -3.10 2260 SLC22A31 0.00000 -4.94 
2204 C1QL1 0.00001 -3.11 2261 GRAMD2 0.00001 -5.01 
2205 UPK3B 0.00017 -3.11 2262 ATOH8 0.00006 -5.10 
2206 TERT 0.00313 -3.12 2263 KCNK15 0.00000 -5.18 
2207 CSF1 0.00000 -3.16 2264 ELF3 0.00000 -5.32 
2208 C10orf54 0.00000 -3.17 2265 SLCO4A1 0.00000 -5.37 
2209 C3 0.00888 -3.17 2266 LY6K 0.00000 -5.37 
2210 TNFRSF11A 0.00479 -3.18 2267 SUSD2 0.00027 -5.42 
2211 CD14 0.00347 -3.20 2268 PTPRH 0.00000 -5.46 
2212 EFHD2 0.00000 -3.20 2269 ADIRF 0.00301 -5.55 
2213 LOC100506860 0.00078 -3.27 2270 CD22 0.00041 -5.59 
2214 TMEM45B 0.00000 -3.29 2271 HHIPL2 0.00000 -5.65 
2215 CLDN3 0.00000 -3.33 2272 SLPI 0.00024 -5.69 
2216 AKR1C1 0.00041 -3.37 2273 PRODH 0.00000 -5.76 
2217 CRABP2 0.00000 -3.43 2274 FBP1 0.00000 -5.90 
2218 PLEKHG4 0.00000 -3.44 2275 RASL11A 0.00000 -6.12 
2219 KRT15 0.00450 -3.44 2276 DNAH11 0.00008 -6.14 
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2277 CBLC 0.00079 -6.18 2291 WBSCR28 0.00015 -9.88 
2278 ACOX2 0.00002 -6.21 2292 S100A9 0.00005 -10.84 
2279 RARRES3 0.00020 -6.57 2293 C11orf86 0.00000 -12.54 
2280 PLLP 0.00000 -6.77 2294 AQP3 0.00000 -13.35 
2281 NAPSA 0.00018 -6.82 2295 SDPR 0.00000 -13.61 
2282 SLCO4A1-AS1 0.00000 -6.88 2296 PTGES 0.00000 -14.21 
2283 ABCG2 0.00000 -7.25 2297 GPX2 0.03012 -14.46 
2284 FGFBP1 0.00000 -7.28 2298 SCARA5 0.00000 -15.11 
2285 CYP4F3 0.00001 -7.33 2299 S100P 0.00015 -20.06 
2286 IL24 0.00466 -7.44 2300 ALPP 0.00000 -22.89 
2287 LCN2 0.00000 -7.98 2301 KRT4 0.00010 -24.70 
2288 MB 0.00007 -8.18 2302 KRT32 0.01098 -27.18 
2289 SCNN1A 0.00000 -9.04 2303 ALPPL2 0.00000 -50.24 
2290 MUC16 0.00029 -9.06 
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1 VIME 0.00000 181.84 56 GELS 0.00000 2.14 
2 FINC 0.00000 19.38 57 ANXA5 0.00322 2.11 
3 BGH3 0.00009 15.05 58 HMCS1 0.00008 2.11 
4 DPYL3 0.00000 11.79 59 TYB10 0.00000 2.10 
5 CALD1 0.00000 7.61 60 ZYX 0.02778 2.09 
6 TSP1 0.00000 5.98 61 GSTO1 0.01402 2.09 
7 TENA 0.00000 5.89 62 ML12A 0.00000 2.08 
8 PALLD 0.00000 5.38 63 TBB5 0.00000 2.05 
9 FLNC 0.00000 5.10 64 MYL6 0.00000 2.05 
10 LAMC2 0.00040 5.00 65 ATOX1 0.00962 2.03 
11 LAMB3 0.02921 4.51 66 ZO1 0.00000 2.02 
12 CACO1 0.00726 4.29 67 STAT1 0.00018 2.02 
13 PDLI7 0.00000 4.09 68 PML 0.00000 1.99 
14 TBB3 0.00000 3.98 69 ACTZ 0.00000 1.98 
15 MYL9 0.00000 3.80 70 AXA82 0.00001 1.98 
16 MT2 0.00000 3.68 71 MRP 0.03424 1.98 
17 TGM2 0.00001 3.68 72 ADHX 0.00011 1.96 
18 LMCD1 0.00000 3.66 73 PLOD1 0.00935 1.96 
19 SH3K1 0.00000 3.64 74 ARFG1 0.00004 1.96 
20 PACS1 0.00000 3.24 75 ARPC5 0.00014 1.96 
21 TPM1 0.00000 3.24 76 MT1E 0.00012 1.96 
22 INP4B 0.00000 3.17 77 PI42C 0.00876 1.94 
23 PRDBP 0.00000 3.11 78 TAGL2 0.00000 1.93 
24 ITA2 0.00383 2.87 79 ARPC3 0.01371 1.93 
25 SH3L3 0.00000 2.83 80 DCTN1 0.00731 1.90 
26 DDAH2 0.00000 2.83 81 AKA12 0.00000 1.89 
27 P4HA2 0.00000 2.78 82 K1C17 0.00084 1.86 
28 FSCN1 0.00000 2.76 83 CATB 0.00000 1.84 
29 TBB2A 0.00000 2.74 84 VAT1 0.00000 1.83 
30 GOPC 0.02105 2.69 85 THIC 0.00000 1.81 
31 ANXA3 0.00004 2.67 86 TPM4 0.00213 1.81 
32 CSRP2 0.00000 2.66 87 PP14B 0.00001 1.77 
33 DREB 0.00000 2.65 88 PLOD2 0.00000 1.74 
34 CNN2 0.00000 2.56 89 TLN1 0.00000 1.73 
35 MYH9 0.00000 2.54 90 UGPA 0.04892 1.71 
36 TPM2 0.00000 2.54 91 CSRP1 0.00002 1.70 
37 MAGD2 0.00302 2.54 92 PSMD2 0.00081 1.70 
38 NAGK 0.00073 2.54 93 ARP2 0.00386 1.70 
39 NPC2 0.00016 2.47 94 TB182 0.00000 1.70 
40 FLNA 0.00062 2.44 95 AKAP2 0.00052 1.70 
41 PLCG1 0.00068 2.44 96 ARC1B 0.00472 1.69 
42 TBA4A 0.00000 2.37 97 GDIA 0.00000 1.68 
43 MOES 0.00000 2.33 98 ILK 0.00092 1.67 
44 PPR18 0.00000 2.33 99 MANF 0.00215 1.65 
45 TX1B3 0.00000 2.29 100 CALU 0.00000 1.65 
46 RAI14 0.00078 2.28 101 KCRB 0.03349 1.65 
47 HMGA1 0.00003 2.27 102 TBA1C 0.00004 1.63 
48 BASP1 0.00268 2.25 103 PYGB 0.00002 1.62 
49 FBLI1 0.00000 2.24 104 CLIC4 0.00551 1.61 
50 ACTN1 0.00000 2.20 105 DCTN2 0.00000 1.60 
51 HSPB1 0.00000 2.19 106 UPP1 0.00053 1.60 
52 ANXA6 0.00034 2.19 107 ACTB 0.00000 1.59 
53 PAWR 0.00000 2.18 108 VINC 0.00217 1.58 
54 RRBP1 0.00000 2.17 109 AP2A1 0.02731 1.58 
55 CNN3 0.00011 2.17 110 MAP4 0.01799 1.56 
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111 ZO2 0.00000 1.54 168 RL18A 0.00445 -1.15 
112 1433S 0.00000 1.54 169 RL5 0.02421 -1.16 
113 CAP1 0.00008 1.53 170 AHSA1 0.00550 -1.16 
114 ARP3 0.00014 1.53 171 LC7L2 0.01725 -1.17 
115 STMN1 0.00013 1.53 172 MDHC 0.02684 -1.17 
116 TPM3 0.00000 1.52 173 RL29 0.00554 -1.17 
117 PA1B3 0.00001 1.52 174 RS8 0.00782 -1.19 
118 SC31A 0.00083 1.50 175 TXND5 0.00480 -1.19 
119 SNX12 0.00017 1.49 176 PSB1 0.04562 -1.19 
120 CATZ 0.00000 1.48 177 PSA5 0.00164 -1.21 
121 DAP1 0.00367 1.48 178 SODC 0.00044 -1.22 
122 VIGLN 0.00005 1.47 179 RL15 0.01627 -1.22 
123 BACH 0.00002 1.47 180 SRC8 0.00000 -1.23 
124 DTD1 0.00005 1.47 181 TCPE 0.04756 -1.23 
125 FKB10 0.00075 1.47 182 SAHH 0.00035 -1.24 
126 COR1C 0.00000 1.46 183 PSB6 0.04428 -1.24 
127 USO1 0.00144 1.44 184 ROA1 0.01048 -1.24 
128 SERPH 0.00000 1.43 185 IRAK4 0.00034 -1.25 
129 4EBP1 0.00066 1.43 186 RL21 0.02824 -1.25 
130 COPG1 0.00003 1.43 187 PRSR2 0.00285 -1.25 
131 CD2A1 0.00332 1.43 188 RUVB2 0.00066 -1.26 
132 GNS 0.00044 1.43 189 CHM2B 0.00094 -1.26 
133 HN1L 0.00475 1.42 190 SET 0.00135 -1.27 
134 COPZ1 0.00881 1.42 191 PRDX1 0.00076 -1.28 
135 PAK2 0.00063 1.41 192 DNJB1 0.00921 -1.28 
136 NSF1C 0.00004 1.41 193 TCOF 0.00466 -1.28 
137 PDLI5 0.00000 1.40 194 EPIPL 0.04719 -1.28 
138 GRP78 0.00000 1.39 195 GUAD 0.03579 -1.29 
139 COPB 0.00606 1.39 196 HS90A 0.00001 -1.29 
140 S10AD 0.00001 1.38 197 RBM39 0.00735 -1.29 
141 FA98B 0.01883 1.38 198 SNRPA 0.03255 -1.29 
142 ERO1A 0.00001 1.38 199 AATC 0.01653 -1.30 
143 TF65 0.00013 1.37 200 EIF3J 0.03683 -1.30 
144 SCRN1 0.04790 1.36 201 LDHB 0.00004 -1.31 
145 PP1A 0.00191 1.36 202 PQBP1 0.04068 -1.31 
146 ANXA2 0.00000 1.35 203 RL13 0.01677 -1.32 
147 TES 0.00003 1.34 204 SPEE 0.00005 -1.33 
148 TYB4 0.04076 1.32 205 EFHD2 0.00401 -1.35 
149 COF1 0.00171 1.31 206 RL36 0.02569 -1.36 
150 1433B 0.00071 1.31 207 FA49B 0.00300 -1.36 
151 MARE1 0.00026 1.31 208 AMRP 0.01499 -1.37 
152 CPNS1 0.00940 1.29 209 PSA1 0.00001 -1.37 
153 FKBP9 0.02160 1.29 210 ELOB 0.02459 -1.38 
154 COPB2 0.00001 1.29 211 SNX2 0.00032 -1.38 
155 G3BP1 0.01430 1.29 212 RSRC2 0.00244 -1.39 
156 YTHD3 0.02052 1.28 213 SARG 0.02654 -1.43 
157 VASP 0.00916 1.24 214 PA2G4 0.00000 -1.43 
158 CLH1 0.02739 1.24 215 BIEA 0.00000 -1.45 
159 SNX6 0.00204 1.23 216 RL12 0.02759 -1.45 
160 PAXI 0.00054 1.22 217 PCY2 0.03423 -1.46 
161 CAPZB 0.02199 1.21 218 CRIP1 0.00295 -1.47 
162 CRIP2 0.01024 1.20 219 NASP 0.00004 -1.47 
163 ANXA1 0.04906 1.20 220 LIMA1 0.00001 -1.49 
164 EHD4 0.02634 1.20 221 YBOX3 0.01423 -1.50 
165 ROA0 0.03391 1.19 222 KAD2 0.00573 -1.51 
166 CAZA2 0.00012 1.18 223 MTND 0.00002 -1.52 
167 SEPT2 0.00225 1.17 224 G6PD 0.00088 -1.52 
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Rank Protein 
Corrected 
p-value 
FC Rank Protein 
Corrected 
p-value 
FC 
225 RED 0.00106 -1.53 262 K2C5 0.00001 -2.08 
226 PUR9 0.00012 -1.53 263 IMDH2 0.00000 -2.11 
227 NUDT5 0.00007 -1.53 264 FAS 0.00000 -2.18 
228 TKT 0.00000 -1.54 265 PTGR2 0.00001 -2.22 
229 RNPS1 0.02061 -1.55 266 AL1A3 0.00005 -2.23 
230 EF1B 0.00000 -1.56 267 DCXR 0.00591 -2.32 
231 PGM2 0.01137 -1.57 268 K2C8 0.00000 -2.36 
232 CAPG 0.00002 -1.57 269 IL18 0.01063 -2.37 
233 SHLB2 0.00428 -1.58 270 K1C19 0.00000 -2.43 
234 NDRG1 0.00073 -1.61 271 TOPK 0.00004 -2.43 
235 NPM 0.00000 -1.62 272 EFHD1 0.00000 -2.55 
236 TRXR1 0.00002 -1.62 273 PDLI1 0.00000 -2.68 
237 FKBP4 0.00008 -1.64 274 ADIRF 0.00145 -2.71 
238 CAH2 0.00017 -1.67 275 FKBP5 0.00000 -2.72 
239 ACPH 0.00000 -1.67 276 KCRU 0.00000 -2.74 
240 TACD2 0.00827 -1.68 277 CADH1 0.00000 -2.75 
241 LG3BP 0.00070 -1.69 278 EVPL 0.00216 -2.85 
242 CAYP1 0.00111 -1.69 279 TRAD1 0.00009 -2.88 
243 EBP2 0.00000 -1.72 280 PEPL 0.00000 -2.91 
244 C1TC 0.00102 -1.72 281 GSHR 0.00000 -3.04 
245 BAIP2 0.00000 -1.74 282 ASSY 0.00000 -3.08 
246 PRDX6 0.00000 -1.77 283 SCEL 0.00000 -3.52 
247 PUR6 0.00000 -1.78 284 TFR1 0.00019 -3.65 
248 PPT1 0.00537 -1.84 285 SDPR 0.00000 -3.80 
249 GDIR2 0.00000 -1.85 286 POMP 0.00010 -3.87 
250 IPYR 0.00000 -1.87 287 NHRF1 0.00000 -3.99 
251 COMT 0.00024 -1.88 288 GLNA 0.00000 -4.10 
252 LMO7 0.00027 -1.90 289 SYUG 0.00000 -4.19 
253 HPCL1 0.02160 -1.91 290 K1C15 0.00096 -4.20 
254 CI142 0.02238 -1.95 291 S10AE 0.00000 -4.44 
255 PNCB 0.00000 -1.96 292 LIMC1 0.00005 -4.57 
256 AHNK 0.00003 -1.96 293 E41L1 0.00000 -4.75 
257 ANXA4 0.00007 -1.97 294 UPK3L 0.00000 -5.13 
258 K2C7 0.02750 -2.00 295 AGR2 0.00007 -5.91 
259 BRX1 0.00128 -2.02 296 LY6D 0.00083 -6.02 
260 GOLP3 0.04358 -2.05 297 K1C13 0.00000 -39.42 
261 G6PI 0.00000 -2.06 
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A3.5 Significantly deregulated proteins in DU145 upon stimulation 
with TGF-β 
 
Rank Protein 
Corrected 
p-value 
FC Rank Protein 
Corrected 
p-value 
FC 
1 TAGL 0.00000 8.51 56 TES 0.00000 1.63 
2 ITAV 0.01456 8.06 57 LIMA1 0.00178 1.63 
3 QORX 0.00000 6.71 58 CAP1 0.00002 1.62 
4 TPM1 0.00000 6.65 59 TBB3 0.00012 1.60 
5 LMCD1 0.00000 5.22 60 STK24 0.00015 1.59 
6 BGH3 0.00000 4.90 61 NXP20 0.01418 1.58 
7 GAPR1 0.02220 3.75 62 DREB 0.00000 1.58 
8 PADI2 0.00021 3.74 63 TWF2 0.03928 1.57 
9 TSP1 0.00004 3.56 64 COF1 0.01623 1.56 
10 TBA4A 0.00000 3.52 65 MYH9 0.00001 1.56 
11 INP4B 0.00702 3.51 66 TAGL2 0.00069 1.56 
12 NPC2 0.00000 3.22 67 ML12A 0.00000 1.55 
13 P4HA1 0.00000 3.19 68 VINC 0.00726 1.54 
14 MYL9 0.01412 3.17 69 TIA1 0.04558 1.53 
15 FBLI1 0.00000 2.89 70 GSTP1 0.00002 1.51 
16 P4HA2 0.00000 2.81 71 CRIP2 0.02680 1.50 
17 MT2 0.00000 2.56 72 FSCN1 0.00000 1.49 
18 HSPB1 0.00000 2.54 73 HMGN1 0.02181 1.49 
19 DPYL3 0.00000 2.52 74 SCRN1 0.01707 1.45 
20 PDLI7 0.00009 2.45 75 PAWR 0.00543 1.44 
21 PLST 0.00000 2.38 76 DPP9 0.00856 1.44 
22 PACS1 0.00679 2.36 77 HMGB3 0.00018 1.44 
23 TYB4 0.00000 2.34 78 FLNB 0.00168 1.43 
24 FKBP9 0.00030 2.33 79 TX1B3 0.00008 1.41 
25 FLNA 0.00000 2.32 80 VASP 0.00000 1.39 
26 ARFG1 0.00664 2.25 81 ENPL 0.02118 1.38 
27 PLOD2 0.00000 2.22 82 PICAL 0.00011 1.37 
28 FERM2 0.00005 2.19 83 DCTN2 0.00887 1.37 
29 ACTN1 0.00000 2.07 84 MYH10 0.00000 1.36 
30 PALLD 0.00015 2.06 85 PAXI 0.00211 1.34 
31 SYNPO 0.00114 2.04 86 SEPT7 0.00289 1.34 
32 CNN2 0.00000 2.01 87 PDLI5 0.00438 1.34 
33 PLOD1 0.00572 2.01 88 1433Z 0.04058 1.26 
34 DNJB4 0.00269 1.98 89 LEG1 0.01802 1.26 
35 CNN3 0.00044 1.89 90 PP1B 0.00012 1.25 
36 AHNK2 0.00001 1.89 91 TBB2A 0.04118 1.24 
37 ACTB 0.00121 1.88 92 KAP0 0.00430 1.23 
38 MT1E 0.00002 1.87 93 MARE1 0.00915 1.18 
39 SERPH 0.00000 1.86 94 DDX17 0.01824 -1.14 
40 FHL2 0.00059 1.86 95 TXNL1 0.00875 -1.18 
41 PTMS 0.00000 1.84 96 PSA3 0.03944 -1.19 
42 ZYX 0.00000 1.80 97 CBR1 0.04640 -1.20 
43 PPR18 0.00447 1.79 98 RL15 0.03649 -1.21 
44 GRN 0.00066 1.78 99 SPTB2 0.00747 -1.22 
45 F177A 0.00022 1.77 100 RL38 0.00080 -1.22 
46 IMA3 0.01524 1.77 101 RL3 0.03381 -1.23 
47 CALD1 0.03002 1.75 102 RUVB2 0.00016 -1.23 
48 UBA6 0.00331 1.74 103 RL17 0.03033 -1.23 
49 GELS 0.00657 1.72 104 RSSA 0.04133 -1.24 
50 MYPT1 0.00021 1.68 105 EF1G 0.00070 -1.24 
51 PPGB 0.00265 1.68 106 YBOX1 0.00223 -1.24 
52 CATB 0.00005 1.67 107 4EBP1 0.01351 -1.24 
53 MOES 0.00002 1.67 108 RS8 0.01484 -1.24 
54 CALU 0.00000 1.66 109 SPEE 0.00006 -1.25 
55 PDIA3 0.00104 1.64 110 PRDX6 0.01171 -1.26 
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Rank Protein 
Corrected 
p-value 
FC Rank Protein 
Corrected 
p-value 
FC 
111 RS4X 0.00095 -1.27 150 RL27 0.01246 -1.59 
112 RL39 0.02376 -1.27 151 PYGB 0.00006 -1.59 
113 PSMD7 0.04349 -1.27 152 BAG2 0.00244 -1.60 
114 PSME2 0.03342 -1.27 153 PLSI 0.02119 -1.62 
115 PCBP1 0.01309 -1.27 154 SYAC 0.00013 -1.63 
116 SORCN 0.02600 -1.27 155 SIAS 0.00000 -1.63 
117 FPPS 0.04770 -1.29 156 FLNC 0.00154 -1.64 
118 CDV3 0.01212 -1.29 157 RANG 0.00185 -1.64 
119 RL18 0.00180 -1.29 158 PDLI2 0.02387 -1.64 
120 IF4B 0.00585 -1.29 159 PHB 0.00200 -1.65 
121 PUR6 0.01484 -1.30 160 NDRG1 0.00014 -1.67 
122 SAHH 0.00000 -1.31 161 SERC 0.00174 -1.69 
123 NQO1 0.03717 -1.31 162 GSH1 0.00299 -1.70 
124 ACLY 0.00000 -1.31 163 IDHC 0.00726 -1.73 
125 IMUP 0.00037 -1.32 164 ASNS 0.00708 -1.75 
126 AHSA1 0.00406 -1.33 165 HPRT 0.01196 -1.76 
127 RL7 0.00911 -1.33 166 HSP71 0.00090 -1.76 
128 SERA 0.02034 -1.34 167 SYWC 0.00000 -1.81 
129 RL4 0.00073 -1.35 168 ENOB 0.00147 -1.88 
130 EIF3G 0.00741 -1.35 169 MTND 0.00000 -1.88 
131 NUDC 0.00005 -1.35 170 ANXA5 0.04123 -1.89 
132 UBQL4 0.00025 -1.36 171 NAMPT 0.00015 -1.89 
133 AATC 0.00015 -1.38 172 AHNK 0.03975 -1.90 
134 IMDH2 0.00007 -1.39 173 K1C19 0.00001 -1.91 
135 PA2G4 0.03605 -1.40 174 LMNA 0.00000 -1.97 
136 GSHR 0.00478 -1.40 175 SYK 0.04154 -1.98 
137 TRXR1 0.00008 -1.40 176 S10A6 0.00007 -2.09 
138 UGDH 0.00526 -1.41 177 AK1C2 0.00098 -2.14 
139 NUCL 0.00007 -1.41 178 AIM1 0.00015 -2.29 
140 RL13A 0.00369 -1.42 179 LMO7 0.00055 -2.40 
141 IF6 0.00250 -1.43 180 KCC2D 0.00006 -2.60 
142 NPM 0.00007 -1.44 181 UPP1 0.00000 -2.69 
143 DCPS 0.03955 -1.46 182 ANXA1 0.00000 -2.78 
144 FKBP4 0.00023 -1.47 183 KCRB 0.00006 -2.91 
145 HMGA1 0.00102 -1.48 184 EFHD2 0.00000 -2.92 
146 HS90A 0.00004 -1.49 185 CL043 0.00634 -3.10 
147 NH2L1 0.00469 -1.54 186 TACD2 0.00006 -3.66 
148 RS11 0.03234 -1.55 187 SDPR 0.00000 -7.51 
149 TGM2 0.00147 -1.57 
 
 
 
